

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |  |
|--|-----------|--|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>A01H 1/00, C07H 21/04, C07K 14/00,<br/>C12N 5/04, 5/10, C12P 19/34, C12Q 1/68</b>   | <b>A1</b> | <b>(11) International Publication Number: WO 98/30083</b><br><b>(43) International Publication Date: 16 July 1998 (16.07.98)</b>   |
| <b>(21) International Application Number:</b> PCT/US98/00615<br><b>(22) International Filing Date:</b> 9 January 1998 (09.01.98)<br><br><b>(30) Priority Data:</b><br>08/781,734 10 January 1997 (10.01.97) US<br><br><b>(71) Applicant:</b> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612 (US).<br><br><b>(72) Inventors:</b> SHEN, Kathy; 44228 Country Club Drive, El Macero, CA 95618 (US). MEYERS, Blake; 904 Drake Drive, Davis, CA 95616 (US). MICHELMORE, Richard, W.; 36757 Russel Boulevard, Davis, CA 95616 (US).<br><br><b>(74) Agents:</b> EINHORN, Gregory, P. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US). |           | <b>(81) Designated States:</b> CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS<br><br><b>(57) Abstract</b><br><br>The present invention provides RG nucleic acids and proteins which confer disease resistance to plants. The nucleic acids can be used to produce transgenic plants resistant to pests. Antibodies to proteins of the invention are also provided.   |           |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PL | Poland                                       |    |                          |
| CN | China                    | KZ | Kazakhstan                               | PT | Portugal                                     |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SD | Sudan  |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SE | Sweden                                       |    |                          |
| EE | Estonia                  |    |  | SG | Singapore                                    |    |                          |

## RG NUCLEIC ACIDS FOR CONFERRING DISEASE RESISTANCE TO PLANTS

5

The present application is a continuation-in-part application ("CIP") of U.S. Patent Application Serial No. ("USSN") 08/781,734, filed January 10, 1997. The  
10      aforementioned application is explicitly incorporated herein by reference in its entirety and  
for all purposes.

This invention was made with Government support under Grant Nos. 92-37300-7547 and 95-37300-1571, awarded by the United States Department of Agriculture.  
15      The Government has certain rights in this invention.

## FIELD OF THE INVENTION

The present invention relates generally to plant molecular biology. In particular, it relates to nucleic acids and methods for conferring pest resistance in plants.  
20      particularly lettuce.

## BACKGROUND OF THE INVENTION

Recently, several resistance genes have been cloned by several groups from several plants. Many of these genes are sequence related. The derived amino acid  
25      sequences of the most common class, *RPS2*, *RPM1* (bacterial resistances in *Arabidopsis* (Mindrinos *et al.* *Cell* 78:1089-1099 (1994)); Bent *et al.* *Science* 265:1856-1860 (1994); Grant *et al.*, *Science* 269:843-846 (1995)), *L6* (fungal resistance in flax; Lawrence, *et al.*, *The Plant Cell* 7:1195-1206 (1995)), and *N*, (virus resistance in tobacco; Whitham, *et al.*, *Cell* 78:1101-1115 (1994); and U.S. Patent No. 5,571,706), all contain leucine-rich  
30      repeats (LRR) and nucleotide binding sites (NBS).

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

The NBS is a common motif in several mammalian gene families encoding signal transduction components (e.g., *Ras*) and is associated with ATP/GTP-binding sites.

LRR domains can mediate protein-protein interactions and are found in a variety of proteins involved in signal transduction, cell adhesion and various other functions. LRRs are leucine rich regions often comprising 20-30 amino acid repeats where leucine and other aliphatic residues occur periodically. LRRs can function extracellularly or intracellularly.

Since the onset of civilization, plant diseases have had catastrophic effects on crops and the well-being of the human population. Plant diseases continue to effect enormous human and economic costs. An increasing human population and decreasing amounts of arable land make all approaches to preventing and treating plant pathogen destruction critical. The ability to control and enhance a plant's protective responses against pathogens would be of enormous benefit. Tissue-specific and temporal control of mechanisms responsible for plant cell death would also be of great practical and economic value. The present invention fulfills these and other needs.

What is needed in the art are plant disease resistance genes and means to create transgenic disease resistance plants, particularly in lettuce. Further, what is needed in the art is a means to DNA fingerprint cultivars and germplasm with respect to their disease resistance haplotypes for use in plant breeding programs. The present invention provides these and other advantages.

### SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acid constructs. These constructs comprise an RG (resistance gene) polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and an RG4 polypeptide. RG1, RG2, RG3, RG4, and the like, represent individual "RG families." Each "RG family," as defined herein, is a group of polypeptide sequences that have at least 60% amino acid sequence identity. Individual members of an RG family, *i.e.*, individual species of the genus, typically map to the same genomic locus. The invention provides for constructs comprising nucleotides encoding the RG families of the



invention, which can include sequences encoding a leucine rich region (LRR), and/or a nucleotide binding site (NBS), or both.

The invention provides for an isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide. In alternative embodiments, the nucleic acid construct comprises an RG polynucleotide which encodes an RG polypeptide comprising an leucine rich region (LRR), or, an RG polypeptide comprising a nucleotide binding site (NBS). The nucleic acid construct can comprise a polynucleotide which is a full length gene. In another embodiment, the nucleic acid construct encodes a fusion protein.

In one embodiment, the nucleic acid construct comprises a sequence encoding an RG1 polypeptide. The RG1 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 and SEQ ID NO:137 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).

In another embodiment, the nucleic acid construct comprises a sequence encoding an RG2 polypeptide. The RG2 polypeptide can be encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In other embodiments, the nucleic acid construct comprises a RG3 sequence (SEQ ID NO:68) encoding an RG3 polypeptide (SEQ ID NO:138) (RG3). In other embodiments, the nucleic acid construct comprises an RG4 sequence (SEQ ID NO:69) encoding an RG4 polypeptide (SEQ ID NO:139) (RG4).

5 In other embodiments, the nucleic acid construct comprises a RG5 sequence (SEQ ID NO:134) encoding an RG5 polypeptide (SEQ ID NO:135). The RG5 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

The invention also provides for a nucleic acid construct which comprises an RG7 sequence encoding an RG7 polypeptide. The RG7 polypeptide can be encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.

10 In further embodiments, the nucleic acid construct can further comprise a promoter operably linked to the RG polynucleotide. In alternative embodiments, the promoter can be a plant promoter; a disease resistance promoter; a lettuce promoter; a constitutive promoter; an inducible promoter; or, a tissue-specific promoter. The nucleic acid construct can comprise a promoter sequence from an RG gene linked to a heterologous polynucleotide.

The invention also provides for a transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide. The expression cassette can comprise a plant promoter or a viral promoter; the plant promoter can be a heterologous promoter. In one embodiment, the transgenic plant is lettuce. In alternative embodiments, the transgenic plant comprises an expression cassette which includes an RG polynucleotide selected from the group consisting of SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO:3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J); SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104

(RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W); SEQ ID NO:68 (RG3); SEQ ID NO:69 (RG4); SEQ ID NO:134 (RG5); or SEQ ID NO:136 (RG7).

The invention provide for a transgenic plant comprising an expression cassette comprising an RG polynucleotide which can encode an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W); an RG4 polypeptide as set forth by SEQ ID NO:72; an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135; or, an RG7 polypeptide.

The invention also provides for a method of enhancing disease resistance in a plant, the method comprising introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence. In this method, the plant can be a lettuce plant; and, the RG polynucleotide can encode an RG polypeptide selected from the group consisting of an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO:13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ ID

NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), or SEQ ID NO:20 (RG1J); or, an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:72; SEQ ID NO:74; SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W). In this method, the promoter can be a plant disease resistance promoter, a tissue-specific promoter, a constitutive promoter, or an inducible promoter.

The invention also provides for a method of detecting RG resistance genes in a nucleic acid sample, the method comprising: contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and, wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample. In this method, the RG polynucleotide can be an RG1 polynucleotide, an RG2 polynucleotide, an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide. In this method, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide, and, the RG resistance gene can be amplified by the polymerase chain reaction. In one embodiment, the RG polynucleotide is labeled.

The invention further provides for an RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification, the figures and claims.

All publications, patents and patent applications cited herein are hereby  
5 expressly incorporated by reference for all purposes.

### DETAILED DESCRIPTION OF THE INVENTION

This invention relates to families of RG genes, particularly from *Lactuca sativa*. Nucleic acid sequences of the present invention can be used to confer resistance in  
10 plants to a variety of pests including viruses, fungi, nematodes, insects, and bacteria. Sequences from within the RG genes can be used to fingerprint cultivars or germplasm for the presence of desired resistance genes. Promoters of RG genes can be used to drive heterologous gene expression under conditions in which RG genes are expressed. Further, the present invention provides RG proteins and antibodies specifically reactive to RG  
15 proteins. Antibodies to RG proteins can be used to detect the type and amount of RG protein expressed in a plant sample.

The present invention has use over a broad range of types of plants, including species from the genera *Cucurbita*, *Rosa*, *Vitis*, *Juglans*, *Fragaria*, *Lotus*,  
*Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*,  
20 *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*,  
*Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*,  
*Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*,  
*Pelargonium*, *Panieum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*,  
*Browaalia*, *Glycine*, *Pisum*, *Phaseolus*, *Lolium*, *Oryza*, *Zea*, *Avena*, *Hordeum*, *Secale*,  
25 *Triticum*, and, *Sorghum*. In particularly preferred embodiments, species from the family *Compositae* and in particular the genus *Lactuca* are employed such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

The nucleic acids of the present invention can be used in marker-aided selection. Marker-aided selection does not require the complete sequence of the gene or  
30 precise knowledge of which sequence confers which specificity. Instead, partial sequences can be used as hybridization probes or as the basis for oligonucleotide primers to amplify nucleic acid, e.g., by PCR. Partial sequences can be used in other methods, such as to

follow the segregation of chromosome segments containing resistance genes in plants. Because the RG marker is the gene itself, there can be negligible recombination between the marker and the resistance phenotype. Thus, RG polynucleotides of the present invention provide an optimal means to DNA fingerprint cultivars and wild germplasm with respect to their disease resistance haplotypes. This can be used to indicate which germplasm accessions and cultivars carry the same resistance genes. At present, selection of plants (e.g., lettuce) for resistance to some diseases is slow and difficult. But linked markers allow indirect selection for such resistance genes. Moreover, RG markers also allow resistance genes to be identified and combined in a manner that would not otherwise be possible. Numerous accessions have been identified that provide resistance to all isolates of downy mildew (*Bremia lactucae*). However, without molecular markers it is impossible to combine such resistances from different sources. The nucleic acid sequences of the invention provide for a fast and convenient means to identify and combine resistances from different sources. The RG markers of the invention can also be used to identify recombinants that have new combinations of resistance genes in *cis* on the same chromosome.

In addition, RG markers may allow the identification of the Mendelian factors determining traits, such as field resistance to downy mildew. Once such markers have been identified, they will greatly increase the ease with which field resistance can be transferred between lines and combined with other resistances.

In another application, primers to RG sequences can be also designed to amplify sequences that are conserved in multiple RG family members. This gives genetic information on multiple RG family members. Alternatively, one or more primers can be made to sequences unique to a single resistance gene genus or a single RG specie. This allows an analysis of individual family groups (an RG genus) or an individual family member (a specie). Primers made to individual RGs at the edge of each cluster can be used to select for recombinants within the cluster. This minimizes the amount of linkage drag during introgression. Classical and molecular genetics has shown that pest resistance genes tend to be clustered in the genome. Pest resistance loci comprise arrays of genes and exhibit a variety of complex haplotypes rather than being simple alternate allelic forms. Pest resistance is conferred by families, or genuses, of related RG sequences, individual members, or species, of which have evolved to have a different specificity.

Oligonucleotide primers can be designed that amplify members from multiple haplotypes, or genuses, or amplify only members of one genus, or only amplify an individual specie. This will provide codominant information and allow heterozygotes to be distinguished from homozygotes.

5                   Further, comparison of RG sequences will allow a determination of which sequences are critical for resistance and will ultimately lead to engineering resistance genes with new specificities. Resistance gene sequences were not previously available for lettuce. Marker-aided selection will greatly increase the precision and speed of breeding for disease resistance. Transgenic approaches will allow pyramiding of resistance genes  
10 into a single Mendelian unit, transfer between sexually-incompatible species, substitute for conventional backcrossing procedures, and allow expression of other genes in parallel with resistance genes.

                  The RG polynucleotides also have utility in the construction of disease resistant transgenic plants. This avoids lengthy and sometimes difficult backcrossing  
15 programs currently necessary for introgression of resistance. It is also possible to transfer resistance polynucleotides between sexually-incompatible species, thereby greatly increasing the germplasm pool that can be used as a source of resistance genes. Cloning of multiple RG sequences in a single cassette will allow pyramiding of genes for resistance against multiple isolates of a single pathogen such as downy mildew or against multiple  
20 pathogens. Once introduced, such a cassette can be manipulated by classical breeding methods as a single Mendelian unit.

                  Transgenic plants of the present invention can also be constructed using an RG promoter. The promoter sequences from RG sequences of the invention can be used with RG genes or heterologous genes. Thus, RG promoters can be used to express a  
25 variety of genes in the same temporal and spatial patterns and at similar levels to resistance genes.

### **Nucleic acids of the Invention and Their Preparation**

#### ***RG Polynucleotide Families***

30                   The present invention provides isolated nucleic acid constructs which comprise an RG polynucleotide. In alternative embodiments, the RG polynucleotide is at least 18 nucleotides in length, typically at least 20, 25, or 30 nucleotides in length, more

typically at least 100 nucleotides in length, generally at least 200 nucleotides in length, preferably at least 300 nucleotides in length, more preferably at least 400 nucleotides in length, and most preferably at least 500 nucleotides in length.

In particularly preferred embodiments, the RG polynucleotide encodes a RG protein which confers resistance to plant pests. This RG protein can be longer, equivalent, or shorter than the RG protein encoded by an RG gene. In various embodiments, an RG polynucleotide can hybridize under stringent conditions to members of an RG family (an RG genus); *e.g.*, it can hybridize to a member of the RG1 RG family, such as an RG1 polynucleotide selected from the group consisting of: SEQ ID NO:1 (RG1A); SEQ ID NO:2 and SEQ ID NO:137 (RG1B); SEQ ID NO: 3 (RG1C); SEQ ID NO:4 (RG1D); SEQ ID NO:5 (RG1E); SEQ ID NO:6 (RG1F); SEQ ID NO:7 (RG1G); SEQ ID NO:8 (RG1H); SEQ ID NO:9 (RG1I) and SEQ ID NO:10 (RG1J).

In other embodiments, the polynucleotide can also hybridize under stringent conditions to a member of the RG2 family; such as an RG2 polynucleotide selected from the group consisting of: SEQ ID NO:21 and SEQ ID NO:27 (RG2A); SEQ ID NO:23 and SEQ ID NO:28 (RG2B); SEQ ID NO:29 (RG2C); SEQ ID NO:30 (RG2D); SEQ ID NO:31 (RG2E); SEQ ID NO:32 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:34 (RG2H); SEQ ID NO:35 (RG2I); SEQ ID NO:36 (RG2J); SEQ ID NO:37 (RG2K); SEQ ID NO:38 (RG2L); SEQ ID NO:39 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

In alternative embodiments, each RG2 gene can also include an AC15 sequence which hybridizes under stringent conditions to a polynucleotide selected from the group consisting of: SEQ ID NO:56 (AC15-2A); SEQ ID NO:57 (AC15-2B); SEQ ID NO:58 (AC15-2C); SEQ ID NO:59 (AC15-2D); SEQ ID NO:60 (AC15-2E); SEQ ID NO:61 (AC15-2G); SEQ ID NO:62 (AC15-2H); SEQ ID NO:63 (AC15-2I); SEQ ID



NO:64 (AC15-2J); SEQ ID NO:65 (AC15-2L); SEQ ID NO:66 (AC15-2N); SEQ ID NO:67 (AC15-2O).

In other embodiments, an RG polynucleotide can hybridize under stringent conditions to an RG3 (SEQ ID NO:68), an RG4 (SEQ ID NO:69), and RG5 (SEQ ID NO:135), and an RG7 (SEQ ID NO:137), RG family member.

The present invention further provides nucleic acid constructs which comprise an RG polynucleotide which encodes RG polypeptides from various RG families; such as an RG polypeptide having at least 60% sequence identity to an RG polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, and RG4 polypeptide, and RG5 polypeptide, and an RG7 polypeptide.

Exemplary RG1 polypeptides have the sequences shown in SEQ ID NO:2 (RG1A), SEQ ID NO:4 (RG1B), SEQ ID NO:6 (RG1C), SEQ ID NO:8 (RG1D), SEQ ID NO:10 (RG1E), SEQ ID NO:12 (RG1F), SEQ ID NO:14 (RG1G), SEQ ID NO:16 (RG1H), SEQ ID NO:20 (RG1J). Exemplary RG2 polypeptides have the sequences shown in SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

An exemplary RG3 polypeptide has the sequence shown in SEQ ID NO:138. An exemplary RG4 polypeptide has the sequence shown in SEQ ID NO:139. RG polynucleotides will have at least 60% identity, more typically at least 65% identity, generally at least 70% identity, and preferably at least 75% identity, more preferably at least 80% identity, and most preferably at least 85%, 90%, or 95% identity at the deduced amino acid level. The regions where substantial identity is assessed can be inclusive or exclusive of the nucleotide binding site or the leucine rich region.

### Vectors and Transcriptional Control Elements

The invention, providing methods and reagents for making novel species and genres of RG nucleic acids described herein, further provides methods and reagents for expressing these nucleic acids using novel expression cassettes, vectors, transgenic  
5 plants and animals, using constitutive and inducible transcriptional and translational *cis*-  
(*e.g.*, promoters and enhancers) and *trans*-acting control elements.

The expression of natural, recombinant or synthetic plant disease resistance polypeptide-encoding or other (*i.e.*, antisense, ribozyme) nucleic acids can be achieved by operably linking the coding region a promoter (that can be plant-specific or not,  
10 constitutive or inducible), incorporating the construct into an expression cassette (such as an expression vector), and introducing the resultant construct into an *in vitro* reaction system or a suitable host cell or organism. Synthetic procedures may also be used. Typical expression systems contain, in addition to coding or antisense sequence, transcription and translation terminators, polyadenylation sequences, transcription and  
15 translation initiation sequences, and promoters useful for transcribing DNA into RNA. The expression systems optionally at least one independent terminator sequence, sequences permitting replication of the cassette *in vivo*, *e.g.*, plants, eukaryotes, or prokaryotes, or a combination thereof, (*e.g.*, shuttle vectors) and selection markers for the selected expression system, *e.g.*, plant, prokaryotic or eukaryotic systems. To ensure proper  
20 polypeptide expression under varying conditions, a polyadenylation region at the 3'-end of the coding region can be included (see Li (1997) *Plant Physiol.* 115:321-325, for a review of the polyadenylation of RNA in plants). The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA (*e.g.*, using *Agrobacterium tumefaciens* T-DNA replacement vectors, see *e.g.*, Thykjaer (1997) *Plant*  
25 *Mol Biol.* 35:523-530; using a plasmid containing a gene of interest flanked by *Agrobacterium* T-DNA border repeat sequences; Hansen (1997) "T-strand integration in maize protoplasts after codelivery of a T-DNA substrate and virulence genes," *Proc. Natl. Acad. Sci. USA* 94:11726-11730.

To identify the promoters, the 5' portions of the clones described here are  
30 analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs upstream of the transcription start site. In plants, further

upstream from the TATA box, at positions -80 to -100, there is typically a promoter element with a series of adenines surrounding the trinucleotide G (or T) N G (see, *e.g.*, Messing, in *Genetic Engineering in Plants*, pp. 221-227, Kosage, Meredith and Hollaender, eds. 1983). If proper polypeptide expression is desired, a polyadenylation region at the 3'-end of the RG coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from viral genes, such as T-DNA.

The nucleic acids of the invention can be expressed in expression cassettes, vectors or viruses which are transiently expressed in cells using, for example, episomal expression systems (*e.g.*, cauliflower mosaic virus (CaMV) viral RNA is generated in the nucleus by transcription of an episomal minichromosome containing supercoiled DNA, Covey (1990) *Proc. Natl. Acad. Sci. USA* 87:1633-1637). Alternatively, coding sequences can be inserted into the host cell genome becoming an integral part of the host chromosomal DNA.

Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences coding for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode biocide resistance, such as antibiotic resistance, particularly resistance to chloramphenicol, kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta, to permit selection of those cells transformed with the desired DNA sequences, see for example, Blondelet-Rouault (1997) *Gene* 190:315-317; Aubrecht (1997) *J. Pharmacol. Exp. Ther.* 281:992-997. Because selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo*. See also, Mengiste (1997) "High-efficiency transformation of *Arabidopsis thaliana* with a selectable marker gene regulated by the T-DNA 1' promoter," *Plant J.* 12:945-948, showing that the 1' promoter is an attractive alternative to the cauliflower mosaic virus (CaMV) 35S promoter for the generation of T-DNA insertion lines, the 1' promoter may be especially beneficial for the secondary transformation of transgenic strains containing the 35S promoter to exclude homology-mediated gene silencing.

The endogenous promoters from the RG genes of the present invention can be used to direct expression of the genes. These promoters can also be used to direct expression of heterologous structural genes. The promoters can be used, for example, in recombinant expression cassettes to drive expression of genes conferring resistance to any number of pathogens or pests, including fungi, bacteria, and the like.

#### *Constitutive Promoters*

In construction of recombinant expression cassettes, vectors, transgenics, of the invention, a promoter fragment can be employed to direct expression of the desired gene in all tissues of a plant or animal. Promoters that drive expression continuously under physiological conditions are referred to as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include those from viruses which infect plants, such as the cauliflower mosaic virus (CaMV) 35S transcription initiation region; the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*; the promoter of the tobacco mosaic virus; and, other transcription initiation regions from various plant genes known to those of skill. See also Holtorf (1995) "Comparison of different constitutive and inducible promoters for the overexpression of transgenes in *Arabidopsis thaliana*," *Plant Mol. Biol.* 29:637-646.

#### *Inducible Promoters*

Alternatively, a plant promoter may direct expression of the plant disease resistance nucleic acid of the invention under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include pathogenic attack, anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters. For example, the invention incorporates the drought-inducible promoter of maize (Busk (1997) *supra*); the cold, drought, and high salt inducible promoter from potato (Kirch (1997) *Plant Mol. Biol.* 33:897-909).

Embodiments of the invention also incorporate use of plant promoters which are inducible upon injury or infection to express the invention's plant disease resistance (RG) polypeptides. Various embodiments include use of, e.g., the promoter for a tobacco (*Nicotiana tabacum*) sesquiterpene cyclase gene (EAS4 promoter), which is expressed in wounded leaves, roots, and stem tissues, and upon infection with microbial pathogens (Yin

(1997) *Plant Physiol.* 115(2):437-451); the ORF13 promoter from *Agrobacterium rhizogenes* 8196, which is wound inducible in a limited area adjacent to the wound site (Hansen (1997) *Mol. Gen. Genet.* 254:337-343); the Shpx6b gene promoter, which is a plant peroxidase gene promoter induced by microbial pathogens (demonstrated using a fungal pathogen, see Curtis (1997) *Mol. Plant Microbe Interact.* 10:326-338); the wound-inducible gene promoter wun1, derived from potato (Siebertz (1989) *Plant Cell* 1:961-968); the wound-inducible *Agrobacterium pmas* gene (mannopine synthesis gene) promoter (Guevara-Garcia (1993) *Plant J.* 4:495-505).

Alternatively, plant promoters which are inducible upon exposure to plant hormones, such as auxins, are used to express the nucleic acids of the invention. For example, the invention can use the auxin-response elements E1 promoter fragment (AuxREs) in the soybean (*Glycine max L.*) (Liu (1997) *Plant Physiol.* 115:397-407); the auxin-responsive Arabidopsis GST6 promoter (also responsive to salicylic acid and hydrogen peroxide) (Chen (1996) *Plant J.* 10: 955-966); the auxin-inducible parC promoter from tobacco (Sakai (1996) 37:906-913); a plant biotin response element (Streit (1997) *Mol. Plant Microbe Interact.* 10:933-937); and, the promoter responsive to the stress hormone abscisic acid (Sheen (1996) *Science* 274:1900-1902).

Plant promoters which are inducible upon exposure to chemicals reagents which can be applied to the plant, such as herbicides or antibiotics, are also used to express the nucleic acids of the invention. For example, the maize In2-2 promoter, activated by benzenesulfonamide herbicide safeners, can be used (De Veylder (1997) *Plant Cell Physiol.* 38:568-577); application of different herbicide safeners induces distinct gene expression patterns, including expression in the root, hydathodes, and the shoot apical meristem. Coding sequence can be under the control of, *e.g.*, a tetracycline-inducible promoter, *e.g.*, as described with transgenic tobacco plants containing the *Avena sativa L.* (oat) arginine decarboxylase gene (Masgrau (1997) *Plant J.* 11:465-473); or, a salicylic acid-responsive element (Stange (1997) *Plant J.* 11:1315-1324. Using chemically- (*e.g.*, hormone- or pesticide-) induced promoters, harvesting of fruits and plant parts would be greatly facilitated. A chemical which can be applied to the transgenic plant in the field and induce expression of a polypeptide of the invention throughout all or most of the plant would make an environmentally safe defoliant or herbicide. Thus, the invention also provides for transgenic plants containing an inducible gene encoding for the RG

polypeptides of the invention whose host range is limited to target plant species, such as weeds or crops before, during or after harvesting.

Abcission promoters are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. In some embodiments, when a plant disease resistant polypeptide-encoding nucleic acid is under the control of such a promoter, rapid cell death, induced by expression of the invention's polypeptide, can accelerate and/or accentuate abcission, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like. Induction of rapid cell death at this time would accelerate separation of the fruit from the plant, greatly augmenting harvesting procedures. See, *e.g.*, Kalaitzis (1997) *Plant Physiol.* 113:1303-1308, discussing tomato leaf and flower abcission; Payton (1996) *Plant Mol. Biol.* 31:1227-1231, discussing ethylene receptor expression regulation during fruit ripening, flower senescence and abcission; Koehler (1996) *Plant Mol. Biol.* 31:595-606, discussing the gene promoter for a bean abcission cellulase; Kalaitzis (1995) *Plant Mol. Biol.* 28: 647-656, discussing cloning of a tomato polygalacturonase expressed in abcission; del Campillo (1996) *Plant Physiol.* 111:813-820, discussing pedicel breakstrength and cellulase gene expression during tomato flower abcission.

#### *Tissue-Specific Promoters*

Tissue specific promoters are transcriptional control elements that are only active in particular cells or tissues. Plant promoters which are active only in specific tissues or at specific times during plant development are used to express the nucleic acids of the invention. Examples of promoters under developmental control include promoters that initiate transcription only in certain tissues, such as leaves, roots, fruit, seeds, ovules, pollen, pistils, or flowers. Such promoters are referred to as "tissue specific". The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

For example, a seed-specific promoter directs expression in seed tissues. Such promoters may be, for example, ovule-specific, embryo-specific, endosperm-specific, integument-specific, seed coat-specific, or some combination thereof. A leaf-specific promoter has been identified in maize, Busk (1997) *Plant J.* 11:1285-1295. The ORF13 promoter from *Agrobacterium rhizogenes* exhibits high activity in roots (Hansen (1997) *supra*). A maize pollen-specific promoter has been identified in maize (Guerrero (1990)

*Mol. Gen. Genet.* 224:161-168). A tomato promoter active during fruit ripening, senescence and abscission of leaves and, to a lesser extent, of flowers can be used (Blume (1997) *Plant J.* 12:731-746). A pistil specific promoter has been identified in the potato (*Solanum tuberosum* L.) SK2 gene, encoding a pistil-specific basic endochitinase (Ficker (1997) *Plant Mol. Biol.* 35:425-431). The Blec4 gene from pea (*Pisum sativum* cv. Alaska) is active in epidermal tissue of vegetative and floral shoot apices of transgenic alfalfa, making it a useful tool to target the expression of foreign genes to the epidermal layer of actively growing shoots. The activity of the Blec4 promoter in the epidermis of the shoot apex makes it particularly suitable for genetically engineering defense against insects and diseases that attack the growing shoot apex (Mandaci (1997) *Plant Mol Biol.* 34:961-965).

The invention also provides for use of tissue-specific plant promoters include a promoter from the ovule-specific *BEL1* gene described in Reiser (1995) *Cell* 83:735-742, GenBank No. U39944. Suitable seed specific promoters are derived from the following genes: *MAC1* from maize, Sheridan (1996) *Genetics* 142:1009-1020; *Cat3* from maize, GenBank No. L05934, Abler (1993) *Plant Mol. Biol.* 22:10131-1038; the gene encoding oleosin 18kD from maize, GenBank No. J05212, Lee (1994) *Plant Mol. Biol.* 26:1981-1987; viviparous-1 from *Arabidopsis*, Genbank No. U93215; the gene encoding oleosin from *Arabidopsis*, Genbank No. Z17657; *Atmyc1* from *Arabidopsis*, Urao (1996) *Plant Mol. Biol.* 32:571-576; the 2s seed storage protein gene family from *Arabidopsis*, Conceicao (1994) *Plant* 5:493-505; the gene encoding oleosin 20kD from *Brassica napus*, GenBank No. M63985; *napA* from *Brassica napus*, GenBank No. J02798, Josefsson (1987) *JBL* 26:12196-1301; the napin gene family from *Brassica napus*, Sjodahl (1995) *Planta* 197:264-271; the gene encoding the 2S storage protein from *Brassica napus*, Dasgupta (1993) *Gene* 133:301-302; the genes encoding oleosin a, Genbank No. U09118, and, oleosin B, Genbank No. U09119, from soybean; and, the gene encoding low molecular weight sulphur rich protein from soybean, Choi (1995) *Mol Gen, Genet.* 246:266-268. The tissue specific E8 promoter from tomato is particularly useful for directing gene expression so that a desired gene product is located in fruits. Other suitable promoters include those from genes encoding embryonic storage proteins.

One of skill will recognize that a tissue-specific promoter may drive expression of operably linked sequences in tissues other than the target tissue. Thus, as

used herein a tissue-specific promoter is one that drives expression preferentially in the target tissue, but may also lead to some expression in other tissues as well.

The invention also provides for use of tissue-specific promoters derived from viruses which can include, *e.g.*, the tobamovirus subgenomic promoter (Kumagai (1995) *Proc. Natl. Acad. Sci. USA* 92:1679-1683; the rice tungro bacilliform virus (RTBV), which replicates only in phloem cells in infected rice plants, with its promoter which drives strong phloem-specific reporter gene expression; the cassava vein mosaic virus (CVMV) promoter, with highest activity in vascular elements, in leaf mesophyll cells, and in root tips (Verdaguer (1996) *Plant Mol. Biol.* 31:1129-1139).

In some embodiments, the nucleic acid construct will comprise a promoter functional in a specific plant cell, such as in a species of *Lactuca*, operably linked to an RG polynucleotide. Promoters useful in these embodiments include RG promoters. In additional embodiments, the nucleic acid construct will comprise a RG promoter operably linked to a heterologous polynucleotide. The heterologous polynucleotide is chosen to provide a plant with a desired phenotype. For example, the heterologous polynucleotide can be a structural gene which encodes a polypeptide which imparts a desired resistance phenotype. Alternatively, the heterologous polynucleotide may be a regulatory gene which might play a role in transcriptional and/or translational control to suppress, enhance, or otherwise modify the transcription and/or expression of an endogenous gene within the plant. The heterologous polynucleotide of the nucleic acid construct of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable plant characteristics.

#### *Modifying and Inhibiting RG Gene Expression*

The invention also provides for RG nucleic acid sequences which are complementary to the RG polypeptide-encoding sequences of the invention; *i.e.*, antisense RG nucleic acids. Antisense technology can be conveniently used to modify gene expression in plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, *e.g.*,



Sheehy (1988) *Proc. Nat. Acad. Sci. USA* 85:8805-8809; Hiatt et al., U.S. Patent No. 4,801,340.

Antisense sequences are capable of inhibiting the transport, splicing or transcription of RG-encoding genes. The inhibition can be effected through the targeting of genomic DNA or messenger RNA. The transcription or function of targeted nucleic acid can be inhibited, *e.g.*, by hybridization and/or cleavage. One particularly useful set of inhibitors provided by the present invention includes oligonucleotides which are able to either bind RG gene or message, in either case preventing or inhibiting the production or function of RG. The association can be through sequence specific hybridization. Such inhibitory nucleic acid sequences can, for example, be used to completely inhibit a plant disease resistance response. Another useful class of inhibitors includes oligonucleotides which cause inactivation or cleavage of RG message. The oligonucleotide can have enzyme activity which causes such cleavage, such as ribozymes. The oligonucleotide can be chemically modified or conjugated to an enzyme or composition capable of cleaving the complementary nucleic acid. One may screen a pool of many different such oligonucleotides for those with the desired activity.

#### *Antisense Oligonucleotides*

The invention provides for with antisense oligonucleotides capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing antisense oligonucleotides are well described in the scientific and patent literature, and the skilled artisan can design such RG oligonucleotides using the novel reagents of the invention. In some situations, naturally occurring nucleic acids used as antisense oligonucleotides may need to be relatively long (18 to 40 nucleotides) and present at high concentrations. A wide variety of synthetic, non-naturally occurring nucleotide and nucleic acid analogues are known which can address this potential problem. For example, peptide nucleic acids (PNAs) containing non-ionic backbones, such as N-(2-aminoethyl) glycine units can be used. Antisense oligonucleotides having phosphorothioate linkages can also be used, as described in WO 97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197; Antisense Therapeutics, ed. Agrawal (Humana Press, Totowa, N.J., 1996). Antisense oligonucleotides having synthetic DNA backbone analogues provided by the invention can also include phosphoro-dithioate, methylphosphonate,

phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, and morpholino carbamate nucleic acids, as described herein.

Combinatorial chemistry methodology can be used to create vast numbers of oligonucleotides that can be rapidly screened for specific oligonucleotides that have appropriate binding affinities and specificities toward any target, such as the sense and antisense RG sequences of the invention (for general background information, see, *e.g.*, Gold (1995) *J. of Biol. Chem.* 270:13581-13584).

#### *Inhibitory Ribozymes*

The invention provides for with ribozymes capable of binding RG message which can inhibit RG activity by targeting mRNA. Strategies for designing ribozymes and selecting the RG-specific antisense sequence for targeting are well described in the scientific and patent literature, and the skilled artisan can design such RG ribozymes using the novel reagents of the invention. Ribozymes act by binding to a target RNA through the target RNA binding portion of a ribozyme which is held in close proximity to an enzymatic portion of the RNA that cleaves the target RNA. Thus, the ribozyme recognizes and binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cleave and inactivate the target RNA. Cleavage of a target RNA in such a manner will destroy its ability to direct synthesis of an encoded protein if the cleavage occurs in the coding sequence, or, preventing transport of the message from the nucleus to the cytoplasm. After a ribozyme has bound and cleaved its RNA target, it is typically released from that RNA and so can bind and cleave new targets repeatedly.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of any plant gene. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described, *e.g.*, in Haseioff (1988) *Nature* 334:585-591.

In some circumstances, the enzymatic nature of a ribozyme can be advantageous over other technologies, such as antisense technology (where a nucleic acid

molecule simply binds to a nucleic acid target to block its transcription, translation or association with another molecule) as the effective concentration of ribozyme necessary to effect a therapeutic treatment can be lower than that of an antisense oligonucleotide. This potential advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single  
5 ribozyme molecule is able to cleave many molecules of target RNA. In addition, a ribozyme is typically a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding, but also on the mechanism by which the molecule inhibits the expression of the RNA to which it binds. That is, the inhibition is caused by cleavage of the RNA target and so specificity is defined as the ratio  
10 of the rate of cleavage of the targeted RNA over the rate of cleavage of non-targeted RNA. This cleavage mechanism is dependent upon factors additional to those involved in base pairing. Thus, the specificity of action of a ribozyme can be greater than that of antisense oligonucleotide binding the same RNA site.

The enzymatic ribozyme RNA molecule can be formed in a hammerhead  
15 motif, but may also be formed in the motif of a hairpin, hepatitis delta virus, group I intron or RNaseP-like RNA (in association with an RNA guide sequence). Examples of such hammerhead motifs are described by Rossi (1992) *Aids Research and Human Retroviruses* 8:183; hairpin motifs by Hampel (1989) *Biochemistry* 28:4929, and Hampel (1990) *Nuc. Acids Res.* 18:299; the hepatitis delta virus motif by Perrotta (1992) *Biochemistry* 31:16;  
20 the RNaseP motif by Guerrier-Takada (1983) *Cell* 35:849; and the group I intron by Cech U.S. Pat. No. 4,987,071. The recitation of these specific motifs is not intended to be limiting; those skilled in the art will recognize that an enzymatic RNA molecule of this invention has a specific substrate binding site complementary to one or more of the target gene RNA regions, and has nucleotide sequence within or surrounding that substrate  
25 binding site which imparts an RNA cleaving activity to the molecule.

#### *Sense Supression*

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method  
30 to modulate expression of endogenous genes see, Napoli et al., *The Plant Cell* 2:279-289 (1990), and U.S. Patent No. 5,034,323.

#### *Cloning of RG Polypeptides*

Synthesis and/or cloning of RG polynucleotides and isolated nucleic acid constructs of the present invention are provided by methods well known to those of ordinary skill in the art. Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. These techniques and various other techniques are generally performed according to Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989).

The isolation of RG genes may be accomplished by a number of techniques. For instance, oligonucleotide probes based on the sequences disclosed here can be used to identify the desired gene in a cDNA or genomic DNA library. To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired organ, such as roots and a cDNA library which contains the RG gene transcript is prepared from the mRNA. Alternatively, cDNA may be prepared from mRNA extracted from other tissues in which RG genes or homologs are expressed.

The cDNA or genomic library can then be screened using a probe based upon the sequence of a cloned RG gene such as the genes disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species.

Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide. For example, the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through manipulation of the concentration of formamide within the range of 0% to 50%.

Alternatively, the RG nucleic acids of the invention can be amplified from nucleic acid samples using a variety of amplification techniques, such as polymerase chain reaction (PCR) technology, to amplify the sequences of the RG and related genes directly from genomic DNA, from cDNA, from genomic libraries or cDNA libraries. PCR and other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes.

Oligonucleotides can be used to identify and detect additional RG families and RG family species using a variety of hybridization techniques and conditions. Suitable amplification methods include, but are not limited to: polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, *ed.* Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), *ed.* Innis, Academic Press, Inc., N.Y. (Innis)), ligase chain reaction (LCR) (Wu (1989) *Genomics* 4:560; Landegren (1988) *Science* 241:1077; Barringer (1990) *Gene* 89:117); transcription amplification (Kwoh (1989) *Proc. Natl. Acad. Sci. USA* 86:1173); and, self-sustained sequence replication (Guatelli (1990) *Proc. Natl. Acad. Sci. USA*, 87:1874); Q Beta replicase amplification and other RNA polymerase mediated techniques (*e.g.*, NASBA, Cangene, Mississauga, Ontario); see Berger (1987) *Methods Enzymol.* 152:307-316, Sambrook, and Ausubel, as well as Mullis (1987) U.S. Patent Nos. 4,683,195 and 4,683,202; Arnheim (1990) *C&EN* 36-47; Lomell *J. Clin. Chem.*, 35:1826 (1989); Van Brunt, *Biotechnology*, 8:291-294 (1990); Wu (1989) *Gene* 4:560; Sooknanan (1995) *Biotechnology* 13:563-564. Methods for cloning *in vitro* amplified nucleic acids are described in Wallace, U.S. Pat. No. 5,426,039.

The degree of complementarity (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will optimally be 100 percent; however, it should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the hybridization and/or wash medium as described earlier.

In some preferred embodiments, members of this class of pest resistance genes can be identified by their ability to be amplified by PCR primers based on the sequences disclosed here. Appropriate primers and probes for identifying RG sequences

from plant tissues are generated from comparisons of the sequences provided herein. See, e.g., Table 1. For a general overview of PCR see *PCR Protocols: A Guide to Methods and Applications*. (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), *Academic Press*, San Diego (1990), incorporated herein by reference.

5                    Briefly, the first step of each cycle of the PCR involves the separation of the nucleic acid duplex formed by the primer extension. Once the strands are separated, the next step in PCR involves hybridizing the separated strands with primers that flank the target sequence. The primers are then extended to form complementary copies of the target strands. For successful PCR amplification, the primers are designed so that the  
10                    position at which each primer hybridizes along a duplex sequence is such that an extension product synthesized from one primer, when separated from the template (complement), serves as a template for the extension of the other primer. The cycle of denaturation, hybridization, and extension is repeated as many times as necessary to obtain the desired amount of amplified nucleic acid.

15                    In the preferred embodiment of the PCR process, strand separation is achieved by heating the reaction to a sufficiently high temperature for an sufficient time to cause the denaturation of the duplex but not to cause an irreversible denaturation of the polymerase (see U.S. Patent No. 4,965,188). Template-dependent extension of primers in PCR is catalyzed by a polymerizing agent in the presence of adequate amounts of four  
20                    deoxyribonucleotide triphosphates (typically dATP, dGTP, dCTP, and dTTP) in a reaction medium comprised of the appropriate salts, metal cations, and pH buffering system. Suitable polymerizing agents are enzymes known to catalyze template-dependent DNA synthesis.

                    Polynucleotides may also be synthesized by well-known techniques as  
25                    described in the technical literature. See, e.g., Carruthers *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982), and Adams *et al.*, *J. Am. Chem. Soc.* 105:661 (1983). Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer  
30                    sequence.

#### RG Proteins

The present invention further provides isolated RG proteins encoded by the RG polynucleotides disclosed herein. One of skill will recognize that the nucleic acid encoding a functional RG protein need not have a sequence identical to the exemplified genes disclosed here. For example, because of codon degeneracy a large number of nucleic acid sequences can encode the same polypeptide. In addition, the polypeptides encoded by the RG genes, like other proteins, have different domains which perform different functions. Thus, the RG gene sequences need not be full length, so long as the desired functional domain of the protein is expressed.

The resistance proteins are at least 25 amino acid residues in length. Typically, the RG proteins are at least 50 amino acid residues, generally at least 100, preferably at least 150, more preferably at least 200 amino acids in length. In particularly preferred embodiments, the RG proteins are of sufficient length to provide resistance to pests when expressed in the desired plants. Generally then, the RG proteins will be the length encoded by an RG gene of the present invention. However, those of ordinary skill will appreciate that minor deletions, substitutions, or additions to an RG protein will typically yield a protein with pest resistance characteristics similar or identical to that of the full length sequence. Thus, full-length RG proteins modified by 1, 2, 3, 4, or 5 deletions, substitutions, or additions, generally provide an effective degree of pest resistance relative to the full-length protein.

The RG proteins which provide pest resistance will typically comprise at least one of an LRR or an NBS. Preferably, both are present. LRR and/or NBS regions present in the RG proteins of the present invention can be provided by RG genes of the present invention. In some embodiments, the LRR and/or NBS regions are obtained from other pest resistance genes. See, e.g., Yu *et al.*, *Proc. Natl. Acad. Sci. USA*, 93: 11751-11756 (1996); Bent *et al.*, *Science*, 265: 1856-1860 (1994).

Modified protein chains can also be readily designed utilizing various recombinant DNA techniques well known to those skilled in the art. For example, the chains can vary from the naturally occurring sequence at the primary structure level by amino acid substitutions, additions, deletions, and the like. Modification can also include swapping domains from the proteins of the invention with related domains from other pest resistance genes.

Pests that can be targeted by RG genes and proteins of the present invention include such bacterial pests as *Erwinia carotovora* and *Pseudomonas marginalis*. Fungal pests which can be targeted by the present invention include *Bremia lactucae*, *Marssonina panattoniana*, *Rhizoctonia solani*, *Olpidium brassicae*, root aphid, *Sclerotinia sclerotiorum* and *S. minor*, and *Botrytis cinerea* which causes gray mold. RG genes also provide resistance to viral diseases such as lettuce and turnip mosaic viruses.

#### *Fusion Proteins*

RG polypeptides can also be expressed as recombinant proteins with one or more additional polypeptide domains linked thereto to facilitate protein detection, purification, or other applications. Such detection and purification facilitating domains include, but are not limited to, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between the purification domain and plant disease resistant polypeptide may be useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising the sequence encoding a plant disease resistant polypeptide of the invention and nucleic acid sequence encoding six histidine residues followed by thioredoxin and an enterokinase cleavage site (*e.g.*, see Williams (1995) *Biochemistry* 34:1787-1797). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described, see *e.g.*, Kroll (1993) *DNA Cell. Biol.*, 12:441-53.

#### *Antibodies Reactive to RG Polypeptides and Immunological Assays*

The present invention also provides antibodies which specifically react with RG proteins of the present invention under immunologically reactive conditions. An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. "Immunologically reactive conditions" includes reference to conditions which allow an antibody, generated to a particular epitope of an antigen, to bind to that



epitope to a detectably greater degree than the antibody binds to substantially all other epitopes, generally at least two times above background binding, preferably at least five times above background. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay protocols.

"Antibody" includes reference to an immunoglobulin molecule obtained by *in vitro* or *in vivo* generation of the humoral response, and includes both polyclonal and monoclonal antibodies. The term also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies (e.g., bispecific antibodies), and recombinant single chain Fv fragments (scFv). The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab', F(ab')<sub>2</sub>, Fab, Fv, rIgG, and, inverted IgG). See, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL). An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. See, e.g., Huse *et al.* (1989) *Science* 246:1275-1281; and Ward, *et al.* (1989) *Nature* 341:544-546; and Vaughan *et al.* (1996) *Nature Biotechnology*, 14:309-314.

Many methods of making antibodies are known to persons of skill. A number of immunogens are used to produce antibodies specifically reactive to an isolated RG protein of the present invention under immunologically reactive conditions. An isolated recombinant, synthetic, or native RG protein of the present invention is the preferred immunogens (antigen) for the production of monoclonal or polyclonal antibodies.

The RG protein is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies can be generated for subsequent use in immunoassays to measure the presence and quantity of the RG protein. Methods of producing monoclonal or polyclonal antibodies are known to those of skill in the art. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY.

Frequently, the RG proteins and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide

variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

The antibodies of the present invention can be used to screen plants for the expression of RG proteins of the present invention. The antibodies of this invention are also used for affinity chromatography in isolating RG protein.

The present invention further provides RG polypeptides that specifically bind, under immunologically reactive conditions, to an antibody generated against a defined immunogen, such as an immunogen consisting of the RG polypeptides of the present invention. Immunogens will generally be at least 10 contiguous amino acids from an RG polypeptide of the present invention. Optionally, immunogens can be from regions exclusive of the NBS and/or LRR regions of the RG polypeptides. Nucleic acids which encode such cross-reactive RG polypeptides are also provided by the present invention. The RG polypeptides can be isolated from any number plants as discussed earlier. Preferred are species from the family *Compositae* and in particular the genus *Lactuca* such as *L. sativa* and such subspecies as *crispa*, *longifolia*, and *asparagina*.

"Specifically binds" includes reference to the preferential association of a ligand, in whole or part, with a particular target molecule (i.e., "binding partner" or "binding moiety") relative to compositions lacking that target molecule. It is, of course, recognized that a certain degree of non-specific interaction may occur between a ligand and a non-target molecule. Nevertheless, specific binding, may be distinguished as mediated through specific recognition of the target molecule. Typically specific binding results in a much stronger association between the ligand and the target molecule than between the ligand and non-target molecule. Specific binding by an antibody to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. The affinity constant of the antibody binding site for its cognate monovalent antigen is at least  $10^7$ , usually at least  $10^8$ , preferably at least  $10^9$ , more preferably at least  $10^{10}$ , and most preferably at least  $10^{11}$  liters/mole. A variety of immunoassay formats are appropriate for selecting antibodies specifically reactive with a particular protein. For

example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically reactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific reactivity. The antibody may be polyclonal but preferably is monoclonal. Generally, antibodies cross-reactive to such proteins as RPS2, RPM1 (bacterial resistances in *Arabidopsis*, L6 (fungal resistance in flax, PRF (resistance to *Pseudomonas syringae* in tomato), and *N*, (virus resistance in tobacco), are removed by immunoabsorption.

Immunoassays in the competitive binding format are typically used for cross-reactivity determinations. For example, an immunogenic RG polypeptide is immobilized to a solid support. Polypeptides added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above polypeptides to compete with the binding of the antisera to the immobilized RG polypeptide is compared to the immunogenic RG polypeptide. The percent cross-reactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% cross-reactivity with such proteins as RPS2, RPM1, L6, PRF, and *N*, are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with these non-RG resistance proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay to compare a second "target" polypeptide to the immunogenic polypeptide. In order to make this comparison, the two polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the antisera to the immobilized protein is determined using standard techniques. If the amount of the target polypeptide required is less than twice the amount of the immunogenic polypeptide that is required, then the target polypeptide is said to specifically bind to an antibody generated to the immunogenic protein. As a final determination of specificity, the pooled antisera is fully immunosorbed with the immunogenic polypeptide until no binding to the polypeptide used in the immunosorption is detectable. The fully immunosorbed antisera is then tested for reactivity with the test polypeptide. If no reactivity is observed, then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.

Production of transgenic plants of the invention

Isolated nucleic acid constructs prepared as described herein can be introduced into plants according techniques known in the art. In some embodiments, the introduced nucleic acid is used to provide RG gene expression and therefore pest resistance  
5 in desired plants. In some embodiments, RG promoters are used to drive expression of desired heterologous genes in plants. Finally, in some embodiments, the constructs can be used to suppress expression of a target endogenous gene, including RG genes.

To use isolated RG sequences in the above techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for  
10 transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, for example, Weising *et al. Ann. Rev. Genet.* 22:421-477 (1988).

A DNA sequence coding for the desired RG polypeptide, for example a cDNA or a genomic sequence encoding a full length protein, will be used to construct a  
15 recombinant expression cassette which can be introduced into the desired plant. An expression cassette will typically comprise the RG polynucleotide operably linked to transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the RG gene in the intended tissues of the transformed plant.

Such DNA constructs may be introduced into the genome of the desired  
20 plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation, PEG poration, particle bombardment and microinjection of plant cell protoplasts or embryogenic callus, or the DNA constructs can be introduced directly to  
25 plant tissue using ballistic methods, such as DNA particle bombardment. Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria.

Transformation techniques are known in the art and well described in the  
30 scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al. Embo J.* 3:2717-2722 (1984).

Electroporation techniques are described in Fromm *et al. Proc. Natl. Acad. Sci. USA* 82:5824 (1985). Ballistic transformation techniques are described in Klein *et al. Nature* 327:70-73 (1987).

*Agrobacterium tumefaciens*-mediated transformation techniques are well  
5 described in the scientific literature. See, for example Horsch *et al. Science* 233:496-498 (1984), and Fraley *et al. Proc. Natl. Acad. Sci. USA* 80:4803 (1983). Although *Agrobacterium* is useful primarily in dicots, certain monocots can be transformed by *Agrobacterium*. For instance, *Agrobacterium* transformation of rice is described by Hiei *et al. Plant J.* 6:271-282 (1994). A particularly preferred means of transforming lettuce is  
10 described in Michelmore *et al., Plant Cell Reports*, 6:439-442 (1987).

Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired RG-controlled phenotype. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth  
15 medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the RG nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans *et al., Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176, Macmillan Publishing Company, New York, 1983; and Binding, *Regeneration of Plants, Plant Protoplasts*, pp. 21-73, CRC Press, Boca Raton, 1985.  
20 Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al. Ann. Rev. of Plant Phys.* 38:467-486 (1987).

The methods of the present invention are particularly useful for incorporating the RG polynucleotides into transformed plants in ways and under  
25 circumstances which are not found naturally. In particular, the RG polypeptides may be expressed at times or in quantities which are not characteristic of natural plants.

One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be  
30 used, depending upon the species to be crossed.

#### Detection of RG Resistance Genes

The present invention further provides methods for detecting RG resistance genes in a nucleic acid sample suspected of comprising an RG resistance gene. The means by which the RG resistance gene is detected is not a critical aspect of the invention. For example, RG resistance genes can be detected by the presence of amplicons using RG resistance gene specific primers. Additionally, RG resistance genes can be detected by assaying for specific hybridization of an RG polynucleotide to an RG resistance gene. In some embodiments, the RG resistance gene can be amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

In a typical detection method, the nucleic acid sample is contacted with an RG polynucleotide to form a hybridization complex. The hybridization complex may be detected directly (e.g., in Southern or northern blots), or indirectly (e.g., by subsequent primer extension during PCR amplification). The RG polynucleotide hybridizes under stringent conditions to an RG polynucleotide of the invention. Formation of the hybridization complex is directly or indirectly used to indicate the presence of the RG resistance gene in the nucleic acid sample.

Detection of the hybridization complex can be achieved using any number of well known methods. For example, the nucleic acid sample, or a portion thereof, may be assayed by hybridization formats including but not limited to, solution phase, solid phase, mixed phase, or *in situ* hybridization assays. Briefly, in solution (or liquid) phase hybridizations, both the target nucleic acid and the probe or primer are free to interact in the reaction mixture. In solid phase hybridization assays, probes or primers are typically linked to a solid support where they are available for hybridization with target nucleic acid in solution. In mixed phase, nucleic acid intermediates in solution hybridize to target nucleic acids in solution as well as to a nucleic acid linked to a solid support. In *in situ* hybridization, the target nucleic acid is liberated from its cellular surroundings in such as to be available for hybridization within the cell while preserving the cellular morphology for subsequent interpretation and analysis. The following articles provide an overview of the various hybridization assay formats: Singer *et al.*, *Biotechniques* 4(3):230-250 (1986); Haase *et al.*, *Methods in Virology*, Vol. VII, pp. 189-226 (1984); Wilkinson, "The theory and practice of *in situ* hybridization" In: *In situ Hybridization*, Ed. D.G. Wilkinson. IRL Press, Oxford University Press, Oxford; and *Nucleic Acid Hybridization: A Practical Approach*, Ed. Hames, B.D. and Higgins, S.J., IRL Press (1987).

The effect of the modification of RG gene expression can be measured by detection of increases or decreases in mRNA levels using, for instance, Northern blots. In addition, the phenotypic effects of gene expression can be detected by measuring nematode, fungal, bacterial, viral, or other pest resistance in plants. Suitable assays for determining pest resistance are well known. Micheltore and Crute, *Trans. Br. mycol. Soc.*, 79(3): 542-546 (1982).

The means by which hybridization complexes are detected is not a critical aspect of the present invention and can be accomplished by any number of methods currently known or later developed. RG polynucleotides can be labeled by any one of several methods typically used to detect the presence of hybridized nucleic acids. One common method of detection is the use of autoradiography using probes labeled with  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ , or the like. The choice of radioactive isotope depends on research preferences due to ease of synthesis, stability, and half lives of the selected isotopes. Other labels include ligands which bind to antibodies labeled with fluorophores, chemiluminescent agents, and enzymes. Alternatively, probes can be conjugated directly with labels such as fluorophores, chemiluminescent agents or enzymes. The choice of label depends on sensitivity required, ease of conjugation with the probe, stability requirements, and available instrumentation. Labeling the RG polynucleotide is readily achieved such as by the use of labeled PCR primers.

The choice of label dictates the manner in which the label is bound to the probe. Radioactive probes are typically made using commercially available nucleotides containing the desired radioactive isotope. The radioactive nucleotides can be incorporated into probes, for example, by using DNA synthesizers, by nick translation with DNA polymerase I, by tailing radioactive DNA bases to the 3' end of probes with terminal deoxynucleotidyl transferase, by treating single-stranded M13 plasmids having specific inserts with the Klenow fragment of DNA polymerase in the presence of radioactive deoxynucleotides, dNTP, by transcribing from RNA templates using reverse transcriptase in the presence of radioactive deoxynucleotides, dNTP, or by transcribing RNA from vectors containing specific RNA viral promoters (e.g., SP6 promoter) using the corresponding RNA polymerase (e.g., SP6 RNA polymerase) in the presence of radioactive ribonucleotides rNTP.

The probes can be labeled using radioactive nucleotides in which the isotope resides as a part of the nucleotide molecule, or in which the radioactive component is attached to the nucleotide via a terminal hydroxyl group that has been esterified to a radioactive component such as inorganic acids, *e.g.*,  $^{32}\text{P}$  phosphate or  $^{14}\text{C}$  organic acids, or esterified to provide a linking group to the label. Base analogs having nucleophilic linking groups, such as primary amino groups, can also be linked to a label.

Non-radioactive probes are often labeled by indirect means. For example, a ligand molecule is covalently bound to the probe. The ligand then binds to an anti-ligand molecule which is either inherently detectable or covalently bound to a detectable signal system, such as an enzyme, a fluorophore, or a chemiluminescent compound. Enzymes of interest as labels will primarily be hydrolases, such as phosphatases, esterases and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescers include luciferin, and 2,3-dihydrophthalazinediones, *e.g.*, luminol.

Ligands and anti-ligands may be varied widely. Where a ligand has a natural anti-ligand, namely ligands such as biotin, thyroxine, and cortisol, it can be used in conjunction with its labeled, naturally occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody.

Probes can also be labeled by direct conjugation with a label. For example, cloned DNA probes have been coupled directly to horseradish peroxidase or alkaline phosphatase, (Renz, M., and Kurz, K. (1984) A Colorimetric Method for DNA Hybridization. *Nucl. Acids Res.* 12: 3435-3444) and synthetic oligonucleotides have been coupled directly with alkaline phosphatase (Jablonski, E., *et al.* (1986) Preparation of Oligodeoxynucleotide-Alkaline Phosphatase Conjugates and Their Use as Hybridization Probes. *Nuc. Acids. Res.* 14: 6115-6128; and Li P., *et al.* (1987) Enzyme-linked Synthetic Oligonucleotide probes: Non-Radioactive Detection of Enterotoxigenic *Escherichia Coli* in Faeca Specimens. *Nucl. Acids Res.* 15:5275-5287).

### Definitions

Units, prefixes, and symbols can be denoted in their SI accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation, respectively. The



headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

5                   As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants.

10                   As used herein, "pest" includes, but is not limited to, viruses, fungi, nematodes, insects, and bacteria.

                  As used herein, "heterologous" is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its original form. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form.

                  As used herein, "RG gene," alternatively referred to as "RLG gene," is a gene encoding resistance to plant pests, such as viruses, fungi, nematodes, insects, and bacteria, and which hybridizes under stringent conditions and/or has at least 60% sequence identity at the deduced amino acid level to the exemplified sequences provided herein. RG genes encode "RG polypeptides," alternatively referred to as "RLG polypeptides," which can comprise LRR motifs and/or NBS motifs. The RG polypeptides encoded by RG genes have at least 55% or 60% sequence identity, typically at least 65% sequence identity, preferably at least 70% sequence identity, often at least 75% sequence identity, more preferably at least 80% sequence identity, and most preferably at least 90% sequence identity at the deduced amino acid level relative to the exemplary RG sequences provided herein. The term "RG family" or "RG family genus" or "genus" includes reference to a group of RG polypeptide sequence species that have at least 60% amino acid sequence identity, and, the nucleic acids encoding these polypeptides. The individual species of a genus, i.e., the members of a family, typically are genetically mapped to the same locus.

                  As used herein, "RG polynucleotide" includes reference to a contiguous sequence from an RG gene of at least 18, 20, 25, 30, 40, or 50 nucleotides in length, up to

at least about 100 or at least about 200 nucleotides in length. In some embodiments, the polynucleotide is preferably at least 100 nucleotides in length, more preferably at least 200 nucleotides in length, most preferably at least 500 nucleotides in length. Thus, RG polynucleotide may be a RG gene or a subsequence thereof.

5           As used herein, "isolated," when referring to a molecule or composition, such as, for example, an RG polypeptide or nucleic acid, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (*e.g.*, RNAs), or other contaminants with which it is associated *in vivo* or in its naturally occurring state. Thus, an RG polypeptide or nucleic acid is considered isolated  
10       when it has been isolated from any other component with which it is naturally associated, *e.g.*, cell membrane, as in a cell extract. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state and can be in a dry or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-  
15       PAGE) or high performance liquid chromatography (HPLC).

          The term "nucleic acid" or "nucleic acid molecule" or "nucleic acid sequence" refers to a deoxyribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogues of natural nucleotides which have similar or  
20       improved binding properties, for the purposes desired, as the reference nucleic acid. The term also includes nucleic acids which are metabolized in a manner similar to naturally occurring nucleotides or at rates that are improved thereover for the purposes desired. The term also encompasses nucleic-acid-like structures with synthetic backbones. DNA backbone analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester,  
25       sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs); see *Oligonucleotides and Analogues, a Practical Approach*, edited by F. Eckstein, IRL Press at Oxford University Press (1991); *Antisense Strategies*, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and  
30       Denhardt (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; *Antisense Research and Applications* (1993, CRC Press). PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine units. Phosphorothioate linkages are described in WO

97/03211; WO 96/39154; Mata (1997) *Toxicol Appl Pharmacol* 144:189-197. Other synthetic backbones encompassed by the term include methyl-phosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup (1997) *Biochemistry* 36:8692-8698), and benzylphosphonate linkages (Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156). The term nucleic acid is used interchangeably with  
5 gene, cDNA, mRNA, oligonucleotide primer, probe and amplification product. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.

The term "exogenous nucleic acid" refers to a nucleic acid that has been  
10 isolated, synthesized, cloned, ligated, excised in conjunction with another nucleic acid, in a manner that is not found in nature, and/or introduced into and/or expressed in a cell or cellular environment other than or at levels or forms different than the cell or cellular environment in which said nucleic acid or protein is found in nature. The term encompasses both nucleic acids originally obtained from a different organism or cell type  
15 than the cell type in which it is expressed, and also nucleic acids that are obtained from the same cell line as the cell line in which it is expressed. invention.

The term "recombinant," when used with reference to a cell, or to the nucleic acid, protein or vector refers to a material, or a material corresponding to the natural or native form of the material, that has been modified by the introduction of a new  
20 moiety or alteration of an existing moiety, or is identical thereto but produced or derived from synthetic materials. For example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise expressed at a different level, typically, under-expressed or not expressed at all. The term "recombinant means" encompasses all means of expressing, *i.e.*, transcription  
25 or translation of, an isolated and/or cloned nucleic acid *in vitro* or *in vivo*. For example, the term "recombinant means" encompasses techniques where a recombinant nucleic acid, such as a cDNA encoding a protein, is inserted into an expression vector, the vector is introduced into a cell and the cell expresses the protein. "Recombinant means" also encompass the ligation of nucleic acids having coding or promoter sequences from  
30 different sources into one vector for expression of a fusion protein, constitutive expression of a protein, or inducible expression of a protein, such as the plant disease resistant, or RG. polypeptides of the invention.

The term "specifically hybridizes" refers to a nucleic acid that hybridizes, duplexes or binds to a particular target DNA or RNA sequence. The target sequences can be present in a preparation of total cellular DNA or RNA. Proper annealing conditions depend, for example, upon a nucleic acid's, such as a probe's length, base composition, and the number of mismatches and their position on the probe, and can be readily determined empirically providing the appropriate reagents are available. For discussions of nucleic acid probe design and annealing conditions, see, *e.g.*, Sambrook and Ausubel.

The terms "stringent hybridization," "stringent conditions," or "specific hybridization conditions" refers to conditions under which an oligonucleotide (when used, for example, as a probe or primer) will hybridize to its target subsequence, such as an RG nucleic acid in an expression vector of the invention but not to a non-RG sequence. Stringent conditions are sequence-dependent. Thus, in one set of stringent conditions an oligonucleotide probe will hybridize to only one specie of the genus of RG nucleic acids of the invention. In another set of stringent conditions (less stringent) an oligonucleotide probe will hybridize to all species of the invention's genus but not to non-RG nucleic acids. Longer sequences hybridize specifically at higher temperatures. Stringent conditions are selected to be about 5°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium (if the target sequences are present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, *i.e.*, about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60°C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Often, high stringency wash conditions preceded by low stringency wash conditions to remove background probe signal. An example of medium stringency wash conditions for a duplex of, *e.g.*, more than 100 nucleotides, is 1x SSC at 45°C for 15 minutes (see Sambrook for a description of SSC buffer). An example low stringency wash for a duplex of, *e.g.*, more than 100 nucleotides, is 4-6x SSC at 40°C for 15 minutes. a signal to noise ratio of 2x (or higher) than that observed for an unrelated

probe in the particular hybridization assay indicates detection of a "specific hybridization." Nucleic acids which do not hybridize to each other under stringent conditions can still be substantially identical if the polypeptides which they encode are substantially identical. This can occur, *e.g.*, when a nucleic acid is created that encodes for conservative  
5 substitutions. Stringent hybridization and stringent hybridization wash conditions are different under different environmental parameters, such as for Southern and Northern hybridizations. An extensive guide to the hybridization of nucleic acids is found in, *e.g.*, Sambrook, Tijssen (1993) *supra*.

As used herein "operably linked" includes reference to a functional linkage  
10 between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

15 In the expression of transgenes one of skill will recognize that the inserted polynucleotide sequence need not be identical and may be "substantially identical" to a sequence of the gene from which it was derived. As explained herein, these variants are specifically covered by this term.

In the case where the inserted polynucleotide sequence is transcribed and  
20 translated to produce a functional RG polypeptide, one of skill will recognize that because of codon degeneracy, a number of polynucleotide sequences will encode the same polypeptide. These variants are specifically covered by the term "RG polynucleotide sequence". In addition, the term specifically includes those full length sequences substantially identical (determined as described herein) with an RG gene sequence which  
25 encode proteins that retain the function of the RG protein. Thus, in the case of RG genes disclosed here, the term includes variant polynucleotide sequences which have substantial identity with the sequences disclosed here and which encode proteins capable of conferring resistance to nematodes, bacteria, viruses, fungi, insects or other pests on a transgenic plant comprising the sequence.

30 Two polynucleotides or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence, as described below. The term

"complementary to" is used herein to mean that the complementary sequence is identical to all or a specified contiguous portion of a reference polynucleotide sequence.

The terms "sequence identity," "sequence similarity" and "homology" refer to when two sequences, such as the nucleic acid and amino acid sequences or the polypeptides of the invention, when optimally aligned, as with, for example, the programs PILEUP, BLAST, GAP, FASTA or BESTFIT (see discussion, *supra*). "Percentage amino acid/nucleic acid sequence identity" refers to a comparison of the sequences of two polypeptides/nucleic acids which, when optimally aligned, have approximately the designated percentage of the same amino acids/nucleic acids, respectively. For example, "60% sequence identity" and "60% homology" refer to a comparison of the sequences of two RG nucleic acids or polypeptides which, when optimally aligned, have 60% identity. For example, in one embodiment, nucleic acids encoding RG polypeptides of the invention comprise a sequence with at least 50% nucleic acid sequence identity to SEQ ID NO:1. In other embodiments, the RG polypeptides of the invention are encoded by nucleic acids comprising a sequence with at least 50% sequence identity to SEQ ID NO:1, or, are encoded by nucleic acids comprising SEQ ID NO:1, or, have at least 60% amino acid sequence identity to the polypeptide of SEQ ID NO:2.

"Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 55% or 60% sequence identity, generally at least 65%, preferably at least 70%, often at least 75%, more preferably at least 80% and most preferably at least 90%, compared to a reference sequence using the programs described above (preferably BESTFIT) using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding

identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 55% or 60%, preferably at least 70%, more preferably at least 80%, and most preferably at least 95%. Polypeptides having "sequence similarity" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under appropriate conditions. Appropriate conditions can be high or low stringency and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C to about 20°C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent wash conditions are those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 50°C. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

Nucleic acids of the invention can be identified from a cDNA or genomic library prepared according to standard procedures and the nucleic acids disclosed here used as a probe. Thus, for example, stringent hybridization conditions will typically include at least one low stringency wash using 0.3 molar salt (*e.g.*, 2X SSC) at 65°C. The washes

are preferably followed by one or more subsequent washes using 0.03 molar salt (e.g., 0.2X SSC) at 50°C, usually 60°C, or more usually 65°C. Nucleic acid probes used to identify the nucleic acids are preferably at least 100 nucleotides in length.

As used herein, "nucleotide binding site" or "nucleotide binding domain" ("NBS") includes reference to highly conserved nucleotide-, *i.e.*, ATP/GTP-, binding domains, typically included in the "kinase domain" of kinase polypeptides, such as a kinase-1a, kinase 2, or a kinase 3a motif, as described herein. For example, the tobacco N and Arabidopsis RPS2 genes, among several recently cloned disease-resistance genes, share highly conserved NBS sequence. Kinase NBS subdomains further consist of three subdomain motifs: the P-loop, kinase-2, and kinase-3a subdomains (Yu (1996) *Proc. Acad. Sci. USA* 93:11751-11756). As discussed in detail herein, examples include the *Arabidopsis* RPP5 gene (Parker (1997) *supra*), the *A. thaliana* RPS2 gene (Mindrinos (1997) *supra*), and the flax L6 rust resistance gene (Lawrence (1995) *supra*) which all encode proteins containing an NBS; and Mindrinos (1994) *Cell* 78:1089-1099; and Shen (1993) *FEBS* 335:380-385. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can identify members having NBS domains, including any of the genus of NBS-containing plant disease resistant polypeptides of the invention.

As used herein, "leucine rich region" ("LRR") includes reference to a region that has a leucine content of at least 20% leucine or isoleucine, or 30% of the aliphatic residues: leucine, isoleucine, methionine, valine, and phenylalanine, and arranged with approximate repeated periodicity. The length of the repeat may vary in length but is generally about 20 to 30 amino acids. An LRR-containing polypeptide typically will have the canonical 24 amino acid leucine-rich repeat (LRR) sequence, which is present in different proteins that mediate molecular recognition and/or interaction processes; as described in Bent (1994) *Science* 265:1856-1860; Parker (1997) *Plant Cell*. 9:879-894; Hong (1997) *Plant Physiol.* 113:1203-1212; Schmitz (1997) *Nucleic Acids Res.* 25:756-763; Hipskind (1996) *Mol. Plant Microbe Interact.* 9:819-825; Tornero (1996) *Plant J.* 10:315-330; Dixon (1996) *Cell* 84:451-459; Jones (1994) *Science* 266:789-793; Lawrence (1995) *Plant Cell* 7:1195-1206; Song (1995) *Science* 270:1804-1806; as discussed in further detail *supra*. Using the teachings disclosed and incorporated herein and standard nucleic acid hybridization and/or amplification techniques, one of skill can



identify polypeptides having LRR domains, including any member of the genus of LRR-containing RG polypeptides of the invention.

The term "promoter" refers to a region or sequence determinants located upstream or downstream from the start of transcription and which are involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating and/or regulating transcription in plant cells; see also discussion on plant promoters, *supra*.

The term "constitutive promoter" refers to a promoter that initiates and helps control transcription in all tissues. Promoters that drive expression continuously under physiological conditions are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation; see also detailed discussion, *supra*.

The term "inducible promoter" refers to a promoter which directs transcription under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as "inducible" promoters; see also detailed discussion, *supra*.

The term "abscission-induced promoter" or "abscission promoter" refers to a class of promoters which are activated upon plant ripening, such as fruit ripening, and are especially useful incorporated in the expression systems (*e.g.*, expression cassettes, vectors) of the invention. When the plant disease resistant polypeptide-encoding nucleic acid is under the control of an abscission promoter, rapid cell death, induced by expression of the invention's polypeptide, accelerates and/or accentuates abscission of the plant part, increasing the efficiency of the harvesting of fruits or other plant parts, such as cotton, and the like; see also detailed discussion, *supra*.

The term "tissue-specific promoter" refers to a class of transcriptional control elements that are only active in particular cells or tissues. Examples of plant promoters under developmental control include promoters that initiate transcription only (or primarily only) in certain tissues, such as roots, leaves, fruit, ovules, seeds, pollen, pistols, or flowers; see also detailed discussion, *supra*.

As used herein "recombinant" includes reference to a cell, or nucleic acid, or vector, that has been modified by the introduction of a heterologous nucleic acid or the alteration of a native nucleic acid to a form not native to that cell, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

As used herein, a "recombinant expression cassette" or "expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a target cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes a nucleic acid to be transcribed, and a promoter.

As used herein, "transgenic plant" includes reference to a plant modified by introduction of a heterologous polynucleotide. Generally, the heterologous polynucleotide is an RG structural or regulatory gene or subsequences thereof.

As used herein, "hybridization complex" includes reference to a duplex nucleic acid sequence formed by selective hybridization of two single-stranded nucleic acids with each other.

As used herein, "amplified" includes reference to an increase in the molarity of a specified sequence. Amplification methods include the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (SSR). A wide variety of cloning methods, host cells, and *in vitro* amplification methodologies are well-known to persons of skill.

As used herein, "nucleic acid sample" includes reference to a specimen suspected of comprising RG resistance genes. Such specimens are generally derived, directly or indirectly, from lettuce tissue.

The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments or synthetic or recombinant analogues thereof which specifically bind and recognize analytes and antigens, such as a genus or subgenus of polypeptides of the invention, as described *supra*.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

5

### EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

#### Example 1

10 Example 1 describes the use of PCR to amplify RG genes from lettuce.

Multiple primers with low degeneracy, particularly at the 3' end, were designed based on the sequences of two known resistance genes from tobacco and flax.

#### **DNA Templates**

15 Lettuce genomic DNA was extracted from cultivar Diana and a mutant line derived from cultivar Diana using a standard CTAB protocol. To generate cDNA templates, RNA was isolated from cultivar Diana and the mutant following standard procedures; first strand cDNA was synthesized using Superscript reverse transcriptase from 1  $\Phi$ g total RNA as specified by the manufacturer (Life Technologies). BAC (bacterial artificial chromosome) clones from the *Dm3* region were isolated from a BAC library of  
20 over 53,000 clones using marker AC15 that was known to be closely linked to *Dm3*. Bacterial plasmids containing clones of *L6* and *RPS2* were used as positive controls.

#### **PCR with degenerate oligonucleotide primers**

25 Oligonucleotide primers were designed based on conserved motifs in the nucleotide binding sites (NBS) of *L6*, *RPS2*, and *N*. Eight primers were made corresponding to the GVGKTT motif in the sense direction; each had 64-fold degeneracy. Six primers were made to the GLPLAL motif in the anti-sense direction; with either 16 or 256-fold degeneracy (Table 1).

30 Oligonucleotides included 14-mer adaptors of (CUA)<sub>4</sub> at the 5' end of the sense primers and (CAU)<sub>4</sub> at the 5' end of the antisense primers to allow rapid cloning of the PCR products into pAMP1 (Life Technologies).

PCR amplification was performed in 50  $\Phi$ l reaction volume with 1  $\Phi$ M of each of a pair of sense and antisense primers. The templates were denatured by heating to 94EC for 2 min. This was followed by 35 cycles of 30 sec at 94EC, 1 min at 50EC, 2 min at 72EC, with a single final extension of 5 min at 72EC. 25 ng of genomic DNA or cDNA was used. BAC clones as templates required less. The final dNTP concentration was 0.2 mM;  $MgCl_2$  was 1.5 mM.

Forty-eight combinations of sense and antisense primers were tested on a panel of nine templates consisting of two genomic DNA samples, two cDNA preparations, three BAC clones and plasmids containing *L6* and *RPS2* as positive controls. Amplification from *L6* and *RPS2* resulted in fragments of 516 and 513 repectively. Seven combinations of primers resulted in fragments of approximately this size with multiple templates (Table 2). Primers that gave RLG products were: PLOOPAA, PLOOPAG, PLOOPGA, PLOOPGG, PLOOPAC, GLPL3, GLPL4.

15

20 (Intentionally left blank)

25

Table 1

## DEGENERATE PRIMER SEQUENCES for NBS PCR

Sense primers based on GVGKTT amino acid sequence from L6, N and rps2 PLOOP motif:

PLOOPAG 5' GGN GTN GGN AAA ACG AC 3'

PLOOPAA 5' GGN GTN GGN AAA ACA AC 3'

PLOOPAT 5' GGN GTN GGN AAA ACT AC 3'

PLOOPAC 5' GGN GTN GGN AAA ACC AC 3'

PLOOPGG 5' GGN GTN GGN AAG ACG AC 3'

PLOOPGA 5' GGN GTN GGN AAG ACA AC 3'

PLOOPGT 5' GGN GTN GGN AAG ACT AC 3'

PLOOPGC 5' GGN GTN GGN AAG ACC AC 3'

Antisense primers based on GLPLAL amino acid sequence:

GLPL1 5' AGN GCN AGN GGN AGG CC 3'

GLPL2 5' AGN GCN AGN GGN AGA CC 3'

GLPL3 5' AGN GCN AGN GGN AGT CC 3'

GLPL4 5' AGN GCN AGN GGN AGC CC 3'

GLPL5 5' AAN GCC AAN GGC AAA CC 3'

GLPL6 5' AAN GCC AAN GGC AAT CC 3'

TABLE 2. Characteristics of RLGs isolated from lettuce.

|    | Template | Primers     | Number <sup>a</sup> | Size <sup>b</sup><br>(bp) | Copy<br>number <sup>c</sup> | Dm<br>linkage |
|----|----------|-------------|---------------------|---------------------------|-----------------------------|---------------|
| 5  | RLG1     | genomic DNA | PLOOPGA+GLPL6       | 6/6                       | 522                         | DM4,          |
|    |          | cDNA        | PLOOPGA+GLPL6       | 1/5                       |                             | DM13          |
|    |          | genomic DNA | PLOOPAA+GLPL6       | 5/5                       |                             |               |
|    |          | cDNA        | PLOOPAA+GLPL6       | 1/1                       |                             |               |
|    | RLG2     | BACH8       | PLOOPGG+GLPL3       | 3/3                       | 510                         | DM1,<br>Dm3   |
|    | RLG3     | gemonic DNA | PLOOPGA+GLPL4       | 3/6                       | 461                         | Dm5<br>Dm8    |
| 10 | RLG4     | genomic DNA | PLOOPGA+GLPL4       | 1/6                       | 524                         |               |

<sup>a</sup> Number of RLG sequences out of total number of clones sequenced.

<sup>b</sup> Size of fragment amplified from the nucleotide binding domain.

<sup>c</sup> Estimated copy number from genomic Southern blot analysis and numbers of clones in the BAC library.

### Example 2

Example 2 describes the genetic analysis used to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes.

Bulked segregant analysis was performed to obtain a preliminary indication of the linkage relationships of the amplified products and known clusters of resistance genes. DNA from individuals were pooled for each susceptible and resistant bulk. Amplified products were then mapped by RFLP analysis from our intraspecific mapping population. Resistances from four clusters of resistance genes as well as over six hundred markers have now been mapped on this population. Linkage analysis was done using JIONMAP or MAPMAKER mapping programs. Due to a suppression of recombination in the *Dm3* region, sequences were mapped relative to *Dm3* using a panel of deletion mutants that provided greater genetic resolution than the mapping population (Anderson *et al.* 1996). All blots were washed twice at 63EC in 2x SSC/1% SDS for 20 min, followed by one wash at 63EC in 1x SSC/0.1% SDS for 10 or 30 min.

Most of the RLG sequences were analyzed by bulked segregant analysis (BSA) using pools of resistant and susceptible individuals for each of the four clusters of resistance genes. In genomic Southern analyses, all the RLGs revealed numerous fragments of varying intensity. The numbers of bands was highly dependent of the stringency of hybridization. BSA demonstrated that RLG1 was linked to the *Dm4,7* and *Dm13* clusters. Segregation analysis confirmed this linkage.

RLG2 was derived from BAC H8 that was known to be from the *Dm3* region. BSA with RLG2 demonstrated that the polymorphic bands that distinguished the parents of our mapping population mapped to the *Dm1,Dm3* cluster. Several bands absolutely cosegregated with *Dm1* or *Dm3*. To provide finer genetic resolution, RLG2 was also mapped using a panel of *Dm3* deletion mutants. A number of fragments were missing in largest deletion mutant demonstrating that several RLG2 family members are physically located very close to *Dm3*. No fragment was missing in all deletion mutants; however, this is not unexpected as there is extensive duplication within the region.

### Example 3

Example 3 describes the screening of a bacterial artificial chromosome library.

Over 53,000 BAC clones containing lettuce genomic DNA were screened with two of the amplified products. High density filters each containing 1536 clones were hybridized to <sup>32</sup>P labelled probes. Filters were washed at 65EC with 40 mM Na<sub>2</sub>PO<sub>4</sub>/0.1 % SDS for 5 min followed by 20 min in the same solution.

To isolate additional RLG sequences we screened our genomic BAC library. Clones were identified that hybridized to RLG1 and RLG2. Nearly all the clones that hybridized to RLG2 also hybridized to marker AC15 that had already been shown by deletion mutant analysis to be clustered around *Dm3*. This provided further evidence for clustering of RLG2 sequences.

Using primers conserved within each family, part of the NBS was amplified from each unique BAC clone and sequenced. This revealed that members within each family varied from 64% identical at the deduced amino acid level. The most divergent members only weakly cross-hybridized to each other. Currently, RLG sequences are

considered to be part of the same family of sequences if they are at least 55% identical at the deduced amino acid level and map to the same region of the chromosome.

**Example 4:**

5                   Example 4 describes the cloning, identification, sequencing and characterization of RG polynucleotide sequences; including use of RG sequences from plasmid and PCR products.

                  Doubled stranded plasmid DNA clones and PCR products were sequenced using an ABI377 automated sequencer and fluorescently labelled di-deoxy terminators.  
10               Sequences were assembled using Sequencher (Genecodes), DNASTar (DNASTar) and Genetics Computer Group (GCG, Madison, WI) software. Database searches were performed using BLASTX and FASTA (GCG) algorithms.

                  Sequences flanking the NBS region for RLG2 and for some of RLG1 were obtained by a series of IPCR and the products sequenced directly. IPCR worked less well  
15               for RLG1. Therefore RLG1 was subcloned from a BAC clone into pBSK (Stratagene) and the double stranded plasmid sequenced by long range sequencing.

                  Initially, a total of 30 clones were sequenced. Three of these seven primer combinations yielded sequences that comprised continuous open reading frames with sequence identity to the NBS of known resistance genes. Seven out of 10 clones amplified  
20               from genomic DNA with the primer pair PLOOPGA/GLP6 were 522 bp long; they were identical to each other and named RLG1. All six clones amplified from genomic DNA or cDNA using the primers PLOOPAA/GLP6 were similar/the same as RLG1. All three clones sequenced from BAC clone H8 were 510 bp long, identical to each other but different from RLG1 and were therefore designated RLG2. The 11 clones sequenced from  
25               four other primer combinations had no similarity to any NBS motifs and therefore were not studied further. Therefore, sequencing resulted in the identification of clones containing NBS motifs representing four RLG sequences.

                  Comparison of the deduced amino acid sequences of RLG1 and RLG2 to those of known resistance genes revealed that RLG1 and RLG2 are as similar to each other  
30               as they are to resistance genes from other species and that this is the same level of identity shown between the known resistance genes (Table 3). The percent identity (upper quadrant) and percent identity (lower quadrant) were determined using the MEGALIGN



routine of the DNASTAR package. Identity refers to the proportion of identical amino acids; identity refers to the proportion of identical and similar amino acids and takes into account substitutions of amino acids with similar chemical characteristics. RG1 and RG2 are as similar to each other and to cloned resistance genes as cloned resistance genes from a variety of species are to each other. L6, resistance to *Melampsora lini* in flax (Lawrence *et al.*, 1995). N, resistance to tobacco mosaic virus in tobacco (Whitham *et al.*, 1994). PRF, required for resistance to *Pseudomonas syringae* in tomato. RPS2, resistance to *Pseudomonas syringae* in *Arabidopsis thaliana* (Bent *et al.*, 1994; Mindrinos *et al.*, 1994). RPM1, resistance to *Pseudomonas syringae* pv. *maculicola* in *A. thaliana* (Grant *et al.*, 1995). The initial RG1 and RG2, sequences were amplified from lettuce using degenerate primers.

Table 3

## IDENTITIES OF

## RESISTANCE GENE HOMOLOGUES

|                    |        | RG1 | RG2  | RG3  | RG4  | N gene | RPS2 |
|--------------------|--------|-----|------|------|------|--------|------|
| Lettuce            | RG1    | *** | 22.7 | 15.0 | 29.2 | 25.4   | 23.8 |
| Lettuce            | RG2    |     | ***  | 32.2 | 21.6 | 22.7   | 33.0 |
| Lettuce            | RG3    |     |      | ***  | 17.2 | 15.0   | 32.8 |
| Lettuce            | RG4    |     |      |      | ***  | 44.3   | 22.7 |
| Tobacco            | N gene |     |      |      |      | ***    | 21.6 |
| <i>Arabidopsis</i> | RPS2   |     |      |      |      |        | ***  |

The regions homologous to the primers are included in this analysis as the genomic sequences for RLG1 and RLG2 were determined by IPCR. Interestingly, the genomic sequences for RLG1 exactly matched that of the primers used.

To obtain further evidence that we had amplified resistance genes, we amplified the regions flanking the NBSs of RLG1a and RLG2a by IPCR of BAC clones. These products were then directly sequenced without cloning to minimize the introduction of PCR artifacts. Sequence analysis of the 5' regions failed to detect any homology to known resistance genes. However, the sequence of the 3' region contained leucine-rich

repeats (LRRs). When this sequence was used to search GENBANK using BLASTX, it detected identity to the *Arabidopsis* resistance gene, *RPS2*. This region does not contain as regular LRRs as in some resistance genes; however, the repeat structure seems to be consistent with that of the flax resistance gene, *L6*. Therefore, the presence of an LRR region is further evidence that the sequences we amplified using degenerate oligonucleotide primers are probably resistance genes.

The sequences of the IPCR products also provided the genomic sequences of the regions complementary to the sequences of the degenerate oligonucleotide primers.

The genomic sequences for RLG1 were identical to one of the primers in the mixture.

The RLG sequences are resistance genes as supported by three criteria: the presence of multiple sequence motifs characteristic of resistance genes, genetic cosegregation with known resistance genes, and their existence as clustered multi-gene families. The presence of LRR regions in a similar position relative to the NBS as in cloned resistance genes provides stronger evidence than relying solely sequence similarity between NBS regions.

The clustering of RLG sequences at the same position as the known clusters of resistance genes make them strong candidates for encoding resistance genes. The hybridization patterns and genetic distribution of the RLG sequences are similar to that of cloned resistance genes in other species. Most of these hybridize to small multigene families and preliminary genetic evidence indicates that they are clustered in the genome. Therefore, the degenerate primers that we designed from other resistance genes seemed to have been specific enough to amplify resistance genes rather than P-loop containing proteins in general.

(intentionally left blank)

SEQ ID NO: 1

FLG1A  
(Strand)

```
1   ATCGTAAACGTTGGTACGAG  ANCGCTGTCCTCCTTCATC  TTTTGTATATGTCATATTC  TCATNATNTGCCACATNT
81  AATTTTGTGGTTATTTTAAA  TTAATTTTATTTCCACATGT  CATTTTATGAGTTTTCAT  TTTATTTGAGTTTCACATAAT
161  ATTTAAATGTAATAACAATA  AATGCATATTTATTTTCTT  TAAATAAACGCATATAATAT  ATAGATTAAAAATCATATAAT
241  ACATAGGTTAAACTCATATA  ATACATATGTTTCATCCCCAG  TTTATTTATATGTCCTCATCC  TTAATTTTATTTATTTAT
321  TTATTAGAGTAGATGATCTT  TGTGATATTAATAATTAAT  TTGTTCAAATTTAAATTA  TTAATAATCCCAATTTGA
401  ATAAAATTAAAAAAATGGN  CCCACCATTAGTCCATCACT  TTTTCAGCTCATCAATATCG  TGAGTATCTCCTTCGTTTC
481  CACCCTAATCAATATTTCCA  GCGAATGACAGACTCCTACG  GCGTTTCTGAAATTTGCGTTC  CGACACTGTTTCATTGAAGGA
561  GATAATAAATCAAAATGGAGC  TGCTCCAAATGTTTCATTGCTG  ATGAAAGGTGAATTTGTATGT  GAAGANAATGTCAGCGATCN
641  ATCTCCATCCGGAACCCACC  ACATTATCAGTGTACCACCA  AACCACCTCAAACCGVGGAA  GTAGRRKACWRKAAAGTCA
721  TGAAGAATAGATTATTTTGG  TCCTCATGGGCTGACTGAGG  AGCGGGTTTATGTTTCATCAT  TTTCTTTGANCANAAAGAAATTA
801  TCGGTCCATCGAATTTTAC  ATCGACAAAGAAGTTTCACT  TCGCAATGTTTGTGTTAAACA  ATTTTAACTCTTTTATCTT
881  TTCGTTGAACTCCTCAATT  GCACTTGCAACTTGCACACT  TTTGGGCCCAAAATTTGTG  GTGGCGTTAATTTAATCCA
961  CATATTCACTGTAACAATA  ATTCAAATCGATCTCTGTTC  ATCCAATTCATCAACATCTC  TTGATAATTGAAATCATTCA
1041  CGCTTCATCCATTTCTTCCA  CATCTATACTATATTCCTG  CTCCTATCATATTAACAGAT  GGCTGAAATCGTTCTTCTG
1121  CCTCTTTGACAGTGGTGTTC  GAAAAGCTGGCATTTGAAGC  CTTGAAGAAGATTGTTCCCT  CCAAAAGAATTGAATCTGAG
1201  CTTAAGAAATTTGAAGGAGAC  ATTAGACCAAATCCAAGATC  TGCTTAACGATGCTTCCAG  AAGGAAGTAACTAATGAAGC
1281  CGTTAAAGATGGCTGAATG  ATCTCCAACATTTGGCTTAT  GACATAGACGACCTACTTGA  TGATTTGCAACTGAAGCTG
1361  TGCACGCTGAGTTGACCGAG  GAGGGTGGAGCCTCCTCCAG  TATGGTAAGAAAATAATCC  CAAGTTGTTCCACAAGTTTC
1441  TCACAAAGTAATAGGATGCA  TGCCAAAGTTAGATGATATG  CCACCAGGTTACRAGAACTG  GTAGAGGCAAAAATAATCT
1521  TGGTTTAAAGTGTGATAACAT  ATGAAAAGCCAAAATTTGAA  AGGTATGAGGCGTCTTTGGT  AGATGAAAGCGGTACTGTG
1601  GACGTGAAGATGATAAGAAA  AAATTGCTGGAGAAGCTGTT  GGGGATAAAGATGAATCAG  GGAGTCAAACCTTCAGCATC
1681  GTGCCCATAGTTGGTATGGG  TGGAGTTGGTAAAACAATC  TAGCTAGACTTTTGTATGAT  GAAAAGAAGTGAAGGATCA
1761  CTTGGAACCTCAGGCTTGGG  TTTGTGTTTCTGATGAGTTC  AGTGTCCCAATATAAGCAG  AGTTATTTATCAATCTGTA
1841  CTGGGGAAAAGAAGGATTT  GAAGACTTAAATCTGCTTCA  AGAAGCTCTTAAAGAGAAAC  TTAGGAACCAAGCTATTTCTA
1921  ATAGTTTTGGATGATGTGTG  GTCTGAAAGCTATGTTGAT  GGGAGAAAATTAGTGGGCCCA  TTCTTCCGGGGTCTCCCTG
2001  AAGTAGAATAATCATGACAA  CTCGGAAGGACAAATTTGCT  AGAAAGCTGGGCTTTTCTCA  TCAAGACCTCTGGAGGGTC
2081  TTAGACTAAGCTATGAATGAT  TCCTTGTGTTGCTCAACACG  ATTTGGTGTACCAAACTTTG  ATTCAATCCCACTAAGG
2161  CCACATGGAGAACTGTTTGT  GAAGAAATGTGATGGCTTAC  CTCTAGCTTAAAGAACACTT  GGAAGGTTATTAAGGACAAA
2241  AACAGACGAGGACAAATGGA  AGGAGCTGTTGGATAGTAG  ATATGAGGTTAGGAAAGAG  CGATGAGATTGTTCCGGCTC
2321  TTAGACTAAGCTATGAATGAT  CTTTCTGCCCTTTTGAAGCT  RTTCTTTCATATGCTCCT  TGTTTCCCAAGGACTATGAG
2401  TTTGACAAGGAGGATTTGAT  TCTATTGTGGATGGCAGAAG  GGTTTTTGCRCAACCAACT  AYAAACAAGTCAAAGCAAG
2481  KTTGGGCTCTGAAATTTTTR  AAGAGTTTGTGCAAGRTCR  TTTTTCACATGCTCTCTAA  TRRCAATCTSTGTTTGTGA
2561  TGCAATGACCTAATGAATGAT  TTGGCTACATTTGTTGCTGG  AGAATTTTTTCAAGGTTAG  ACATAGAGATGAAGAAGGAA
2641  TTTAGGATGSAATCTTTGGA  RAAGCACCGCATATGTCAT  TTGTATGTGAGRATTACATA  GGTACAAAARGTTCCGAGCC
2721  ATTTAGAGGAGCTAAAAATT  TGAGAACATTTTATGACTTG  TCTGTTGGGGTGGTAGAAGA  TTGGAAGATGTTTACTTAT
2801  CAAACAAGGCTTTGAATGAC  WTACTTCARGATTTACCAAT  GTTAAGGGTCTTRAKTTTGA  TTRRTCTTAYATAASYRAG
2881  GTACCAAAATCTGSGTAG  TATGAASCATTTGCGGTATC  TTAATCTATCWRGAACCTTWA  ATCACHCATTTACCGGAWA
2961  TKTCGTCAATCTTTATAATT  TACARACCTGATTTATCT  GGCCTGAMTATTTAGTTAA  KTTGCCCAARACCTCTCAA
3041  ASCTTAAAAATTTGCASCAT  TTTGACATGAGGRTACTCC  KAAKTTRAARAACATGCCCT  TARGGATTGGTGARTTGA
3121  ARTCTCAAACTCTCTTTCG  TAACATTTGCCATAGCAATAA  CCGAGCTTAAGAACTTGCAM  AAYCTCCATGGGAAARTTTG
3201  TATTGGCGGGCTGGGAAAAA  TGGAAAATGCMGTGGGATGC  ACGTTAAGCGAACTTGTCTC  AAAAAAGGTTWAATGARTTA
3281  NAAACTGGRTTGGGGGTGA  TPAATTTAATGTTTCCGAA  ATGGGAACACTTGAAAAAGA  AGTCTCTCAATGAAGTATGC
3361  CTCATAATGGTACTCTANAA  AAAACCCANAAATATGTTCT  TAGGGGTTATAGAGTTTCCA  AATTGGGTTGGTTNCACTAA
3441  GGGTTTCTGAACTAGAGAT  GTGTTCAATGGTATGAAAA  AGANTGTTTACGTAGTTTC  ATCAATCACCAGTGGGAAA
3521  TAGATGATATTTTACGGGCT  TACTGATGAGATGTTGGAGAG  GTATGATAGGTTTCTTGGG  GCGGTAGAAGAAATAAGCAT
3601  CCAATCTTGTAAATGAATAA  GATATTTGTTGGGAATCAGAA  GCAGAGGCAAGTAAGGTTCT  TATGAATTTAAAGAAGTTG
3681  ATTTAGGTGAATGTGAAAT  TTGGTGAGTTTACGGGAGAA  AAAGGAGGATAATCATAATA  TTAATAGTGGGAGCAGCCTA
3761  ACATCTTTTAGGAGGTTGAA  TGTATGGAGATGTAACAGCT  TGGAGCATTTGACAGGTGCCA  GATAGCATGGAGAAATTTGTA
3841  TATGCAATGTGTGATTCAA  TNACATCCGCTCTCTCCCA  ACAGGAGGAGGACAGAAGAT  CAAGTCACTTACCATCACTG
3921  ATTGCAAGAAGCTTTCCGAA  GAGGAGTTGGGAGGACGAGA  GAGGACAAGAGTCTTATAA  ACTCAAAAATGCAGATGCTT
4001  GAATCTAGATATACGTAA  TTGGCCAAATCTGAAATCTA  TCAGTGAATTTAGTTGCTTC  ATTCACCTGAACAGATTATA
4081  TATATCAAAGTGTCCGAGTR  TGGAGTCAATTTCTGACCAT  GAGTTGCCAAATCTCACCTC  CTTAACAGATCGAAGGAGAG
4161  GACAGCGATTTTCTGACGAA  CGGTACGATTCGACTGGCC  GTCGTTTT
```

# SEQ ID NO: 2

RLG1B

[Strand]

```

1   AACCGTTCGT ACCGAGAATCG CTGTCCCTCTC CTTCTCTGTAA TATAATGATA AGAAAAAATA TGATTAAAGG
71  TTTAAATCCA AAATCCATTA TTCCACCGGT GATATGATGC ACTAGCTGTA GTATGCAAAA ACAGTATTAT
141 AAATGCTAAC CAAAACAGCA GCTAAGAAAC AATATAAATA ATGGTTTGAA TCGTCCCTTC TCCGTACAQT
211 CATTTCTTCC AAATCCCTAT CATTCATACA TACAAGTGCT CCCATATTAG GTTTTCACTA TAAGCAATGG
281 CTGAAATCCT TGGTTCCTCG TTCTTTGCGG TGTTCCTTGA AAAGCTTGCT TCTGAAGCCT TGAAGAGGGT
351 TGCTTGCTCC AAAGTAATTG ACAAGGAGCT CGAGAAATTG AATAGCTCAT GAATCAATAT AAAAGCTCTG
421 CTCAATGATG CTTCTCAGAA GGAATAAGT AAGGAAGCTG TTAAGAATG GTTGAATGCT CTTCAACATT
491 TGCTTTACGA CATAGATGAT CTACTTGGCG ATTTGGCAAC CAAAGCTATC CATCGTAAGT TCTCTGAGGA
561 ATACGGGGCC ACCATCAACA AGGTACGAAA GTTAATTCCA TCTTGTTCCT CTAGTTTGTC AAGTACTAAG
631 ATGCGCAACA AGATACATAA TATTACCAGC AAGTTACAAG AACTATTAGA AGAGAGAAAT AATCTTGGAT
701 TATGTGAAT TGGTGAAGC CGAAAACTTC GAAATAGAAA ATCAGAGACC TCNTGTCTAG ATCCATCTAG
771 TATTGTTGGA CGCACAGATG ATAAGGAAGC GTTGCTTCTC AAGCTATATG AACCATGTGA TAGAAACTTT
841 AGCATCTTGC CNATAGTGG TATGGGTGGG TTAGATAAGA CCACTTTAGG TAGACTTTTG TATGATNAAA
911 TGCAAGTGAA GGATCACTTC GAACTCAGG CGTGGGTTTG TGTTCCTGAT GAGTTTGATA TCTTCGGTAT
981 AAGCAAAACC ATTTTCGAAT CGATAGAGGG GGGAAACCAA GAGTTTAAGG ATTTAAATCT GCTTCAGGTG
1051 GCTTTAAAGG AGAAAACTCT AAAGAAACGA TTCTTTGTTG TTCTTGATGA TGTATGGAGC GAGAGCTATA
1121 CTGATTGGGA AATTCTAGAA CGTCCATTTC TAGCAGGAGC ACCAGGAAGT AAAGTAATCA TCACAACCCG
1191 CAAGTTTGCG TTGCTAAACC AATTGGGTCA TGATCAACCA TACCAATTGT CTGATTTGTC ACATGACAAAT
1261 GCTCTATCCT TATTTTGTC ACACGCATT GTGTGTAATA GCTTTGATTC ACATCCGATA CTTAAACCCAC
1331 ATGGTGAAGG TATTGTTGAA AAATGTGATG GTTTGCCATT GGCTTTGATT GCACTTGGGA GGTATTGAG
1401 GACAAAAGA GATGAGGAAG AATGGAAGGA ACTATTGAAT AGTGAGATAT GGAGGTTAGG AAAGAGAGAT
1471 GAGATTAATC CGGTCCTTAG ACTAAGCTAT AATGATCTTT CTGCCCTCTT GAAGCAGTTG TTTGCATATT
1541 GCTCCTTGTT CCCCAAAGAC TATGTGTTCA ACAAGGAGAA GTTGATTTTA TTATGGATGG CAGAAGGGTT
1611 TTTGCACAAT GAAAATACAA ACAAGTCAAT GGAACGCTTA GNTCTTGAAT ATTTTGACGA CTGTGTGTCA
1681 AGGTCTTTT TTCAACATGC ACTCGATGAC AAATCGTTGT TTGTGGTGCA CGACCTCATG AATGACTTGG
1751 CCACATCTGT TGCTGGAGAT TATTTTTTAA GATTAGACAT TGAAATGAAA AAGGAAGCTT TGGAAAAATA
1821 CCGACATATG TCATTTGTTT GTGAGAGTTA CATGGTTTAC AAAAGGTTCC AACCATTTAA AGGAGCTAAA
1891 AAATTGAGAA CTTTCTTAGC AATGCCTGTT GGGATGATAA AAAGTTGGAC AACATTTTAC TTATCAAAATA
1961 AGGTCTTTGA TGACTTACTT CACGAATTAC CATTGTTGAG AGTTCCTAAGT TTGAGTTATC TTAGCATCAA
2031 GGAGGTAACCT GAAATAATAG GCAATTTGAA ACACTTGGCG TATCTTAATT TATCACACAC GAGTATCACA
2101 CATTTACAG AAAATGTCTG CAATCTTTAC AACTTACAAA CATTGATCCT TTGTGGCTGT TGTTTTATAA
2171 CCAAGTTTCC CAACAACCTC TTAAAGCTTA GAAATTTACG GCATTTGGAC ATTAGCGATA CTCCCGGTTT
2241 GAAGAAAGATG TCCTCGGGGA TTGGTGAATT GAAGAACCTA CACACYCTCT CCAAGCTCAT TATTTGGAGT
2311 GAAAAATAGAC TAAACGAGCT TAAGAACTTA CAAAATCTCC ATG

```

RLG1b - Diana  
[Strand]

```
1  TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71  GGATCACTTC GAACTTAAGG CGTGGGTATG TGTTTCTGAT GAGTTTGATA TCITCAATAT AAGCAAAATT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAABAG
211 AGAAGATCTC AAAGAAAAGA TTTCTTCTTG TTCTTGATGA TGTITGGAGT GAAAGCTATA CCGATTGGGA
281 AATTNTAGAA CGCCCATTTT TTGCAGGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTTAAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTGTG ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTTAAACCAC ATGGCGGAGG
491 TATTGTTGAA AAATGTGATG GATTGCCATT GGCATTGTCT ACATGATGAT GATG
```

SEQ ID 137

# SEQ ID NO: 3

RLGIC  
[Strand]

```
1   TCCCGTGCAG CGTATATCAT TCAGAAGGCG CCAAAGACCA NAGATNTGTT TAANGNTGNT TINTCAGAAGG
71  AAGTAATTGA TGAAGCTGTN AAAAGATGGC TGATTGATNT CCAACAATTG GCTTACGACA CTGANGACNA
141 ACTTGATGAT NTCCGCAACAG AAGCTATTCA TCGTGAGTTG ATCCGTGAAA CTGGAGCTTC CNCCAGCAATG
211 GTAAGAAAGC TAATCCCAAG TTGTTGCACA AGTTTCTCAC AAAGTAATAG GATGCATGCC AGGTTAGATG
281 ATATTGCCGC TAAGTACAA GAACTGGTAG AGGCGAAAAA TAATCTTGGT TTAAGTGTGA TAACATACGA
351 AAAACCCAAA ATTGAAAGAG ATGAGGCGTN TTGGTAGAT GCAAGTGGTA TCATGGGACG TGAAGATGAT
421 AAGAAAAAAT TGCTTCAGAA GCTGTTGGGG GATACTTATG AATCAAGTAG TCAAAACTTC AACATCGTGC
491 CCATAGTTGG TATGGGTGGG GTAGGTAAAA CAACTCTAGC TAGACTTTTG TATGATGAAA AAAAAGTGAA
561 GGATCACITC GAACTCAGGG TTGGGTTTG TGTTCIGAT GAGTTCAGTG TTCCAATAT AAGCAGAGTT
631 ATCTATCAAT CTGTGACTCG TGAAAACAAA GAATTTCAG ATTAAATCT GCTTCAAGAA GCCCTTAAAG
701 AGAAACTTCA GAACAACTA TTCTAATAG TTTTAGATGA TGTATGGTCT GAAAGCTATG GTGATTGGGA
771 GAAATTAGTG GGCCCATTTT ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTACTCG GAAGGAGCAA
841 TTACTCAAAC AGCTGGGTTT TTCTCATGAA GACCCCTGCG ATAGTATAGA CTCCCTGCAA CGTCTATCAC
911 AAGAAGATGC TTTGTCTTTG TTTTCTCAAC ACGCATTTGG TGTACCTAAC TTTGATTAC ATCCAACACT
981 AAGGCCATAT GGGGACAGT TTGTGAAAAA ATGTGGGGA TTGCCTTTGG CCTTGT
```

SEQ ID NO:4

RLG1D

[Strand]

```
1  CNTACCCNTC TACGAGATCG CTGTCCCTCC TCGATCTGCT TAACGATGCT TCCCAGAAGG AAGTNACTAA
71  TGAAGCCGTT AAAAGATGGC TGAATGATCT CCAACATTTC GCTTATGACA TANACGACCT ACTTGATGAT
141 CTTGCCACAS AAAGCTATTTC NTCSTGAGTT GACCGANGAA GGTGGAGCCT CCACCAATAT GGTAAGAAAA
211 CTAATCCCAA GTTGTGTCAC AAGTTTCTCA CAAAGTTATA GGATGCATGC CAAGTTAGAT GATATTGCCA
281 CCAGGTTACA AGAACTGGTA GAGGCAAAAA ATAATCTTGG TTTAAGTGTG ATAACATATG AAAAGCCCCA
351 AATTGAAAGG TATGAGGCAT CTTTGGTAGA CGAAAGTGGT ATTTTGGGAC GTTNAGATGA TNAGAAAAAA
421 TTGATGGAGA AGCTGTGGGA GGATAAAGAT GAATCCGGAG TONAACTTC AGCATCCTGC CCATAATTGG
491 TATGGGTGGA GTTGGCNAAA CAACTCTAGC TAGACTCTTG TTTGATGAAA AGACAGTGAA GGATCACTTC
561 GAACTCAGGG CTGGGGTTTG TGTTCCTGAT GAATTCAGTA TTCTCAACAT AAGCAAAGTT ATCTATCAAT
631 CTGTGACCCG GGAAGAAGAA GAGTTTGAAG ACTTAAATCT GCTTCAAGAA GCTCTTAGAG GGAAACTACA
701 AAACAAACTA TTCTAATAG TTTTGGATGA TGTATGGTCG GAAAGCTATG GTGATTGGGA GAAATTAGTG
771 GGCCCTTTTC ATGCTGGGAC TTCTGGAAGT AGAATAATCA TGACTIONCG GAAGGAGCAA TTACTIONAAC
841 AGTTGGSTTT TTCTCATCAA GACCCCTCTGC GTTGATATGA CTCCCTGCAA CGTCTATCAC AAGATGATGC
911 TTTGTCTTTG TTGCTCAAC ACGCATTTCG TGWCCA
```

RLGLE  
[Strand]

```
1   TCTAGCTAGA CTTTGTGATG ACGAGATGCA AGAGAAGGAT CACTTCGAAC TCAAGGCGTG GGTITGTGTT
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAATCGAT AGGAGGTGGA AACCAAGAAT
141 TTAAGGACTT AAATCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTCAAAG AAACGATTC TACTTGTTC
211 TGATGATGTT TGGAGTGAAA GCTATGCCGA TTGGGAAATT CTGGAACGCC CATTTCCTGC AGGGGCAGCC
281 GGAAGTAAAA TTATCATGAC GACCCGGAAG CAGTCATTGC TAACCAAACG CGGTTACAAG CAACCTTACA
351 ACCTTTCCGT TTTGTACAT GACAGTGCTC TCTCTTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CGATTCCAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCT
```

SEQ ID NO:5



RLG1F  
[Strand]

```
1   ATTTTCNGCT  CNAACAAAN  AAAAGCAATG  GCTGAAATCT  TTCTTTGNGC  ATTCTAGACC  AGTATTCTTT
71  GAAAAAGNTGG  CTTCTGAAGC  CTTGAAGAAG  ATCGCTCGCT  TCCATCGGAT  TGATTCTGAG  CTCAAGAAAC
141 TGAAGAGGTC  ATTAATCCAG  ATCAGATCTG  TGCTTAATGA  TGCTTCTGAG  AAGGAAATAA  GTGATGAAGC
211 TGTTAAAGAA  TGGCTGAATG  GTCTCCAACA  TTTGTCTTAC  GACATAGACG  ACCTACTTGA  TGATTTGGCA
281 ACCGAAACTA  TGCATCGTGA  GTTGACCCAC  GGATCTGGAG  CCTCCACCAG  CTTGTAAGAA  AGATAATCCC
351 AACTTGTTCG  ACAGATTCTT  CACTAAGTAG  TAAGATGCGT  AACAAAGTAG  ATAATATTAC  CATCAAGTTA
421 CAAGAACTGG  TAGAGGAAAA  AGATAATCTT  GGCTTAAGTG  TGAAGGTGA  AAGCCCAAAA  CATACCAACA
491 GAAGATTACA  GACCTCTTTG  GTAGATGCAT  CTAGCATTAT  TGGTCGTGAA  GGTGATAAGG  ATGCATTGCT
561 CCATAAGCTG  CTGGAGGATG  AACCAAGTGA  TAGAAACTTT  AGCATCGTGC  CAATAGTTGG  TATGGGTGGT
631 GTGGGTAAAG  CGACTCTAGC  TAGACTTTTG  TATGACGAGA  TGCAAGAGAA  GGATCACTTC  GAACTCAAGG
701 CGTGGGTTTG  TGTTCCTGAT  GAGTTTGATA  TCTTCAATAT  AAGCAAAGTT  ATCTTCCAAT  CGATAGGTGG
771 TGGARACCAA  GAATTTAAGG  ACTTAAATCT  CCTTCAAGTA  GCTGTAAAAG  AGAAGATTTC  AAAGAAACGA
841 TTTCCTTATT  TTCTGGATGA  TGTTTGGAGT  GAAAGCTATA  CAGAATGGGA  AATTCTAGCA  CGTCCATTTT
911 TTGCAAGGGC  ACCAGGAAGT  AAGATTATCA  TGACGACCCG  GAAGTTGTCG  TTGCTAACCA  AACTCGGTTA
981 CAATCAACCT  TACAACCTTT  CSGTTTGTTC  ACATGATAAT  GCTTGTCTTT  TATTCTGTCA  GCAYGCATTG
1051 GGTGAAGATA  ACTTCGATTC  ACATCCAACA  CTTAAACCA  ASGGTGAAAG  TATTGTTGAA  AAATGTGACG
1121 GTTTACCATT  GGCCTTTRATT  GCACTTGGGA  GRTTGTGTAR  GACAAAAACA  GATGAGGAAG  AATGGAARGA
1191 AGTGTGAAT  AGTGAAATAT  GGGGTCAGG  AAAGGGAGAT  GAGATTGTTT  CGGCTCTTAA  ACTAAGCTAC
1261 AATGATCTCT  CTGCCTCTTT  GAAGAAGTTG  TTTGCATACT  GCTCCTTGTT  CCCAAAAGAC  TATGTGTTCG
1331 ATAAGGAGGA  GTTGATTTTG  TTGTGGATGG  CAGAAGGGTT  TTTGCACCAA  TCAACCACAA  GCAAGTCBAT
1401 GGAACGCTTG  GGHCATGAAG  GTTTTGATGA  ATTGTGTGCA  AGATCATTTT  TTCAACATGC  CCCTGATGCC
1471 AAATCGATGT  TTGTGATGCA  TGACCTGATG  AATGACTTGG  CHACATCTGT  TGCTGGAGAT  TTTTTTCAA
1541 GGATGGACAT  TGAGATGAAG  AARGAATTTA  GGAAGGAAGC  TTTGSAAAAG  YAYCGCCATA  TGTCATTTGT
1611 TTGTGAKGAT  TACATGGTKI  ACAAAGGTT  CRAGCCATTS  ACAAGGAGCT  AG
```

SEQ ID NO: 6

RLG1G  
[Strand]

```
1  GTGAAGGATC ACTTCGAACT CAGGGGCTTGG GTTTGTGTTT CTGATGAATT TAATATCCTC AATATAAGCA
71  AAGTAATTTA TCAATCTGTA ACCGGGGGAAA AAAAGGAGTT TGAAGACTTA AATCTGCTTC AAGAAGCTCT
141 TAAAGAAAAA CTTTGGAATC AGTTATTTCCT AATAGTTCCTG GATGATGTGT GGTCTGAAAG CTATCGTGAT
211 TGGGAGAAAT TAGTGGGCCC ATTTTTTTCG GGGTCTCCCTG GAAGTATGAT TATCATGACA ACTCGGAAGG
281 AGCAATTGCC AAGAAAGCTG GGTTTTCCTC ATCAAGACCC TTTGCAAGGT CTATCACATG ACGATGCITT
351 GTCTTTGTTT GCTCAACACG CATTTGGTGT ACCA
```

SEQ ID NO:7

RLG1H  
[Strand]

```
1  TCTAGCTAGA CTTTGTATG AGGAAATGCA AGGGAAGGAT CACTTCGAAC TCAAGGCGTG GGTATGTGTT
71  TCTGATGAGT TTGATATCTT CAATATAAGC AAAATTATCT TACAATCGAT AGGTGGTGGA AACCAAGAAT
141 TTACGGACTT AAACCTGCTT CAAGTAGCTT TAAAAGAGAA GATCTCAAAG AAAAGATTTC TTCTTGTTCT
211 TGATGATGTT TGGAGTGAAA GCTATACCGA TTGGGAAATT CTAGAACGCC CATTTCTTGC AGGGGCACCT
281 GGAAGTAAGA TTATTATCAC CACCCGGAAG CTGTCATTGT TAAACAACT CGGTTACAAT CAACCTTACA
351 ACCTTTCGGT TTGTTCACAT GAGAATGCTT TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGATAACTT
421 CAATTCACAT CCAACACTTA AACCACATGG CGAAGGTATT GTTGAAAAAT GTGAT
```

SEQ ID NO: 8

RLGI  
[Strand]

```
1  TCTAGCTAGA CTTGTGTATG ATGAGATGCA AGAGAAGGAT CACTTTGAAC TCAAGGCGTG GGTATGTGTT
71  TCTGATGAGT TTGATATATT CAATATAAGC AAAATTATTT TCCAATCGAT AGGAGGTGGA AACCAGAAT
141 TTAAGGACTT AAACCTCCTT CAAGTAGCTG TAAAAGAGAA GATTTTAAAG AACGATTTC TTCTGTTCCT
211 TGACGACGTT TGGAGTGAAA GCTATGCCGA TTGGGAAATT NTGGAACGCC CATTTCTTGC AGGGGCAGCC
281 GGAAGTAAAA TTATCATGAC AACCCGAAAG CAGTCATTGC TAACCAAACT CGGTACAAAG CAACCTTACA
351 ACCTTTCGGT TTTGTCACAT GACAGTGCTC TGTCTTTATT CTGTCAGCAT GCATTGGGTG AAGGTAACCT
421 CGATTTCACAT CCAACACTTA AACCACATGG CGAAGGCATT GTTGAAAAAT GTGCTGGATT GCCATTGGCA
491 TTGTCGACA
```

SEQ ID NO. 9

RLGLJ  
[Strand]

```
1  TACTACTACT AGAATTCGGT GTTGGTAAGA CGACTCTAGC TAGACTTTTG TATGAGGAAA TGCAAGGGAA
71  GGATCACTTC GAACCTAAGG CGTGGGTATG TGTTCCTGAT GAGTTTGATA TCTTCAATAT AAGCAAATTT
141 ATCTTACAAT CGATAGGTGG TGGAAACCAA GAATTTACGG ACTTAAACCT GCTTCGAGTA GCTTTAAAAG
211 AGAAGATcTC AAAGAAAAGa TTCTTCTTG TTCTTGATGA TGTMTGGAGT GAAAGCTATA CCGATIGGGA
281 AATINTAGAA CGCCCATTTT TTGCAGGGGC ACCTGGAAGT AAGATTATTA TCACCACCCG GAAGCTGTCA
351 TTGTTAACA AACTCGGTTA CAATCAACCT TACAACCTTT CGGTTTGTG ACATGAGAAT GCTTTGTCTT
421 TATTCTGTCA GCATGCATTG GGTGAAGATA ACTTCAATTC ACATCCAACA CTTAAACCAC ATGGCGaAGG
491 TATTGTTGAA AAATGTGATG GaTTGCCATT GGCATTGTG ACATGATGAT GATG
```

SEQ ID NO:10

RLGIA aa.

IVTVRTR?LSLLHLLSYVIFS?I?PH?ILWLF.INFYSTCHFMSFSILLSFT.YLNVITINAYLFFFK.THIIYR  
LKSynt.VKLI.YICSSPVYLYVSSLIYLLFIY.SR.SL.Y.KFNLFKI.NY..SHNLNKKIKKNGPTISPSLFQLINIV  
SILLRFHPNQYFQRM TDSYGVSEFAFRHCSLKEIINQMELLOCSLLMKGELYVK?MSAI?LHPEPTTSLV  
YHQTTONGGSR?T?KS.RIDYFCPHGLTEERV.FIIFL?KNYRSIEFLHRQRSFTSQCFVKQFLIFLSFR.NS  
SIATCNLQLLGPGICGGR.FNPHIHCKQ.FKSISVHPIHQHLLIIEIHHASSISSTSIYSLLSY.TMAEIVLS  
AFLTUVFEKLA?EALKKIVRSKRIESELKKLKETLDQIQDLLNDASQKEVTNEAVKRWLNDLOHLAYDID  
DLLDD?ATEAV?RELTEEGGASSSMVRKLIPSCCTSFQSQRNMHAKLDDIATRLQELVEAKNNLGLSVI  
TYEKP KIERYEASLVDES GTVGREDDKKKLEKLLGDKDESGSQNF SIVPIVGMGGVGKTTARLLYDEK  
KVKDHFELRAWVCVSDEFSVPNISRVYQSVTGEKKEFEDLNLQEALKEKLRNQLFLVLDVWSESY  
GDWEKLVGPFLAGSPGSRIIMTTRKEQLLRKLGFSHQDPLEGLSQDDALSFAQHAFGVPNFD SHPTLR  
PHGELFVKKCDGLPLALRTLGRLLRTKTDEEQWKELLDSEIWRGKSD EIVPALRLSYNDLSA?LKLLFA  
YCSLFPKDYEF DKEEL'LLWMAEGFLHQPT?NKS KQRLGLE YF?ELLSRSFFQHAPN?KSLFVMHDL MND  
LATFVAGEFFSRLDIEMKKEFRM?SLEKHRHMSFVCE?YIGYK?FEPFRGAKNLR TFLALSVGVVEDWK  
MFYLSNKVLND?LQDLPLLRVL?LI?L?I??VP??VGSM?HLRYLNLS?T?ITHLPE??CNLYNLQTLIV  
SGC?YLV?LPKTF?LKNL?HFD MR?TP?LKNMPL?IGELK?LQTLF?NIGIAITELKNL?NLHGK?CIGG  
LGK MENAVGCTLSELVSKKV?..??NW??G..I.CFPKWEHLKKKSSMK.CLIMVL?KKP?IMSIGGIEFPN  
WVGSLRVSETRDVFMVYEK?CFT.FHQSPSGK.MIFSG?TDEMWRGMIG?LGAVEEISIHSCNEIRYLWE  
SEAEASKVLMNLKKLDLGECE NVSLGEKKEDNHNINSGSSLTSFRRLNVWR CNSLEHCROPDSMENLY  
MHMCDS?TSVSFPTGGGQKIKSLTITDCKKLEEEELGGRERTRVLIN SKMQMLESVDIRNWP NLKSISEL  
SCFIHLNRLYISNCPS?ESFPDHEL PNLTSLTDRRRGQRFSYERLRFDWPSF

SEQ ID NO:11

RLGIB a.a.

NRSYENRCPLLPVI...EKI.LKV.IQNPLFHR.YDALAVVCKNSIINANQNSS.ETI.IMV.IVLSPTYTHFFQIPII  
HTYKCSHIRFSLAMAEILGSAFFAVFFEKLASEALKRVACSKVIDKELEKLNSS.INIKALLNDASQKEIS  
KEAVKEWLNALQHLPYDIDDLGDLATKAIHRKFSEEGATINKVRKLIPSCFSSLSSTKMRNKIHNITS  
KLQELLEERNLGLCEIGESRKLNRKSETS?LDPSSIVGRTDDKEALLKLYEPCDRNFSILPIVGMGGL  
DKTTLGRLLYD?MQVKDHFELKAWVCVSDEFDIFGISKTIFESIEGGNQEFKDLNLLQVALKEKISKKRFL  
VLLDDVWSESYTDWEILERPFLAGAPGSKVIITTRKLSLLNQLGHDQPYQLSDLSHDNALSIFCQHAFG  
VNSFDSHPILKPHGEGIVEKCDGLPLALIALGRLLRTKRDEEWEKELLNSEIWRGKRDEIIP?LRLSYND  
LSASLKQLFAYCSLFPKDYVFNKEKLILLWMAEGFLHNENTNKSMERL?LEYFDDLLSRFFQHALDDKS  
LFVVDLMDLATS VAGDYFLRDLIEMKKEALEKYRHMSFVCESYMVYKRFEPPFGAKKLRTFLAMPV  
GMIKSWTTTFYLSNKVLDLLHELPLLRVLSLSYLSIKEVPEIIGNLKHRLRYLNLSTHSITHLPENVCLYN  
LQTLILCGCCFITKFPNNFLKLRNLRHLDISDTPGLKKMSSGIGELKNLHTLSKLJIGGENRLNELKNLQNL  
H

SEQ ID NO:12

RLG 1c a.a.

SRAT?IIQK?PKT?D?F????QKEVIDEAVKRWLID?QQLAYDT?D?LDD?ATEAIHRELIRETGAS?S  
MVRKLIPSCCTSFSQSNRMHARLDDIAAK?QELVEAKNNLGLSVITYEKP KIERDEA?LVDASGIIGRED  
DKKKLLQKLLGDTYESSQNFNIVPIVGMGGVGKTTLARLLYDEKKVKDHFELRVWVCVSDEFVSNIS  
RVIIQSVTGENKEFADLNLLQEALKEKLQNKLFLLVDDVWSESYGDWEKLVGPFHAGTSGSRIIMTTR  
KEQLLKQLGFSHEDPLHSIDSLQRLSQEDALSLFSQHAFGVNFD SHPTLRPYGEQFVKKCGGLPLAL

SEQ ID NO:13



RLGID

?T?LRDRCPSSICLTMLPRRK?LMKPLKDG.MISNIWLMT?TTYLMILQ?KAI??ELT?EGGASTSMVRK  
LIPSCCTSFSSQSYRMHAKLDDIATRLQELVEAKNNLGLSVITYEKPRIERYEASLVDESGIFGR?DD?KK  
LMEKLLEDKDESGVKLQHLPIIGMGGVG?TTLARLLFDEKTVKDHFELEAWVCVSDEFSILNISKVIYQS  
VTGEKKEFEDLNLLQEALRGKLQNKLFIVLDDVWSESYGDWEKLVGPFHAGTSGSRIIMTTRKEQLLK  
QLGFHQDPLRCIDSLQRLSQDDALSLFAQHAFG?

SEQ ID NO: 14

RLGIE

LARLLYDEM QE K D H F E L K A W V C V S D E F D I F N I S K I I F Q S I G G G N Q E F K D L N L L Q V A V K E K I S K K R F L L V L D  
D W S E S Y A D W E I L E R P F L A G A A G S K I I M T T R K Q S L L T K L G Y K Q P Y N L S V L S H D S A L S L F C Q H A L G E D N F  
D S H P T L K P H G E G I V E K C A

SEQ ID NO: 15

RLGIF

FSA?NK?KQWLKSFF?HSRPVFFEK?ASEALKKIARFHRIDSELKKLKRSIJQIRSVLNDASEKEISDEA  
VKEWLNGLQHLSYDIDDLDDLATETMHRELTTDLEPPPACKKDNPTCCTDFSLSSKMRNKLDNITIKL  
QELVEEKDNLGLSVKGESPKHTNRRLQTSLVDASSIIGREGDKDALLHKLLEDEPSDRNFSIVPIVGMGG  
VGKTTLARLLYDEMQEKDHFELKAWVCVSDEFDIFNISKVIFQSIGGG?QEFKDLNLLQVAVKEKISKKR  
FL?VLDDVWSESYTEWEILARPFLAGAPGSKIIMTTRKLSLLTKLGYNQPYNLSVLSHDNALSLFCQHA  
LGEDNFDSHPTLKP?GESIVEKCDGLPLALIALGRLL?TKTDEEEWKEVLNSEIWGSGKGDEIVPALKLS  
YNDLSASLKKLFAYCSLFPKDYVFDKEELJLLWMAEGFLHQSTTSKSMERLGHEGFDELLSRFFQHAPD  
AKSMFVMHDLMNDLATS VAGDFFSRMDIEMKKEFRKEAL?K?RHMS?VC?DYMV?KRF?P?TRS.

SEQ ID NO: 16

RLG1 G

VKDHFE LRAWVCVSDEFN ILNISKVIYQSVTGEKKEFEDLNLLQEALKEKLWNQLFLIVLDDVWSESYR  
DWEKLVGPFFSGSPGSMIIIMTTTRKEQLPRKLGFPHQDPLQGLSHDDALS LFAQHAFGVP

SEQ ID NO: 17

RLG 1 H

LARLLYEEMQGGKDHFEKAWVCVSDEFDIFNISKIILQSIGGGNQEFTDLNLLQVALKEKISKKRFLLVLD  
DVWSESYTDWEILERPFLAGAPGSKIITTRKLSLLNKLGYNQPYNLSVLSHENALSLFCQHALGEDNFN  
SHPTLKPHGEGIVEKCD

SEQ ID NO: 18

RLGI I

LARLVYDEMQEKDHFELKAWVCVSDEFDIFNISKIIFQSIGGGNQEFKDLNLLQVAVKEKILKKRFLLVLD  
DVWSESYADWEI?ERPFLAGAAGSKIIMTTRKQSLTKLGYKQPYNLSVLSHDSALSFCQHALGEGNF  
DSHPTLKPHGEGIVEKCAGLPLALST

SEQ ID NO: 19

RLG 15

EFGVGKTTLARLLYEEMQGKDHFELKAWVCVSDEFDIFNISKIILQSIGGGNQEFTDLNLLRVALKEKISK  
KRFLLVLDDVWSESYTDWEI?ERPFLAGAPGSKIITTRKLSLLNKLGYNQPYNLSVLSHENALSLFCQH  
ALGEDNFNSHPTLKPHG?GIVEKCDGLPLALS

SEQ ID NO: 20

SEQ ID NO: 21  
RLG 2A

```
1   TTNACACCAT AAATCTCNA CCTGNGGGGA CAAAAACCTA AAAATGGTCC ATAATGCNCA AATCAGNAAG
71  GTTGANAAGG CTCTAAGTTT TINACCTCCA NCTGATGCNC NNTCTCNTA AAGTTCANAT CCAAGCTTGC
141 CCTCCAACCTC TANCNCCTTC AATGGCACCT CCTTCTCTTC AAAAGCACAC AAGAACACTT TCAAGCTCAA
211 CCACACTCAC ACAAGCTCTA GAACNAGGGT TAGGGCAGAT TTAGGGTTTT GCTCTCTGGA AATGGTGTCT
281 AAAAGTGAGG CCATAATGTT CCTTATATAA GGCTCAGTCC CACAATTAGG CTTTCAATCT GAACGTANTA
351 CGCCAGTGT ACACATATGGT ACGCCCAACG TACTCGGTAG TCTCCGGTCC AANAATACAC TCATGAGTAC
421 GCGCAACGTA CTTTCCCTTA CGCCAGCGT ACTCAAAAGC CAAACATTCT TTTCAAGGAC TAATTTTGAC
491 AACTTGAAGG AAGAAAAGGA TCAAGANAT ATACTTGAAT TCCGGGATGT TACAATGAAG TTGANACCTT
561 GGCTAAAAAA TTAATTTGGT TGTGGAAGCC GTTGGCTGAG CAAGCAACAA GGGTAAAAAT CGTAATCTAC
631 AAATGGTGT ATTTTCTATT TCTTCTTATT ATTTTACTTG ATTTACGGGT AGTTTTTTTT TCTTACAAAA
701 AATATTAAAG TTGATAAAGT ATAGCCACTA AAATTGACTT TTTCCAAAAC ATAATGTCAA ATGGTCCGTA
771 TATGTATCAT GTTGATTATT ATAATGAATA TGATGATNCT GTTCTATTTA ANCCGAAAAA ATTATCTAAT
841 GATTTTATAT TGGAAAACAA AGTTGTGATT TTTNGCATAA TATAATCAAA TCCNCTTTTG TNGGGAGGT
911 GGATAAATGT GGTAAATTTA NAACAAGTGT TTTNACNTG AAGGGTNGG AAAGTTGAA AAAAGTTAAA
981 ATGATAAAAT GTTTACACAA ATGTTGTATC CGACTGAATA TNAATTTAA GGATNATTGT ATTAAATGT
1051 TGATATATAG TAAGCATAAA TATTTAGAAT TGTGACTTAA ATTTATAAGT TATNCNACT GGATTGAAAC
1121 ATTTTGTATA TANATTAGGA ATGAAAATGA GCAACCCTAA CACTTATATC TTTGGTAGTT TGGTTATTAT
1191 ATTTTATATA NAATATAGAA NCATCCCTTT ATTTTAAACC CATATTGTGG ACGGACTTGA ATAAATGGGA
1261 AAAATGTACC TTGCTATTTA GCACAAAAAA ATTATAAAAA TGTACATTGC TATTTAGCAC AAACAAAAAA
1331 AAAAAACTTA TCCTTTTGTG ATTAGGTGAC AAAGAAATAT AAAATGGGAA ATGTTGTGCT ATTTAATGCA
1401 CTAAAAAGAA CTATTTTGCC TTTATTAAAC CGGGTAAACC AATAGAAAAA TGGAAAGTAA TTGTCATTTA
1471 GCATGAAAAA AAATAACTTT CCATTTTTTG CATCCGGTCA CAATAATAGA AAAATGAAAG TACGTTGCTA
1541 TTTAGCGAAA CTAACCTCCT TTTTCTTTTT TGGCATCGTA TCATAAAAAA TAGACTAAAA TACGTTAGTT
1611 TTACATTTTT AATACATTGA AATGTCTAAT CCACATGTTA TTCTATAAAA AGGGAAATGT AATTTACTTA
1681 TTCTTTGATT CTTTGGCTTC TTTTGTATAC CCAAAACATC CCTCTATCCA TCTATTCCAA CTAAAAATAA
1751 GAAAACATAA TTCCCTCCAT TGTAGGGATG TTATAAATTT TGTAAATGTT TTTATGCAAA AAAGTGTTTT
1821 TTGTTAACTA GATTAAACGAG ATTCATTTTT CAGCATTTTA GGAGAAGTTC ATCCATCTTT TGGATATGAA
1891 GTGCAAGCCA AGTTCTTTAA CATGGAATAT GAGGTCCCTA TATGCTCAAA AAATAGCAAA TGAGAAATTT
1961 TTTAAATTTG ATCCCCATAA AAGAAAAATTT GTTAATGGTT GTTTTAAATAT TGGTCAATGT GTCCACCGGA
2031 TGAGCAATAA ACTAGTTTAT AAGGGGTAA AAGGGGTGTT GTTGGCCCAT TTATCTTTAT TATTTCTAAA
2101 AGTCAGAAAT AAGTAAAAAA AATTATAAGA TAAATACCAT AAGGATAAAA AATCATTTTA TTTGGACCAA
2171 AGACCAAAAG TGTAAAGGGG CTGTTTGTTT TTTTGTGAAA GAGCTGTGCA ACCACTTTTG TCTGCGCCCG
2241 ACAGACAAGC TGCAGACATA TGCCCTCGCA GAGTGTGTTT TTTTGTAAAG TCGCGAGACC AAAAAACGT
2311 CTGCGCGAGG TCATCTGGGC GCATATATGT GTCAGTGTCT TCAAAGGTCT TCAGACCTCA TTTTAAACCA
2381 AAAAAAATAA GACCACCGGT TTTTTTTTTT TTTTNTTCT TTTCTTTGTA GCTGAAAATG CATTTTAAAT
2451 CTTTATGACA TGAAATTAAG TTTGAAAAAT TAATTTATTT CAACAGCTGT AGACGTTAAA AACAAACAGT
2521 CTTCTTTGTT CAGACTGTGG ACATTTGGTC CACCTCTTCT ACCGCAGAGA CTTGCAGATG TGGTCCCGAG
2591 ACTGCAGACA TTTTGGCTTC AAATAAACAA ACATCACCTA ATTTGACTAC ACCACACGGA CCTCCAATGT
2661 AACAAAAAAA AGGTTGAAAC AAAGTTGCCT ATTTCTCCAT ATCCAGGGGC CATTTATGTA AGAGTTATCT
2731 AAAATTTAGT TCGGTAGATC AGTTCTCACA TTTTAAACCG GTAAAGTGTA TGTGTGTACG CGCGCACCTG
2801 AAAGGTTTGA ANGTAACTTC CAAACTGAAN CAANAATCGA TATGAAGTAT CAAGTTAGAG GTTCAATTGG
2871 TGAAGGAATC AGCTGGAGGT TGGGGAATCG AGCTTCCACT ATTAAGGTAA AATCCATAAC CCTTAAATGT
2941 GGTACGCTCA TATATCAAAAT TGCGTGTTTT GTTGAATGAA AAAAGCATGC TCAAAAAACC AGTGTAAAGC
3011 ACGGTATATG ACATATTTAT AGTTACTGAT AACAAATTAT GATAATTTTG GGTTTACGTA AGTTAGGATT
3081 CGTACTTCAA CCAAAATGTA TAGTTTTTGT GAGTCTATCT ATGTATTTGG GGAATCACAT TAGCAACGGG
3151 ATTGTACTAG TAATTCGAAA AAGTCTTTTA AATAATTTT CTGTTTATA TTTATGAATA GTTTTAGCGA
3221 CATCTAATAT TAAATAGAAT GTATCTGATA TTGAATTAAT GTCCTTAATG TGAACATAGA CCTTTTCCAT
3291 TTAATAATGC CTAATTATTA GTTCTAATC AATAAATTTT AATTTCTGTT TTATGCTTCT AAGACAATAA
3361 AAATCCATGA TTTACCTTTA AATATTAACA AAAATGACCA TAAATAAATA AAAAATTAGG ATACCAAAAC
3431 CCCCCGCCAT GCCCAATGTC TAAATATTCT TAGTGCTTTT GCTTTTCCCT CTTTCTCTTG TTAGTCTATT
3501 ATTTCTGAGA GTTTGAGAGA GTTTCATACA AGAAAATTTT AAGAAGAAAG CAAAGGTCCA GGTATTCTCT
3571 TTTCTAATT ATGTATTAAC TTACAAGCAT TTTTACACG ATCCATGGTT TTTTGTGTAT GTTTTCTAAA
3641 TTGAAACTAG ATTTGGACTT TTGCCCTTGA TGATTCATAA GATAITGCAT GGAGTTGAGA TTGTGTAAGA
3711 AAAGTCTGTA ATAGAAAGAG CAAGTGAATC CAGATATAGT ATTGGTAATA TATGATGATG AGATAGAGAT
3781 ATGTTAAAAA TGGCTAGAAA ATTTGTTTTAA TTTGAAATTT AGGTGTGTGA ATTTGAAAGA TACCAAGCTA
3851 ATAACTAATT AGTTATGCTA AAGAACAAAC AACTCGTAGT TTTTCTTTCA TTTTCTTTCA TGAATTTTCA
3921 CCTCTCTGTA CCAAACTAAA TTATAACAAA ATTTGAATATC ATTTCTGCTA ATCAATTTTA ACTTTTGTTA
3991 TTATCATCAT GTCTAAATTT GCCACAAGTT TATTTTCATA GTCATATTGG ATTATGAAAG GACTATTTTT
4061 ACCAATZACA TCTTACTTTT ATGGCCAAAG CTAATACAAT CCGACTAAAC TAAAGGATTC TAGGATGCAT
```



SEQ ID NO: 2/  
RLG ZA cont.

```

4131 ATAGTTTGGCT CCCCGATTAT AGATTTCAT CTAATTGTG TATTGTACTA ATTTAGGTGC CACCACAAGT
4201 AAATTCCTGA AATGGATGTC GTTAATGCCA TTCTTAAACC AGTTGTGCGAG ACTCTCATGG TACCCGTTAA
4271 GAAACACATA GGGTACCTCA TTTCTGCAG GCAATATATG AGGGAATGG GTATCAAAAT GAGGGGATTG
4341 AATGCTACAA GACTTGGTGT CGAAGAGCAC GTGAACCGGA ACATAAGCAA CCAGCTTGAG GTTCCAGCCC
4411 AAGTCAGGGG TTGTTTGA GAAGTAGGAA AGATCAATGC AAAAGTGGAA AATTTCCCTA CGGATGTTGG
4481 CAGTTGTTTC AATCTTAAGG TTAGACACGG GGTCCGAAAG AGAGCCTCCA AGATAATTGA GGACATCGAC
4551 AGTGTCTATG GAGAACACTC TATCATCATT TGGAAATGATC ATTCCATGCC TTTAGGAAGA ATTGATTCCA
4621 CGAAAGCATC CACCTCAATA CCATCAACCG ATCATCATGA TGAGTTCCAG TCAAGAGAGC AAACTTTCAC
4691 AGAAGCACTA AACGCACTCG ATCCTAACCA CAAATCCCAC ATGATAGCCT TATGGGGAAT GGGCGGAGTG
4761 GGAAGACGA CAATGATGCA TCGGCTCAA AAGTTGTGA AAGAAAAGAA AATGTTTAA TTTATAATTG
4831 AGGCGGTGT AGGGGAAAAA ACAGACCCCA TTGCTATTCA ATCAGCTGTA GCAGATTACC TAGGTATAGA
4901 GCTCAATGAA AAAACTAAAC CAGCAAGAAC TGAGAAGCTT CGGAAATGGT TTGTGGACAA TTCTGGTGGT
4971 AAGAAGATCC TAGTCATACT CGACGATGTA TGGCAGTTTG TGATCTGAA TGATATTGGT TTAAGTCCCT
5041 TACCAATCA AGGTGTCGAC TTCAAGGTGT TGTGTACATC ACAGAGACAAA GATGTTTGCA CTGAGATGGG
5111 AGCTGAGTGT AATCAACTT TTAATGTGAA AATGTTAATA GAAACAGAA CACAAAGTTT ATTCCACCAA
5181 TTTATAGAAA TTTCCGATGA TGTGTATCCT GAGCTCCATA ATATAGGAGT GAATATTGTA AGGAAGTGTG
5251 GGGGTCTACC CATTGCCATA AAAACCATGG CGTGTACTCT TAGAGGAAAA AGCAAGGATG CATGGAAGAA
5321 TGCACTTCTT CGTTTAGAGC ACTATGACAT TGAAAATATT GTTAATGGAG TTTTAAAAAT GAGTTACGAC
5391 AATCTCCAG ATGAGGAGAC TAAATCCACC TTTTGTCTTT GTGGAATGTA TCCCGAARAC TTTGATATTC
5461 TTACCGAGGA GTTGGTGAGG TATGGATGGG GGTGAAATTT ATTTAAAAAA NIGTATACTA TAGGAGAAGC
5531 AAGAACCAGG CTCACACAT GCATTGAGCG GCTCATTCTT ACAAATTTGT TGATGGAAGT TGATGATGTT
5601 AGGTGCATCA AGATGCAATGA TCTTGTTCGT GCTTTTGTGT TGGATATGTA TTCTAAAGTC GAGCATGCTT
5671 CCATTGTCAA CCATAGTAAT ACACTAGAGT GGCATGCAGA TAATATGCAC GACTCTTGT TAAGACTTTC
5741 ATTAACATGC AAGGTATGT CTAAGTTTCC TCAGAGCCTG AAGTTTCCAA ACCTCTCCAT TTTGAAACTT
5811 ATGCTGAAG ATATATCATT GAGGTTTCCC AAAAATTTT ATGAAGAAAT GGAGAGCTT GAGGTATAT
5881 CCTATGATAA AATGAAATAT CCATTGCTTC CCTCATCACC TCAATGTTCC GTCAACCTTC CGGTGTTTCA
5951 TCTACATAAA TGCTCGTTAG TGATGTTTGA CTGCTCTTGT ATGGGAAATC TGTCGAATCT AGAAGTCTCT
6021 AGCTTGTCTG ATCTGCCAT TGACCGGTG CCTTCCACAA TCGGAAAGTT GAAGAAGCTA AGGCTACTGG
6091 ATTTGACGAA TTGTTATGGT GTTCGTATAG ATAATGGTGT CTTAAAAAA TTGGTCAAAC TGGAGGAGCT
6161 CTATATGACA GTGGTTGATC GAGGTGCAAA GGGGATTAGC CTCACAGATG ATAACCTGCA GAGATGGCA
6231 GAGCGTTCAA AAGATATTTA TGCAATTAGAA CTGTAGTTCT TTGAAAACGA TGCTCAACCA AAGATATGT
6301 CATTTGAGAA GCTACAACGA TTCCAGATCT CAGTGGGGCG CTATTTATAT GGAGATTCCA TAAAGAGTAG
6371 GCACCTCGTAT GAAAACACAT TGAAGTTGGT TCTTGAAGAA GGTGAATTAT TGGAGCTCG AATGAACGAG
6441 TTGTTTAAAG AAACAGAGGT GTTATGTTTA AGTGTGGGAG ATATGAATGA TCTTGAAGAT ATTGAGGTTA
6511 AGTCATCTTC ACAACTTCTT CAATCTTCTT CGTTCAACAA TTTAAGAGTC CTGTGCTTT CAAAGTGTGC
6581 AGAGTTGAAA CACTTCTTCA CACCTGGTGT TGCAAAACCT TTAAGAAAGC TTGAGCATCT TGAAGTTTAC
6651 AAATGTGATA ATATGGAAGA ACTCATACGT AGCAGGGGTA GTGAAGAAGA GACGATTACA TTCCCCAAGC
6721 TGAAGTTTAT ATCTTTGTGT GGGCTACCAA AGCTATCGGG TTTGTGCGAT AATGTCAAAA TAATTGAGCT
6791 ACCACAACCT ATGGAGTTGG AACTTGACGA CATTCCAGGT TTCACAAGCA TATATCCCAT GAAAAAGTTT
6861 GAAACATTTA GTTTGTTGAA GGAAGAGGTA AATATAAATT TTTAATGCTA ATACATTACA AAGGATCTTT
6931 TCAGTTAAAT CTTTCAAAAT ATATTGTAAT TTGATTGTAT GGGGTATTAT TGTGGATGG GACTATTAAAT
7001 AAATGATTAT CTGCAAGTT CTGATTCCCTA AGTTAGAGAA ACTGCATGTT AGTAGTATGT GGAATCTGAA
7071 GGAGATATGG CCTTGCGAAT TTAATATGAG TGAGGAAGTT AAGTTCAGAG AGATTAAAGT GAGTAAGTGT
7141 GATAAGCTTG TGAATTTGTT TCCGCACAAG CCCATATCTC TGCTGCATCA TCTTGAAGAG CTTAAAGTCA
7211 AGAATTTGTG TTCCATTGAA TCGTTATTCA ACATCCATTT GGATTGTGTT GGTGCAACTG GAGATGAATA
7281 CAACAACAGT GGTGTAAGAA TTATTAAAGT GATCAGTTGT GATAAGCTTG TGAATCTCTT TCCACACAAT
7351 CCCATGTCTA TACTGCATCA TCTTGAAGAG CTTGAAGTCG AGAATTGTGG TTCCATTGAA TCGTTATTCA
7421 ACATTGACTT GGATTGTGCT GGTGCAATTG GGAAGAAGA CAACAGCATC AGCTTAAGAA ACATCAAAGT
7491 GGAGATTATA GGAAGCTAA GANAGGTGTG GAGGATAAAA GGTGGAGATA ACTCTCGTCC CTTGTTCAT
7561 GGCCTTCAAT CTGTTGAAAG CATAAGGGTT ACNAAATGTN AGAAGTTTAG AAATGTATTC ACACCTACCA
7631 CCACAAATTT TAATCTGGGG GCACCTTTGG AGATTTCAT AGATGACTGC GGAGAAAAA GGGGAAATGA
7701 CGAATCGGAA GAGAGTAGCC ATGAGCAAGA GCAGGTAAGG ATTTCAATTT CACTGTCTTA ATTAATGATT
7771 AAGCTCTCTG TTTTGAATA AAAAAGGGAC AAACCATTTT ATGACTTAAT GTAGCAATAC AAGTCATGTA
7841 TAAGATGAC CAACTCTTTT TTATTTATAA AATGACTACA AAATATTTT TTTTATTAGA GATCATGTAT
7911 AAATGTGACT AATTTTTCAT CACCTAAGTT TAGTTGATAA ATCTTTATAA ATGTCAGTAG TTACTTTTCA
7981 CTAATAAATC AATTTTAAAT AATTATCAAC AAAAAGCATC AACTAAAAA ATCCCAACAC CCGTAATAAT
8051 TTAATAAATA AGGATTAAAC ATCTAATACG AACAAATTTT TTTCTAAACA TGATTGGAC CAAATATCAC
8121 CAGCAACTCA AGTTTGAAT CGATTACGCT TAAACTTGA CCAGCATAAT TAGATAGATG AGAGTTGAAG
8191 CTAAGGTGCC TATATAAGTT CGTTTCATCT TTTTCTTGA TCTTGATAGC AAGTTGAATG ATTTTCTTCT

```

RLG 2A cont.

8261 TCAAAATTGA TAAAAATCTA CATTATAAAG AGACTAGCTT GAAAAAAAAT GGTCTAGGTG GGTCTTGGGT  
8331 TCTGGTAGAT GAAGATGGAA GGGGAGAGTA TGATTTTCAA GACACAACAC ATCCTTTCATT TTATTTTATT  
8401 ATTATTATTA TTATTTTTTG ATATCTTGCT CATATTTGTT ACAGATATGT GAGGTCTATT AATCTTTTAA  
8471 AATATATAAA AAAATAAATA ACATAAATGA GAAATTTAAA TAAAGAATAA ATTAATAAGG GCACAATAGT  
8541 CTTTTTAGGT AAGACAAGGA CCAACACGCG AACAAAAATA AACAGTAGGG ACCATCCGAT TTAAAAAAA  
8611 TAATTAGGGA CCAAAAACAT AAATTCCTCC AAACCATAGG GACCATTCTT GTAATTTACT CTACTTTTTC  
8681 GTTTTGTGTA TATTTGGGTA ACTATTTTTT TTGTACACAT CTAGGTAACG AACTTGTGTA AGTGTTCCTA  
8751 TTTAGGATGT GACCTACTAC AACCGATCAT AATAGTCATA TGTGAACACT TCCAACAACCT TTATTACTTA  
8821 GGTGTGTACA AAAAAACAAT AGTTACCATG ATGTGAACAT ACTGAAAAAT TAATTACCTT AGCAAGTTAT  
8891 TTTCCCATTT AGGTTGTATG GAAACAGTTC CGTGAGACCG TGACTTGGAT GGTAGATAAA TTTAGTAAAC  
8961 TTAACCCCTT AATTAACCTA CCTTTTCTT ATTAACCTCA TTTCAACCTA AATTCIGATT CTGTGTTGAA  
9031 AGTAAGTTGC ATCTTTTATT TTGTATTATC TTGTGTCATA GGATCCTTAG CATCTTTTAA TAATTTATTT  
9101 GAAGGTGAAA GATCCAACTA TTTTAAATCT GTTGGCATTT TCCATCATTT GCAACTGTTT CTGTGAAAAA  
9171 AAATACCTAA AATCAAAATA ACCATTTTCA AATCCAAAAT TATAAGAGAG AATTGTAAAT GGACATGGAA  
9241 TCATAAATCA TTAACACAGT TCAGTAAACA AGTTGCTAAT TACATTTCTT GCTGTGCAGA TTGAAATTTCT  
9311 ATCAGAGAAA GAGACATTAC AAGAAGCCAC TGACAGTATT TCTAATGTTG TATTCCTATC CTGTCTCATG  
9381 CACTCTTTTC ATAACCTCCA GAAACTTATA TTGAACAGAG TTAAGGAGT GGAGGTGGTG TTTGAGATAG  
9451 AGAGTGAGAG TCCAACAAGT AGAGAATTGG TAACAACCTA CCATAACCAA CAACRACCTA TTATACTTCC  
9521 CAACCTCCAG GAATTGATTC TATGGAATAT GGACAACATG AGTCATGTGT GGAAGTGCAG CAACTGGAAT  
9591 AAATCTTTCA CTCTTCCAAA ACAACAATCA GAATCCCCAT TCCACAACCT CACAACCATA AAAATTTATG  
9661 ATTGCAAAAG CATTAAGTAC TTGTTTTGCG CTCTCATGGC AGAACTTCTT TCCAACCTAA AGCATATCAA  
9731 GATAAGAGAG TGTGATGGTA TTGGAGAAGT TGTTTCAAAC AGAGATGATG AGGATGAAGA AATGACTACA  
9801 TTTACATCTA CCCACACAAC CACCATTGTC TTCCCTAGTC TTGATTTCTT CACTCTAAGT TTCTGGAGA  
9871 ATCTGAAGTG TATTGGTGGA GGTGGTGCCA AGGATGAAGG GAGCAATGAA ATATCTTTCA ATATACCAC  
9941 TGCAACTACT GCTGTTCTTG ATCAATTGTA GGTATGCTTT GTACATATTC AATTATTTAT TTAATTTCTT  
10011 TTTTTATTG CAATATTCTA TAAATAATAC ATTTTATACC CACTATACTA AGATAATAAT TACCTAGAGG  
10081 GATGATGCT ATGACACAGC TGCTACACTT CAGAAACTCT AGTAAGGGCA GTTATGGAAG TTCAATAAAA  
10151 TGATAATGGC ATCTTTTGAT GGGTAATATA GGCAATTTAA GTTTTATTTT TGTAAAGCA GTATTTAGCA  
10221 AGTACTGGCC AGTAGGAGAG GAGAATATCA CCTTTTGIGA AAATCTGGTC ATTGTACCCA GAATTTAGTT  
10291 AAATGTACA TTTTAGATAT CAGGGGTCAT CAGGTGACAG ATATTGTAGA ATAGAACAAT ATATAATATC  
10361 ACCCAAAACT ATTTTCTCTA AGGTATTTCT GTTAAATATG TGCTTTCTTG TTTTCAINGA ATINGCATTC  
10431 GTATATTTTA GGTGTTAAAG TGATTTTNTC TTCAATAAAT CCCGAAATTA ATTAAAAAAA AAAAAACAAA  
10501 AGTACATTTT TGATGTGGAG AGCACTGGTA TCACTTAGTA TATAAAAAGC TTGATTTTGA ATTAACTTTC  
10571 TTATACAAAA GTTGTGTATA TAGTTTAATT AGTTTACAT CATTTTCCCA TGTGGTGTG CAGTTGTCG  
10641 AAGCAAGTGG TGTTCCTTGG AGCTTATGCC AATACGCTAG AGAGATGAGA ATAGAATTCT GCAATGCATT  
10711 GTCAAGTGTA ATTCCATGTT ATGCAGCAGG ACAAATGCAA AAGCTGAAGG AGAGGACAGC GATTCTCGTA  
10781 CGAACGGTTA CGATTGCACT GGCCGTCGTT TTACA

SEQ ID NO: 21

RLGIA a.a.

MDVVNAILKPVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVNRNISNQLEVPQV  
RGWFEEVVGKINAKVENFSPDVGSCFNLVKVRHGVGKRASKIIEDIDSVMREHSIIIWNDHSIPLGRIDSTK  
ASTSIPSTDHHDDEFQSREQTFTALNALDPNHKSHMIALWGMGGVGKTTMMHRLKKVVKEKKMFNFII  
EAVVGEKTDPIAQSAVADYLGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLS  
PLPNQGVDFKVLTSRDKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIGVNIVRK  
CGGLPIAIKTMACTLRGKSKDAWKNAALLRLEHYDIENIVNGVFKMSYDNLQDEETKSTFLCQMYPE?FD  
ILTEELVRYGWGLKLFKK?YTIGEARTRLNTCIERLIHTNLLMEVDDVRCIKMHDLVRAFLDMYSKVEH  
ASIVNHSNTLEWHADNMHDSCKRLSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFKPNFYEEMEKE  
VISYDKMKYPLLPSSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVL SFADSAIDRLPSTIGLKKLR  
LLDLTNCYGVRI DNGVLKLVKLEELYMTVVDGRGRKAISLTDDNCKEMAERSKDIYALEFFENDAQPK  
NMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKLVLKGELEARMNELFKKTEVLCLSVGDMNDLEDIE  
VKSSSOLLQSSSFNNLRVLVSKCAELKHFFTPGVANTLKKLEHLEVYKCDNMEELJRSRGSEEEETTFP  
KLKFLSLCGLPKLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLKKEVLIPKLEKLHVSSM  
WNLKEIWPCEFNMSSEEVKFREIKVSNCDKLVNLFPHKPISSLHHLEELKVKNCGSIESLFNIHLDCVGAT  
GDEYNNSGVRIIKVISCDKLVNLFPHNPMSSILHHLEEELEVENCGSIESLFNIDLDCAGAIGQEDNSISLRNI  
KVENLGKLR?VWRIKGGDNSRPLVHGFQSVESIRVTKC?KFRNVFTPTTTNFNLGALLEISIDDCGENR  
GNDESEESSHEQEIEILSEKETLQEATDSISNVVFPSCLMHSFHNLQKLILNRVKGVEVVFIESESPTS  
RELVTTHHNQQQPIILPNLQELILWNMDNMSHWKCSNWNKFFTLPKQQSESPFHNLTITIKIMYCKSIKY  
LFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTTFTSTHTTTTLFPSLDSLTSFLENLKCIGGG  
GAKDEGSNEISFNNTTATTAVLDQFEVCFVHIQLFI.

SEQ ID NO:22

RLG 2B

SEQ ID NO: 23

1 AGTTTTTTTTT TTTCCCAATA TCCATTATATA TCGGATTAT TCTGAAATA ATTTATCAAA AACGACGAGAA  
71 ACAATGTAGA ATAATACTGG TATAATTAAT TATATAAAGT TATTAGGCTG AAATCTTGAG GCTACTATAA  
141 TTTAATTATC ATAATTGAA AATCATCAAA TTGTATTCCA TGTATATTTA TGTATCAGA TAATTAATAA  
211 TATGTGAGCC ACACAAATCC ACATCATCAG ACACCCACC TTATTGTCGG CTACCTCACC ACTTGACATGA  
281 TCCCGACATC TTCCCAACCC CACCGACGAC TTGGGGTCTC CTTAATATAT CAATTATTTT CTGTAAGTAT  
351 TTATTGTGT AAATGTGTAA TGTCATTTTA CCTTTTCTCT AATATATACA GAAACATAAA TTTTAAATGA  
421 AATTCAACTG CGTTTCATTC TTGCATTAAA AAAAAAGACT GTACTGTGT CAATATTTTA CTTATAACCT  
491 GATTAAATTAA TTAAGCGTA ATTGCATAAT TTGCATTAGG TTGTAATTTT GTGTTTTATA GGGAGGGTGA  
561 GGGTCACCGG GAATCAAAGC ACTTATGTAA AAGCAGGGGA AATACAAAAA ATTTACTCGA AACAAATTTT  
631 ATTCAAATTAA AGTGAGATAA TAATGTTCTG ATTAGATTAT GAGAACTAGG AGATTTAAGT GATATATCCC  
701 ATTTAAAGA AATTGCATTA TTAATTTTGG ATCTCTTGAT GATGACAAAA TTAACCTGTG ACAGGTTATA  
771 TATCATATAC AAAATGAGTG GCTATGCTTT CGCTTTCCAA AAAGCAATTA TAGTTTACT ACACCTACAA  
841 ATTTTAAAG GGGTTAAACA TATCAAAATA CTGTATAAGT AATTATATAA ATATGCATTT AACCCCTTAA  
911 AGAAAATGCT ACTAAGCTTG GACCATCTCA GAATTACAAT CATACCCCTC CCCTCAAAAA AGATTGCTAT  
981 ATATCATGTC ATTTGGCATT CATTTCTTTT TCACAATTCA TAGTTCTATT CTCAAAAAAT TCGAGTTCTC  
1051 GTATTGTGTA GGAAGATCAG AAGAGACTGT TCACACAGGT ACTCTCTTTT ATTTATTGAT TCACATTCAT  
1121 ATATGTTTATT GTTTTCTTGC TTAATGGTTT CGTCAGTCTA ACTGCGCTTG CTGATTTAAA TTTCTTCACT  
1191 TTCTTCCACG GATTTTTTAA ATATTAGTTT TGTGAATGAA CAATTGGTGA AGGAAAGAAA CATGGGAGTC  
1261 TTTTCTAAG TAAACCTAGA TACTTAGGTT ATAAGGGTAT ATGCTAAAAA GAACTATGCC CATTCACTT  
1331 TGCCCTTTCT TTTACTTTTT AGTTTTTGA ATCCAAGTTT TCATATGTAT CTCGATGTGT GAGAAGAATA  
1401 GGCATTAAGAA AGGTAAAGGA CGTACATAAA ATTGATTAAT TAGTGAATGT TCTTTGATAT CATTATTTTT  
1471 ACTCTCATAA AAAGCATATA GATCAAAAC AAATTGCTAC TTGTTAGTGT AACAACTCG ACTTAATAAT  
1541 GTTAATAATC AAGATTCTCT TGATTTCAC TATTTCTTAA CCGAACAAGC TCATAAAAA CTCAATTGCT  
1611 TTTGAGTCTG AGTGGTTTAT ATTTGGGGTT TTACATTFAA TTTTITGTC ATGAATGTGA AAATAGACTG  
1681 CTTATTGATT CTTTGTGTTT CATTGAGTTG ATTTTCATTA TTAACCTT ACAAAATGCT CAGTGATAGA  
1751 TTTCCTAATA TTTCCTAATT CGGTTGCTTC TAAATATGTA GGAGCTACTA AAAGCAAAAA TATCGAGCAA  
1821 TGTCCGACCC AACGGGGATT GCTGGTGCCA TTATTAACCC AATTGCTCAG ACGGCTTGG TTCCCGTTAC  
1891 GGACCATGTA GGCTACATGA TTTCTGTCAG AAAATATGTG AGGGTCATGC AGATGAAAAT GACAGAGTTG  
1961 AATACCTCAA TGATCAGTGT AGAGGAACAC ATTAGCCGGA ACACAAGAAA TCATCTTCAG TTCCATCTCA  
2031 AACTAAGSAA TGGTTGGACC AAGTAGAAGG GATCAGAGCA AATGTGGAAG ACTTTCCGAT TGATGTCATC  
2101 ACTTGTGTA GTCTCAGGAT CAGGCACAAG CTTGGACAGA AAGCNITCAA GATAACTGAG CAGATTGAAA  
2171 GTCTAAGCAG ACAACTCTCC CTGATCAGTT GGACTGATGA TCCAGTTCYT CTAGGAAGAG TTGGTTCCAT  
2241 GAATGCTACC ACCTCTGCAT CATTAAGTGA TGATTTCCCA TCAAGAGAGA AAACITTTAC ACAAGACTA  
2311 ATAGCACTCG AACCCAAACCA AAAATTCCAC ATGGTAGCCT TGTGTGGGAT GGGTGGAGTG GGGAGACTA  
2381 GAATGATGCA AAGGCTGAAG AAGGCTGHTG AAGAAAAGAA ATTTGTTAAT TATATTGTTG GGGCAGTTAT  
2451 AKGGGAAGAG ACGGACCCCT TTGCCAATCA AGAAGCTATA GCAGATTACC TCGGTATACA ACTCAATGAA  
2521 AAAAATCAGC CAGCAAGAGC TGATAAGCTT CGTGAATGTT TCAAAAAGAA TTCAGATGGA GGTAAAGACTA  
2591 AGTTCCTCAT AGTACTTGAC GATGTTTGGC AATTAGTTGA TCTTGAAGAT ATTTGGGTTAA GTCCTTTTCC  
2661 AAATCAAGGT GTCGACTTCA AGGTCTTGTG GACATCAGCA GACTCACAAG TTTGCACTAT GATGGGGGTT  
2731 GAAGCTAATT CAATTATTAA CGTGGGCTT CTAAGTGAAG CAGAAAGCTCA AAGTCTGTTT CAACAAATTG  
2801 TAGAACTTTC TGAGCCCGAG CTCCAGAAGA TAGGAGAGGA TATCGTAAAG AAGTGTGCG GTCTACCTAT  
2871 TGCCATAAAA ACCATGGCAT GTWCTCTTAG AAATAAAGAA AAGGATGCAT GGAAGGATGC ACTTTCCGCG  
2941 ATAGAGCACT ATGACATICA CAATGTTGCG CCCAAAGTCT TTGAAAAGAG CTACCACAAT CTCCAAGAAG  
3011 AGGAGACTAA ATCCACTTTT TTAATGTGTG GTTTGTTTCC CGAAGACTTC GATATTCTTA CTGAGGAGTT  
3081 GATGAGGATAT GGATGGGGCT TGAAGCTATT TGATAGAGTT TATACGATTA GAGAAGCAAG AACCAAGGCTC  
3151 AACACCTGCA TTGAGCGACT GGTGCAGACA AATTGTGTTA TTGAAAGTGA TGATGTTGGG TGTGTCAAGA  
3221 TGCAATGATCT GGTCCGTGCT TTTGTTTTGG GTATGTTTTT TGAAGTCGAG CATGCTTCTA TTGTCAACCA  
3291 TGGTAAATATG CCTGGGTGGC CTGATGAAAA TGATATGATC GTGCACCTTT GCAAAAAGAA TTTATTAACA  
3361 TGCAAGGGTA TGATTGAGAT TCCAGTAGAC CTCAAGTTTC CTAACTAAC GATTTTGAAG CTTATGCAATG  
3431 GAGATAAGTC GCTAAGGTTT CCTCAAGACT TTATGAAAG AATGGAAAAG CTCCATGTTA TATCATACGA  
3501 TAAAAATGAG TACCAATTGC TTCCCTTTGGC ACCTCGATGC TCCACCAACA TTCCGGTGCT TCATCTCACT  
3571 GAATGTTTAT TAAAGATGTT TGATTGCTCT TCTATCGGAA ATCTATCGAA TCTGGAAGTG CTGAGCTTTG  
3641 CAAATCTTCA CATGAAATGG TTACTTTCCA CAGTCAGAAA TTTAAAGAAAG CTAAGGTTAC TTGATCTGAG  
3711 ATTTTGTGAT GGTCTCGTA TAGAACAGGG TGCTTGAAA AGTTTTGTCA AACTTGAAGA ATTTTATATT  
3781 GGAGATGAT CTGGGTTTTT AGATGATAAC TGCAATGAGA TGGCAGAGCG TTCTTACAAC CTTTCTGCAT  
3851 TAGAAATCCG GTTCTTTAAT AACAAAGGCTG AAGTGAAAAA TATGTCATTT GAGAATCTTG AACGATTCAA  
3921 GATCTCAGTG GGATGCTCTT TTGATGAAAA TATCAATATG AGTAGCCACT CATACGAAAA CATGTTGCAA  
3991 TTGGTGACCA ACAAAGGTGA TGTATTAGAC TCTAAACTTA ATGGGTTATT TTTGAAAAA GAGGTGCTTT  
4061 TTTTAAAGTG GCATGGCATG AATGATCTTG AAGATGTTGA GGTGAAGTCG ACACATCCTA CTCAGTCTCT

RLG2B cont.

SEQ ID NO: 23

4131 TTCATCTGCG AATTTAAAG TTCTTATTAT TTCAAAGTGT GTAGAGTTGA GATACCTTTT CAAACTCAAT  
4201 CTTGCAACA CTTTGTCAG ACTTGAGCAT CTAGAAGTTT GTGAATGTGA GAATATGGAA GAACTCATAC  
4271 ATACTGGAAT TGGGGGTTGT GGAGAAGAGA CAATTACTTT CCCTAAGCTG AAGTTTTTAT CTTTGAGTCA  
4341 ACTACCGAAG TTATCAAGTT TGTGCCATAA TGTCACATA ATTGGGCTAC CACATCTCGT AGACTTGATA  
4411 CTTAAGGGCA TTCCAGGTTT CACAGTCATT TATCCGCAGA ACAAGTTGCG AACATCTAGT TTGTTGAAGG  
4481 AAGGGGTAGA TATATGTTCT TTATGTTAAT ACAATTTAAA TAATATTTTC AACCATAATT TCATAATATA  
4551 TCTGTAATTT GATTGTATGA TGTGTTATG TTTTATATG GCTATTAAGG GATGATTATT TTGCAGGTTG  
4621 TGATTCTCTA GTTGGAGACA CTTCAAATTG ATGACATGGA GAACCTAGAA GAAATATGGC CTTGTGAAC  
4691 TAGTGGAGGT GAGAAAGTTA AGTTGAGAGC GATTAAAGTG AGTAGCTGTG ATAAGCTTGT GAATCTATTT  
4761 CCGCGCAATC CCATGTCCTT GTTGCAATCAT CTTGAAGAGC TTACAGTCCA GAATTGCGGT TCCATTGAGT  
4831 CGTTATCTCA CATTGACTTG GATTGTGTCG GTGCAATTGG AGAAGAAGAC AACAGAGGCC TCTTAAGAAG  
4901 CATCAACGTG GAGAATTTAG GGAAGCTAAG AGAGGTGTG AGGATAAAAG GTGCAGATAA CTCTGATCTC  
4971 ATCAACGGTT TTCAAGCTGT TGAAGCATA AAGATTGAAA AATGTAAGAG GTTTAGAAAT ATATTCACAC  
5041 CTATCACCGC CAATTTTTAT CTGGAGGCAC TTTTGGAGAT TCAGATAGAA GGTTCGGGAG GAAATCAGCA  
5111 ATCAGAAGAG CAGGTAACGC TTTCATTTTC ACTTTCTTAA TTAATTAAGG ACTAAGCTCC TGTTTTTTGA  
5181 ATAAATAAGA GGTGGGATGA CTAAACTTGG GCATCACAAT TGCAACAAAA TGTTCACAAAC CATGAAACGT  
5251 TCAAAACCAT TCTTGAATTA AGGTTTCAAT ACAAGTCATT TAAAAATATG GCTTAAATTT TTTTATATT  
5321 TATGTATCAA CATGATTTTT CATTAGAGAT CATTATTATA ATAGTAAGTT TAAAGCAATT TAAATCAGAA  
5391 CTAATCTCAA CTTTAGCTAA TAAATCGTTA TAAATGTAAA TAATTACTTT TTAGTGAAAT AAGCAACGGA  
5461 TTTAATAAGT TAACAACCTA AATGTCATTT CCTAACAAAA AAAACTTTGG TTCAGAAAAA CCGCAATTCA  
5531 AGATAACTAA AATAAAAAATA TTTGACATTC ACTAAGAGCA TTTTTTTTTC TAAATATGAT TGCAAAATGAA  
5601 TAAAACTTAA ATTTATACAG AAAATTCCTT TATATATGTT ATACAAAAAT TACAAATGTA AATGGATAT  
5671 GTTAATTAAC GGTTTATAAT TCTGGTATCA CAAAGGGATA TATAATAAAA TATTATTTTC TGTAGTCATT  
5741 TGTAAITGTA CTAGTTTATA ACCCGTGGGA ACCATGAGTT CTAAAAATTAG TTAACCTTTC ATAATAAAAA  
5811 TTTATAATTA TTATTTATTT TAAATAAATT ATTAATTAAAG AGATATATCA AAAATTTAAA GTTATTATAA  
5881 CTTCAAAATTT AACATATAAT TAGAAAAATAT ATGATCATAA CTCTGCACT CTCTTTGTAT AAATGCAGAG  
5951 AAGCTATTAG TATATTCTA ATCAAGTCCA AACCTAATGA AGCCTATATA ATTTTGTGAA AACTCAATTA  
6021 GCATTAGGTT TTAAGAGTCA CCAAAATCAA AGAATAATCC AATGCTTTCA TTACCCTATC GGAGAAAAATA  
6091 TTTCTCTAGT TTAATAGTAA TGAAACAAA CATTCAAACCT AATGTTGCT TATTAAACCA AAGACCCATT  
6161 ACTTAGCCAA GAGTTTAAAC AAAAAAATT ACATTCAATG ATCATTTATC ATGACTAGAT ATATATGAAC  
6231 ATGAAGGGAG TTTTATAGA AATATAATC ATAGATATTC AACATAACTT CAGGGAATTC CTCAAAATTA  
6301 CCAAGTTATT CAAGAAATTA CATCCAAGTC AACCAAGAG AAGTTTAGCC TAGCATGGCT AAACCAAGA  
6371 AACTTAAATA AGGATTAGAA GTACCAAAAC TGTAGTAAGA ATCAGAGTAA AAGATGATGT TGTCTTGTAT  
6441 GTTCTTCTAA GTTCTTCAAG TCTCCAGTTG CTCTTAATAA TGCAAGGAG AGCCATTAAA TTCGTATGTA  
6511 TTGATCCCTT CAAAAGCTGC ACCAACCTCC CTTAAATAAC ACTCAAAGCA AAAATGACAA AATGCCCTGA  
6581 AGGACCTTAT GTGGGTGCTT TCGCGGGGTG GAGCTGCATA CGAAAGGCTT TTGGTCTTTG TGAGGGTGTAT  
6651 GTTGTGCGGG ATAGCTTGTG GCATGCTTCC GCGCGGTTCA CGCACATGTG CACAGGTGAT GCATGGTGTG  
6721 TGCGTCTTGT AGTTTGTAGC CTCCGATGCT TAGTCCACTT GGCCCAATTC GAGTCCAATC AGCTTATAAC  
6791 CCATTTTCTT TCAAGTTATC TTCAAGTTAA GCCCAATTTG GCTTCTCCAA ATCATCCATA ACTTCACAGA  
6861 ATGCGCCGTT CATCTTAATC CCGGATGCAC AATTATTCTC CCGTCTTCAT TTTAAGCAAG ATACCACTT  
6931 CTTCAATGCTT CATCCATCAA TAGTACACTT CATGTATCAT CTCTACTAGT TATTTAGTCC ACAAACTCTT  
7001 GTTGTCTCTC AAATTTAATT ATCTCATTTA GTTCCCGTT CCGCTACTTT CCTTAAATTT TGAATTAAG  
7071 CTCAGAGAAA TATTAAGTAC CCGAAATGGT CATAAAATTA ACAAAAAGGA AAATGCATGA AGATTAACTA  
7141 AATGATGAAC GAAATATGCT AAAATAGACT ATAAATAGAA GTAAATAAAA TGAAATTATC GCCTCCGAC  
7211 CACCCCTATG GCTGTAGTGC CACCCACCTT TCATTCCTTG TACCAATATG GATGGAAC ATCATTAATT  
7281 AAGCCAAAAA GCTAACATAT AAGGGTTTAG TGACAAAGGT AAGTACTAAA GATGAAAAATA ATCCATTTT  
7351 CTTGTTTITA CACAACACAC ACATAGGGGC AGACGTAGGA TTTCAAAGTA CAGATTGTTG GTGGCACATA  
7421 AGTGTGCTG GTGACATTTT TTTTCTCTTT TTACGTGGTG GCACAACAGT AGGAAAAACG AAAAATTCGA  
7491 AATTTTTCAC AATTTGTCTT AAAAAAACA GGGGTTGTTG GTGCCACTAT GGCAACAAAA GTTGAACCTC  
7561 CCTACGCGCG CACACACACA CACACACATA GAGAGAGAGA GAGAGAGAGA GAGAGAGAGA AAGAAAGAAA  
7631 GAGAGAGAGA GTTTGGGATG TGATACTTCT TTTAGGAAAA TGGAGTTATA TCTTTGATAT TGTATTTTTT  
7701 TAATGTAATT TATNTATTTA ATCATTTTAG TTTTATAAGT NTATTTATIN GGNATGAAA AAAAAAGTCT  
7771 TTTATACATT GGATTTAACA TAAAAATCCA ACAAATTTAA TCAAAAAGAC CAAACATGTG GACAATTATG  
7841 TATATAATTA ATTCACAATA GTCTTTAGGA ATAGTATTAT ATATATAATT AATCTCAAT GGTCTTAGGA  
7911 ATAGTAAGTT CTTATATTTT AAACCTTTTG CACAATTTCT TGCTTACTTT GACACTTTTC CTTCTTAAC  
7981 TTACATATAT ATATATATTA AAGCGCAAAG GTCATAGGAA TATAATATTT TCTATTATTC TACGTTTTCG  
8051 CACAAAAGTT TGAACACTTT GCCACTTTTT GTCCCTCTCT AACCTTTTCA ATGTTTTGCG ACAAAAGTTC  
8121 CAAAACCTTG CCACTTTGAT CATTCCTCAA CTTTTACCG CATTAGTTTG TGGAGTTGGC AGTTTTGGTC  
8191 CCTCTAACCT CGATATTCTC TACTGCTAGC CAAAAGGGT TCCAGAGTTT CACACTTTTG GTCCCTGACA

RLG 2B cont.

8261 GTAACCAAAT GTGAGATGTC AAATTTTTGC CACATTAGTT TGTGGAGTTG TCCCTTTTGG TCCCCCACA  
8331 TTCGATATTC TACTATACGA TCATTATTTT CTCAAATAAC AACACGTATA TTTCATC:CT AATTGGAAAA  
8401 AGAGTTTAA AA:AAATAAC GACTAGG::: G:GC:GAGTT TTTTTT:ACA AGTTTGTATC AAATCATATC  
8471 AAAATTTAAG GTGGAACGGT GACCACATTA ACCAGAAATG TAATTTATTC TTGATTTTG ATAATTTTITA  
8541 ATATTTTGTG GTGATCTATG TATTTAAAAG TAAACAACAA AGAACATAAT CCAAAACCCCT AAATTGCAAG  
8611 TCTCGCCCCA TTTCTCTATC ACTAGTCCTC ACTTACGATG GCGTTACGTC GCTCTCTCAC TGCTTACAAC  
8681 CCTTTGTGTC TACTCATTAC AATAACGAAA AGTTGAATAT CCATATATTT ATTTGGATGT GGAATTGAAC  
8751 GAATCTCTGC AAAATTTTGA TTTTGTGAT GGAATTGAGT AGAAGTTTGG GCAGAACGGG AATGATGGTC  
8821 TGCAAGTGGT TATAAACTTG ATTCTGAGTT ATTACTATAT ATGTAGCCTC TTTACAACGA CCAAGGTTTC  
8891 TTCAGGTAC CATTTGATCT TTTTAGAAGT TAGTTTTCTG AAACACCCCTG ATTTGGATCA AATATCACCA  
8961 ACAACTCTTA AAAACTTGAT TAATCAATG TTTTCTTCAT CTGTATAACA AGTGGAAATGA TTTTCTACTT  
9031 AGATTAACCT GAAAAAAAAG GTCCATGTGC GTCTGGTGA TCCTGGTAAAT GAAGATGGAA GGGAGAGCTG  
9101 ACTTTAAAGA CACAAACAG TCACCATATC TCTTATTTTA TTTTAAATTT GCTTTTGGTG TATTTTCTTT  
9171 TTCTCTATTT CTTTCTTTCT TGATCTCCAG ATGGTATGTG GTGTGGATAA TTTCACCTTA GAGATTGGGA  
9241 ACGATGGGAA GGGGTCTGTG ATTTATGGCT GGCCGAGTTT TACTTATTA CTCAATTTCA ACCTAAATTC  
9311 TGATCTCTGT TTGAAAAATA GTTGCACTCT TATTTTGTGA TTATCTTGT GCATAGGATC CTTAGCATCT  
9381 TTTAATAATT TATTTGAAGG TGAAAGATCC AACTATTTTT TAGCTGTGG CATTTTCCAT CATTTGCAAC  
9451 TGTTCTTGA AAAAAAATA CCTAAAATA AAATAACCAT TTTCAAATCC AAAATTATA GAGAGAATTG  
9521 TAAATGGACA TGGAAATATA AATCATTAAC ACAGTTCACT AAACAAGTTG CTAATTACAT TTCTTGCTGT  
9591 GCAGATTGAA ATTCTATCAG AGAAAGAGAC ATTACAAGAA GCCACTGGCA GTATTTCAA TCTTGATATC  
9661 CCATCCCTGC TCATGCATC TTTTCATAAC CTCCTGTGTC TTACATTGGA TAATTATGAA GGAGTGGAGG  
9731 TGGTATTGGA GATAGAGAGT GAGAGTCCAA CATGTAGAGA ATTTGGTAACA ACTCGCAATA ACCAACAACA  
9801 CCCTATTATA CTTCCTTACC TCCAGGATTT GTATCTAAGG AATATGGACA ACACGAGTCA TGTGTGGAAG  
9871 TGCAGCACT GGAATAAATT CTTCCTCTT CCAAAACAAC AATCAGAATC CCCATTCCAC AACCTCACAA  
9941 CCATAAATAT TCTTAAATGC AAAAGCATT AGTACTTGT TTCGCTCTC ATGGCAGAAC TTCTTTCCAA  
10011 CCTAAAGGAT ATCCGATAA GTGAGTGTGA TGGTATTAAA GAAGTTGTTT CAAACAGAGA TGATGAGGAT  
10081 GAAGAAATGA CTACATTTAC ATCTACCCAC ACAACCACCA CTTTGTTCCC TAGTCTTGAT TCTCTCACTC  
10151 TAAGTTTCTT GGAGAATCTG AAGTGTATTG GTGGAAGTGG TGCCAAGGAT GAGGGGAGCA ATGAAATATC  
10221 TTTCAATAAT ACCACTGCAA CTACTGCTGT TCTTGATCAA TTTGAAGTAT GCTTTGTACA TATTCCATTA  
10291 TTTATTTAAT TTCTTTTAT ATTGCAATA TTCTATAAAT AATACATTTT ATACCCACTA TACTAAGATA  
10361 ATAATTACCT AGAGGATGG ATGCTATGAC ACAGCTGCTA CACTTCAGAA ACTCTARTAA GGGCAGTTAT  
10431 GGAAGTTCAT TAAATGATA ATGGCATCTT TTGATGGGTA ATATAGGCAA TTTAAGTTTT ATTTCTGTTA  
10501 AAGCAGTATT TAGCAAGTAC TGGCCAGTAG GAGAGGAGAA TATCACCTTT TGTGAAATC TGGTCATTGT  
10571 ACCCAGAAAT TAGTTAAATG TAACATTTTA GATATTAGGG GTTATCAGGT GACAGATATT GTAGAATAGA  
10641 ACAATATGTA ATATTACCCA AAACATTTTT TTCTAAGGTT GCCTGTATA ATATGTGCTT TCTTGATTTT  
10711 ATTGAATTTG CATTCCTATA TTTTAGGTGG TAAAGTGATT GTCTCTTCAA TAAATCCCGA AATTTTTTAA  
10781 TTAATAAAAA AAAAAACAAA AGTAAATTTT TGATATGGAG AGCACTGGTA TCATTTAGTA TATAAAAAAC  
10851 AGATTTTGAA TTAAGTTTCT TATATAAAG CTGTGTATAT AGTTTAAATTA GTTTTACATC ATTTTCCAT  
10921 GTGGTGTGTC AGTTGTCTGA AGCAGGTGGT GTTCTTGGG GCTTATGCCA ATACGCTAGA GAGATAAAAA  
10991 TAGGCAACTG CCATGCATTG TCAAGTGTGA TTCCATGTTA TGCAGCAGTA CAAATGCAGA AAGCTT

SEQ ID NO: 23

RLG2B a.u.

MSDPTGIAGAIINPIAQ TALVPVTDHVG YMISCRKYVRVMQMKMTELNTSRISVEEHISRNTRNHLQIP  
SQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKL GQKAFKITEQIESLTRQLSLISWTDDPV?LGRVG  
SMNASTSASLSDDFPSREKTFTQALIALEPNQKFHMVALCGMGGVGKTRMMQRLKKA?EEKKLFNYIV  
GAVI?EKTDPFAIQEAIADYLG IQLNEKTKPARADKLREWFKNSDGGKTKFLIVLDDVWQLVDLEDIGL  
SPFPNQGVDFKVL LTSRDSQVCTMMGVEANSIINVGLL TEAEAQSLFQQFVETSEPELQKIGEDIVRKC  
CGLPIAKTMAC?LRNKRKDAWKDALSRIEHYDIHN VAPKVFETSYHNLQEEETKSTFLMCGLFPEDFDI  
PTEELMRYGWGLKLFDRVYTIREARTR LNTCIERLVQTNLLIESDDVGCVKMHDLVRAFVLGMFSEVEH  
ASIVNHGNMPGWPDENMIVHSCKRISLTCKGMIEIPVDLKF PKLTILKLMHGDKSLRFPQDFYEGMEKL  
HVISYDKMKYPLLAPRCSTNIRVLHLTECSLKMFD CSSIGNLSNLEVLSFANSHIEWLPSTVRNLKKL  
RLDLRFCDGLRIEQGV LKSFVKLEEFYIGDASGFID DNCNEMAERSYNLSALEFAFFNNKA EVKNMSFE  
NLERFKISVGCSFDENINMSSH SYENMLQLVTNKG DVLD SKLNGFLFKTEVLFLSVHGMNDLEDVEVKS  
THPTQSSSFCNLKVLIISKVELRYL FKLNLANTLSRLEHLEVCECENMEELIHTGIGGCGEETITFPKLKF  
LSLSQLPKLSSLCHNVNII GLPHLVDLILKGIPGFTVIYPQNK LRTSSLLKEGVVIPKLETLOIDDMENLEE  
IWPCELSGGEKV LRAIKVSSCDKLVNLFPRNPMSLLHHLEELTVENCGSIESLFNIDLDCVGAIGEEDN  
KSLLSINVENLGKLREVVRIKGADNSDLINGFQAVESIKIEKCKRFRNIFT PITANFYLEALLEIQIEGCG  
GNHESEEQVTL SISLS

SEQ ID NO: 24

→ 25

[illegible]



[illegible]

[illegible]

|       |     |     |     |     |     |     |     |     |     |     |
|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| RLG2A | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2B | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2C | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2D | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2E | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2F | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2G | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2H | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2I | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2J | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2K | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2L | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2M | 610 | 620 | 630 | 640 | 650 | 660 | 670 | 680 | 690 | 700 |
| RLG2A | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2B | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2C | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2D | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2E | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2F | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2G | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2H | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2I | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2J | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2K | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2L | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |
| RLG2M | 710 | 720 | 730 | 740 | 750 | 760 | 770 | 780 | 790 | 800 |

RLG2A  
RLG2B  
RLG2C  
RLG2D  
RLG2E  
RLG2F  
RLG2G  
RLG2H  
RLG2I  
RLG2J  
RLG2K  
RLG2L  
RLG2M

|       |   |      |      |      |      |      |      |      |      |      |      |
|-------|---|------|------|------|------|------|------|------|------|------|------|
| RLG2A | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTAACGATTTTCAAACTTATGCAATGAGATTAAGTGGCT | 1010 | 1020 | 1030 | 1040 | 1050 | 1060 | 1070 | 1080 | 1090 | 1100 |
| RLG2B | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1011 | 1021 | 1031 | 1041 | 1051 | 1061 | 1071 | 1081 | 1091 | 1101 |
| RLG2C | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1012 | 1022 | 1032 | 1042 | 1052 | 1062 | 1072 | 1082 | 1092 | 1102 |
| RLG2D | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1013 | 1023 | 1033 | 1043 | 1053 | 1063 | 1073 | 1083 | 1093 | 1103 |
| RLG2E | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1014 | 1024 | 1034 | 1044 | 1054 | 1064 | 1074 | 1084 | 1094 | 1104 |
| RLG2F | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1015 | 1025 | 1035 | 1045 | 1055 | 1065 | 1075 | 1085 | 1095 | 1105 |
| RLG2G | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1016 | 1026 | 1036 | 1046 | 1056 | 1066 | 1076 | 1086 | 1096 | 1106 |
| RLG2H | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1017 | 1027 | 1037 | 1047 | 1057 | 1067 | 1077 | 1087 | 1097 | 1107 |
| RLG2I | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1018 | 1028 | 1038 | 1048 | 1058 | 1068 | 1078 | 1088 | 1098 | 1108 |
| RLG2J | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1019 | 1029 | 1039 | 1049 | 1059 | 1069 | 1079 | 1089 | 1099 | 1109 |
| RLG2K | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1020 | 1030 | 1040 | 1050 | 1060 | 1070 | 1080 | 1090 | 1100 | 1110 |
| RLG2L | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1021 | 1031 | 1041 | 1051 | 1061 | 1071 | 1081 | 1091 | 1101 | 1111 |
| RLG2M | AAAGATTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1022 | 1032 | 1042 | 1052 | 1062 | 1072 | 1082 | 1092 | 1102 | 1112 |
| RLG2A | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1110 | 1120 | 1130 | 1140 | 1150 | 1160 | 1170 | 1180 | 1190 | 1200 |
| RLG2B | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1111 | 1121 | 1131 | 1141 | 1151 | 1161 | 1171 | 1181 | 1191 | 1201 |
| RLG2C | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1112 | 1122 | 1132 | 1142 | 1152 | 1162 | 1172 | 1182 | 1192 | 1202 |
| RLG2D | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1113 | 1123 | 1133 | 1143 | 1153 | 1163 | 1173 | 1183 | 1193 | 1203 |
| RLG2E | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1114 | 1124 | 1134 | 1144 | 1154 | 1164 | 1174 | 1184 | 1194 | 1204 |
| RLG2F | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1115 | 1125 | 1135 | 1145 | 1155 | 1165 | 1175 | 1185 | 1195 | 1205 |
| RLG2G | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1116 | 1126 | 1136 | 1146 | 1156 | 1166 | 1176 | 1186 | 1196 | 1206 |
| RLG2H | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1117 | 1127 | 1137 | 1147 | 1157 | 1167 | 1177 | 1187 | 1197 | 1207 |
| RLG2I | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1118 | 1128 | 1138 | 1148 | 1158 | 1168 | 1178 | 1188 | 1198 | 1208 |
| RLG2J | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1119 | 1129 | 1139 | 1149 | 1159 | 1169 | 1179 | 1189 | 1199 | 1209 |
| RLG2K | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1120 | 1130 | 1140 | 1150 | 1160 | 1170 | 1180 | 1190 | 1200 | 1210 |
| RLG2L | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1121 | 1131 | 1141 | 1151 | 1161 | 1171 | 1181 | 1191 | 1201 | 1211 |
| RLG2M | AAAGCTTTTCATTTAACAATGCAAGGGTATGTCAGGTTTCCAGTAGACCTCAAGTTTCCAAACCTTCCAACTTATGCAATGAGATTAATCAAT           | 1122 | 1132 | 1142 | 1152 | 1162 | 1172 | 1182 | 1192 | 1202 | 1212 |

[illegible]

ATTTCTGGGNTTGAATGGTTACTTCACCAATTTCAGAAAGCTTAGCCTTACTGTATTGCACAAA TTCTTATGGCTTCGCTCGTN TAGAANA TGSTGT

|       |                      |                   |                      |                    |                      |      |
|-------|----------------------|-------------------|----------------------|--------------------|----------------------|------|
| RLG2A | ATCTCCATCCGCTGCTTCCA | CAATCGGAAATGTG    | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1371 |
| RLG2B | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1375 |
| RLG2C | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1367 |
| RLG2D | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1345 |
| RLG2E | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1364 |
| RLG2F | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1369 |
| RLG2G | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1382 |
| RLG2H | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1360 |
| RLG2I | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1374 |
| RLG2J | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1358 |
| RLG2K | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1374 |
| RLG2L | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1314 |
| RLG2M | ATCTCCATCCGCTGCTTCCA | CAGTCAGCAAAATTTAA | AGAGCTTACGGCTACTGGAT | TTTGAAGCAAAATGTTAT | GTGTCGTAATAGTAATCGGT | 1349 |

1410 1420 1430 1440 1450 1460 1470 1480 1490 1500  
 CTTAAAGAAATTTGGTCAAACTTGGAGGCTCTATAT-GACAGTG-----GAT-----CGAGGTGAAAAGG-----CGA----- 1437  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1475  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1417  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1411  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1412  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1432  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1437  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1466  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1420  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1442  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1449  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1423  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1398  
 CTTGAAAGATTTGGTCAAACTTGGAGGCTCTATATTTGAGATGCAATCGATGCAATCGAGAGCGTTCTTACAACTT 1441

XXX  
 XXX

1439  
 1500  
 1417  
 1412  
 1432  
 1438  
 1466  
 1420  
 1442  
 1474  
 1437  
 1398  
 1441

1510 1520  
 TCTGCATTTAGAAATTCGGCTTCTTTA -TTA -SEQ ID NO: 27  
 -SEQ ID NO: 28  
 -SEQ ID NO: 29  
 -TG -SEQ ID NO: 30  
 -SEQ ID NO: 31  
 -TA -SEQ ID NO: 32  
 -SEQ ID NO: 33  
 -SEQ ID NO: 34  
 -SEQ ID NO: 35  
 TCGAAATGCGAGAGCTTTTTCACA -SEQ ID NO: 36  
 -SEQ ID NO: 37  
 TCGATATCAAAAGC -SEQ ID NO: 38  
 -A -SEQ ID NO: 39

SER ID NO:
























40

RG2A protein in OKTHM4RIKQVVKKQNFIIENAVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 98-41  
 RG2B protein in OKTHM4RIKQVVKKQNFIIENAVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 100-42  
 RG2C protein in NTRX--AKAEVAKKKEFGYIIENAVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 98-43  
 RG2D protein in EVAK--KK--FGYIIENAVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 90-44  
 RG2E protein in GRND--MYVEVAKENRHHFVNVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 99-45  
 RG2F protein in GRND--MYVEVAKENRHHFVNVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 100-46  
 RG2G protein in GRND--MYVEVAKENRHHFVNVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 97-47  
 RG2H protein in GRND--MYVEVAKENRHHFVNVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 94-48  
 RG2I protein in ERGR--MYVEVAKENRHHFVNVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 89-49  
 RG2J protein in ERGR--MYVEVAKENRHHFVNVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 89-50  
 RG2K protein in LEDTHMRLKNI--MYVEVAKENRHHFVNVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 100-51  
 RG2L protein in LEDTHMRLKNI--MYVEVAKENRHHFVNVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 82-52  
 RG2H protein in AEE--MYVEVAKENRHHFVNVGKTDPIAIOAVADYVIGELNEKTPARTGAKFVTVNSQ--KKTIIVTIIVMAQFVDIANDIGISPLPQQ 92-53

RG2A protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 196  
 RG2B protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 195  
 RG2C protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 193  
 RG2D protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 185  
 RG2E protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 193  
 RG2F protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 195  
 RG2G protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 194  
 RG2H protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 189  
 RG2I protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 194  
 RG2J protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 195  
 RG2K protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 177  
 RG2L protein in VDFKVLITSRDSQVCTHGVGVEANSIIIVGLLIEAQAQSLFQQFVETS--E---PELQKIGEDIVRKCCGLPIAINTACTLRKGRKQAKDALSRIEYD 187



IGS--VAPKVFETSYNQLQDEETKSIIFLHGLFPEDFIPIEELRYGGLKLFPRVTIIEARNRLNTCIERLVQTNLLIESDDGCVKRDIDLVRAPVL 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

TNLAVILHLCSPFDCSSIGNLNLVLFSPANSIGTEMLPSTIGLAKKLLDLITVCTGCTGTENGVLNKLVLDELYTGANG-FG-----  
 410 420 430 440 450 460 470 480 490  
 RUG2A protein VNLVILVFIHJHCSLFIWHFKVSCSLGNLNLVLSFVSNVANAHLRLFTLVKLRILRLILRLILHFLHFLVTRVGVVILNLRVKKLVKLLELYMTLV-----DRGRKAI  
 479  
 RUG2B protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIHLEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 481  
 RUG2C protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSICIMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 472  
 RUG2D protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIRIMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 470  
 RUG2E protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 471  
 RUG2F protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 477  
 RUG2G protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 477  
 RUG2H protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 488  
 RUG2I protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 472  
 RUG2J protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 472  
 RUG2K protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 479  
 RUG2L protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 479  
 RUG2M protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 478  
 RUG2N protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 465  
 RUG2O protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 480  
 RUG2P protein TNVRLVILHTECSLRFDCSSIGNLNLVLFSPANSIEMLPSTVRLNKKLRLLDLRPTCGGLRIEQQVLSKVLSEFYFIDGSG-FIDGNC  
 480

SEQUENCE:

10 20 30 40 50 60 70 80 90 100  
 TGTGAGACCGTGAAGTGGTGAAGTAAATTTAGTAACTTAACC-CTTC--AATTAACTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG → 54  
 110 120 130 140 150 160 170 180 190 200  
 JUTVAGACCGTGAAGTGGTGAAGTAAATTTAGTAACTTAACC-CTTC--AATTAACTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG 97-56  
 TGTGAGACCGTGAAGTGGTGAAGTAAATTTAGTAACTTAACC-CTTC--AATTAACTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG 97-57  
 -GTGAGACCGTGAAGTGGTGAAGTAAATTTAGTAACTTAACC-CTTC--AATTAACTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG 96-58  
 -GTGAGACCGTGAAGTGGTGAAGTAAATTTAGTAACTTAACC-CTTC--AATTAACTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG 96-59  
 TGTGAGACCGTGAAGTGGTGAAGTAAATTTAGTAACTTAACC-CTTC--AATTAACTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG 95-60  
 TGTGAGACCGTGAAGTGGTGAAGTAAATTTAGTAACTTAACC-CTTC--AATTAACTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG 97-61  
 -GTGAGACCGTGAAGTGGTGAAGTAAATTTAGTAACTTAACC-CTTC--AATTAACTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG 96-62  
 C-CAAAACAAATTTGAAACCGGATCATCCAAATCAATTCATTCOA--GGTCTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG 74-63  
 ---GA-----TAAATTAG-----TAACTCAATTTCAAGCTAAATTCG 97-64  
 TGTGAGACCGTGAAGTGGTGAAGTAAATTTAGTAACTTAACC-CTTC--AATTAACTTACCTTTTCTTAACTCAATTTCAAGCTAAATTCG 97-65  
 AG-AGCAGACGAGTATGAGATTTTCACTTTT-----CTACTTACTTAAAGATTTGCTTCTTCTTTTTCGAATTA-----AA-----AAGGGGACATCT- 85-67

AC15-2A  
 AC15-2B  
 AC15-2C  
 AC15-2D  
 AC15-2E  
 AC15-2G  
 AC15-2H  
 AC15-2I  
 AC15-2J  
 AC15-2L  
 AC15-2N  
 AC15-2O

110 120 130 140 150 160 170 180 190 200  
 ATTCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG  
 ATCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 187  
 ATCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 187  
 ATCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 186  
 TCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 188  
 ACTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 137  
 ATCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 176  
 ATCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 164  
 CCATCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 194  
 TCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 122  
 ATCTTGTTCGAAATTAAGTT-GCATCTTTTATTTT-TG--TATTATCTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 187  
 ---TCT-----AATAA--TGCATCTTAAATTAAGATTTTATTTTGTTCGATAGCATCTT-TAGCATCTTTTAAATTTTATTT-----GAAGGTG 168

AC15-2A  
 AC15-2B  
 AC15-2C  
 AC15-2D  
 AC15-2E  
 AC15-2H  
 AC15-2I  
 AC15-2J  
 AC15-2L  
 AC15-2N  
 AC15-2O

AC15-2A  
AC15-2B  
AC15-2C  
AC15-2D  
AC15-2E  
AC15-2G  
AC15-2H  
AC15-2I  
AC15-2J  
AC15-2L  
AC15-2N  
AC15-2O

|         |   |     |     |     |     |     |     |     |     |     |     |
|---------|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| AC15-2A | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2B | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2C | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2D | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2E | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2H | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2I | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2J | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2L | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2N | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |
| AC15-2O | ---TCGAGATTCAAAATTCATCAGAGAGAGAGCATTTACAGAGAGCCACTGGCA---GTATTTCTAAAT---GTGTATT---CCCATCTGTCTCTCATGCA | 410 | 420 | 430 | 440 | 450 | 460 | 470 | 480 | 490 | 500 |

AC15-2A  
AC15-2B  
AC15-2C  
AC15-2D  
AC15-2E  
AC15-2G  
AC15-2H  
AC15-2I  
AC15-2J  
AC15-2L  
AC15-2N  
AC15-2O

SEQ ID NO:

|         |                               |     |
|---------|-------------------------------|-----|
| AC15-2A | TAAGTACTTGTGTTTCACTCTCAGG -56 | 779 |
| AC15-2B | TAAGTACTTGTGTTTCACTCTCAGG -57 | 777 |
| AC15-2C | TAGGTACTTGTGTTTCACTCTCAGG -58 | 777 |
| AC15-2D | TAGGTACTTGTGTTTCACTCTCAGG -59 | 788 |
| AC15-2E | TAAGTACTTGTGTTTCACTCTCAGG -60 | 721 |
| AC15-2G | TAAGTACTTGTGTTTCACTCTCAGG -61 | 781 |
| AC15-2H | TAAGTACTTGTGTTTCACTCTCAGG -62 | 738 |
| AC15-2I | TAAGTACTTGTGTTTCACTCTCAGG -63 | 722 |
| AC15-2J | TAAGTACTTGTGTTTCACTCTCAGG -64 | 784 |
| AC15-2L | TAAGTACTTGTGTTTCACTCTCAGG -65 | 699 |
| AC15-2N | TAAGTACTTGTGTTTCACTCTCAGG -66 | 778 |
| AC15-2O | TAAGTACTTGTGTTTCACTCTCAGG -67 | 763 |

( ) ( )

SEQ ID NO: 68

RLG3 (real RLG3)

[Strand]

```
1  AATGGCAAAA GAAGTCGGAG CAAGAGCTAA GTTAGAGCAT CTATTGACG TCATTATCAT GGTAGATGTC
71  ACTCAAGCAC CCAACAAGAA CACAATTCAA AGTAGTATTT CAGAACAGTT GGGATTAAAA CTGCAAGAAG
141 AGAGCTTGTTT GGTAAAGACA GCTAGGGTAA GTGCGAGGTT AAAAATGCTT ACAAGGGTGC TGGTGATATT
211 AGACGATATA TGGTCAAGGC TTGACATGGA GGAACCTGGG ATTCCCTTTG GATCAGATAG ACAACACCAC
281 GGCTGCAAAA TCTTGTGGAC TTCAAGAAGT ATTAGTGCTT GTAACCGAT GAGAGCTGAT AGAATCTTTA
351 AAATACGAGA AATGCCACTG AATGAAGCAT GGCTTCTTTT CGAAAGAACA GCTAAAAAAG CTCCGAATCT
421 GCATCAAGTA GCAAGAGATA TCGTGGAGGA GTGTGGTGGG C
```



RLG4  
SEQ ID NO: 69

```
1  GAATTCGGTG TTGGTAAGAC AACTCTTGCC TCTTCTGTTT ATGATGAAAT CTCTAGCAAG TTGATGGTT
71  GCTGCTTTCT AAAAATATCT GGGAGGAATC AAGTAATAAA GACGGTATAG AAAGATTGCA AGAAAAAATC
141 ATTGTGTATG TTTTGAAACA AGAGCAAGTG GCGGTAGGGA GAGTTGAAGA AGGAAAGCGC ATGATAAAGG
211 ATAGGTTACA ACATAGAAAG GTATTGATTG TGCTTGATGA TGTGACAAC GTTGAGCAGC TAGCTAGAAC
281 AGTTGGCTGG ATCACAATGAT TGGTTTGCTG AAGGTAGCCG CATAATAATC ACAACTAGAG ATGAACATGT
351 ATTAATTGCA CACAAAGTAG ATGTGATACA CAATATAAGC TTGTTAAACA ACGATGAAGC TATGCATCTC
421 TTCTGCAAGC AAGCACCACG GGGTCACAAA CGTATACAAG ATTATGAGCA ACTTTTAAAA CATGTGGTTT
491 CTTATGCTGG TGGGCTTCCA CTAGCACTGT CGAC
```

SEQ. ID NO: 70  
RLG1-E169  
[Strand]

```
1 ATCGTAACCG TTGCTACGAG ANCGCTGTCC CTCCTTCATC TTTGTGCTATA TGTCATATTC TCATNNATN
71 TGCCACATCT AATTTTGTGG TTATTTTAAA TTAATTTTTA TTCCACATGT CATTTTATGA GTTTTCTAT
141 TTTATTGAGT TTCACATAAT ATTTAAATGT AATAACAATA AATGCATATT TATTTTCTT TAAATAAACG
211 CATATAATAT ATAGATTAAA ATCATATAAT ACATAGGTTA AACTCATATA ATACATATGT TCATCCCCAG
281 TTTATTTATA TGCTCATCC TTAATTTATT TATTTATTAT TTATTAGAGT AGATGATCTT TGTGATATTA
351 AAAATTTAAT TTGTTCAAAA TTTAAATTA TTAATAATCC CACAATTGA ATAAATTAA AAAAAATGGN
421 CCCACCATTA GTCCATCACT TTTTCAGCTC ATCAATATCG TGAGTATTCT CCTTCGTTTC CACCCTAATC
491 AATATTTCCA GCGAATGACA GACTCCTACG GCGTTTCTGA ATTTCCGTTT CGACACTGTT CATTTGAAGGA
561 GATAATAAAT CAAATGGAGC TGCTCCAATG TTCAATTGCTG ATGAAAGGTG AATTGTATGT GAAGANAATG
631 TCAGCGATCT ATCTCCATCC GGAACCCACC ACATTATCAG TGTACCACCA AACCACTCAA AACGGYGGAA
701 GTAGRRAKAC WRKAAAGTCA TGAAGARTAG ATTATTTTGG TCCTCATGGG CTGACTGAGG AGCGGTTTA
771 GTTCATCACT TTCTTTTGAN CAAAGAATTA TCGGTCCATC GAATTTTAC ATCGACAAG AGCTTTCCT
841 TCGCAATGTT TTGTTAACA ATTTTAAATC TTTTATCTT TCGTTGAAA CTCTCAATT GCAACTTGCA
911 ACTTGCAACT TTGCGGCCCA CAAATTTGTG GTGGGCGTTA ATTTAATCCA CATATTCCT GTAAACAATA
981 ATTCAAATCG ATCTCTGTT ATCCAATFCA TCAACATCTC TTGATAATTG AAATCATFCA CGCTTCATCC
1051 ATTTCAATCCA CATCTATACT ATATTCTCTG CTCTTATCAT ATTAAACGAT GGCTGAATC GTTCTTCTG
1121 CCTTCTTGAC AGTGGTGTGT GAAAGCGTGG CATYTGAAAG CTGGAAGAAG ATTTGTCTGT CCAAAAGAA
1191 TGAATCTGAG CTTAGAATAT TGAAGGAGAC ATTAGACCAA ATCCAAGATC TGCTTAACGA TGCTTCCAG
1261 AAGGAAGTAA CTAATGAAGC CGTTAAAGA TGGCTGAATG ATCTCCAACA TTTGGCTTAT GACATAGACG
1331 ACCTACTTGA TGATYTTCCA ACTGAAGCTG TTCAACGTGA GTTGACCGAG GAGGGTGGAG CCTCTCCAG
1401 TATGGTAAGA AAACATATCC CAAGTTGTG CACAAGTTTC TCACAAAGTA ATAGGATGCA TGCCAAGTTA
1471 GATGATATTC CCACAGGTT ACAAGAATCG GTAGAGCCAA AAAATAATCT TGGTTAAGT GTGATAACAT
1541 ATGAAAAGCC AAAAATTGAA AGGTATGAGG CGCTTTGGT AGATGAAAGC GGTACTGTCC GACGTGAAGA
1611 TGATAAGAAA AAATTCCTGG AGAAGCTGTT GGGGGATAAA GATGAATCAG GGAGTCAAAA CTTCAGCATC
1681 GTGCCCATAG TTGGTATGGG TGGAGTTGCT AAAACAATC TAGCTAGACT TTTGTATGAT GAAAAGAAAG
1751 TGAAGGATCA CTTCGAATC AGGGCTTGGG TTTGTGTTTC TGATGAGTTT AGTGTTCCTA ATATAAGCAG
1821 AGTTATTTAT CAATCTGTGA CTGGGGAATA GAAGGAGTTT GAAGACTTAA ATCTGCTTCA AGAAGCTCTT
1891 AAAGAGAAAT AGTGGGCCCA TTCTTCTCTA ATAGTTTGG ATGATGTGTG GTCTGAAAGC TATGGTGATT
1961 GGGAGAAAT AGTGGGCCCA TTCTTCTCTA ATAGTTTGG ATGATGTGTG GTCTGAAAGC TATGGTGATT
2031 GCAATTCCTC AGAAGCTGGG GCTTTCTCTA TCAAGACCTT CTGGAGGCTC TATCACAAGA TGATGCTTTC
2101 TCTTTGTGTT CTCAACAGCC ATTTGGTGTG CCAAACTTTG ATTCACATCC AACTCAAGG CCACATGGAG
2171 AACGTGTTGT GAAGAAATGT GATGGCTTAC CTCTAGCTTT AAGAACACTT GGAAGGTTAT TAAGGACAAA
2241 AACAGACGAG GAACAATGGA AGGAGCTGTT GGATAGTGAG ATATGGAGGT TAGGAAAGAG CGATGAGATT
2311 GTTCCGCTTC TTAGACTAAG CTACAATGAT CTCTCTGCTC CTTTGAAGCT RTTTRTTGCA TAYTGCTCTC
2381 TGTTTTCCCA GGACTATGAG TTGACAAAGG AGGAGTTGAT TCTATGTGG ATGGCAGAG GGTTTTTCGA
2451 CCAACCAACT AYAAACAAGT CAAAGCAAGC KITGGGTCTT GAATATTTTR AAGAGTTTTR GTCAAGRTCR
2521 TTTTTCACAC ATGCTCCTAA TRRCAATCS TTGTTTGTGA TGCAAGCTT AATGAATGAT TTGGCTACAT
2591 TTGTTGCTGG AGAATTTTTT TCAAGGTTAG ACATAGAGAT GAAGAAGGAA TTTAGGATGS AATCTTTGGA
2661 RAAGCACCCT CATATGTCAT TTGTATGTGA GRATTACATA GGTACAAAAA RGTTCGAGCC ATTTAGAGGA
2731 GCTAAAAAT TGAGAACATT TTTAGCATTG TCTGTGGGG TGGTAGAAGA TTGGAAGATG TTTTACTTAT
2801 CAAACAAGGT CTGTAATGAC WTACTTCARG ATTTACCATT GTTAAGGGTC CTRAKTTTGA TTRRTCTTAY
2871 AATAASYRAG GTACCAAAK TCGTSGGTAG TATGAASCAC TTCCGGTATC TTAATCTATC WGRAACTTWA
2941 ATCACHCAAT TACCGGAWA TKTCTGCAAT CTTTATAATT TACARACCTT GATGTGNTCT GCGTGTGANT
3011 ATTTAGTTAA KITGGCCCAAR ACCTTCTCAA ASCTTAAAAA TTTCGASCAT TTTGACATGA GGGRTACTCC
3081 KAAKTTTAA AACTGCCCCT TARGGATTGG TGARTTGAAA ARTCTACAAA CTCTCTTYNG TAACATTGGC
3151 ATAGCAATTA CCGAGCTTAA GAACCTGCAM AAYCTCCATG GGAAARTTTG TATTTGGGGG TWAATGARTT ANAACTGGR
3221 TGGAAAAATC NGTJGGATGC ACCTTAAGCG AACTTGTCTC A: AAAAAGGT TAAATGARTT AATGAATTGA
3291 WTKGGGGCTG ATRAATTTAA TGTTTTCCGA AATGGGAACA CTGAAAAA NAAGGTCTCT AATGAATTGA
3361 ATGCTCACA ATGCTATTCY AAMWAARRRY YWTRWAT TWKAWRRK KGKTTYATRR TKTTHYRAW
3431 WAGRTKTR KARGTAGTT TCATCCAATC ACCCAAGTGG GAAATAGAT GATATTTTCA GGCYACTG
3501 ATGAGATGCT GAGAGGTATG ATAGGNTVTC TTGGGGCGGT AGAAGAAATA AGCATCCATT CTGTAAATGA
3571 AATAAGATA YTGTTGGAAAT CAGAAGCAGA GGCAAGTAAG GTTCTATGA ATTTAAAGAA GTTGGATTTA
3641 GGTGAATGCT AAAATTTGTT GAGTTTGGG GAGAAAAAGG AGGATAATCA TAATATTAT ATGGGGAGCA
3711 CCCTAACATC TTTTAGAGG TTGAATGTAT GGAGATGTAA CAGCTTGGAG TCCGCTCTCT TCCCAACAGG AGGAGGACAG
3781 CATGGAGAA TTGTATATGC ACATGTGTGA TTCAATNACA TCCGCTCTCT TCCCAACAGG AGGAGGACAG
3851 AAGATCAAGT CACTTACCAT CACTGATTGC AAGAAGCTTT CGGAAGAGGA GTTGGGAGGA CGAGAGGACAG
3921 CAAGAGTCTC TATAAATCA AAAATGCCAG TGCTTGAATC AGTAGATATA CTTAATTGGC CAAATCTGAA
3991 ATCTATCACT GAATTGAGTT GCTTCATTCA CCTGAACAGA TTATATATAT CAAACTGTCC GAGRTGGAG
4061 TCATTTCTCT ACCATGAGTT GCCAAATCTC ACCTCTTAA CAGATCGAAG GAGAGGACAG CGATTTTCTT
```

RLG1-E169  
[Strand]

4131 ACGAACGGTT ACGATTGGAC TGGCCGTCGT TTT

SEQ ID NO: 70

*Further Characterization of RG2 Family Members:*

Further sequencing of cloned RG2 polynucleotide sequences, as discussed above, identified additional RG2 species, listed below. Additionally, further sequencing of the 5' sections of RG2 sequences listed above resulted in modified and/or new sequence information, also listed below. The AC15 sequences found in the 3' sections of RG2 family have not changed.

Listed below are: four full length species, RG2A, RG2B, RG2C and RG2S; two near complete, but with a gap in the largest intron, RG2D and RG2J; three nearly complete RG2 gene sequences, RG2K, RG2N, and RG2O. The deduced translation products (polypeptides) encoded by these RG2 species are listed below. The polynucleotide sequences do not contain any gaps (as with some of the polynucleotide sequences), because all of the gaps in the sequences are in introns, *i.e.*, there are no gaps in exon, or coding, sequences.

They include: an RG2A polynucleotide sequence (SEQ ID NO:87) and its deduced polypeptide sequence (SEQ ID NO:88); an RG2B polynucleotide sequence (SEQ ID NO:89) and its deduced polypeptide sequence (SEQ ID NO:90); an RG2C polynucleotide sequence (SEQ ID NO:91) and its deduced polypeptide sequence (SEQ ID NO:92); an RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94), and its deduced polypeptide sequence (SEQ ID NO:95); an RG2E polynucleotide sequence (SEQ ID NO:96) and its deduced polypeptide sequence (SEQ ID NO:97); an RG2F polynucleotide sequence (SEQ ID NO:98) and its deduced polypeptide sequence (SEQ ID NO:99); an RG2G polynucleotide sequence (SEQ ID NO:100) and its deduced polypeptide sequence (SEQ ID NO:101); an RG2H polynucleotide sequence (SEQ ID NO:102) and its deduced polypeptide sequence (SEQ ID NO:103); an RG2I polynucleotide sequence (SEQ ID NO:104) and its deduced polypeptide sequence (SEQ ID NO:105); an RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107), and its deduced polypeptide sequence (SEQ ID NO:108); an RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110), and its deduced polypeptide sequence (SEQ ID NO:111); an RG2L polynucleotide sequence (SEQ ID NO:112) and its deduced polypeptide sequence (SEQ ID NO:113); an RG2M polynucleotide sequence (SEQ ID NO:114) and its deduced polypeptide sequence (SEQ ID NO:115); an RG2N polynucleotide sequence (SEQ ID NO:116) and its deduced polypeptide sequence (SEQ ID NO:117); an RG2O

polynucleotide sequence (SEQ ID NO:118) and its deduced polypeptide sequence (SEQ ID NO:119); an RG2P polynucleotide sequence (SEQ ID NO:120) and its deduced polypeptide sequence (SEQ ID NO:121); an RG2Q polynucleotide sequence (SEQ ID NO:122) and its deduced polypeptide sequence (SEQ ID NO:123); RG2S polynucleotide  
5 sequence (SEQ ID NO:124) and its deduced polypeptide sequence (SEQ ID NO:125); an RG2T polynucleotide sequence (SEQ ID NO:126) and its deduced polypeptide sequence (SEQ ID NO:127); an RG2U polynucleotide sequence (SEQ ID NO:128) and its deduced polypeptide sequence (SEQ ID NO:129); and RG2V polynucleotide sequence (SEQ ID NO:130) and its deduced polypeptide sequence (SEQ ID NO:131); and, an RG2W  
10 polynucleotide sequence (SEQ ID NO:132) and its deduced polypeptide sequence (SEQ ID NO:133).

*Characterization of New RG Family Groups and RG Species:*

Further BAC insert characterization and sequencing, as discussed above,  
15 identified new RG polynucleotide sequences. The new sequences were characterized as belonging to new RG families; designated RG5 and RG7. These RG polynucleotides sequences, and their predicted translation products (the polypeptides which are encoded by these sequences) are summarized and listed below.

Identified and listed below is an RG5 family member, designated as the RG5  
20 polynucleotide sequence set forth in SEQ ID NO:134, and its deduced polypeptide sequence (SEQ ID NO:135). This sequence contains an NBS region sequence.

Also identified and listed below is an RG7 family member, designated as the  
RG7 polynucleotide sequence set forth in SEQ ID NO:136. No deduced polypeptide  
sequence is given for the new RG7 family member as this sequence appears to be a  
25 pseudogene.

**RG2A polynucleotide sequence (SEQ ID NO:87)**

AAAGTTCATATCCAAGCTTGCCCTCCAACCTAGCTCCTTCAATGGCACC  
TCCTTCTCTTCAAAAGCACACAAGAACACTTTCAAGCTCAACCACACTCA  
30 CACAAGCTCTAGAACGAGGGTTAGGGGCACATTTAGGGTTTTGCTCTCTGG  
AAATGGTGTCTAAAAGTGAGGCCATAATGTTTCCTTATATAAGGCTCACTC  
CCACAATTAGGCTTTCAATCTGAACGTANTACGCCAGTGTAACACTATGG  
TACGCCCAACGTAACGCTAGTCTCCGCGTCAANAATACTCATGAGTA

CGCGCAACGTACTTTCCCTTACGCCAGCGTACTCAAAAGCCAAACATTC  
TTTTCAAGGACTAATTTTGACAACTTGAGGAAAGAAAAGGATCAAAGANA  
TATACTTGAATTCCGGGATGTTACAATGAAGTTGANACCTTGGCTAAAAA  
ATTAAATTGGTTGTGGAAGCCGTTGGCTGAGCAAGCAACAAGGGTAAAT  
5 TCGTAATCTACAAATGGTGTTATTTTCTATTTCTTCTTATTATTTTACTT  
GATTTACGGGTAGTTTTTTTTTCTTACAAAAAATATTAAAGTTGATAAAG  
TATAGCCACTAAAATTGACTTTTTTCCAAAACATAATGTCAAATGGTGCGT  
ATATGTATCATGTTGTATTANATAATGAATATGATGATNCTGTTCTATTT  
AANCCGAAAAAATTATCTAATGATTTTATATTGGAAAACAAAGTTGTGAT  
10 TTTTNGCATAATATAATCAAATCCNCTTTTGTNTGGGAGGTGGATAAATG  
TGGTAAATTTANAACAAGTGTTTTNACNTTGAAGGGTNTGGAAAGGTTGA  
AAAAAGTTAAATGATAAAATGTTTACACAAATGTTGTATCCGACTGAAT  
ATNATGTTTAAGGATNATTGTATTAAATTGTTGATATATAGTAAGCATAA  
ATATTTAGAATTGTGACTTAAATTTATAAGTTATNCNAACTGGATTGAAA  
15 CATTTTTGATATANATTAGGAATGAAAATGAGCAACCCTAACATACTTAT  
CTTTGGTAGTTTGGTTATTATATTTTTATTANAATATAGAANCATCCCTT  
TATTTTAAACCCATATTGTGGACGGACTTGAATAAATGGGAAAAATGTAC  
CTTGCTATTTAGCACAAAAAAATTATAAAAATGTACATTGCTATTTAGCA  
CAAACAAAAAATAAATCTTATCCTTTTTGCATTAGGTCACAAAGAAATA  
20 TAAATGGGAAATGTGTTGCTATTTAATGCACTAAAAGAACTATTTTGC  
CTTTATTAACCGGGTAAACCAATAGAAAAATGGAAGTACATTGTCATTT  
AGCATGAAAAAAATAACTTTCCATTTTTTGCATCCGGTCACAATAATAG  
AAAAATGAAAGTACGTTGCTATTTAGCGAACTAACTCCTTTTTTCTTT  
TTGGCATCGTATCATAAAATATAGACTAAAATACGTTAGTTTTACATTTT  
25 TAATACATTGAAATGTCTAATCCACATGTTATTCTATAAAAAGGGAAATG  
TAATTTACTTATTCTTTGATTCTTTGGCTTCTTTTTAGTACCCAAAACAT  
CCCTCTATCCATCTATTCCAATAAATAATGAAAATATATTCCTTCCA  
TTGTAGGGATGTTATAAATTTTGTAAATTGTTTTTATGCAAAAAAGTGTTT  
TTTGTTAACTAGATTAACGAGATTCATTTTTCAGCATTTTAGGAGAAGTT  
30 CATCCATCTTTTGATATGAAGTGCAAGCCAAGTTCTTTAACATGGAATA  
TGAGGTCCCTATATGCTCAAAAAATAGCAAATGAGAAATTTTTTAAATTG  
GATCCCCATAAAAGAAAATTTGTTAATGGTTGTTTTAATATTGGTCAATG  
TGTCCACCGGATGAGCATAATACTAGTTTATAAGGGGTAAAGGTGGGTTT  
GGTGGGCCCATTTATCTTTATTATTTCTAAAAGTCAGAATTAAGTAAAAA  
35 AAATTATAAGATAAATACCATAAGGATAAAAAATCATTTTATTTGGACCA  
AAGACCAAAGTTGTTAAGGGGCTGTTTGTTTTTTTTGTGAAGAGCTGTGC  
AACCACTTTTGTCTGCGCCGCACAGACAACGTGCAGACATATGCCCTCGC  
AGAGTGTTTGTTTTTTGAAGGTGCGCAGACCAAAAAAACGTCTGCGCGAG  
GTCATCCTGGCGCATATATGTGTCACTGTCTTCAAAGGTCTTCAGACCTC  
40 ATTTTAACCAAAAAAAGACCACCGGTTTTTTTTTTTTTTTNTTC  
TTTCTCTGTAGCTGAAAATGCATTTTAAATCTTTATGACATGAAATTAA  
GTTTGAAAAATTAATTTATTTCAACAGCTGTAGACGTTAAAAACAAACAG  
TCTTCTTGTTGCAGACTGTGGACATTTGGTCCACCTCTTCTACCGCAGAG

ACTTGCAGATGTGGTCCGCAGACTGCAGACATTTTGGCTTCAAATAAACA  
AACATCACCTAATTTGACTACACCACACGGACCTCCAATGTAACAAAAA  
AAGGTTGAAACAAAGTTGCCTATTTCTCCATATCCAGGGGCCATTTATGT  
AAGAGTTATCTAAATTTTAGTTCGGTAGATCAGTTCTCACATTTTAACCG  
5 GGTAAAGTGTATGTGTGTACGCGCGCACCTGAAAGGTTTGAANGTAACTT  
CCAACTGAANCAANAATCGATATGAAGTATCAAGTTAGAGGTTCAATTG  
GTG.AAGGAATCAGCTGGAGGTTGGGGAATCGAGCTTCCACTATTAAGGTA  
AAATCCATAACCCTAAATGTTGGTACGCTCATATATCAAATTGCGTGT  
TGTTGAATGAAAAAAGCATGCTCAAAAAACCAGTGTAAAGGCACGGTATAT  
10 GACATATTTATAGTTACTGATAACAAATTATGATAATTTTGGGTTTACGT  
AAGTTAGGATTTCGTACTTCAACCAAATGTAATAGTTTTTGTGAGTCTATC  
TATGTATTTGGGGAATCACATTAGCAACGGGATTGTACTAGTAATTCGAA  
AAAGTCTTTTAAATAATTTTCTGTTTATAATTTATGAATAGTTTTAGCG  
ACATCTAATATTAATAAGAATGTATCTGATATTGAATTAATGTCCTTAAT  
15 GTG.AACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTTCTAAT  
CAATAAATTTAATTTCTGTTTTATGCTTCTAAGACAATAAAAAATCCATG  
ATTTACCTTTAAATATTAACAAAAATGACCATAAATAAAAAAATTAG  
GATACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGATGCTTT  
TGCTTTTCCCTCTTTTCCCTTGTTAGTCTATTATTCTGGAGAGTTTGAGAG  
20 AGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTATTCTC  
TTTTCTTAATTATGTATTAACCTTACAAGCATTTTTTACACGATCCATGGT  
TTTTTGTGTATGTTTTTCAAATTGAAACTAGATTGGGACTTTTGCCCTTG  
ATG.ATTCATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAGTGGTG  
AAT.AGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATGATGAT  
25 GAG.ATAGAGATATGTTAAAACCTGGCTAGAAAATTGTTTTAATTTGAAATT  
TAGGTTGTTGAATTTGAAAGATACCAAGCTAATAACTAATTAGTTATGCT  
AAATAGTTATAAAGAACAACAACTCGTAGTTTTTTTTTCATGATTTTCA  
ACCTCTTCGTACCAAATAAATTATAACAAAATTGAATATCATTCTCTGC  
AATCAATTTTAACTTTTGTTATTATCATCATGTCTAAAATTGCCACAAGT  
30 TTATTTTCATAGTCATATTGGATTATGAAAGGACTATTTTACCAATTAC  
ATCTTTACTTTATGGCCAAAGCTAATACAATCCGACTAACTAAAGGATT  
CTAGGATGCATATAGTTTGCTCCCCGATTATAGATTCTATCTAATTTGT  
CTATTGTACTAATTTAGGTGCCACCACAAGTAAATTCCTGAAATGGATGT  
CGTTAATGCCATTCTTAAACCAGTTGTCTGAGACTCTCATGGTACCCGTTA  
35 AGAAACACATAGGGTACCTCATTTCCTGCAGGCAATATATGAGGGAAATG  
GGTATCAAAATGAGGGGATTGAATGCTACAAGACTTGGTGTCTGAAGAGCA  
CGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCAAGTCAGGG  
GTTGGTTTGAAGAAGTAGGAAAGATCAATGCAAAAGTGGAAAATTTCCCT  
AGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGGTCGGAAA  
40 GAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTGATGAGAGAACACT  
CTATCATCATTTGGAATGATCATTCCATTCTTTAGGAAGAATTGATTCC  
ACGAAAGCATCCACCTCAATACCATCAACCGATCATCATGATGAGTTCCA  
GTC.AAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGATCCTAACC

ACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGGGAAGACG  
ACAATGATGCATCGGCTCAAAAAGGTTGTGAAAGAAAAGAAAATGTTTAA  
TTTTATAATTGAGGCGGTTGTAGGGGAAAAAACAGACCCCATTTGCTATTC  
AATCAGCTGTAGCAGATTACCTAGGTATAGAGCTCAATGAAAAAACTAAA  
5 CCAGCAAGAACTGAGAAGCTTCGGAATGGTTTGTGGACAATTCTGGTGG  
TAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGTGGATCTGA  
ATGATATTGGTTTAAGTCCTTTACCAAATCAAGGTGTCGACTTCAAGGTG  
TTGTTGACATCACGAGACAAAGATGTTTGCAGTGAAGTGGGAGCTGAAGT  
TAATTCAACTTTTAATGTGAAAATGTTAATAGAAACAGAAGCACAAAGTT  
10 TATCCACCAATTTATAGAAATTCGGATGATGTTGATCCTGAGCTCCAT  
AATATAGGAGTGAATATTGTAAGGAAGTGTGGGGGTCTACCCATTGCCAT  
AAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCATGGAAGA  
ATGCACTTCTTCGTTTAGAGCACTATGACATTGAAAATATTGTTAATGGA  
GTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTAAATCCAC  
15 CTTTTTGCTTTGTGGAATGTATCCCGAAGACTTTGATATTCTTACCGAGG  
AGTTGGTGAGGTATGGATGGGGGTGAAATTATTTAAAAAAGTGTATACT  
ATAGGAGAAGCAAGAACCAGGCTCAACACATGCATTGAGCGGCTCATTCA  
TACAAATTTGTTGATGGAAGTTGATGATGTTAGGTGCATCAAGATGCATG  
ATCTTGTTTCGTGCTTTTGTGTTTGGATATGTATTCTAAAGTCGAGCATGCT  
20 TCCATTGTCAACCATAGTAATACACTAGAGTGGCATGCAGATAATATGCA  
CGACTCTTGTAAGAAAGACTTTTCAATTAACATGCAAGGGTATGTCTAAGTTTC  
CTACAGACCTGAAGTTTCCAAACCTCTCCATTTTGAACTTATGCATGAA  
GATATATCATTGAGGTTTCCCAAAAACTTTATGAAGAAATGGAGAAGCT  
TGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCCTCATCAC  
25 CTC.AATGTTCCGTCAACCTTCGCGTGTTCATCTACATAAATGCTCGTTA  
GTGATGTTTGACTGCTCTTGATTTGGAATCTGTGCAATCTAGAAGTGCT  
TAGCTTTGCTGATTCTGCCATTGACCGTTGCCTTCCACAATCGGAAAGT  
TGAAGAAGCTAAGGCTACTGGATTGACGAATTGTTATGGTGTTCGTATA  
GATAATGGTGTCTTAAAAAAATTGGTCAAACCTGGAGGAGCTCTATATGAC  
30 AGTGGTTGATCGAGGTGCGAAAGGCGATTAGCCTCACAGATGATAACTGCA  
AGGAGATGGCAGAGCGTTCAAAAGATATTTATGCATTAGAACTTGAGTTC  
TTTGAAAACGATGCTCAACCAAAGAATATGTCATTTGAGAAGCTACAACG  
ATTCCAGATCTCAGTGGGGCGCTATTTATATGGAGATTCCATAAAGAGTA  
GGCACTCGTATGAAAACACATTGAAGTTGGTTCTTGAAAAGGTGAATTA  
35 TTGGAAGCTCGAATGAACGAGTTGTTTAAGAAAACAGAGGTGTTATGTTT  
AAGTGTGGGAGATATGAATGATCTTGAAGATATTGAGGTAAAGTCATCCT  
CACAACTTCTTCAATCTTCTTCGTTCAACAATTTAAGAGTCCTTGTCGTT  
TCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTGTGCAACAC  
TTTAAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGATAATATGGAAG  
40 AACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTACATTCCTCAAG  
CTGAAGTTTTATCTTTGTGTGGGCTACCAAAGCTATCGGGTTTGTGCGA  
TAATGTCAAAATAATTGAGCTACCACAACCTCATGGAGTTGGAAGTTGACG  
ACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTTTGAAACATTT



AGTTTGTGAAGGAAGAGGTAATATAAATTTTAAATGCTAATACATTAC  
AAAGGATCTTTTCAGTTAAATCTTTCAAAATATATTGTAATTTGATTGTA  
TGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTATCTTGCAGGT  
TCTGATTCCCTAAGTTAGAGAAACTGCATGTTAGTAGTATGTGGAATCTGA  
5 AGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGTTAAGTTCAGA  
GAGATTAAAGTGAGTAACTGTGATAAGCTTGTGAATTTGTTTCCGCACAA  
GCCCATATCTCTGCTGCATCATCTTGAAGAGCTTAAAGTCAAGAATTGTG  
GTTCCATTGAATCGTTATTCAACATCCATTTGGATTGTGTTGGTGCAACT  
GGAGATGAATACAACAACAGTGGTGTAAGAATTATTAAAGTGATCAGTTG  
10 TGATAAGCTTGTGAATCTCTTTCCACACAATCCCATGTCTATACTGCATC  
ATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCCATTGAATCGTTATTC  
AACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAGACAACAGCAT  
CAGCTTAAGAAACATCAAAGTGGAGAATTTAGGGAAGCTAAGAGAGGTGT  
GGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTTGTTTCATGGCTTTCAA  
15 TCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAAGTTTAGAAATGTATT  
CACACCTACCACCACAAATTTTAATCTGGGGGCACCTTTTGGAGATTTCAA  
TAGATGACTGCGGAGAAAACAGGGGAAATGACGAATCGGAAGAGAGTAGC  
CATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTGTCTTAATTAATGAT  
TAAGCTCCTGCTTTTTGAATAAAAAAGGGACAAACCATTTTCATGACTTAA  
20 TGTAGCAATACAAGTCATGTATAAGAGTGACCAACTCTTTTTTATTTATA  
AAATGACTACAAAATATTTTTTTTTCATTAGAGATCATGTATAAATGTGAC  
TAATTTTTTCATCACCTAACTTTAGTTGATAAATCTTTATAAATGTCACTA  
GTTACTTTTTAGTAAATAACAAATTTAATAAATTATCAACAAAAAAGCAT  
CAACTAAAAAATCCCACAACCCGTAATAATTTAAAAATAAAAGGATTTAA  
25 CATCTAATACGAACAATTTTTTTTCTAAACATGATTTGGACCAAATATCA  
CCAGCAACTCAAGTTTGAATCGATTTCAGCTTAAAACTTGACCAGCATAA  
TTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATATAAGTTCGTTTCATC  
TTTTTTCTTGATCTTGATAGCAAGTTGAATGATTTTCTTCTTCAAAATTG  
ATAAAAATCTACATTATAAAGAGACTAGCTTGAAAAAAAATGGTCTAGGT  
30 GGGTCTTGGGTCTGCTAGATGAAGATGGAAGGGGAGAGTAGATTTCAAA  
GACACAACACATCCTTCATTTTATTTATTATTATTATTATTTTTTG  
ATATCTTGCTCATATTTGTTACAGATATGTGAGGTCTATTAATCTTTTTA  
AATATATAAAAAAATAAATAACATAAATGAGAAAATTAAATAAAGAATAA  
ATTAATAAGGGCACAATAGTCTTTTTTAGGTAAGACAAGGACCAAACACGC  
35 AACAAAAATAAACAGTAGGGACCATCCGATTTAAAAAAAATAATTAGGGA  
CCAAAAACATAAATTCCCCCAAACCATAGGGACCATTCATGTAATTTACT  
CTTACTTTTCGTTTTGTTTCATATTTGGGTAACCTATTTTTTTGTACACAT  
CTAGGTAACGAACCTGTTGAAGTGTTCCCATTTAGGATGTGACCTACTAC  
AACCGATCATAATAGTCATATGTGAACACTTCCAACAACCTTATTACTTA  
40 GGTGTGTACAAAAAACAATAGTTACCATGATGTGAACATACTGAAAAAT  
TAATTACCTTAGCAAGTTATTTCCCATTTAGGTTGTATGGAAACAGTTC  
CGTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAACTTAACCCTTC  
AATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGATT

CTTGTTTGAAAGTAAGTTGCATCTTTATTTTGTATTATCTTGTTGCATA  
GGATCCTTAGCATCTTTAATAATTTATTTGAAGGTGAAAGATCCAACATA  
TTTTTAATCTGTTGGCATTTCATCATTGCAACTGTTTCTTGAAAAA  
AAATACCTAAAATCAAAATAACCATTTTCAAATCCAAAATTATAAGAGAG  
5 AATTGTAAATGGACATGGAATCATAAATCATTAACACAGTTCAGTAAACA  
AGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAA  
GAGACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATC  
CTGTCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAG  
TTAAAGGAGTGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGT  
10 AGAGAATTGGTAACAACCTACCATTAACCAACAACAACCTATTATACTTCC  
CAACCTCCAGGAATTGATTCTATGGAATATGGACAACATGAGTCATGTGT  
GGAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAACAATCA  
GAATCCCCATTCCACAACCTCACAACCATAAAAATTATGTATTGCAAAAG  
CATTAAGTACTTGTTCGCTCTCATGGCAGAACTTCTTCCAACTAA  
15 AGCATATCAAGATAAGAGAGTGTGATGGTATTGGAGAAGTTGTTTCAAAC  
AGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAAC  
CACCCTTTGTTCCCTAGTCTTGATTCTCTCACTCTAAGTTTCCTGGAGA  
ATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAA  
ATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCAATTTGA  
20 GGTATGCTTTGTACATATTCAATTATTTATTTAATTTCTTTTATTTG  
CAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAAT  
TACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCT  
AGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGAT  
GGGTAATATAGGCAATTTAAGTTTATTTCTGTAAAGCAGTATTTAGCA  
25 AGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTC  
ATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGTCAT  
CAGGTGACAGATATTGTAGAATAGAACAATATATAATATCACCCAAAAC  
ATTTTTCTAAGGTTATTCTGTAAATATGTGCTTTCTTGTTTTTCATNGA  
ATTNGCATTCGTATATTTTAGGTGTTAAAGTGATTTTNTCTTCAATAAAT  
30 CCCGAAATTAATTAACCAACCAACCAACCAACCAAGTACATTTTGATGTGGAG  
AGCACTGGTATCACTTAGTATATAAAAGCTTGATTTTGAATTAACCTTC  
TTATACAAAAGTTGTGTATATAGTTTAATTAGTTTTACATCATTTTCCA  
TGTGGTGTGTCAGTTGTCTGAAGCAGGTGGTGTCTTGAGGCTTATGCC  
AATACGCTAGAGAGATGAGAATAGAATTCTGCAATGCATTGTCAAGTGTA  
35 ATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGACAGT  
AAGTGATTGCAAAGGGATGAAGGAGGTATTTGAACTCAATTAAGGAGGA  
GCAGCAACAAAACAACAAGAGTGGTGCAGGTGAGGAAGGAATTCCAAGA  
GTAAATAACAATGTTATTATGCTTTCTGGTCTGAAGATATTGGAAATCAG  
CTTTTGTGGGGTTTGGAACATATATTCACATTCTCTGCACTTGAAAGCC  
40 TGAGACAGCTCCAAGAGTTAAAGATAACATTTTGCTACGGAATGAAAGTG  
ATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGTAAACAACAACAAC  
AACACAATAACGAAGGGGGCATCATCATCATCTTCTTCATCTTCTA  
AGGAGGTTGTGGTCTTTCCTCGTCTCAAATCCATTGAACTAAATGATGTA

CCAGAGCTGGTAGGATTCTTCTTGGGGAAGAATGAGTTCCGGTTGCCTTC  
ATTGGAAGAAGTTACCATCAAGTATTGCTCAAAAATGATGGTGTTCAG  
CTGGTGGGTCCACAGCTCCCCAACTCAAGTATATACACACAGAATTAGGC  
AGACATGCTCTTGATCAAGAATCTGGCCTTAACCTTCATCAGGTATATAT  
5 ATTTCTTTAATTGGCATCATCTAATTAAGAAAGATATCATTCTGCCAAG  
TAAATTTACTTCAAACACATTACACTGGTTTCAGTCTAAGTTTATGTTG  
TTCTAGGAAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTT  
CAGTGGAAGGGTATTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGG  
CTTTTTAGTACCTGGAATCGTGTGTGGGAGGAGCATTATTATTCTGATTT  
10 GCTTGTTTCTTTATCATTTTTTCTTAGCCTCTGGAACAGCTAGAAACCCT  
TTTAACTTTTTGATTTTCAATGACAAAATTTTCTGTACTACATTTGA  
TTGTTGTTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCT  
TTTGATTGTTATTTTCATATCATGTTAGTCACTTGAATCAAGCTTTTCTA  
TTTTCAACCAGGGCAAAAGGTCAAAAGTAACCTACTTTATGAGATCAAAA  
15 ACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACC  
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAATTGGTAC  
AGCACATATATGACATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCT  
GGCGTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTG  
ACACCTTGGGCCCTGTAACCTCAGAAGGGACAACCTGTTCTTTTCATAAC  
20 TTGATCGAATTATATATGGAATTTAATGATGCTGTAAAAAGATTATTCC  
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTCATGTGACTT  
ATTGTAATTGGGTAGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGG  
AGAAATGGAAATAGTGGAATTGGTTTTGATGAATCGTCACAAACAACCTAC  
CACTACTCTTGTCAATCTTCCAAACCTCAGAGAAATGAAGTTATGGTATC  
25 TAAATTTGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG  
TTTCCAAACCTAACAAGAGTCGATATATGGGGATGTGATAGGTTAGAACA  
TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAC  
GCATATGGAAGTGCAGTCAGATAGAGGTCGTGATTGTTTCAGGATGCAGAT  
GTTTGTGTAGAAGAAGACAAAAGAGAAAGAATCTGATGGCAAGACGAATAA  
30 GGAGATACTTGTGTTACCTCGTCTAAAGTCCTTGATATTAACACCTTC  
CAWGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTA  
TTGGATACYTTGGAAATCTACRAATGCCCAGCAATAACCACCTTCACCAA  
GGGAAATTCCRCTACTCCACAGCTAAAAGAAATTGAAACAMATTTTGGCT  
TCTTTTATGCTGCAGGGGAAAAAGACATCAACTCCTCTATTATAAAGATC  
35 AAACAACAGGTAAACCAGATCTTTGTTGCTTNNATAATTCTTAAACNACA  
TNTGAAAAGCTTCATGCAAGTTTTTTTTNGTTATATNGTCAAAAACCGCAA  
CCTACATTTTCAGCTTTANATTTATGTACTTTATGCAGGATTTCAAACAA  
GACTCTGATTAATGTGAAGTGAATATTAAAGGTAAATTATATTTTCATGT  
TCCTAGTNGCCTATTAATTAAGGCCTTTTAGTTTCGNGATTTTGGATGT  
40 ATTCCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTTGGTTG  
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA  
TATGAAGGACATTAAAGAACATGGATGCTCTGAAGATGTTGGGAACACA

**RG2A deduced polypeptide sequence (SEQ ID NO:88)**

MDVVNAILKPVVETLMVPVKKHIGYLISCRQYMREMGIKMRGLNATRLGVEEHVN  
RNISNQLEVPAQVRGWFEVVGKINAKVENFPSDVGSCFNLKVRHGVGKRASKIIEDI  
DSVMREHSIIWNHDSIPLGRIDSTKASTSIPSTDHDEFQSREQTFTEALNALDPNHK  
5 SHMIALWGMGGVGKTTMMHRLKKVVKEKKMFNFIEAVVGEKTDPIAIQSAVADY  
LGIELNEKTKPARTEKLRKWFVDNSGGKKILVILDDVWQFVDLNDIGLSPLPNQGV  
DFKVLLTSRKDVCTEMGAEVNSTFNVKMLIETEAQSLFHQFIEISDDVDPELHNIG  
VNIVRKCGGLPIAIKTMACTLRGKSKDAWKNALLRLEHYDIENIVNGVFKMSYDNL  
QDEETKSTFLLCGMYPEDFDILTEELVRYGWGLKLFKKVYTIGEARTRLNTCIERLI  
10 HTNLLMEVDDVRCIKMHDLVRAFLDMYSKVEHASIVNHSNTLEWHADNMHDSC  
KRLSLTCKGMSKFPTDLKFPNLSILKLMHEDISLRFKPNFYEEMEKLEVISYDKMKY  
PLPSSPQCSVNLRVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDRLPSTIGKLG  
KLRLLDLTNCYGVRIIDNGVLKKLVKLEELYMTVVDRGRKAISLTDDNCKEMAERS  
KDIYALELEFFENDAQPKNMSFEKLQRFQISVGRYLYGDSIKSRHSYENTLKLVLK  
15 GELLEARMNELFKKTEVLCLSVGDMNDLEDIEVKSSSQLLQSSSFNNLRVLVSKC  
AELKHFFTPGVANTLKKLEHLEVYKCDNMEELIRSRGSEETITFPKLFSLCGLP  
KLSGLCDNVKIIELPQLMELELDDIPGFTSIYPMKKFETFSLKKEEVLIPKLEKLHVSS  
MWNLKEIWPCEFNMSSEEVKFREIKVSNCDKLVNLFPHKPISLLHHLEELKVKNCGSI  
ESLFNIHLDCVGATGDEYNNSGVRIKVISCDKLVNLFPHNPMSILHHLEEELEVEN  
20 GSIESLFNIDLDCAGAIGQEDNSISLRNIKVENLGKLREVWRIKGGDNSRPLVHGFQS  
VESIRVTCKCKFRNVFTPTTTNFNLGALLEISIDDCGENRGNDESEESSHEQEIEILS  
EKETLQEATDSISNVVFPSCMLMHSFHNLQKLILNRVKGVEVVFEIESESPTSRELVT  
HHNQQQPIILPNLQELILWNMDNM SHVWKCSNWNKFFTLPKQQSES PFHNLT  
TIKI  
MYCKSIKYLFSPLMAELLSNLKHIKIRECDGIGEVVSNRDEDEEMTTFTSTHTTTT  
25 LFPSLDSLTLFLENLKCIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSW  
SLCQYAREMRIEFCNALSSVIPCYAAGQMQLQVLTVSDCKGMKEVFETQLRRSSN  
KNNKSGAGEEGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFSALESRLQLQELKITFC  
YGMKVIVKKEEDEYGEQ.TTTTTITKGASSSSSSSSKEVVVFPRLKSIELNDVPELV  
GFFLGKNEFRLP SLEEVTIKYCSKMMVFAAGGSTAPQLKYIHTELGRHALDQESGL  
30 NFHQTSFQSLYGDTLGPVTSEGTTCSFHNLIELYMEFNDAVKKIIPSELLQLQKLEK  
IHVTYCNWVEEVFETALEAAGRNGNSGIGFDESSQTTTTLVNLPNLREMKLWYL  
NCLRYIWKSQWTA FEFPNLTRVDIWGCDRLEHVFTSSMVGSLQLQELRIWNCSQ  
IEVVIVQDADVCVEEDKEKESDGKTNKEILVLPRLKSLILKHLPCCLKGFSLGKEDFSF  
PLLDLTLEIYKCPAITTFTKGNSTTPQLKEIETHFGFFYAAGEKDINSSI KIKQQDFKQ  
35 DSD.CEVNIK

**RG2B polynucleotide sequence (SEQ ID NO:89)**

TTTTTTAAGATCAGGGATTCAAATTCAGCCCTAGTGATTACAATTGTGTC  
TAAACTTTCCCATACCTTCACATTATTGTAAGTATACTTTCTCAGTTTCT  
40 CTCTTGGAAGCTTCCTTGGTATTTTAACTCGTGTCTAATATTTAACTCT  
GATAGTTATTTTGGCCAATCTACTATCTGCATGTCCGGTTATTGAATCCG  
AAGGCACTGGAATCTTGGATTCCATTCCGTTGTGTGTTTGGTTGCCAAAT

GAACGGAATTGAATTATGTAAGATTCCTTCAAAATCCATGTTTAGGTATA  
TCGTTGTTTCTTGGGATGGATGGTAAAGAACGGAATTTCTCCTGTTTCATT  
TTTTAATGAAAGACCAAATTGACCTTATAAACCTGTAAAAAAATTACAT  
TCCAGTTTTCTTAACAACTGAAAAATGGTAAAGGAGTGTGATTGAATTCC  
5 AATCTGTTTCCTGTCCAAAACACGTGACGGAATATTACAATTCCTTCAAA  
TTTCATTTTCTTAAATTGTTATTCCCTTTCTTACAAAAACAAGGTAAACG  
AAACACCCGCTTACTTAATCATACTCCTACATGATGTAAATGAAAAGGGT  
ATAAATGGTATTTTATTACAGGGATGAGTCACCATGGTCATGAAAGAAT  
CATTAACCGCCCTTACCCAATTCATGTTTGCCCCTAAAATATGATTTAAA  
10 GTAATATTGGCTTATGGGATTCAAGTTGACTTTTTTTGTGGCGAAGAAATA  
ATGAAAATCTTCATTTCTAAAGTGTCTTCTACCACTGACATTTCTAAGA  
AAGAACTTGCTAGAAGAAGGTGGGTGTTTAGTCTTTTACTCTTTAAAT  
GTGAAGACTGTTGAGTTATTATTATTTTGGCAACTATGGACAACCTTG  
TTTAGTTTTTTTTTTTCCCAATATCCATTTATATGCGATTTATTTCTGA  
15 AAT.AATTTTATCAAAACGCAGGAAACAATGTAGAATAATACTGGTATAAT  
TAATTATATAAAGTTATTAGGCTGAAATCTTGAGGCTACTATAATTTAAT  
TATCATAATTTGAAAATCATCAAATTGTATTCCATGTATATTTATGTTAT  
CAGATAATTAATAATATGTGAGCCACACAAATCCACATCATCAGACACCC  
CACCTTATTGTGGCTACCTCACCACTTGCATGATCCCGACATCTTCCCA  
20 ACCCCACCGACGACTTGGGGTCTCCTTAATATATCAATTATTTTCTGTAA  
GTATTTATTTGTGTAAATGTGTAATGTCATTTTACCTTTTTTCTAATATA  
TAC.AGAAACATAAATTTTAAATGAAATTCAACTGCGTTTCATTCTTGCAT  
TAAAAAAAAGACTGTACTGTTGTCAATATTTTACTTATAACCTGATTAA  
TTAATTAAGCGTAATTGCATAATTTGCATTAGGTTGTAATTTTGTGTTT  
25 TAT.AGGGAGGGTGAGGGTCACCGGGAATCAAAGCACTTATGTAAAAGCAG  
GGAAATACAAAAAATTTACTCGAAACAAATTTTATTCAATTTAAGTGAGA  
TAATAATGTTCTGATTAGATTATGAGAACTAGGAGATTTAAGTGATATAT  
CCC.ATTTAAAGAAATTGCATTATTAATTTTGGATCTCTTGATGATGACA  
AAATTAACCTCGTGACAGGTTATATATCATATACAAAATGAGTGGCTATGC  
30 TTTCGCTTTCCAAAAAGCAATTATAGTTATACTACACCTACAAATTTTAA  
AAGGGGTAAACATATCAAAATACTTGATAAGTAATTATATAAATATGCA  
TTT.AACCCTCTAAAGAAAATGCTACTAAGCTTGGACCATCTCAGAATTAC  
AATCATACCCTTCCCCTCAAAAAAGATTCGTATATATCATGTCATTTGGC  
ATTCATTTCTTTTTTACAATTCATAGTTCTATTCTCAAAAAATTCGAGTT  
35 CTCGTATTTGTAAGGAAGATCAGAAGAGACTGTTACACAGGTA CTCTCT  
TTT.ATTTATTGATTCACATTCATATATGTTATTGTTTTCTTGCTTAATGG  
TTTCGTCACTCTAACTGCGCTTGCTGATTTAAATTTCTTCACTTTCTTCC  
ACGGATTTTTTAAATATTAGTTTTGTGAATGAACAATTGGTGAAGGAAAG  
AAACATGGGAGTCTTTTCTAAAGTAAACCTAGATACTTAGGTTATAAGGG  
40 TATATGCTAAATGAACTATGCCATTACCTTTGCCTTTTCTTTTACTT  
TTTAGTTTTTAGAATCCAAGTTTTTCATATGTATCTCGATGTGTGAGAAGA  
ATAGGCATTAGAAAGGTAAAGGACGTACATAAAATTGATTAATTAGTGAA  
TGTTCTTTGATATCATTATTTTTACTCTCATAAAAAAGCATATAGATCAAA

CACAAATTGCTACTTGTTAGTGTAACAACCTCGACTTAATAATGTAAATA  
ATC.AAGATTCTCTTGATTTCAACTATTTTCTAACCGAACAAGCTCACTAA  
AAACTCATATTGCTTTGAGTCTGAGTGGTTTATATTTGGGGTTTACATT  
5 TAAATTTTTGTGCATGAATGTGAAAATAGACTGCTTATTGATTCTTTGTG  
TTTCATTGAGTTGATTTTCATTATTACTACCTTACAAATTGCTCAGTGAT  
AGATTTCCATTAATTTGCTAATTCGGTTGCTTCTAAATATGTAGGAGCTA  
CTAAAAGCAAAAATATCGAGCAATGTCGGACCCAACGGGGATTGCTGGTG  
CCATTATTAACCCAATTGCTCAGACGGCCTTGGTCCCGTTACGGACCAT  
GTAGGCTACATGATTTCCCTGCAGAAAATATGTGAGGGTCATGCAGATGAA  
10 AATGACAGAGTTGAATACCTCAAGAATCAGTGTAGAGGAACACATTAGCC  
GGAACACAAGAAATCATCTTCAGATTCCATCTCAAACCTAAGGAATGGTTG  
GACCAAGTAGAAGGGATCAGAGCAAATGTGGAAAACCTTCCGATTGATGT  
CATCACTTGTTGTAGTCTCAGGATCAGGCACAAGCTTGGACAGAAAAGCCT  
TCAAGATAACTGAGCAGATTGAAAGTCTAACGAGACAACCTCTCCCTGATC  
15 AGTTGGACTGATGATCCAGTTCCTCTAGGAAGAGTTGGTTCCATGAATGC  
ATCCACCTCTGCATCATTAAAGTGATGATTTCCCATCAAGAGAGAAAACCTT  
TTACACAAGCACTAAAAGCACTCGAACCCAACCAAAAATTCACATGGTA  
GCCTTGTTGGGATGGGTGGAGTGGGGAAGACTAGAATGATGCAAAGGCT  
GAAGAAGGCTGCTGAAGAAAAGAAATTGTTTAATTATATTGTTGGGGCAG  
20 TTATAGGGGAAAAGACGGACCCCTTTGCCATTCAAGAAGCTATAGCAGAT  
TACCTCGGTATACAACCTCAATGAAAAAACTAAGCCAGCAAGAGCTGATAA  
GCTTCGTGAATGGTTCAAAAAGAATTCAGATGGAGGTAAGACTAAGTTCC  
TCATAGTACTTGACGATGTTTGGCAATTAGTTGATCTTGAAGATATTGGG  
TTAAGTCCTTTTCCAAATCAAGGTGTCGACTTCAAGGTCTTGTGACATC  
25 ACGAGACTCACAAGTTTGCATATGATGGGGGTTGAAGCTAATTCAATTA  
TTAACGTGGGCCTTCTAACTGAAGCAGAAGCTCAAAGTCTGTTCCAACAA  
TTTGTAGAACTTCTGAGCCCGAGCTCCAGAAGATAGGAGAGGATATCGT  
AAGGAAGTGTTGCGGTCTACCTATTGCCATAAAAACCATGGCATGTACTC  
TTAGAAATAAAAAGAAAGGATGCATGGAAGGATGCACTTTCGCGCATAGAG  
30 CACTATGACATTACAAATGTTGCGCCCAAAGTCTTTGAAACGAGCTACCA  
CAATCTCCAAGAAGAGGAGACTAAATCCACTTTTTTAATGTGTGGTTTGT  
TTCCCGAAGACTTCGATATTCCTACTGAGGAGTTGATGAGGTATGGATGG  
GGCTTGAAGCTATTTGATAGAGTTTATACGATTAGAGAAGCAAGAACCAG  
GCTCAACACCTGCATTGAGCGACTGGTGCAGACAAATTTGTTAATTGAAA  
35 GTGATGATGTTGGGTGTGTCAAGATGCATGATCTGGTCCGTGCTTTTGT  
TTGGGTATGTTTTCTGAAGTCGAGCATGCTTCTATTGTCAACCATGGTAA  
TATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACTCTTGCAAAA  
GAAATTCATTAACATGCAAGGGTATGATTGAGATTCCAGTAGACCTCAAG  
TTTCCTAAACTAACGATTTTGAAGCTTATGCATGGAGATAAGTCGCTAAG  
40 GTTTCCTCAAGACTTTTATGAAGGAATGGAAAAGCTCCATGTTATATCAT  
ACGATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTCGATGCTCCACC  
AACATTCGGGTGCTTCATCTCACTGAATGTTCAATTAAGATGTTTGATTG  
CTCTTCTATCGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCAAATT

CTCACATTGAATGGTTACCTTCCACAGTCAGAAATTTAAAGAAGCTAAGG  
TTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAACAGGGTGTCTT  
GAAAAGTTTTGTCAAACCTTGAAGAATTTTATATTGGAGATGCATCTGGGT  
TTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTTACAACCTTTCT  
5 GCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTGAAAAATATGTC  
ATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGCTCTTTTGATG  
AAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCAATTGGTG  
ACCAACAAAGGTGATGTATTAGACTCTAACTTAATGGGTTATTTTTGAA  
AACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAGATG  
10 TTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCATTCTGCAATTTA  
AAAGTTCCTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAAAC  
CAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTGAAT  
GTGAGAATATGGAAGAACTCATACATACTGGAATTGGGGGTGTGGAGAA  
GAGACAATTACTTTCCCTAAGCTGAAGTTTTTATCTTTGAGTCAACTACC  
15 GAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACCACATC  
TCGTAGACTTGATACTTAAGGGCATTCCAGGTTTCACAGTCATTTATCCG  
CAGAACAAGTTGCGAACATCTAGTTTGTGGAAGGAAGGGGTAGATATATG  
TTCTTTATGTTAATAACAATTTAAATAATATTTTCAACCAAATTTTCATAA  
TATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGGCTATT  
20 AAGGGATGATTATTTTGCAGGTGTGATTCCTAAGTTGGAGACACTTCAA  
ATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTTAGTGG  
AGGTGAGAAAGTTAAGTTGAGAGCGATTAAAGTGAGTAGCTGTGATAAGC  
TTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTTGAA  
GAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACATTGA  
25 CTTGGATTGTGTCGGTGCAATTGGAGAAGAAGACAACAAGAGCCTCTTAA  
GAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGGATA  
AAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTCAAGCTGTTGAAAG  
CATAAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTACACCTATCA  
CCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGTTGC  
30 GGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTCAATTTCACTTTC  
TTAATTAATTAAGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGTGGG  
ATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCATGAA  
ACGTTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAAAAA  
TATGGCTTAAATTTTTTTTATATTTATGTATCAACATGATTTTTTCATTAG  
35 AGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATCAGAATAATT  
CTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTTAGTG  
AAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCTTAAC  
AAAAAAACTATTTGGTTCAGAAAAACCGTAATTCAAGATAACTAAAATA  
AAAATATTTGACATTCATAAGAGCATTTTTTTTTCTAAATATGATTGCA  
40 AATGAATAAAACTTAAATTTATACAGAAAATTCTTTTATATATGTTATAC  
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG  
GTATCACAAGGGATATATAATAAAATATTATTTTCTGTAGTCATTTGTA  
ATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTAA

[illegible]



TNGCCACAATTCTTTGKTTACTTWGACACTTYCCTCTCTCTAATTATATA  
TATATATATATATATATATATATATATATACACACACACACACACACTAG  
ATGTGTGCCCCGCGCAAAGCAGTGACGTNNNGGAGAANACTTTCTTAAGCA  
TAAATAATTATTATATTTTTTTATTGGGTATTATATAATAAAAAAATTACAA  
5 CTTTTAAATAAAATATTTATGTTTATACTTTATATTTATATTGCTTGTAT  
ACTATTAATATAATAAAATTAATATTTATGTCTAATTTATGAAATGTAAAT  
TAATTTAAATACATGAATTTAATATTTTTTAAATTTTCAGTTTGCTTCAA  
ATTGAGTTTCTTAATTATTTTTTTTTAATTCANGTATTCAAACCTTTGGTA  
AGTATTAAGAATTATTTATGCATAATTGATTTATACAAAAAATTTGTA  
10 ACTTATACATCTTAAATTTCAAGATATAACTAACATGTTTTACAATATAT  
AT  
TAAAGCGCAAAGGTCATAGGAATAGAATATTTTCTATTATTCTACGTTTT  
GCCACAAAAGTTTGAACACTTTGCCACTTTTTGTCCCTCCTTAACCTTTT  
CAATGTTTTGCGACAAAAGTTCCAAAACCTTTGCCACTTTGATCATTCCTC  
15 AACTTTTCACCGCAATTAGTTTGTGGAGTTGGCAGTTTGTATCCCCCTAA  
CTTCGATATTCTCTACTGCTAGCCAAAAAGGGTTCCAGAGTTTCACACTT  
TTGGTCCCTGACAGTAACCAAATGTGAGATGTCAAATTTTTGCCACATTA  
GTTTGTGGAGTTGTCCCTTTTGGTCCCCCACCATTTCGATATTCTANTATA  
CGACCTTATTTTTNTCAAATAACAACACGTATATTTAATTACCAATTATA  
20 GAAATAGATATCAAATAAAGTATTTGTAACACTGTGTAAGAACGGTGCTA  
CTATAGGTAAAAATAAACATTTCAAAGTACGATATCCTAATTGAAAAAAG  
AGTTTTTAAAAAATAACGACTAGGGGCGAGTTTTTTTTTACAAGTTTGTAT  
CAAATCATATCAAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAAT  
GTAATTTATTCTTTGATTTTGATAATTTTTAATATTTTGTGTGATCTAT  
25 GTATTTAAAAAGTAAACAACAAAGAACATAATCCAAAACCCTAAATTGCAA  
GTCTCGCCCAATTTCTCTATCACTAGTCCTCACTTACGATGGCGTTACGT  
CGCTCTCTCACTGCTTACAACCCTTTGTTGCTACTCATTACAATAACGAA  
AAGTTGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGT  
CAAATTTTGTATTTTGTGATGGATTTGAGTAGAAGTTTGGGCAGAACGG  
30 GAATGATGGTCTGCAAGTGGTTATAAACTTGATTCTGAGTTATTACTATA  
TATGTAGCCTCTTTACAACGACCAAGGTTTCTTCCAGGTACCATTTGATC  
TTTTTAGAACTTAGTTTTCTGAAACACCCTGATTTGGATCAAATATCACC  
AACAACTCTTAAAAACTTGATTAATCAATTGTTTTCTTCATCTTGATAAC  
AAGTGGAATGATTTTCTACTTAGATTAACCTGAAAAAAAAGGTCCATGTG  
35 CGTCTGGTGGATCTGGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAG  
ACACAAACACGTCACCATATCTCTTATTTTATTTTAAATTTGCTTTTGGT  
GTATTTTCTTTTTCTTATTTCTTTCTTTGATCTCCAGATGGTATGT  
GGTGTGGATAATTTACACCTAGAGATTGGGAACGATGGGAAGGGGTCTGT  
GATTTATGGCTGGCCGAGTTTTACTTATTAACCTCAATTTCAACCTAAATT  
40 CTGATTCTTGTGTTGAAAATAAGTTGCATCTTTATTTTTGTATTATCTTGT  
TGCATAGGATCCTTAGCATCTTTAATAATTTATTTGAAGGTGAAAGATC  
CAACTATTTTTTAGCTGTTGGCATTTTCCATCATTGCAACTGTTTCTTG  
AAAAAAAATACCTAAAATAAAAATAACCATTTTCAAATCCAAAATTATA

AGAGAGAATTGTAAATGGACATGGAATCATAAATCATTAACACAGTTCAG  
TAAACAAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCA  
GAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTTCAAATCTTGTATT  
CCCATCCTGTCTCATGCACTCTTTTCATAACCTCCGTGTGCTTACATTGG  
5 ATAATTATGAAGGAGTGGAGGTGGTATTTGAGATAGAGAGTGAGAGTCCA  
ACATGTAGAGAATTGGTAACAACCTCGCAATAACCAACAACAGCCTATTAT  
ACTTCCCTACCTCCAGGATTTGTATCTAAGGAATATGGACAACACGAGTC  
ATGTGTGGAAGTGCAGCAACTGGAATAAATTCTTCACTCTTCCAAAACAA  
CAATCAGAATCCCCATTCCACAACCTCACAACCATAAATATTCTTAAATG  
10 CAAAAGCATTAAAGTACTTGTTCGCTCTCATGGCAGAACTTCTTTCCA  
ACCTAAAGGATATCCGGATAAGTGAGTGTGATGGTATTAAGAAGTTGTT  
TCAAACAGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCA  
CACAAACCACCACTTTGTTCCCTAGTCTTGATTCTCTCACTCTAAGTTTCC  
TGGAGAATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGC  
15 AATGAAATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTTGATCA  
ATTTGAGGTATGCTTTGTACATATTCAATTATTTATTTAATTCCTTTTT  
TATTTGCAATATTCTATAAATAATACATTTTATACCCACTATACTAAGAT  
AAT.AATTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGA  
AACTCTAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCT  
20 TTTGATGGGTAAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTAT  
TTAGCAAGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAAT  
CTGGTCATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGG  
GGACATCAGGTGACAGATATTGTAGAATAGAACAATATATAATATTACCC  
AAAACATTTTTTTCTAAGGTTATTCTGTAAATATGTGCTTTCTTGATTT  
25 CATTGAATTTGCATTCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCA  
ATAAATCCCGAAATTAATTAAAAAAGAAAAAACAAAAGTAAATTTTGA  
TATGGAGAGCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAAT  
TAAGTTTCTTATATAAAAGCTGTGTATATAGTTTAATTAGTTTACATCA  
TTTTTCCATGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTTCCTGGAG  
30 TTTATGCCAATACGCTAGAGAGATARAATAGKTGGATGCTATGCATTGT  
CAAGTGTGATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTG  
CTGAGAATAGAGTCTTGTGATGGCATGAAGGAGGTATTTGAAACTCAATT  
AGGGACGAGCAGCAACAAAAACAACGAGAAGAGTGGTTGCGAGGAAGGAA  
TTCCAAGAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTA  
35 AGTATTGGAAATTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACT  
TGAAAGCCTGAGACAGCTCCAAGAGTTAAAGATAAAATTTTGCTACGGAA  
TGAAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAAACA  
ACAACAACAACAACGAAGGGGGCATCTTCTTCTTCTTCTTCTTCTTCTC  
TTCTTCTTCTAAGAAGGTTGTGGTCTTTCCTTGTCTAAAGTCCATTGTAT  
40 TGGTCAATCTACCAGAGCTGGTAGGATTCTTCTTGGGGATGAATGAGTTC  
CGGTTGCCTTCATTAGATAAACTTAAGATCAAGAAATGCCCAAAATGAT  
GGTGTTCACAGCTGGTGGGTCCACAGCTCCCCAACTCAAGTATATACACA  
CAAGATTAGGCAAACATACTCTTGATCAAGAATCTGGCCTTAACCTTCAT

CAGGTATATATATATTTCTTTAATTGGCATCATCTAATTAAGAAAGATAT  
CATTCTGCCAAGTAAATTTACTTCAAACACATTCACACTGGTTTCAGTC  
TAAGTTTATGTTGTTCTAAGAAGGCCAAAATGGGAAAGCAAGATAGGGAA  
AAATAGTGTATTTTCAGTGGAAAGGGTATTTTAGGCATTTTCTGTCAAAAG  
5 TTGTTATTGCAGGCTTTTTAGTACCTGGAATCGTGTGTGGGAGGAGCATT  
ATTATTCTGATTGCTTGTCTTTATCATTTTTTCTTAGCCTCTCGAAC  
AGCTAGAAACCCTTTTAATCTTTTGATTTTCAATGACGAAATTTTCCCT  
GTTACTCCATTTGATTGTTGTTCTTCATGGTTCTAAGTGAGTTATTGGCT  
CATCTGTTACTTCTTTTGATTGTTATTTTCATATCATGTTGTCCTTTGAA  
10 TCAAGCTTTTCCATTTTCAACCAGGGCAAAGGTCAAAGTAACCTACTT  
TATGAGATCAAAAACAGCAACCCATCGGATAACTTTTAGTTGGAGTTAAT  
AGTTACAATTACCATTGTGATTAATAATTATAATATCTTGTATTAATTCA  
TAAAAATTGGTACAGCACATATATGACATTTCAAAGGTTTTTGTGTTGACA  
TATATATGCCTCTGGCGTTTTCTTTATTGGACTTGCAGACCTCATTCCAA  
15 AGTTTATACGGTGACACCTTGGGCCCTGCTACTTCAGAAGGGACAACCTTG  
GTCTTTTCATAACTTTATCGAATTAGATGTGGAAGGTAATCATGATGTTA  
AAAAGATTATCCATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAG  
ATT.AATGTAAGGTGGTGTAAGGGGTAGAGGAGGTATTTGAAACTGCATT  
GGAAGCAGCAGGGAGAAATGGAAATAGTGGAATTGGTTTTGATGAATCGT  
20 CACAAACAACCTACCACTACTCTTGTCATCTTCCAAACCTTAGAGAAATG  
AACTTATGGGGTCTAGATTGTCTGAGGTATATATGGAAGAGCAATCAGTG  
GACAGCATTTGAGTTTCCAAACCTAACAAGAGTTGATATCTATAAATGTA  
AAAGGTTAGAACATGTATTTACTAGTTCCATGGTTGGTAGTCTATCGCAA  
CTCCAAGAGCTACATATATCCAAGTGCAGTGAGATGGAGGAGGTGATTGT  
25 TAAGGATGCAGATGATTCTGTAGAAGAAGACAAAGAGAAAGAATCTGATG  
GGGAGACGAATAAGGAGATACTTGTGTTACCTCGTCTAAACTCCTTGATA  
TTAAGAGAACTTCCATGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTT  
TTC.ATTCCCATTATTGGATACTTTAAGAATTGAGGAATGCCAGCAATAA  
CCACCTTCACCAAGGGAAATTCCGCTACTCCACAGCTAAAAGAAATTGAA  
30 ACACATTTTGGCTCGTTTTGTGCTGCAGGGGAAAAAGACATCAACTCTCT  
TATAAAGATCAAACAACAGGTAAATCAGATCTTTGTTGCTTTAATAATTC  
TTAAACTACATTTGAAAAGCTTCATGCAAGTTTTTTTTTGTATATTGTCA  
AAAACCGCAACCTACATTTTCAGCTTTATATTTATGTACTTTATGCAGGA  
GTTCAAACAAGACTCTGATTAATGTGAAGTAAATACTAAAGGTAAATTAT  
35 ATTTTCATGTTCCCTAGTTGCCTATTAATTAATTGCCTTTTAGTTCATGAT  
TTTTGGATGCATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCAT  
TGTTTGGTTGAATGTTGACTCTATGTCTTGATGAATATTCAAGGGAAGAA  
TTGTTTCATCATATGAAGGACATTAAAGAAGACATGGATGCTATGAAGAT  
GTGGGAAAACAA

40

**RG2B deduced polypeptide sequence (SEQ ID NO:90)**

MSDPTGIAGAIINPIAQ TALVPVTDHVG YMISCRKYVRVMQM KMTLNTSRISVEE  
HISRNTRNHLQIPSQTKEWLDQVEGIRANVENFPIDVITCCSLRIRHKL GQKAFKITE  
QIESLTRQLSLISWTDDPVPLGRV GSMNASTSASLSDDFPSREKTFTQALKALEPNQK  
5 FHMVALCGMGGVGKTRMMQRLKKA AEEKKLFNYIVGAVIGEKTDPFAIQEAIADY  
LGIQLNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQ  
GVDFKVL LTSRDSQVCTMMGVEANSIINVGLL TEAEAQSLFQQFVETSEPELQKIGE  
DIVRKCCGLPIAKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQ  
EEETKSTFLMCGLFPEDFDIPT EELMRYGWGLKLFDRVYTIREARLNTCIERLVQ  
10 TNLLIESDDVGCVKMHDLVRAFVLGMFSEVEHASIVNHGNMPGWP DENDMIVHSC  
KRISLTCKGMIEIPVDLKF PKLTILKLMHGDKSLRFPQDFYEGMEKLHVISYDKMKY  
PLLPLAPRCSTNIRVLHLTECSLKMFD CSSIGNLSNLEVLSFANSHIEWLPSTVRNLK  
KLRLDLRFCDGLRIEQGV LKSFVKLEEFYIGDASGFIDDNCNEMAERSYNLSALEF  
AFFNKAAEVKNMSFENLERFKISVGC SFDENINMSSHSYENMLQLVTNKG DVLD SK  
15 LNGLFLKTEVLF LSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKCV ELRYLFKL  
NLANTLSRLEHLEVCECENMEELIHTGIGGCGEETITFPKLKFLSLSQLPKLSSLCHN  
VNIIGLPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEGVVIPKLET LQIDDMENLEEIW  
PCELSGGEKVKLRAIKVSSCDKLVNLFPRNPM SLLHHLEELTVENCGSIESLFNIDLD  
CVGAIGEEDNKSLLRSINVENLGK LREVWRIKGADNSHLINGFQAVESIKIEKCKRFR  
20 NIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFP SCLMH  
SFHNLRVLTLDNYEGVEVVFEIESESPTCRELVTTRNNQQQPILPYLQDLYLRNMD  
NTSHVWKCSNWNKFFTL PKQQSESPFHNLT TINILCKSIKYLFSPLMAELLSNLKDI  
RISECDGIKEVVSNRDDEDEEMTTFTSTHTTTTLFPSLDSLTL SFLENLKCIGGGGAK  
DEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIEIVGCYALSSVIPCYAA  
25 GQMQKL

**RG2C polynucleotide sequence (SEQ ID NO:91)**

ATAATATTACACAAAGGTAACGTCATTAATTAATTACGATACGAGACAGA  
CTTTTTCACTCGGACATNAACGGTCTATTCCTAACTTNANNTAATTNAAT  
30 GAATTTAGGATGTGCTAATATGCATGTAANATTCGCTACCGTCATCTTTC  
AAATGACCATAATTTTTATGTATTTATAATGAATCAATGAAAAACCGGATT  
TCTATTTAAAAATCTTAAAACTTCATCTTTTAAGCCAGGGTGAATACAAT  
TGCTAGATCCACTGTTAATTTCCATCGAATTATGCCTGATCAATTGTTGG  
CTGCCTACGATGCAGGTGCTACCACAAGAATATGGCCATGGAAACTGCTA  
35 ATGAAATTATAAAACAAGTTGTTCCAGTTCTCATGGTTCCTATTAACGAT  
TACCTACGCTACCTCGTTTCCTGCAGAAAGTACATCAGTGACATGGATTT  
GAAAATGAAGGAATTAAGAAGCAAAAGACAATGTTGAAGAGCACAAAGA  
ATCATAACATTAGTAATCGTCTTGAGGTTCCAGCAGCTCAAGTCCAGAGC  
TGGTTGGAAGATGTAGAAAAGATCAATGCAAAAGTGGAAACTGTTCTTAA  
40 AGATGTGCGCTGTTGCTTCAATCTAAAGATTAGGTACAGGGCCGGAAGGG  
ATGCCTTCAATATAATTGAGGAGATCGACAGTGT CATGAGACGACACTCT  
CTGATCACTTGGACCGATCATCCCATTCTTTGGGAAGAGTTGATTCCGT

GATGGCATCCACCTCTACGCTTTCAACTGAACACAATGACTTCCAGTCAA  
GAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACTTGAGGCCAACCATG  
ATAGCCTTATGTGGAATGGGGGGAGTGGGGAAGACCCACATGATGCAAAG  
GCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTTGGTTATATCATCGAGG  
5 CGGTTATAGGGGAAATATCGGACCCCATGCTATTCAGCAAGTTGTAGCA  
GATTACCTATGCATAGAACTGAAAGAAAGCGATAAGAAAACAAGAGCTGA  
GAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGATGGAGGTAACACTAAGT  
TCCTCATAATATTGGATGATGTCTGGCAGTCCGTTGATCTAGAAGATATT  
GGTTTAAGCCCTTCTCCCAATCAAGGTGTGCGACTTCAAGGTCTTGTTGAC  
10 TTCACGAGACGAACATGTTTGCTCAGTGATGGGGGTTGAAGCTAATTCAA  
TTATTAACGTGGGACTTCTAATTGAAGCAGAAGCACAAAGATTGTTCCAG  
CAATTTGTAGAACTTCTGAGCCCGAGCTCCACAAGATAGGAGAAGATAT  
TGTTAGGAGGTGTTGCGGTCTACCCATTGCCATCAAAACCATGGCGTGTA  
CTCTAAGAAATAAAAGAAAGGATGCATGGAAGGATGCACTTTCTCGTTTA  
15 CAACACCATGACATTGGTAATGTTGCTACTGCAGTTTTTTAGAACCAGCTA  
TGAGAATCTCCCGGACAAGGAGACAAAATCTGTTTTTTTGATGTGTGGTT  
TGTTTCCCGAAGACTTCAATATTCTACCGAGGAGTTGATGAGGTATGGA  
TGGGGCTTAAAGTTATTTGATAGAGTTTATACAATTATAGAAGCAAGAAA  
CAGGCTCAACACCTGCATTGACCGACTGGTGCAGACAAATTTACTAATTG  
20 GAAGTGATAATGGTGTACATGTCAAGATGCATGATCTGGTCCGTGCTTTT  
GTTTTGGGTATGTATTCTGAAGTCGAGCAAGCTTCAATTGTCAACCATGG  
TAATATGCCTGGGTGGCCTGATGAAAATGATATGATCGTGCACTCTTGCA  
AAAGAATTTCAATTAACATGCAAGGGTATGATTGAGTTTCCAGTAGACCTC  
AAGTTTCCTAAACTAACGATTTTGAACTTATGCATGGAGATAAATCGCT  
25 AAAGTTTCCTCAAGAATTTTATGAAGGAATGGAAAAGCTCCGGGTATAT  
CATACCATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTCAATGCTCC  
ACCAACATTCGGGTGCTTCATCTCACGGAATGTTCAATTAAGATGTTTGA  
TTGCTCGTGATTGGAAATCTATCGAATCTGGAAGTGCTGAGCTTTGCTA  
ATTCTTGCAATTGAGTGGTTACCTTCCACGGTCAGAAATTTAAAAAAGCTA  
30 AGGTTACTTGATTTGAGATTGTGTTATGGTCTCCGTATAGAACAGGGTGT  
CTTGAAAAGTTTGGTCAAACCTGAAGAATTTTATATTGGAAATGCATATG  
GGTTTATAGATGATAACTGCAAGGAGATGGCAGAGCGTTCTTACAACCTT  
TCTGCATTAGAATTCGCGTTCTTTAATAACAAGGCTGAAGTGAAAAATAT  
GTCATTTGAGAATCTTGAACGATTTAAGATCTCAGTGGGATGCTCTTTTG  
35 ATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGTTGCGATTG  
GTGACCAACAAAGGTGATGTATTAGACTCTAACTTAATGGGTTATTTTT  
GAAAACAGAGGTGCTTTTTTTAAGTGTGCATGGCATGAATGATCTTGAAG  
ATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCATTCTGCAAT  
TTAAAAGTCCTTATTATTTCAAAGTGTGTAGAGTTGAGATACCTTTTCAA  
40 ACTCAATGTTGCAAACACTTTGTCAAGACTTGAGCATCTAGAAGTTTGTA  
AATGCAAGAATATGGAAGAACTCATACATACTGGGATTGGGGGTTGTGGA  
GAAGAGACAATTACTTTCCCCAAGCTGAAGTTTTTATCTTTGAGTCAACT  
ACCGAAGTTATCAGGTTTGTGCCATAATGTCAACATAATTGGGCTACCAC

ATCTCGTAGACTTGAACTTAAGGGCATTCCAGGTTTCACAGTCATTTAT  
CCGCAGAACAAGTTGCGAACATCTAGTTTGTGAAGGAAGAGGTAGATAT  
ATGTTCTTTATGTTAATACAATTTAAACAATATTTTCAACCAAATTTTCA  
TAATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGGCT  
5 ATTAAGGGGATGATAATTTTGAGGTTGTGATTCCTAAGTTGGAGACACTT  
CAAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACCTAG  
TGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAAGTGAGTAGCTGTGATA  
AGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATCTT  
GAAGAGCTTACAGTCGAGAATTGCGGTTCCATTGAGTCGTTATTCAACAT  
10 TGACTTGGATTGTGTGCGGTGCAATTGGAGAAGAAGACAACAAGAGCCTCT  
TAAGAAGCATCAACGTGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGAGG  
ATAAAAGGTGCAGATAACTCTCATCTCATCAATGGTTTTCAAGCTGTTGA  
AAGCATAAAGATTGAAAAATGTAAGAGGTTTAGAAATATATTCACACCTA  
TCACCGCCAATTTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAGGT  
15 TGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTCAATTTCACT  
TTCTTAATTAATTANGGACTAAGCTCCTGTTTTTTGAATAATAAAGAGGT  
GGGATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACCAT  
GAAACGCTCAAACCATTTCTTGAATTAAGGTTTCAATACAAGTCATTTAA  
AAATATGGCTTAAATTTTTTTATATTTATGTATCAACATGATTTTTTCATT  
20 AGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAACTAA  
TTCTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTTAG  
TGAAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTCTTA  
ACAAAAAAACTATTTGGTTCAGAAAACTGTAATTCAAGATAACTAAAA  
TAAAAATATTTGACATTCACTAAGAGCATTTTTTTCTAAATATGATTGCA  
25 AATGAATAAAACTTAAATTTATACAGAAAAGATTTTATATATGTTATAC  
AAAATTTACAAATTGAAATTGGATATGTTAATTAACGGTTTATAATTCTG  
GTATCACAAAGGGATATATAATAAAATATTATTTTTCTGTAGTCATTTAT  
AATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAGTTA  
AACTTTTATAATAAAAAATTTATAATTATTATTTATTTTAAATAAATTATT  
30 AATTAAGAGATATATCAAAAATTTAAAGTTATTATAACTTCAAATTTAAC  
ATATAATTAATAAATATATGATCATAACTTTCCGCAACTCTTCTTTTGTA  
TTAAATGACCAGAGAAGCTCTTAGTATATTTTCTAAATCAAAGTCACAA  
AACTAATGAAGCATATAATTTTGTGAAAATCAATTAGCATTAGGTTTTAA  
GAGTCACCAAATTCAAAGAGTAATCCAATGCTTTTCATTACCACTATGGAG  
35 AAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTCAAACCTAATT  
GTTGCTTATTAAACCAAGACCCATTACTTAGCCAAGAGTTTAACCAAAA  
AAAATTACATTCATGTATCATTATTAATGACTAGATATATATGAATATGA  
AGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTCATG  
GAATTCCTCAAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCAACC  
40 AAAGAGAAGTTTAGCCTAGCATGGCTAAACTCAAGAAAATAAAATAAGGA  
TTAGAAGTACCAACATGTAGTAAGAATCACAGTAAAAGATGATGTTGTT  
CTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAATGCA  
AAGGAGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAAGCTGCACCA

ACCTCCCTTAAATAAACA CTCAAAGCAAAAATGACAAAATTGCCCTGAAG  
GACCCTATGCGGGTGCTTGCGCGGGTGGAGCTGAATATGAAAGGTCTTT  
GGTCTTTGTGAGGGTGATGTTGTGCGGGTTAGCTTGTGCGCATGCTTCCGC  
GCGGTTGCGGCACATGTGCACAGGTGATGCATGGTGTGTACGTTCTTGAC  
5 TTTTGAGCCTCCGATGCTTAGTCCACTTGGCCCAATTCGAGTCCAATCAA  
CTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTAAGCCCAATTTGCC  
TTCTCCAAATCATCCATAACTTCACAGAATCGCCCGTTCATCTTAATCCC  
GAATGAACAATTATTCTCCCGTCTTCATTTTAAGCAAGATACCACCTTCT  
TCATGCTTCATCCATCAATAGTACACTTCATGTATCATCTCTACTAGTTA  
10 TTTAGTCCACAGTCCCTGTTGTCCTCCAAATTTAATTATCTCATTTAGTT  
CCCGTTCGCTAGTTTCCTTAAAATTTGCAATTAAGCTCACAGAAATATT  
AAGTACCCGAAATGGTCATAAAATAACAGAAAGGAAAATATGCATGAAGA  
TTAACTAAATGATGAACGAAATATGCTAAAATAGACTATAAAATGAAGTA  
AATAAAATGAAATTATCGCACTCCGACCACCCTTATAGGCTTGTAGTCCA  
15 CCCACCCTTCATTCCTTGTACCAATATGGGATGGAAACATCATTAATTAA  
GCCAAAAAATAACATATAAGGGGTGAGTGACAAAGGTAAGTACTAAAGA  
TGAAAAAATCCATTTTTCTTGTATATACACAACACACACATAGGGGCAG  
ACGTAGGATTTCATAGTACAGATTGTTGGTGGCACATAAGTGTTGCTAGT  
GACATTTTTTTTTCTTTTACGTAGTGGCACAACAGTARAAAAAACRAAA  
20 AATTCGAAATTTTTTACAATGTGCCTAAAAAAAACAGTGGTTGTTGGTGC  
CACTATGGACACCAAAGTTGAACTGCCCTGCGCGCGCACACACACACAC  
ACATAAAGTTTG  
GGATGTGATACTTCTTTTGGGAAAATGGAGTTATATCTTTGATATTGTAT  
TTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAAGTTTTATT  
25 TATTTKGATATGAAAAAAAAGTCTTTTATACATTGGATTTAACATAAAA  
ATCCAACAATATTAATCAAAAAGACCAAACATGTGGACAATTATGTATAT  
AATTAATTCACAATAGTCTTTAGGAATAGNATTATATATATAATTAATTC  
TCAATGGTCTTAGGAATAGTAAGTTCTTATATTTCAAACNTTTGCCACAN  
TTCTTTGNTTACTTNGACACTTTYCTCTMWNNANWMWWTWATATATATAT  
30 ATATATATATATAHAHAHAHAVACACACACACTAGATGTGTGCCMGCGCA  
AAGCAGTGACGTNNNGAGAANACTTTCTTAAGCATAAATAATTATTATA  
TTTTTTATTGGGTATTATATAATAAAAAATTACAACCTTTAAATAAAATA  
TTTATGTTTATACTTTATATTTATATTGCTTGTATACTATTAATATAATA  
AATTAATATTTATGTCTAATTTATGAAATGTAAATTAATTTAAATACATG  
35 AATTTAATATTTTTTAAAATTTTCAGTTTGCTTCAAATTGAGTTTCTTAAT  
TATTGACCAAACATGTGGACAATTATGTATATAATTAATTCACAATAGTC  
TTTAGGAATAGTATTATATATATAATTAATTCTCAATGGTCTTAGGAATA  
GTAAGTTCTTATATTTCAAACCTTTTGCCACAATTCTTTGCTTACTTTGAC  
ACTTTTCCTTCCTAACTTTACATATATATATATATTAAGCGCAAAGGTC  
40 ATAGGAATATAATATTTTCTATTATTCTACGTTTTGCCACAAAAGTTTGA  
ACACTTTGCCACTTTTTGTCCCTCCTTAACCTTTTCAATGTTTTGCGACA  
AAAGTTCCAAAACCTTTGCCACTTTGATCATTCCTCAACTTTTCACCGCAT  
TAGTTTGTGGAGTTGGCAGTTTTGGTCCCTCTAACTTCGATATTCTCTAC

TGCTAGCCAAAAAGGGTTCAGAGTTTCACACTTTTGGTCCCTGACAGTA  
ACCAAATGTGAGATGTCAAATTTTTGCCACATTAGTTTGTGGAGTTGTCC  
CTTTTGGTCCCCCACATTTCGATATTCTACTATACGATCTTATTTTCTC  
AAATAACAACACGTATATTTAATTACTAATGATAGAAATAGATATCAAAT  
5 AAAGTATTTGTAACACTGTGTAGAGTTTTTTTTTACAAGTTTGTATCAAA  
TCATATCAAAATTTAAGGTGGAACGGTGACCACATTAACCAGAAATGTAA  
TTTATTCTTTGATTTTGATAATTTTAATATTTTGTGTGATCTATGTAT  
TTAAAAGTAAACAACAAAGAACATAATCCAAAACCCTAAATTGCAAGTCT  
CGCCCAATTTCTCTATCACTAGTCCTCACTTACGATGGCGTTACGTCGCT  
10 CTCTCACTGCTTACAACCCTTTGTTGCTACTCATTACAATAACGAAAAGT  
TGAATATCCATATATTTATTTGGATGTGGAATTGAACGAATCTCGTCAAA  
TTTTTGATTTAGTTGATGGATTTGAGTAGAAGTTTGGGCAGAACGGGAAT  
GATGGTCTGCAAGTGGTTATAAACTTGATTCTGAGTTATTACTATATATG  
TAGCCTCTTTACAACGACCAAGGTTTCTTCCAGGTACCATTTGATCTTTT  
15 TAGAACTTAGTTTTCTGAAACACCCTGATTTGGATCAAATATCACCAACA  
ACTCTTAAAAACTTGATTAATCAATTGTTTACTTCATCTTGATAACAAGT  
GGAATGATTTTCTACTTGAAAAAAAAGGTCCATGTGCGTCTGGTGGATCT  
GGTAAATGAAGATGGAAGGGAGAGCTGACTTTAAAGACACAAACACGTCA  
CCATATCTTTTATTTTATTTTAAATTTTCTTTTTTCCATTTTCTTTCTTT  
20 CTTGATCTCCAGATGGTATGTGGTGTGGATAATTTACACATAGAGATTGG  
GAACGACTGTGATTTAGAGAGGACGTGGCTTGGGGTTGAGGATGGTTTAT  
GGCTGGCCGAGTTTCATTTATATAAAACAAACAAATATATAAAACAAGGGG  
TAAATGGCCATCTTATATGTATTTAACCGTCCTCTTTTTTTTTTTTTTTT  
TTTTTTTTTTTTTTTTTTTGTAAATTAAGAAGGGGTATACCAGTGTGAGC  
25 CTCTTATTCCCAACCAGTCAAATAGGGACTTAGGTTGTTTGGAAACAGTT  
CCGTGAGACCGTGACTTGGATGGTAGATAAAATTTAGTAAACTTAACCCTT  
CAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAACCTAAATTCTGAT  
TCTTGTTTGAAAATAAGTTGCATCTTTATTTTTGTATTATCTTGTTGCAT  
AGGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAAAGATCCAAC  
30 ATTTTAAATCTGTTGACGTTTCCATCATTGCAACTGTTTCTTGAAAAA  
AAAATACCTAAAATCAAATAACCATTTCAAATCCAAAATTATAAGAGA  
GAATTGTAAATGGACATGGAATCATAAATCATTAAACACAGTTCAGTAAAC  
AAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATCTATCAGAGAA  
AGAGACATTACAAGAAGCCACTGGCAGTATTCAAATCTTGATTCCCAT  
35 CCTGTCTCATGCACTCTTTTCATAACCTCCGTGTGCTTACATTGGATAAT  
TATGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAG  
TAGAGAATTGGTAACAACTCACAATAACCAACAACAGCCTATTATACTTC  
CCTACCTCCAGGAATTGTATCTAAGGAATATGGACAACACGAGTCATGTG  
TGGAAGTGCAGCAACTGGAATAAATTTCTTCACTCTTCCAAAACAACAATC  
40 AGAATCACCATTCCACAACCTCACAACCATAGAAATGAGATGGTGTGATG  
GCTTTAGGTACTTGTTTTCGCCTCTCATGGCAGAACTCTTTCCAACCTA  
AAGAAAGTCAAGATACTTGGGTGTGATGGTATTAAAGAAGTTGTTTCAAA  
CAGAGATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACAAAA



CCACCAACTTGTTCCCTCATCTTGATTCTCTCACTCTAAACCAACTGAAG  
AATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGA  
AATATCTTTCAATAATACCACTGCAACGACTGCTGTTCTTGATCAATTTG  
AGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCTTTTTTTATTT  
5 GCAATATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAA  
TTACCTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTC  
TAGTAAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGA  
TGGGTAATATAGGCAATTTAAGTTTTATTTCTGTTAAAGCAGTATTTAGC  
AAGTACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGT  
10 CATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGGGGTTA  
TCAGGTGACAGATATTGTAGAATAGAACAATATGTAATATTACCCAAAAC  
TATTTTTTCTAAGGTTGCTCTGTTAAATATGTGCTTTCTTGATTTCATTG  
AATTTGCATTCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAA  
TCCCGAAATTAATTAACAAAAACAAAAGTAAATTTTGTATATGGA  
15 GAGCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAATTAAGTT  
TCTTATATAAAAGCTGTGTATATAGTTTAATTAGTTTTACATCATTTTTC  
CATGTGGTGTGTCAGTTGTCTGAAGCAGGTGGTGTCTTGGAGCTTATG  
CCAATACGCTAGAGAGATAAAAAATAGGCAACTGCCATGCATTGTCAAGTG  
TGATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGAGA  
20 GTAATGGCTTGCAATGGGATGAAGGAGGTATTTGAAACTCAATTAGGGAC  
GAGCAGCAACAAAAACAACGAGAAGAGTGGTGTGAGGAAGGAATTCCAA  
GAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTAAGTATT  
GGAATTTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGAAAG  
CCTGAGACAGCTCCAAGAGTTAACGATTAAGGGTTGCTACAGAAATGAAAG  
25 TGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAAACAACA  
ACAACAACGAAGGGGGCATCTTCTTCTTCTTCTTCTAAGAAGGTGGT  
GGTCTTTCCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGG  
TAGGATTCTTCTTGGGGATGAATGAGTTCGGGTTGCCTTCATTAGATAAA  
CTTATCATCGAGAAATGCCCAAAATGATGGTGTGTTACAGCTGGTGGGTC  
30 CACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACTC  
TTGATCAAGAATCTGGCCTTAACCTTTCATCAGGTACATATATATTCCTTT  
AATTGGCATCATCTAATTAAGAAAGATATCATTCCTGCCAAGTAAATTA  
CTTCAAACACATTCACACTAGTTTCAGTCCAAGTTTATGTTGTTCTAGGA  
AGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGAGTATTTCAGTGGAA  
35 AGGGTATTTTAGGTATTTTCTGTCAAAAATTGTTATTGCAGGCTTTTTAG  
TACCTGGAAGAGCATGATTATTCTCGATTTGCTTGTTTCTTTATCATTTT  
TCTTAGCCTAGCATGATTTTCAATGAAATCTTCCCTGTTACTCCATTG  
ATTGTTGTTCTTCATGGTTCTAAGTGAGTTAGTGGCTCATCTGTTACTTC  
TTTTGATTGTTATTTTCATAGCATGTTGTCACTTGAATCAAGCTTTTCCA  
40 TTTTCAACAAGGACAAAAGGTCAAAACTAACCTACTTTATGAGATCAAAA  
ATAGCAACCCATCGGATAACTTTTAGTTGGAGTTAATACTTACAATTACC  
ATTGTGATTAATAATTATAATATCTTGTATTAATTCATAAAAATTGGTAC  
AGCACATATATGACATTTCAAAGGTTTTTGTGTTGACATATATATGCCTCT

GGCGTTTTCTTTATTGGACATGCAGACTTCATTCCAAAGTTTATACGGTG  
ACACCTTGGGCCCTGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAAC  
TTTATCGAATTAGATGTGAAATCTAATCATGATGTTAAAAAGATTATTCC  
ATCCAGTGAGTTGCTGCAACTGCAAAAGCTGGTAAAGATTAATGTAATGT  
5 GGTGTAAGGGTAGAGGAGGTATTTGAACTGCATTGGAAGCAGCAGGG  
AGAAATGGAAATAGTGAATTGGTTTTGATGAATCGTCACAAACAACCTAC  
CACTACTCTTGTCATCTTCCAAACCTTGGAGAAATGAAGTTACGGGGTC  
TCGATTGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTGAG  
TTTCCAAACCTAACAAGAGTTGAAATTTATGAATGTAATTCATTAGAACA  
10 TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG  
AGATTGGTTTGTGCAACCATATGGAGGTCGTGCATGTTTCAGGATGCAGAT  
GTTTCTGTAGAAGAAGACAAAGAGAAAGAAATCTGATGGCAAGATGAATAA  
GGAGATACTTGTGTTACCTCATCTAAAGTCATTGAAATTACTACTTCTTC  
AAAGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATT  
15 TTGGATACTTTGGAAATCTACGAATGCCAGCAATAACCACCTTCACCAA  
GGGAAATTCCGCTACTCCACAGCTAAAAGAAATGGAAACAAATTTGGCT  
TCTTTTATGCTGCAGGGGAAAAAGACATCAACTCCTCTATTATAAGATC  
AAACAACAGGTAAACCAGATCTTTGTTGCTTTAATAATTCTTAAACTACA  
TTTGAAGAGCTTCATGCAAGTTTTTTTTGTTATATTGTCAAAAACCGCAA  
20 CCTACATTTTCAGCTTTATATTTATGTACTTTATGCAGGATTTCAAACAA  
GACTCTGATTAATGTGAAGTGAATATTAAGGTAAATTATATTTTCATGT  
TCCTAGTTGCCTATTAATTAAGGCCTTTTAGTTCTGTGATTTTGGATGT  
ATTCTTCATGATGATGTCAATCTTCTAATACCCCATTCATTGTTTGGTTG  
AATGTTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCA  
25 TATGAAGGACATTAAAGAACATGGTGCTAT

RG2C deduced polypeptide sequence (SEQ ID NO:92)

MAMETANEIHKQVVPVLMVPINDYLRYLVSCRKYISDMDLKMKEKAKDNVEEH  
KNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGRDAFNI  
30 IEEDSVMRRLITWTDHPIPLGRVDSVMASTSTLSTEHNDFQSREVRFSEALKALE  
ANHMIALCGMGGVGKTHMMQRLKKVAKEKRKFGYIEAVIGEISDPIAIQQVVADY  
LCIELKESDKKTRAELRQGFKAKSDGGNTKFLIILDDVWQSVLEDIGLSPSPNQG  
VDFKVLTSRDEHVCSVMGVEANSIINVGLLIEAEAQRLLFQQFVETSEPELHKIGEDI  
VRRCCGLPIAKTMACTLRNKRKDAWKDALSRQLQHDIGNVATAVFRTSYENLPD  
35 KETKSVFLMCGLPEDFNIPTEELMRYGWGLKLFDRVYTHIARNRLNTCIDRLVQT  
NLLIGSDNGVHVKMHDLVRAFLVGMYSVEQASIVNHGNMPGWPDENMIVHSC  
KRISLTCKGMIEFPVDLKFPLTILKLMHGDKSLKFPQEFYEGMEKLRVISYHKMKY  
PLLPLAPQCSTNIRVLHLTECSLKMFDSCIGNLSNLEVLFSFANSIEWLPSTVRNLK  
KLRLDLRLCYGLRIEQGVLSLVKLEEFYIGNAYGFIDNCKEMAERSYNLSALEF  
40 AFFNKAIEVKNMSFENLERFKISVGCSTGDNINMSSHSYENMLRLVTNKGDVLDK  
LNLGLFKTEVLFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLISKVELRYLFLK  
NVANTLSRLEHLEVCKCKNMEELIHTGIGGCGEETITFPKLKFLSLSQLPKLSGLCH

NVNIIGLPHLVDLKLGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDDMENLEEL  
 WPCELSGGEKVKLREIKVSSCDKLVNLFPRNPMSLLHHLEELTVENC GSIESL FNID  
 LDCVGAIGEEDNKSLLRSINVENLGKLREVWRIKGADNSHLINGFQAVESIKIEKCK  
 RFRNIFTPITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEATGSISNLVFPSC  
 5 LMHSFHNLRVLTLDNYEGVEVVFEIESESPTSRELVTTHNNQQQPILPYLQELYLR  
 NMDNTSHVWKCSNWNKFFTLPKQQSES PFHNLTTIEMRWCHGFRYLFSP LMAELL  
 SNLKVKVILGCDGIKEVVS NRDEDEEMTFTSTHKTTNLFPHLDSLTLNQLKNLK  
 CIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIKIGNCHAL  
 SSVIPCYAAGQMOKLQVLRVMACNGMKEVFETQLGTSSNKNNEKSGCEE GIPRVN  
 10 NNVMILPNLKILSIGNCGGLEHIFTFSALES LRQLQELTIKGCYRMKVIVKKEEDEY G  
 EQQTTTTTTTKGASSSSSSSKVVVFPCLSIVLVNLP ELVGFFLGMNEFRLPSL DKLI  
 EKCPKMMVFTAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLY GDTLGPAT  
 SEGTTWSFHNFIELDVKS NHDVKKIIPSELLQLQKLVKINVMWCKRVEEV FETALE  
 AAGRNGNSGIGFDESSQTTTTTLVNLPNLGEMKLRGLDCLRYIWKS NQWTA FEFPN  
 15 LTRVEIYECNSLEHVFTSSMVGSLQLQELEIGLCNHMEVVHVQDADVSVEEDKEK  
 ESDGKMNKEILVPHL KSLKLLLLQSLKGFSLGKEDFSFPLD TLEIYECPAIT TFTK  
 GNS.ATPQLKEMETNFGFFYAAGEKDINSSIIKIKQQDFKQDSD.

**RG2D polynucleotide sequence (SEQ ID NO:93) and (SEQ ID NO:94)**

20 ACGACCACTATAGGGCGAATTGGGCCCCGACGTCGCATGCTCCCGGCCGCC  
 ATGGCCGCGGGATGTAAAACGACGGCCAGTCAATCGTAACCGTTCGTAC  
 GAGAAATCGCTGTCCTCTCCTTCAACCATTTAATGTATATGAGCTAAATTG  
 AAACATCTACTATCATGTTTAAATTTATAAACTTTTTCCTTTAGATTAC  
 TTGTCTGGATGTGTTAATAAAACCCAATTTCCCACATGCGTAGAGATCA  
 25 TAGATGTA ACTATTGTTAATCAATTTTGCCTGCCAAGTTTAAATAATTAT  
 ACTTGGATATTAACAAAAC TTTATCTAACGACCAAGGTAATATTA AAAAT  
 AGGTTATTATTCTTCATGCTAATTA AAAGATGGGTGCAAAAGTGAGACC  
 ATGAAAACATTAACACGTTGATATTTTCAACTTTTATTCTTTCATATTCA  
 CCATATTTTTTTACTTTTCGTATTGATTAATCATCTTTCAATCACAGGCTCC  
 30 TTGGCAAAAAGTCAGATCTATTAACAAATACTTCCATGTGGTTGCAAATT  
 ACAAGGATTTC AACATAATTACCAAAACATAGCATTATCATAAGATCGAA  
 TAATAATCAAATTCTTCTATAATATTACACAAAGGTAACGTCATTAATTA  
 ATTACGATACGAGACAGACTTTTTCACTCGTGACATCAACGGTCTATTCT  
 AACTTTACTTAATTAAATGAATCTAGGATGTGCTCATATGCATGTAATAT  
 35 TTGCTACCGTCATCTTTCAAATGACCATATTTTTATGTATTTATAATGAA  
 TCAATGAAAAACCGGATTCTATTTAA AATTCTTAAAACTTCATCTTTTA  
 AGCCAGGGTGAATACAATTGTAGATCCACTGTTAATTTCCATCGATTATG  
 CGTGATCAATTGTTGGCTGCATACGATGCAGGTGCTACCACAAGAATATG  
 GCCATGGAACTGCTAATGAAATTATAAAACAAGTTGTTCCAGTTCTCAT  
 40 GGTTCCCTATTAACGATTACCTACGCTACGTCGTTTCCTGCAGAAAGTACA  
 TCAGTGACATGGATTGAAAATGAAGGAATTA AAAAGAAGCAAAAGACAAT  
 GTTGAAGAGCACAAGAATCATAACATTAGTAATCGTCTTGAGGTTCCAGC

AGCTCAAGTCCAGAGCTGGTTGGAAGATGTAGAAAAGATCAATGCAAAAG  
TGGAAGTGTTCCTAAAGATGTGGCTGTTGCTTCAATCTAAAGATTAGG  
TACAGGGCCGGAAGGGATGCCTTCAATATAATTGAGGAGATCGACAGTGT  
CATGAGACGACACTCTCTGATCACTTGGACCGATCATCCCATTCTTTGG  
5 GAAGAGTTGATTCCGTGATGGCATCCACCTCTACGCTTCAACTGAACAC  
AATGACTTCCAGTCAAGAGAGGTAAGGTTTAGTGAAGCACTCAAAGCACT  
TGAGGCCAACCACATGATAGCATTATGTGGAATGGGGAGAGTGGGGAAGA  
CCCACATGATGCAAAGGCTGAAGAAGGTTGCCAAAGAAAAGAGGAAGTTT  
GGTTATATCATCGAGGCAGTTATAGGGGAAATATCGGACCCCATTTGCTAT  
10 TCAGCAAGTTGTAGCAGATTACCTATGCATAGAGCTGAAAGAAAGCGATA  
AGAAAACAAGAGCTGAGAAGCTTCGTCAAGGGTTCAAGGCCAAATCAGAT  
GGAGGTAACACTAAGTTCCTCATAATATTGGATGATGTCTGGCAGTCCGT  
TGATCTAGAAGATATTGGTTTAAAGCCCTTCTCCCAATCAAGGTGTCGACT  
TCAAGGTCTTGTTGACTTCACGAGACGAACATGTTTGCTCAGTGATGGGG  
15 GTTGAAGCTAATTCAATTATTAACGTGGGACTTCTAATTGAAGCAGAAGC  
ACAAAGATTGTTCCAGCAATTTGTAGAACTTCTGAGCCCGAGCTCCACA  
AGATAGGAGAAGATATTGTTAGGAGGTGTTGCGGTCTACCCATTGCCATC  
AAAACCATGGCGTGTACTCTAAGAAATAAAAGAAAGGATGCATGGAAGGA  
TGC.ACTTTCTCGTTTACAACACCATGACATTGGTAATGTTGCTACTGCAG  
20 TTTTGTAGAACCAGCTATGAGAATCTCCCGGACAAGGAGACAAAATCTGTT  
TTTTTGATGTGTGGTTTGTTCCTCGAAGACTTCAATATTCCTACCGAGGA  
GTTGATGAGGTATGGATGGGGCTTAAAGTTATTTGATAGAGTTTATACAA  
TTATAGAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGGTGCAG  
GCAAATTTACTAATTGGAAGTGATAATGGTGTACACGTCAAGATGCATGA  
25 TCTGGTCCGTGCTTTTGTTCCTGAGTATGATTCTGAAGTCGAGCAAGCTT  
CAATTGTCAACCATGGTAATATGCCTGGGTGGCCTGATGAAAATGATATG  
ATCGTGCACTCTTGCAAAGAATTTCAATTAACATGCAAGGGTATGATTGA  
GATTCCAGTAGACCTCAAGTTTCCTAAACTAACGATTTTGAACTTATGC  
ATGGAGATAAGTCTCTAAAGTTTCCTCAAGAATTTTATGAAGGAATGGAA  
30 AAGCTCCAGGTTATATCATACGATAAAATGAAGTACCCATTGCTTCCTTT  
GGCACCTCAATGCTCCACCAACATTCGGGTGCTTCATCTCACTGAATGTT  
CATTAAAGATGTTTGATTGCTCTTCTATCGGAAATCTATCGAATCTGGAA  
GTGCTGAGCTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAG  
AAATTTAAAGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCC  
35 GTATAGAACAGGGTGTCTTGAAAAGTTTGGTCAAACCTTGAAGAATTTTAT  
ATTGGAAATGCATATGGGTTTATAGATGATAACTGCAAGGACATGGCAGA  
GCGTTCTTACAACCTTTCTGCATTAGAATTCGCGTTCTTTAATAACAAGG  
CTGAAGTGAAAAATATGTCATTTGAGAATCTTGAACGATTCAAGATCTCA  
GTGGGGTGCTCTTTTGATGGAAATATCAGTATGAGTAGCCACTCATACGA  
40 AAACATGTTGCAATTGGTGACCAACAAAGGTGATGTATTAGACTCTAAAC  
TTAATGGGTTATTTTGAAGAGAGGTTGCTTTTTTTAAGTGTGCATGGC  
ATG.AATGATCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTC  
CTCTTCATTCTGCAATTTAAAGTCCGTATTATTCAAAGTGTGTAGAGT

5 TGAGATACCTTTTCAAACCTCCATGTTGCAAACACTTTGTCAAGCCTTGAG  
CATCTAGAAGTTTGTGGATGCGAAAATATGGAAGAACTCATACTACTGG  
GATTGGGGGTTGTGGAGAAGAGACAATTACTTTCCCAAGCTGAAGTCTT  
TATCTTTGAGTCAACTACCGAAGTTATCAGGTTTGTGCCATAATGTCAAC  
10 ATAATTGGGCTACCACATCTCGTAGACTTGAACTTAAGGGCATTCCAGG  
TTTCACAGTCATTTATCCGCAGAACAAGTTGCGAACATCTAGTTTGTGTA  
AGGAAGAGGTAGATATATGTTCTTTATGTTAATACAATTTAAATAATATT  
TTCAACCAAATTTTCATAATATATCTGTAATTTGATTGTATGATGTGTTA  
TTGTTTATATGTGGCTATTAAGGGATGATTATTTTGCAGGTTGTGATTCC  
15 TAAGTTGGAGACACTTCAAATTGATGGCATGGAGAACTTAGAAGAAATAT  
GGCCTTGTGAGCTTAGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAA  
GTGAGTAGCTGTGATAAGCTTGTGAATCTATTTCCGCACAATCCCATGTC  
TCTGTTGCATCATCTTGAAGAGCTTAAAGTCAAAAATTGTCGTTCCATTG  
AGTCGTTATTCAACATCGACTTGGATTGTGTCAAGTGAATTGGAGAAGAA  
20 GACAACAAGAGCATCTTAAGAAGAATCAAAGTGAAGAATTTAGGGAAGCT  
AAGAGAGGTGTGGAGGATAAAAGGTGCAGATAACTCTCGTCCCCTCATCC  
ATGGCTTTCCAGCTGTTGAAAGCATAAGTATCTGGGGATGTAAGCGGTTT  
AGAAATATATTCACACCTATCACCGCCAATTTTGATCTGGTGGCACTTTT  
GGAGATTACATAGGAAATTACAGAGAAAATCATGAATCGGAAGAGCAGG  
25 TAACGCTTTCAATTTCACTTTCTTACTTAATTAAGGACTAAGCTCTTGTT  
TTTTGAATAATAAAGAGGTGGGATGACTAACTTGGGCATCACAATTGTA  
ACAAAATGTTACAAACCATGAACGTACAAACCATTTCTTGAATTAAGGTT  
TCAATACAAGTCATTTACAAATATGGCTTAAGTTTTTTTATATTTATGTA  
TCAACATTATTTTTCATTAGAGGTCATTATTATAATAGTAAGTTTAAAGC  
30 AATTTAAATTAGCACTAATTTTTTCATCATCTAACTTTAGCTAATAAATCG  
TTATAAATGTCAATAGCTAAAATAAAAATATTTGACATTCACTGAGAGCA  
ATTTTTTCTAAACATGATTGCAAATGATTAAAACTTAAATTTAAACTAAA  
AAGATTTTTATATATGTTATACAAAATTTACAAATTGAAATTGGATATGT  
TAATTAACAGTTTATAATTATTGTATTACAAAGCGATATATAATAAAATA  
35 TTATTTTTCTGTAGTCATGTATAATTGTATATGTAAATGATTTTTTAAGA  
TGGTAGAAGTGGAAACTAGTCAATCTCACTTAACTCATTGTCACACCAGT  
TTTATATCCGTTTCTCTCTCTCTCTCTTCTTGCCTCCATCTTTTTTCAAC  
TCATAACACATAAAAATAACATATTTTCCAACACATTTAAGTCACTACCA  
CATCATTATTTTTTAATTTAATTAAATTAGAAAATATAAAATTAAATAAAA  
40 CATAACATTTTTTTATTAAAAGGCACTAATACAAATAAAAAGATACACGG  
TAAATAAAAAAACGATAATTAGAAAAAAAACATAATAAAAAAAGACAACA  
TTAAAAATAWAAAGCGACAACATAAATTAACATAATGATCAAGAAAAATTCT  
AAAACCTCCCACCATATTTTTCTGCAATTTGTCATTTATGTTCAAACACCA  
TTCGCAGAATCCCTCCTATCAAGTGATCATGTTGATTGAGAAAAAACTGT  
ATGTCTCTCTCATGTATCTCCAAGTCCAACAAGTTAGCTTTTCATTTCTTC  
ATTTTCTCATGTAAGACGCAAATTTTCATCCCGATATTGTTTTCTATCTT  
CCACCTCTACTTTATTACAGTGTGGATGAAGGAGAGGACAGCGATTCTC  
GTACGAACGGTTACGATTCGACTGGCCGTCGTTTACAATCCCGCGGCCA

TGGCGGCCGGGAGCATGCGACGTCGGGCCCATTCGCCCTATAGTGGTCGT  
AATACA (SEQ ID NO:93)

## Sequence gap

5 TGAGCCTCCGATGCTTAGTCCACTTGGCACAGTTCAAGTCCAATCAACTT  
ATAACCCATTTTTCTTCAAGTTGTCTTCAAGTTAAGCCCAATTTGCCTTC  
TCCAAATCATCCATAACTTCATGGAATCGCCCCTTCATCTTAATCCCGAA  
TGCACAATTATTCTCCCATCTTCATTTTAAGCAAGAGGCCACCTTCTTCA  
TGCTTCATCCATCAATAGTCTGTTGGAATAGTGTCTAAGGCTGCAACTAT  
ATTAGACAAGTATTTGACCCGGTTGTGCATGGTCCTTTTGGGTTGCCTTC  
10 ACCATAGCAACTTGATAGGATGATTTATTAAGAGAGAGTAAATATTATTA  
ATATATTATGAGAATAATATAATGAATAATATATTTGTTATTTGATTAAT  
ATAAGTCATAGAATTAATTAGAATTAATTTGGTGACTTAAAGAGATTAAT  
TAAATAAAGGGGTATAAACTGTCAATTGTTTGATAGTTAAGCTTTAGACT  
GTAAATCCATTTGGATATGGTATGGACGAATCCTAAGGGATTTAGGATAG  
15 CTAAAATCGTCCATATGAGTTATCTAAGAAGGATTTGGATAGCCTTAAGA  
GAAGATTATCTGATAGGGACTTATCTGTAATCCTTAAGGAGTCTACAAGT  
ATAAATAGACCCTATGGCTGATGGAATTCGACACATCTCCTAAAGTAAGA  
GAGCCTTGGCCGAATTCCTCCCCTCACCTCTCTCCTAAATCATTCTTCTT  
GCT.ATTGGTGTTTGTAAGCCATTAGAGGAGTGACATTTGTGACTCTAGAA  
20 TCTCCAAGACCTCAAGATCAACAAGGAATTCAAAGGTATGATTCTAGATC  
TGTTTCAATGTTGTTATTTGTCCTAATTAGTCATTAGAAGACTTGGATTC  
AAAGCATGTTTATTAGAAAGCCTAGATCYGAGCAATAGGGTTTTGCATGC  
GCACATAGGAAAGTTCTTATGGCTAAAACCCATCATAGTCCACTTCATGT  
ATC.ATCTCTACTAGTTATTTAGTCCATAATCCTTGTTGTCCTCCAAGTTT  
25 AATTACCTCCCTTAGTTCCTGTTCTGCTAGTTTCCTTAAAATTTGCTATT  
AAGATCACAGAACTAGAGAGTACCCAAAATGGTTATAAAATAACAAAAAG  
GAA.ATATGCATGAAGATTAATAAATTATAAATGTAATATGCTAAAATA  
AACTATAAAAAAAAAGTAAATAAAATGAACTATCACACTCCGACCACCC  
TTATAGGCTTGTACTGCACCCACCCTTCATTCTTGTACCAATATGGGAT  
30 GGAAACATTATTCATTAAGCCAAAAAACTAACATTTAAGGGGTGAGTGAC  
AAAGGTAAGTACTAAAGACAACAATAATCCATTTTCTTGTACATACACA  
ACACACACATAGGGGCGGACGTAGGATTTGTAGTATGTGTTGTGGGTGAC  
ACATTTTTTCTTTTACGTAGTGACACAATAGTAGAGAAAACGAGAAATTC  
CAATTTTTTACATTGTGTTGAAAAAATATACAGGGGTTGCTGGTGCTAC  
35 TCTGGGCACCAAAGTGGAACCGCCCCTGCACACACACACATAGAGGGA  
GAGAGAGAGGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGATT  
TGGGATGTGATACTTCTTTTGGGAAAAATGGAGCAATATCTTTAATATTGT  
ATTTTTTTAATGTAATTTATATATTTAATCATTTTAGTTTATAACTTTTA  
GTTTTTTTTATTTAATCTGTATATTTAATCATTTTCAGTTTATAAGTTTT  
40 ATTTATTTTGGTATACCAGAAAAAAAGTCTTTTATGTGTTGGATTTAAC  
ATAAAAATCTAACAATATTAATCAAAAAGACCAACATGTGGACAATTAT  
GTATATAATTAATTCTCAATGGTCTTAGTGTAACGATATAAATTTCAAAA  
CAATTTTTTCACATTAAAAAAAACACTTTCAGTCATAATTGTTATAAATTA

TCATTGTATCACAAAATCAGTTCATAACATCACATCCCAAGATCAATAAA  
GTGTAAATACTCCTCATGTGTGTACTAATCAAGCCGACGCCTTCCCGCGA  
TTCTCACTGGTACCTGAAACACGTAACATAACAACGTAAAGCATAAATGC  
TTAGTGAGTTCCCCAAAATACCACATACCACATATATGCCTTTCCAGGCC  
5 ATA ACTCTGTAGGATCTTCCGACCCAAGTGTCTCAGGGGACTTCCGTCCC  
GAATCCCGGTAGACCTTCCGGTCCTACCCGTATTGACCTTCCGGTCCGTA  
TCATACATAACATAACATAACACATACATATCACATAACAACATATAGCAC  
ATACATCTCATAACATAAAAGACCTTCCGGTCACATAAAGGTACCCTTCC  
AGGTACAGTATAGTGAGAANACTCACCTCGTATGATGTCTAATACCTCAC  
10 GTGCTCGATATCCCTGAATCTCGAAACAATGACCTAGCCCCGCCTACTCA  
CATAAAGTAATTATTTCAAATCATTACGGCTCTCAAGGCTAGACTACAT  
CCCTTTCTATAAATCCACAGAAGGGTAAAAGACCATTTTACCCCTCCTTG  
ACCCAAAAGTCCAAATGTTGATCAAAACCCCAAAAAGTCAACGAAAGACAA  
TGGTCAACTTTGACCCTACTCGTGGAGTGCACAAAGGTGACTCGGCAAGT  
15 ACATGCGGGTCCTCTGAATCCTTTTCAGTCTCTCTTGGCTCGTCGAGTCTT  
TCTTCCACCCGACGAGTTACACCTGTCATGAATCGCGGGGCAACCCCGAC  
TCGACTTGTCGAGTCCGCTCATGGACTCAACGAGTTCATTCCATGCTCAC  
ACTCAAATGACCTCCTGAGGTGAGATCTGTTCCCTCTAATCCATAGATCTG  
ACCTTCCCAAGCTCAATAAACACGTAAAGGTTCGAACTTGATACTCATGC  
20 AACGTCCAAATGATTCTACTTGATGATTTAGCCCCAAATACAACATCCTA  
AGTCCATACGACCTTATTTTTCTCAAATAACAACACATATATTTAATTAC  
CAATGACAGTAATAGATATCATATAAAGTATTTGTAACACTTTGTAAGAA  
CCTTGCTACTATAGGTAAAAAGAAACATTTCAAAGTACATGCCCTAATTA  
GAAAAAAAGTTATAAAAAAATAATGACTAGGGGGCGTGTTTTTTTACTAG  
25 TTTGTATCAAATTATATCAAAATTTAAGGTGGAAAAGAATGACGACCACA  
TTAACCAGAAATGTAATTATTTTTTTTATTTGGTAATTTTTTAATATTTGTT  
GTGATCTATGTATTTAAAAGTAAATATCAAACAAGAACATAATCCAAACC  
CTAAATTGCAAGTCTCGCCCAATTTCTCTATCACTAGTCCTCACTTACGA  
TGGCGTTACGTCGCTCTCTCACTTCCCTACAACCCATTGTTGCTACTAATT  
30 AACTAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGAAATTGA  
ACGAATCTCGTCAAATTTTTTATTTTGTGATGGATTTGAGTGGAAGTTT  
AGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACATGGGTGAAGA  
TAAAATGGAGTTGTCGCCGTTGTATTATAGATCTCTTAGGGGTTTGATTCT  
TGAGTTATTACTGTATACGTAGCCTCTTTACAACGACCATTCTTCCAAGT  
35 ACCATTTGATCTTTTTTAGAATCCAGTTGTCTGAAACACCCTGATTTGGAT  
CAAATATCACCAACAACCTCTTAAGAAGTGGACTAATTAATTGTTTCTTG  
ATCTTGATAACAAGAGGAAACACGTCACCATATCTTTTATTTTAAATTTG  
CTTTTGGTGTAATTTCTTTCTTCCCATTTCTTTCTTGATCTGTTCCAGAT  
GGTATTTGGTGTGGATAATTTACACCTGGAGATTGTGAACGATGGGAAGG  
40 GGTATGTGATTTACAGAGGATGTGGCTTGTGGTTGAGGATGGTTTATGGC  
TGGCCGAGTCTAATTTATATTTATATAAACAATAAATATATAAAACAAG  
GGTAAAATATGTATTTAAGCGTCCTCTTTTAATGGTGACAATTTTTACAG  
TTTACTCTCTTTGTTTTTTAATTGTGATGCCACGATCGAACTCATTCAT

CCCCCCCCCTTTTTTTTTTAAAAATAAAAAATTAAGAAGGGGTACCACCAT  
ATACCCGTGTCAGCTTCTTATTCCCAAGCAGTCAAATAGGGACTTAGGTT  
GTATGGAAACAGTTCCGTGACTTGGATGGCAGATAAAATTTAGTAAACTTA  
ACCCTTCAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAAGCTAAAT  
5 TCTGATTCTTGTTTGAAAATAAGTTGCATCTTTATTTTTGCATATTATCT  
TGTTGCATAGGATCCTTAGCATCTTTTAATAGTTTATTTGAAGCTGAAAG  
ATCCAACCTAGTTTTGATCTGTTGGCATTTCATCATTTGCAACTGTTTC  
TTGAAAAAAAATACCTAAAATCAAATAAACCATTTTCAAATCCAAAATTA  
TAAGAGAGAATTGTTAATGGACGTGGAATCATAAATCATTAACACAGTTC  
10 AGTACACAAGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTAT  
CAGAGAAAGAGACATTACAAGAAGTCACTGATACTAATATTTCTAATGAT  
GTTGTATTATTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAA  
ACTTAAATTGGAAAAATTATGAAGGAGTGGAGGTGGTGGTTTGAGATAGAGA  
GTGAGAGTCCAACATGTAGAGAATTGGTAACAACCTCACAATAACCAACAA  
15 CAGCCTATTATACTTCCCAACCTCCAGGAATTGTATCTAAGGAATATGGA  
CAACACGAGTCATGTGTGGAAGTGCAGCAACTGGAATAAATTCTTCACTC  
TTCCAAAACAACAATCAGAATCACCATTCCACAACCTCACAACCATAGAA  
ATGAGATGGTGTATGGCTTTAGGTACTTGTTCGCTCTCATGGCAGA  
ACTTCTTTCCAACCTAAAGAAAGTCAAGATACTTGGGTGTGATGGTATTG  
20 AAGAAGTTGTTTCAAACAGAGATGATGAGGATGAAGAAATGACTACATTT  
ACATCTACCCACACAACCACCAACTTGTTCCTCATCTTGATTCTCTCAC  
TCTAAAATACATGCACTGTCTGAAGTGTATTGGTGGAGGTGGTGCCAAGG  
ATGAGGGGAGCAATGAAATATCTTTCAATAATACCACTACAACCTACCGAT  
CAATTTAAGGTATGTTTGTACATATTTAATTATATATTTAATTTCTTGT  
25 TAATTTCTTTTCTTTGCAATATTCTATGCGAACTCAAGAATGGGATTG  
GAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCTTTTATTTGTT  
ATTTATCATTTTCATATCAAGTACCTATAACATTTCTTTTTTATTTTTCT  
AATTAGAAGAGGTCCACATGTCTAATTAGGTTTTCCATTCTATGTGTAAC  
CTCTATTCTCTCTGTAATCAAGCATCTTAGATTATTTATCCATTTTCATA  
30 ATTGTTGTTTATTTTTACAGTTTTTTTTTTTTTATTTAATTTTAATAATTTAA  
TTTTAATTTATTTATTATTTTTTTTTTTGGTAATTGCAACCTGTCATATAT  
TCAAGTCTTAATGTAACATAATAATACATTTTATACCCACTATACTAAGA  
TAATAATTACCTAAAGGGATGGATGCCATGACACTGCTACACTTCAGNAA  
CTCTAGTAAGGGCAGTTATGGAAGTTCAATAAAAATGATAATGGCATCTTT  
35 TGATGGGTAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATT  
AGCTAGTAGTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTCAAAATCT  
GGTCATTGTACCCAGAATTTAGTTAAATGTAACATTTTAGATATTAGGGG  
TCATCAGGTGACAGATATTGTAGAATAGAACAAATATGTAATATTACCCAA  
AACTATTTTTTCTAAGGTTGCTCTGTAAATATGTGCTTTCTTGATTTC  
40 TTGAATTTGCATTCGTATATTTTAGGTGGTAAACTGATTGTCTCTTCAAT  
AAATCCTGAAATTAATTAACAAAAAACAAGTACATTTTTGATTT  
GGAGAGCACTGGTATCATTTAGTATAGAAAAAACTAGATTTTGAATTAY  
CTTTCTTATATAAAAGTTGTGTATATAGTTTAATTAGTTTTACATCATTT



TTCTATGTGTTGTTGCAGTTGTCTGAAGCAGGTGGTGTGTTGTTGGAGCTT  
ATGCCAATACTCTAGAGAGATAGAGATATATAGGTGTGATGCACTGTCAA  
GTGTAATTCCATGTTACGCAGCAGGACAAATGCAAAAGCTGCAAGTGCTG  
ACAGTCAGTTCTTGTAATGGTCTGAAGGAGGTATTTGAAACTCAATTAGG  
5 GACGAGCAGCAACAAAAACAACGAGAAGAGTGGTTGTGAGGAAGGAATTC  
CAAGAGTAAATAACAATGTTATTATGCTTCCCAATCTAAAGATATTGGAA  
ATCTACGGTTGTGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGA  
AAGCCTGAGACAGCTCCAAGAGTTAACGATTAAGGGTTACTACTCTTGTC  
AATCTTCCAAACCTCAAAGAAATGAGGTTGGAGTGGCTAAGTAATCTGAG  
10 GTATATATGGAAGAGCAATCAGTGGACAGCATTTGAGTTTCCAAACCTAA  
CAAGAGTTGAAATTTGTGAATGTAATTCATTAGAACATGTATTTACTAGT  
TCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTACATATATTTAACTG  
CAGTCTGATGGAGGAGGTAATTGTTAAGGATGCAGATGTTTCTGTAGAAG  
AAGACAAAGAGAAAGAATCTGATGGCAAGACGAATAAGGAGATACTTGTG  
15 TTACCTCATCTAAAGTCCTTGAAATTACAACCTTCTCGAAGTCTTAAGGG  
GTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTATTGGATACTTTAG  
AAATCAAAAGATGCCCAACAATAACCACCTTCACCAAAGGAAATTCGCT  
ACTCCACAACATAAAAGAAATACAAACAAATTTTGGCTTCTTTTATGCTGC  
AGGGGAAAAAGACATCAACTCTCTTATAAAGATCAAACAACAGGTAAATC  
20 AGATCTTTGTTGCTTTAATAATTCTTAAACTACATTTGAAAAGCTTCATG  
CAAGTTTTTTTTGTTATATTGTCAAAAACCGCAACCTACATTCAGCTTTAT  
ATTTATGTACTTTATGCAGGATTTCAAACAAGACTCAGATTAATGTGAAG  
TGAATATTAAAGGTAAATTATATTTTCATGTTCTAGTTGCCTATTAATT  
AATGGCCTTTTAGTTCATGATTTTTGGATGTATTCTTCATGATGATGTGA  
25 ATCTTCTAATACCCCATTCATTGTTTGGTTGAATGTTGACTCTATGTCAG  
GATGAATATTCAAGGGAAGAATTGTTTCATCAWATGAAGGACATTAAAGAA  
CATGGATGCTATGAAGATGTTGGGAAAACATATGTATCAAGTGGCAARCT  
GCTTAATGATCTAAGTTTGTGGTTGANGATGTTGATTTTAATATTTCAA  
ATTCATTGGTTATATGGGCTTATCAATAGTGTTAATGGGATAATGAGTGA  
30 CTTAACCTAAATTATGTTGTTGGTAAATGTTGGACAAGTATGGAAAATTA  
GGAATGACTTGTGAAAAAAAAAATAAAAAAAAAA (SEQ ID NO:94)

**RG2D deduced polypeptide sequence (SEQ ID NO:95)**

MAMETANEIKQVVPVLMVPINDYLRVYVSCRKYISDMDLKMKEKEDNVEE  
35 HKNHNISNRLEVPAAQVQSWLEDVEKINAKVETVPKDVGCCFNLKIRYRAGDAF  
NIIIEIDSVMRRHSLITWTDHPIPLGRVDSVMASSTLSTEHNDFQSREVRFSEALKA  
LEANHMIALCGMGRVVGKTHMMQRLKKVAKEKRKFGYIIEAVIGEISDPIAIQVVVA  
DYLIELKESDKKTRAELRQGFKAQSDGGNTKFLIILDDVWQSVLEDIGLSPSPN  
QGVDFKVLTSRDEHVCVSMGVEANSIINVGLLIEAEAQRLFQQFVETSEPELHKIG  
40 EDIVRRCGLPIAKTMACTLRNKRKDAWKDALSRHQHDIGNVATAVFRTSYENL  
PDKETKSVFLMCGLPEDFNIPTEELMRYGWGLKLFDRVYTHIERNRLNTCIERLV  
QANLLIGSDNGVHVKMHDLVRAFLVGMYSVEQASIVNHGNMGPWPDENDMIVH

SCKRISLTCKGMIEIPVDLKF PKLTILKLMHGDKSLKFPQEFYEGMEKLQVISYDKM  
KYPLLPLAPQCSTNIRVLHLTECSLKMFDCCSIGNLSNLEVLSFANSRIEWLPSTVRN  
LKKLRLLDLRFCDGLRIEQGVLSLVKLEEFYIGNAYGFIDNCKDMAERSYNLSA  
LEFAFFNNKAEVKNMSFENLERFKISVGC SFDGNISMSSH SYENMLQLVTNKG DVL  
5 DSKLNGLFLKTEVLF LSVHGMNDLEDVEVKSTHPTQSSSFCNLKVRI SKCVELRYL  
FKLHVANTLSSLEHLEVCGCENMEELIHTGIGGCGEETITFPKLKSLSLSQLPKLSGL  
CHNVNII GLPHLVDLKLKGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDGMENL  
EEIWPCELSGGEKVKLREIKVSSCDKL VNLFPHPNMSLLHHLEELKVKNCRSIESLF  
NIDLDCVSAIGEEDNKSILRRIKVKNLGK LREVWRIKGADNSRPLIHGFPAVESISIW  
10 GCKRFRNIFT PITANFDLVALLEIHIGNYRENHESEEQIEILSEKETLQEVTD TNISND  
VVLFPSCLMHSFHNHLHKLKLENYEGVEV VFEIESESPTCRELVTTHNNQQPHLPN  
LQELYLRNMDNTSHVWKCSNWNKF FTLPKQQSES PFHNLTTIEMRWCHGFRYLF S  
PLMAELLSNLKKVKILGCDGIEEVVSNR DDEDEEMTFTSTHTTTNLFP HLDLSLTLK  
YMHCLKCIGGGGAKDEGSNEISFNNTTTT TDQFKLSEAGGVCWSLCQYSREIEIYRC  
15 DALSSVIPCYAAGQMOKLQVLT VSSCNGLKEVFETQLGTSSNKNNEKSGCEE GIPR  
VNNNVIMLPNLKILEIYGCGGLEHIFTFSALESRLQLQELTIKGY YTLVNLPNLKEM  
RLEWLSNLRYIWKSNQWTA FEFPNLTRVEICECNSLEHVFTSSMVG SLLQLQELHIF  
NCSLMEEVIVKDADVSV EEDKEKESDGKTNKEILVPHL KSLKLQLLRSLKGFSLGK  
EDFSFPLD TLEIKRCPTITTTFTKGN SATPQLKEIQTNFGFFYAAGEKDINSLIKIKQ  
20 DFKQDSD.CEVNIK

**RG2E polynucleotide sequence (SEQ ID NO:96)**

TGGGAAGACACAATGATGCAAAGGTTGAAGAAGGTTGCTAAAGAAAATAGAAT  
GTTCAATTATATGGTTGAGGCAGTTATAGGGGAAAAGACAGACCCACTTGCTAT  
25 TCA.ACAAGCTGTAGCGGATTACCTTTGTATAGAGTTAAAAGAAAGCACTAAACC  
AGC.AAGAGCTGATAAGCTTCGTGAATGGTTTAAGGCCAACTCTGGAGAAGGTA  
AGA.ATAAGTTCCTTGTAATATTTGATGATGTTTGGCAGTCCGTTGATCTGGAAG  
ACATTGGTTTAAAGTCATTTTCCAAATCAAGGTGTCGACTTCAAGGTCTTGTTGA  
CTTCACGAGACGAACATGTTTGCACAGTAATGGGGGTTGAAGCTAATTCAATTC  
30 TTAATGTGGGACTTCTAGTAGAAGCAGAAGCACAAAGTTTGTTCCAGCAATTTG  
TAG.AAACTTTTGAGCCCGAGCTCCATAAGATAGGAGAAGATATCGTAAGGAAG  
TGTTGTGGTTTACCTATTGCCATTAAAACCATGGCATGTACTCTAAGAAATAAA  
AGAAAGGATGCATGGAAGGATGCACTTTTGCATTTAGAGTACCATGACATTAGC  
AGTGTGCGCCCAAAGTCTTTGAAACGAGCTACCATAATCTCCACAACAAGGAG  
35 ACT.AAATCTGTGTTTTTGTATGTGTGGTTTTTTTCTGAAGACTTCAATATTCCAA  
TCGAGGAGTTGATGAGGTATGGATGGGGCTTAAAGATATTTGATAGAGTTTATA  
CTATTAGACAAGCAAGAATCAGGCTCAACACCTGCATTGAGCGACTGGTGCAG  
ACAAATTTGTTAATAGAAAGTGATGATGGTGTGCACGTCAAGATGCATGATCTG  
GTCCGTGCTTTTCGTTTTGGTTATGTTTTCTGAAGTTGAACATGCTTCAATTATCA  
40 ACCATGGTAATATGCTTGGATGGCCTGAAAATTATATGACCAACTCTTGCAAAA  
CAATTTCAATTAACATGCAAGAGTATGTCTGAATTTCCGGGAGATCTCAAGTTTC  
CAAACCTAACGATTTTGAAGCTCATGCATGGAGATAAGTTGCTAAGATATCCTC

AAGACTTTTATGAAGGAATGGAAAAGCTCTGGGTTATATCATATGATGAAATGA  
AGTATCCATTGCTTCCCTCGTTACCTCAATGCTCCATCAACCTTCGAGTGCTTCA  
CCTCCATCGATGCTCATTAATGATGTTTGATTGCTCTTGTATTGGAAATATGTTG  
AATCTGGAAGTGCTTAGCTTTGTTAAATCTGGCATTGAATGGTTACCTTCCACA  
5 ATAGGAAATTTAAAGAAGCTAAGGTTACTTGATCTGAGAGATTGTTATGGTCTT  
CGTATAGAAAAAGGTGTCTTGAAAAATTTGGTGAAAATTGGAGGAATTTATATT  
GGTAGAGCAGATATTTTATAGAT

**RG2E deduced polypeptide sequence (SEQ ID NO:97)**

10 WEDTMMQRLKKVAKENRMFNYMVEAVIGEKT DPLAIQQA VADYLCIELKESTKP  
ARADKLREWFKANS GEGKNKFLVIFDDVWQSV DLEDIGLSHF PNQGVDFKVLLTS  
RDEHVCTVMGVEANSILNVGLLVEAE AQSLFQQFVETFEPELHKIGEDIVRKCCGL  
PIAKTMACTLRNKRKDAWKDALLHLEYHDISSVAPKVFETSYHNLHNKETKSVFL  
MCGFFPEDFNIPIEELMRYGWGLKIFDRVYTIRQARIRLNTCIERLVQTNLLIESDDG  
15 VHVKMHDLVRAFVLVMFSEVEHASIINHGNMLGW PENYMTNSCKTISLTCKSMSE  
FPGDLKFPNL TILKLMHGDKLLRYPQDFYEGMEKLWVISYDEM KYPLLPSLPQCSI  
NLRVLHLHRCSLMMFDCSCIGNMLNLEVL SFVKS GIEWLPSTIGNLKKLRLLDLRD  
CYGLRIEKGVLKNLVKIGGIYIGRADIL.

**RG2F polynucleotide sequence (SEQ ID NO:98)**

CTGTGGAAGACACAATGATGCAAAGGCTGAAAAAGGTTGTGCATGAAAAGAAA  
ATGTTTAACCTTTATTGTTGAAGCAGTTATAGGGGAAAAGACAGACCCCGTTGCC  
ATTCAGGATGCTATAGCAGATTACCTAGGTGTAGAGCTCAATGAAAAATCTAAG  
CAAGCAAGAGCTGATAAGCTCCGTCAAGGATTCAAGGACAAATCAGATGGAGG  
25 CAAAATAAGTTCTTTGTAATACTTGACGATGTTTGGCAGTCTGTTGATCTGGA  
AGATATTGGTTTAAGTCCTTTTCCAAATCAAGGCGTCGACTTCAAGGTCTTGTT  
GAC.ATCAGGAGACAGACATGTTTGCACAGTGATGGGGGTTGAAGCCAAATTAA  
TTCTAAACGTGGGACTTCTAATTGAAGCTGAAGCACAAAGTTTGTTCACCAAT  
TTGTTGTCACTTCTGAGCCCGAGCTCCATAAGATAGGAGAAGATATTGTAAAGA  
30 AGTGTTCGGTCTGCCAATTGCCATCAAAACCATGGCATGTACTCTACGACATA  
AAAGAAAGGATGCATGGAAGGATGCACTTTCACGTTTAGAGCACCATGACATT  
CAAAGTGTTGTGCCTAAAGTATTTGAAACGAGCTACAACAATCTCAAAGACAA  
GGAGACTAAATCCGTATTTTGTATGTGTGGTTTGTTCCTGAAGACTTGGATAT  
ACCTATCGAGGAGTTGATGAGGTATGGATGGGGCTTAAGATTATTTGATAGAGT  
35 TAATACTATTACACAAGCAAGAAACAGGCTCAACACCTGCATTGAGCGACTGG  
TGCACACAAATTTGTTAATTGAAAGTGTTGATGGTGTGCATGTCAAGATGCATG  
ATCTGGTTCGTGCTTTTGT TTTGGGAATGTTTTCTGAAGTGGAGCATGCTTCAAT  
TGTCAACCATGGTAATATGCCCCGAGTGGACTGAAAATGATATGACTGACTCTTG  
CAAACAAATTTCATTAACATGCAAGAGTATGTTGGAGTTTCCTGGAGACCTCAA  
40 GTTTCCAAACCTAAAGATTTTGAAACTTATGCATGGAGGTAAGTCACTAAGGTA  
TCCTCAAGACTTTTATCAAGGAATGGAAAAGCTGGAGGTTATATCATACGATGA  
AATGAAGTATCCATTGCTTCCCTCGTTGCCTCAATGTTCCACCATCCTTCGAGTG

CTTCATCTCCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTCAATCGGTAATC.  
TTTTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAGCATTGAATTGTTACCTTC  
CGTAATTGGAAATTTGAAGAAGTTGCGGCTGCTAGATTTGACAAACTGTTATGG  
TGTTTCGTATAGAAAAGGATGTCTTGAAAAATTTGGTGAAACTTGAAGAGCTTTA  
5 TATTAGGAATGGTCTACCAGTTTACAGAGGAT

**RG2F deduced polypeptide sequence (SEQ ID NO:99)**

VEDTMMQRLKKVVHEKKMFNFIVEAVIGEKTDPVAIQDAIADYLGVELNEKSKQA  
RADKLRQGFKDKSDGGKNKFFVILDDVWQSVLEDIGLSPFPNQGVDFKVLLTSRD  
10 RHVCTVMGVEAKLILNVGLLIEAEAQSLFHQFVVTSEPELHKIGEDIVKKCFGLPIAI  
KTMACTLRHKRKDAWKDALSRLEHHDIQSVVPKVFETSYNNLKDKETKSVFLMCG  
LPEDLDIPIEELMRYGWGLRFLDRVNTITQARNRLNTCIERLVHTNLLIESVDGVH  
VKMHDLVRAFVLGMFSEVEHASIVNHGNMPEWTENDMTDSCQISLTCKSMLEFP  
GDLKFPNLKILKLMHGGKSLRYPQDFYQGMKLEVISYDEMKYPLLPSLPQCSTILR  
15 VLHLHECSLRMFDCSSIGNLFNMEVLSFANSSIPELLPSVIGNLKKLRLLDLTNCYGV  
RIEKDVLKNLVKLEELYIRNGLPVYRG

**RG2G polynucleotide sequence (SEQ ID NO:100)**

GAAGACACGATGATGAAGAACTGAAGGAGGTCGTGGGACAAAAGAAATCATT  
20 AATATTATTATTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCAATT  
CAAGCTGTAGCAGATTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGC  
AAGAGCTGATAAGCTTCGTAAACGGTTTGAAGCCGATGGAGGAAAGAATAAGT  
TCCTTGTAATACTTGACGATGTATGGCAGTTTGTGCGATCTTGAAGATATTGGTTT  
AAGTCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAGA  
25 TTCACATGTTTGCACCTCTGATGGGAGCTGAAGCAAATTCAATTCTTAATATAAA  
AGTTTTAAAAGATGTAGAAGGACAAAGTTTGTTCGCCAGTTTGCTAAAAATGC  
GGTGATGATGACCTGGATCCTGCTTTCAATGGGATAGCAGATAGTATTGCAAG  
TAGATGTCAAGGTTTGCCCATTCATCAAAACCATTCGCTTAAGTCTTAAAGG  
TAGAAGCAAGTCTGCATGGGACGTTGCACTTTCTCGTCTGGAGAATCATAAGAT  
30 TGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAAATTAGCTACGACAATCTCCA  
AGATGAGGTTACTAAATCTATTTTTTTACTTTGTGCTTTATTTCTGAAGATTTT  
GATATTCTACTGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATA  
GAAGCAAAAACCTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCG  
GCTTAGGGAGACAAATTTGTTATTTGGAAGTGATGACATTGGATGTGTCAAGAT  
35 GCACGATGTGGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAACACGC  
TTCAATTGTCAACCATGGTAACGTGTGAGAGTGGCTAGAGGAAAATCATAGCAT  
CTACTCTTGTAAGAATTTTCATTAACATGCAAGGGTATGTCTCAGTTTCCCAA  
AGACCTCAAATTTCCAAACCTTTCAATTTTGAACTTATGCATGGAGATAAGTC  
ACTGAGCTTTCTGAAAACCTTTATGGAAAAGATGGAAAAGGTTCAAGTAATATC  
40 ATATGATAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACCAA  
CGTTCGAGTGCTTCATCTTCACTTACTGTTTCAATTAAGGATGTTTGATTGCTCTTCA  
ATTGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTGAA

TGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACA  
AATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTTGGTCAAACCTT  
GAAGAGCTTTATATGGGTGTTAATCGTCCGTATGGACAGGCCGTTAGCTTGACA  
GATGAAAA

5

**RG2G deduced polypeptide sequence (SEQ ID NO:101)**

RHDDEELKEVVGQKKSFNIIIQVVIGEKTNPPIAQAVADYLSIELKENTKEARADKL  
RKRFEADGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTL  
MGAEANSILNIKVDVEGQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGLPIAI  
10 KTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYDNLQDEVTKSIFLLCAL  
FPEDFDIPTTEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVK  
MHDVVRDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSQFPKDL  
KFPNLSILKLMHGDKSLSFPENFYGKMEKVQVISYDKLMYPLLPSSLECSTNVRVLH  
LHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRID  
15 NGVLKNLVKLEELYMGVNRPYGQAVSLTDE

**RG2H polynucleotide sequence (SEQ ID NO:102)**

TGAAGGAGGTTGTGGAACGAAAGAAAATGTTCAGTATTATTGTTCAAGTG  
GTCATAGGAGAGAAGACAAACCTATTGCTATTCAGCAAGCTGTAGCAGA  
20 TTACCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATA  
AGCTTCGTAAATGGTTCGAGGCCGATGGAGGAAAGAATAAGTTCCTTGTA  
ATACTTGACGATGTATGGCAGTTTGTGCGATCTTGAAGATATTGGTTTAAG  
TCCTCTGCCAAATAAAGGTGTCAACTTCAAGGTCTTGTTGACGTCAAGAG  
ATTCACATGTTTGCACTCTGATGGGAGCCGAAGCCAATTCAATTCTCAAT  
25 ATAAAAGTTTTAACAGCTGTAGAAGGACAAAGTTTTGTTCCGCCAGTTTGC  
TAAAATGCGGGTGATGATGACCTGGATCCTTGCTTTCAATAGGATAGCAG  
ATAGTATTGCAAGTAGATGTCAAGGTTTGCCCATTGCCATCAAAACCATT  
GCCTTAAGTCTTAAAGGTAGAAGCAAGCCTGCGTGGGACCATGCGCTTTC  
TCGTTTGGAGAACCATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTT  
30 TTAATAATTAGCTATGACAATCTCCAAGATGAGATTACTAAATCTATTTTT  
TTACTTTGTGCTTTATTTCTGAAGATTTTGATATTCCTACTGAGGAGTT  
GATGAGGTATGGATGGGGCTTGAAATTATTTATAGAAGCAAAAACCTATAA  
GAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTTAGGGAGACA  
AATTTGTTATTTGGAAGCGATGACATTGGATGCGTCAAGATGCACGATGT  
35 GGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAGCACGCTTCAA  
TTGTCAACCATGGTAACGTGTGAGAGTGGCTAGAGGAAAATCATAGCATC  
TACTCTTGTAAGAATTTTCAATTAACATGCAAGGGTATGTCTGAGTTTCC  
CAAAGACCTCAAATTTCAAACCTTTCAATTTTGAACTTATGCATGGAG  
ATAAGTCGCTGAGCTTTCCTGAAAACCTTTTATGGAAAGATGGAAAAGGTT  
40 CAGGTAATATCATATGATAAATTGATGTATCCATTGCTTCCCTCATCACT  
TGAATGCTCCACTAACGTTTCGAGTGCTTCATCTCCATTATTGTTCAATTA  
GGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATGGAAGTGCTC

AGCTTTGCTAATTCTAACATTGAATGGTTACCATCTACAATTGGAAATTT  
GAAGAAGCTAAGGCTACTAGATTTGACAAATTGTAAAGGTCTTCGTATAG  
ATAATGGTGTCTTAAAAAATTTGGTCAAACCTGAAGAGCTTTATATGGGT  
GTTAATCATCCGTATGGAC

5

**RG2H deduced polypeptide sequence (SEQ ID NO:103)**

KEVVERKKMFSIIVQVVIGEKTNPVIAIQQAVADYLSIELKENTKEARADKLRKWFEA  
DGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTSRDSHVCTLMGAEAN  
SILNIKVLTAVEGQSLFRQFAKNAGDDDLDPAFNRIADSIASRCQGLPIAIKTIALSLK  
10 GRSKPAWDHALSRLNHHKIGSEEVVREVFKISYDNLQDEITKSIFLLCALFPEDFDIP  
TEELMRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDVVR  
DFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLSI  
LKL.MHGDKSLSPENFYGKMEKVQVISYDKLMYPLLPSSLECSTNVRVHLHLYCSL  
RMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKGLRIDNGVLKN  
15 LVKLEELYMGVNHYPG

**RG2I polynucleotide sequence (SEQ ID NO:104)**

AAGAAGAGCTGAAGGAGGTTGTGGAACAAAAGAAAACGTTCAATATTATT  
GTTCAAGTGGTCATAGGAGAGAAGACAAACCCTATTGCTATTTCAGCAAGC  
20 TGTAGCAGATTCCCTCTCTATAGAGCTGAAAGAAAACACTAAAGAAGCAA  
GAGCTGATAAGCTTCGTAAATGGTTCGAGGCTGATGGAGGAAAGAATAAG  
TTCCTCGTNATACTTGACGATGTATGGCNGTTTGTGATCTTGAAGATAT  
TGGTTTAAAGTCCTCATCCAAATAAAGGTGTCANCTTCAAGGTCTTGTGGA  
CGTCAAGAGATTACATGTTTGCACCTCTGATGGGAGCTGAAGCCAATTCA  
25 ATTCTCAATATAAAAAGTTTAAAAGATGTAGAAGGAAAAAGTTTGTTCG  
CCAGTTTGCTAAAAATGCGGGTGATGATGACCTGGATCCTGCTTTTCATTG  
GGATAGCAGATAGTATTGCAAGTAGATGTCAAGGTTTGCCCATTTGCCATC  
AAAACCATTGCCTTAAGTCTTAAAGGTAGAAGCAAGTCTGCATGGGACGT  
TGC.ACTTTTCTCGTCTGGAGAATCATAAGATTGGTAGTGAAGAAGTTGTGC  
30 GTGAAGTTTTTAAAATTAGCTATGACAATCTCCAAGATGAGGTTACTAAA  
TCT.ATTTTTTTACTTTGTGCTTTATTTCTGAAGATTTTGATATTCCTAC  
TGAGGAGTTGGTGAGGTATGGGTGGGGCTTGAAATTATTTATAGAAGCAA  
AAACTATAAGAGAAGCAAGAAACAGGCTCAACACCTGCACTGAGCGGCTT  
AGGGAGACAAATTTGTTATTTGGAAGTGATGACATTGGATGCGTCAAGAT  
35 GCACGATGTGGTGCGTGATTTTGTGTTTGCATATATTCTCAGAAGTCCAGC  
ACGCTTCAATTGTCAACCATGGTAATGTGTCAGAGTGGCTAGAGGAAAAT  
CATAGCATCTACTCTTGTAAGAATTTCAATTAACATGCAAGGGTATGTC  
TGAGTTTCCCAAAGACCTCAAATTTCCAAACCTTTCAATTTTGAACTTA  
TGCATGGAGATAAGTCGCTGAGCTTTCCTGAAAACCTTTATGGAAAGATG  
40 GAAAAGGTTTCAGGTAATATCATATGATAAATTGATGTATCCATTGCTTCC  
CTC.ATCACTTGAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT  
GTTCAATTAAGGATGTTTGATTGCTCTTCAATTGGTAATCTTCTCAACATG

GAAGTGCTCAGCTTTGCTAATTCTGGCATTGAATGGTTACCATCTACAAT  
TGGAAATTTGAAGAAGCTAAGGCTACTGGATCTGACAGATTGTGGAGGTC  
TTCATATAGATAATGGCGTCTTAAAAAATTTGGTCAAACCTGAAGAGCTT  
TATATGGGTGCTAATCGTCTGTTTGGAAAGTGCCAT

5

**RG2I deduced polypeptide sequence (SEQ ID NO:105)**

EELKEVVEQKKTFNIIVQVVIGEKTNPQIAIQQAVADSLSELKENTKEARADKLRKWF  
EADGGKNKFLVILDDVW?FVDLEDIGLSPHPNKGV?FKVLLTSRDSHVCTLMGAEA  
NSILNIKVLKDVEGKSLFRQFAKNAGDDDLDPAFIGIADSIASRCQGLPIAKTIALSL  
10 KGRSKSAWDVALSRLNHNKIGSEEVVREVFKISYDNLQDEVTKSIFLLCALFPEDFDI  
PTEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIGCVKMHDDV  
RDFVLHIFSEVQHASIVNHGNVSEWLEENHSIYSCKRISLTCKGMSEFPKDLKFPNLS  
ILKL.MHGDKSLSPENFYGKMEKVQVISYDKLMYPLLPSLECSNLRVLHLHECSL  
RMFDCSSIGNLLNMEVLSFANSIGIEWLPSTIGNLKKLRLLDLTDCGGLHIDNGVLKN  
15 LVKLEELYMGANRLFGKCH

**RG2J polynucleotide sequence (SEQ ID NO:106) and (SEQ ID NO:107)**

ATGTCGACCCAACAGGGATTGTTGGTGCCATTATTAACCCAATTGCTCA  
AACGGCCTTGGTTCCCCTTACAGACCATGTAGGCTACATGATTCCTGCA  
20 GAAAATATGTGAGGGACATGCAAATGAAAATGACAGAGTTAAATACCTCA  
AGAATCAGTGCAGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCA  
GATTCATCTCAAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAG  
CGAATGTTGCAAACCTTTCCAATTGATGTCATCAGTTGTTGTAGTCTCAGG  
ATCAGGCACAAGCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATCGA  
25 AAGTCTAACGAGACAAAATTTCGCTGATTATCTGGACTGATGAACCTGTTC  
CCCTGGGAAGAGTTGGTTCCATGATTGCATCCACCTCTGCAGCATCAAGT  
GATCATCATGATGTCTTCCCTTCAAGAGAGCAAATTTTTAGGAAAGCACT  
AGAAGCACTTGAACCCGTCCAAAAATCCACATAATAGCCTTATGGGGGA  
TGGGCGGAGTGGGGAAGACCACGATGATGAAGAAGCTGAAAGAGGTCGTG  
30 GAACAAAAGAAAACGTGCAATATTATTGTTCAAGTGGTCATAGGAGAGAA  
GACAAACCCTATTGCTATCCAGCAAGCTGTAGCAGATTACCTCTCTATAG  
AGCTGAAAGAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTAAACGG  
TTCGAAGCCGATGGAGGAAAGAATAAGTTCCTTGTAATACTTGACGATGT  
ATGGCAGTTTTTTCGATCTTGAAGATATTGGTTTAAGTCCTCTGCCAAATA  
35 AAGGTGTCAACTTCAAGGTCTTGTGACGTCAAGAGATTACATGTTTGC  
ACTCTGATGGGAGCTGAAGCCAATTCTATTCTCAATATAAAAGTTTAAA  
AGATGTAGAAGGAAAAAGTTTGTTCGCCAGTTTGCTAAAAATGCGGGTG  
ATGATGACCTGGATCCTGCTTTCATTGGGATAGCAGATAGTATTGCAAGT  
AGATGTCAAGGTTTGGCCATTGCCATCAAAACCATTGCCTTAAGTCTTAA  
40 AGGTAGAAGCAAGTCTGCATGGGACGTCGCACTTCTCGTCTGGAGAATC  
ATAAGATTGGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAATTAGCTAT  
GACAATCTCCAAGATGAGGTTACTAAATCTATTTTTTTACTCTGTGCTTT

ATTTCTGAAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGT  
GGGGCTTGAAATTATTTATAGAAGCAAAAAGTATAAGAGAAGCAAGAAAC  
AGGCTCAACAACTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGG  
AAGTCATGACTTTGGGTGCGTCAAGATGCACGATGTGGTGCGTGATTTG  
5 TTTTGCATATGTTTTCAGAAGTCAAGCATGCTTCAATTGTCAACCATGGT  
AACATGTCAGAGTGGCCAGAGAAAAATGATACCAGCAACTCTTGTA AAAAG  
AATTTTCATTAACATGCAAGGGTATGTCTAAGTTTCCTAAAGACATCAACT  
ATCCAAACCTTTTGATTTTGAACTTATGCATGGAGATAAGTCGCTGTGC  
TTTCCTGAAAACCTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATA  
10 TGATAAATTGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTA  
ACGTTTCGAGTGCTTCATCTCCATTATTGTTTCAATTAAGGATGTTTGATTGC  
TCTTCAATTGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTC  
TAACATTGAATGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGC  
TACTAGATTTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTA  
15 AAAAATTTGGTCAAACCTTGAAGAGCTTTATATGGGTGTTAATCGTCCGTA  
TGGACAGGCCGTTAGCTTGACAGATGAAAAGTCAATGAAATGGTAGAAG  
GTTCCAAAAAAGTCTTGCCTAGAAATATGAGTTGTTTAAATACAATGCT  
CAAGTGAAGAATATATCCTTCGAGAATCTTAAACGATTCAAGATCTCAGT  
GGGATGTTCTTTACATGGATCTTTCAGTAAAAGCAGGCACTCATACGAAA  
20 ACACGTTGAAGTTGGCCATTGACAAAGGCCAAGTATTGGAATCCCGAATG  
AACGGGTTGTTTGAGAAAACGGAGGTTCTTTGTTTAAAGTGTGGGGGATAT  
GTATCATCTTTCAGATGTTAAGGTGAAGTCCTCTTCGTTCTACAATTTAA  
GAGTCCTTGTCGTTTCAGAGTGTGCAGAGTTGAAACACCTCTTCACACTT  
GGTGTGTCAAATACTTTGTCAAAGCTTGAGCATCTTAAAGTCTACAAATG  
25 CGATAATATGGAAGAACTCATACATACCGGGGGTAGTGAAGGAGATACAA  
TTACATTCCCCAAGCTGAAGCTTTTATATTTGCATGGGCTGCCAAACCTA  
TTGGGTTTGTGTCTTAATGTCAACGCAATTGAGCTACCAAACTTGTGCA  
AATGAAGCTTTACAGCATTCCGGGTTTCACAAGCATTATCCGCGGAACA  
AGTTGGAAGCATCTAGTTTGTGTAAGAAAGAGGTACATATACATATAGTT  
30 TATGTTAATACATTTTAAACAATCTTTTCAACTAAAAGTTTCAGAATATA  
TCTGTATTTTGATTGTATGATGTGTTAGTGTGTTGGATGTGGCTATTAAAG  
GATAATTATTTGGCAGGTTGTGATTCTTAAGTTGGATATACTTGAAATTC  
ATGACATGGAGAATTTAAAGGAAATATGGCCTAGTGAGCTTAGTAGAGGT  
GAGAAAGTTAAGTTGAGAAAGATTAAAGTGAGAAATTGTGATAAACTTGT  
35 GAATCTATTTCCACACAATCCCATGTCTCTGCTGCATCATCTTGAAGAGC  
TTATAGTCGAGAAATGTGGTTCCATTGAAGAGTTGTTCAACATCGACTTG  
GATTGTGCCAGTGTAATTGGAGAAGAAGACAACAACAGCAGCTTAAGAAA  
CATCAATGTGGAGAATTCAATGAAGCTAAGAGAGGTGTGGAGGATAAAAAG  
GTGCAGATAACTCTCGTCCCCTCTTTTCGTGGCTTTCAAGTTGTTGAAAAG  
40 ATAATCATTACGAGATGTAAGAGGTTTACAAATGTATTACACCTATCAC  
CACAAATTTTGATCTGGGGGCACTTTTGGAGATTTGAGTTGATTGTAGAG  
GAAATGATGAATCAGACCAAAGTAACCAAGAGCAAGAGCAGGTATGGATT  
TCAATTTTACTCTTTTACTTAATTAATGATTAAGCCCCTGCTTTTAAATA



AAAAGGGGACAAACCATTTCTTGACTTAATGTTGCAATACAAGTCATGTA  
TAAGAGTGATTAACTTTTTTTTATTTATAAAATAACTACAAAACATGTTT  
TTTCATTATAGATCATGTATAAATGTGACTAATTTTTTTCATCGCCTAAC  
TTTTGTTGATAAATCATTAGAAATGTCACTAATTACTTTTTAGTATTTAT  
5 AAAATAACTACAAAACATGTTTTTTCATTATAGATCATGTATATATCAAC  
TAAAAATATTATTCCCTTACACAAAAAAGGTTCAAGAAAGCCTGTA  
TTTCGAAATAACTAAAAAGAAAATATTTGATATTCACTAAGAGAAATTTT  
TTTCTAAACATGATCGCAAATGATTAAACTTAAATTAAACTAAAAAGA  
TTTTTATATATGTTATNCAAAATTAAATTTGAAATTAAGTTTATAATTC  
10 TNGTNTCACAAAGGGATATATATAGTAAATATTATTTTTTTTGCAGTCAT  
GCATAGTTGTATTTTTTAAATGATTTATTAACGTGGTAGGAGTGGAACCA  
CTCAATCTAGTAGACCCACTATCACATGTCACATCAGCTTTACATCTATT  
TTTCTTTCTCCTTTTTTCATCTTTTTAAACTCATAACACNTAAAANTANC  
ATATTTTCCAACACACTNAACTCATTGTACATTATTATTTTAAATTTAA  
15 TTA.AATTNGAAAATTAAATTAANTAAANCNTAACATTTTTTAATTAATA  
AAT.ATTAATCCAAATAAAAAANTNCACGATAAATTAAAAANGTTTANTTTG  
GAA.AAAAAANCC (SEQ ID NO:106)

Sequence gap

ATAACCCTTTCAAGGGTCAACTCAAGTCCAAGTTAAAGTCAAGGTCAAAA  
20 CCTTGGTTAAAGTCAACTTTGGTCAAAGTCAACATCTACTTGACTCACCT  
CACCGAGTTGGTCCACCAACTTGTCTGAGTCCCTTAATCCACAACTTCAA  
GAACTTCGATCCTACTCGTCGAGTCTTTCAAGAACTCTTCGAGTTTCCAT  
TACACAGAATCGGGACCTTTTGCTCATGACTCGCCGAGTTCATCCTTGAA  
CTTGTCGAGTCTAGCTTCATACGAGTTCGAGTGTTTAGTCCTTGACTCGT  
25 CGAGTTCTTCCTTGAACCTCGTCGAGTCCATCTTCGTATAGTTGGGACATT  
GCCTTGAACCTCACCGAGTTCATCATTGAACCTCATCGAGTCCCTTCGATCTT  
CAAGTCCATAATCCTGTCCATCTTGTTGAGTCCTCTTCTAGACTCAACCA  
GATTCCTCAGAAACAGAAAAGGTTAGGGAACCATTACCTGACTCGCCGAG  
TCCCAAGAACGAATCCCCGAGTCCCCCAATGTCCATGACCATAACAATCGA  
30 TTTTCGTTGGGCTCATTGCATCCAAAGCATAGATCTAACCTCCTAGGGTC  
CAT.ATTACACGTAAAGCTACGAACTTGACGTCCATGCATGGGGGATTTGG  
CTC.AAATGGCATTAAAATGGGGTTTATCTGATGCATGGGACTCCCATGGC  
CAT.AAAGTTAACACCTTTATGCCATGGGAATCCTCAATGGTTCCATATCT  
GAAGTTAACTCTACAATATGTTCTAAACCCGAAGGTGGCTTAGAAATG  
35 CCCCAAAATGGCAAGATTCAAGCCTTAAAGGAGATCTAACAAATGATAAG  
TCAAGGTTCAAGCTTTTTACCTTGAATAAGCTGGAAATGAAGCAAAATCT  
CTGGATCCACTTGCTTCTTCAAGAACCCCCAAGCTTCCACTTCTTCCTTC  
AAGTTTCAAACAACTTTAAACACTCAAAAATGGCTCAAGAACACTCAAAA  
AGCTTTAGGGTTTCGAGTTAGGGCTTTTTGGAAGCGAGAGGGACGATGGG  
40 GGCTGAAATGAGGCTAGAAAAAGTGTTTAAATAGGGGGCAAACCCTAAAT  
ATTAGGGTTTCATCCAGGCAGCCCTACTCGTCGAGTCGGGCTCCCGACTC  
GTCGAGTAGGTCACTTAAAACCCGCGTCCATAATCCAGTCTACTCGACGA  
GTTGGGCCTCCAACCTCGTCGATTCCGAGTGCAAAACGTTCAATTACTTAA

ATTTAAATATGTACCAGGAACCGGGTGTTACAGTTGAGACTTTATACCTC  
CATAAGATAGATCTAGGTGCACATAGCCTGGATCCACAAGCTCCATGTCA  
ACAAGCGACTCTTCAAGAAGTTCATTCTTCCTCCTTAAGCACCAAAAAAC  
ACACAAAATCACCATGAAGCTCAAGAAATACTCAAATAGAGGATAGGGTT  
5 TCGTTCGTAGGGTTAGAGAGGATGGAGGCTAGAGGAAATGAGGGATAGAG  
GCGAGTTAAGGTCTTTAAATAGGGTCCAAGACCCTAAATTAGGGTTTTAA  
TCTGGCCAGACGAACGCAGGGTGTTCCCAAATGCATATGTGTCCAAATTC  
TCGTGTGCGCCATGCGTACCTCCCTTGACGCCATGTGTACCGGGTTTGG  
TCCAAACCCTTCTAACTTCAAATGATCATAACTTGCACCCCTTATCTGTT  
10 TTCGATGTTCTTTATATCCACGGAAAGGTAACAAGAAGCCCTATACTTCT  
ATAAACTTTATTTAATCTGAAAACCAACCGAAATTAAATCCAAAATTCAT  
AAAAGTCCCGAACCAACACATTTACCGATACCCTTGGGCTCCAAAACACA  
AATTGAAAACCCGGATCATCCAACTACATCATCCACCTCCAAATGAGCC  
CAAATCAATTATTCAAGGGTTCTAAGCCTGTAAATGCCCACTCCTCGAT  
15 TACCACCCCGCAATGGGAAACGATTCAAAACAGGGCGTTACATAATTTGT  
TGTGGTTTTGTATTTTTATTTCCGGTGAAGGTGAAAGATCCAATTTT  
TTAATCTGTTGGCATTTTCCATCATTTGCAACTGTTTCTTGAAAAAAAA  
TACCTAAAATCAAAATAACCATTTTCAAATCCAAAATTATAAGAGAGAAT  
TGTAAATGGACATGGAATCTTAAATCATTAACACAGTTCAGTACACAAGT  
20 TGCTAATTACATTTCTTGCTGTGCAGATTGAAATTCTATCAGAGAAAGAG  
ACATTACAAGAAGCCACTGACAGTATTTCTAATGTTGTATTCCCATCCTG  
TCTCATGCACTCTTTTCATAACCTCCAGAACTTATATTGAACAGAGTTA  
AAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGAGTCCAACAAGTAGA  
GAATTGGTAACAACCTCACCATAACCAACAACAGCCTGTTATATTTCCCAA  
25 CCTCCAGCATTTGGATCTAAGGGGTATGGACAACATGATTCGCGTGTGGA  
AGTGCAGCAACTGGAATAAATCTTCACTCTTCCAAAACAACAATCAGAA  
TCCCCATTCCACAACCTCACAACCATAAATATTGATTTTTGCAGAAGCAT  
TAAGTACTTGTTTTACCTCTCATGGCAGAACTTCTTTCCAACCTAAAGA  
AAGTCAATATAAAATGGTGTATGGTATTGAAGAAGTTGTTTCAAACAGA  
30 GATGATGAGGATGAAGAAATGACTACATTTACATCTACCCACACAACCAC  
CATCTTGTTCCCTCATCTTGATTCTCTCACTCTAAGTTTCCTGGAGAATC  
TGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATA  
TCTTTCAATAATAACCACTGCAACTACTGCTGTTCTTGATCAATTTGAGGT  
ATGCTTTGTTTCATATTCAATTATTTATTTAATTTCTTTTTTATTTGCAA  
35 TATTCTATAAATAATACATTTTATACCCACTATACTAAGATAATAATTAC  
CTAGAGGGATGGATGCTATGACACAGCTGCTACACTTCAGAACTCTAGT  
AAGGGCAGTTATGGAAGTTCAATAAAATGATAATGGCATCTTTTGATGGG  
TAAATATAGGCAATTTAAGTTTTATTTCTGTAAAGCAGTATTTAGCAAGT  
ACTGGCCAGTAGGAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATT  
40 GTACCCAGAATTTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAG  
GTGACAGATATTGTAGAATAGAACAATATATAATATTACCCAAAATATT  
TTTTCTAAGGTTTTCTGTAAATATGTGCTTTCTTGATTTCATTGAATT  
TGCATTCCTATATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCC

GAAATTAATTAACAAAAAAAAAAAAACAAAAGTAAATTTTTGATATGGAGA  
GCACTGGTATCATTTAGTATATAAAAAAACTAGATTTTGAATTAAGTTTC  
TTATATAAAAGCTGTGTATATAGTTTAAATTAGTTTACATCATTTTTCCA  
TGTGGTGTTCAGTTGTCTGAAGCAGGTGGTGTTCCTTGGAGCTTATGCC  
5 AATACGCTAGAGAGATAAGTATAGAATTCTGCAATGCATTGTCAAGTGTG  
ATTCCATGTTATGCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGACAGT  
CAGTTCTTGTAATGGTCTGAAGGAGGTATTTGAAACTCAATTAAGGAGGA  
GCAGCAACAAAAACAACGAGAAGAGTGGTTGTGATGAAGGAAATGGTGGA  
ATTCCAAGAGTAAATAACAATGTTATTATGCTTCTGGTCTGAAGATATT  
10 GGAAATCAGCTTTTGTGGGGGTTTGGAAACATATATTCACATTCTCTGCAC  
TTGAAAGCCTGAGACAGCTCGAAGAGTTAACGATAATGAATTGCTGGTCA  
ATGAAAGTGATTGTGAAGAAGGAAGAAGATGAATATGGAGAGCAGCAAAC  
AACAAACAACGAAGGGGACTTCTTCTTCTTCTTCTTCTTCTTCTTCTT  
CTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT  
15 TTTCTTGTCTAAAGTCCATTGTATTGGTCAATCTACCAGAGCTGGTAGG  
ATTCTTCTTGGGGATGAATGAGTTCCGGTTGCCTTCATTAGATGAACTTA  
TCATCGAGAAATGCCCAAAAATGATGGTGTTCACAGCTGGTGGGTCCACA  
GCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACTATTGA  
TCAAGAATCTGGCCTTAACCTTTCATCAGGTATATATGTTTCTTTAATTGG  
20 CATCATCTAATTAAGAAAGATATCATTCTGCCAAGTAAATTTACTTCAA  
ACACATTACACTGGTTTCAGTCTAAGTTTATGTTGTTCTAGGAAGGCCA  
AAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTTCAAGTGGAAGGGTA  
TTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGGCTTTTTAGTACCTG  
GAATCGTGTGTGGGAGGAGCATTATTATTCTGATTTGCTTGTTTCTTTAT  
25 CATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTAATCTTTTGAT  
TTTAAATGACAAAATTTTTCCCTGTTACTCTATTTGATTGTTGTTCTTCA  
TGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTTGATTGTTATT  
TTCATAGCATGTTAGTCACTGAATCAAGCTTTTTCATTTTCAACCAGGG  
CAAAAGGTCAAAAGTAACCTACTTTATGAGATCAAAAACAGCAACCCATC  
30 GGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCAATTGTGATTAATA  
ATTATAATATCCTGTATTAATTCATAAAAATTGGTACAGCACATATATGA  
CATTTCAAAGGTTTTTGTTTGACATATATATGCCTCTGGCGTTTTCTTTA  
TTGGACTTGCAGACCTCATTCCAAAGTTTATACGGTGACACCTTGGGCCC  
TGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAACTTGATTGAATTAG  
35 ATGTGAAATTTAATAAGGATGTTAAAAAGATTATCCATCCAGTGAGTTG  
CTGCAACTGCAAAAGCTGGAAAAGATAAATATAAACAGTTGTGTTGGGGT  
AGAGGAGGTATTTGAAACTGCATTGGAAGCAGCAGGGAGAAATGGAAATA  
GTGGAATTGGTTTTGATGAATCGTCACAAACAACCTACCACTACTCTTGTC  
AATCTTCCAAACCTTAGAGAAATGAACTTATGGGGTCTAGATTGTCTGAG  
40 GTATATATGGAAGAGCAATCAGTGGACAGCATTGTGAGTTCCAAAATAA  
CAAGAGTTGAAATTAGTAATTGCAACAGTTTAGAACATGTATTACTAGT  
TCCATGGTTGGTAGTCTATCGCAACTCCAAGAGCTACATATAAGTCAGTG  
CAAACTTATGGAGGAGGTGATTGTTAAGGATGCAGATGTTTCTGTAGAAG

AAGACAAAGAGAAAGAATCTGATGGCAAGATGAATAAGGAGATACTTGCG  
TTACCTAGTCTAAAGTCCCTGAAATTAGAAAGCTTACCATCTCTTGAGGG  
GTTTAGCTTGGGGAAGGAGGATTTTTCATTCCCATTATTGGATACTTTAA  
GAATTGAGGAATGCCCAGCAATAACCACCTTCACCAAGGGAAATTCCGCT  
5 ACTCCACAATAAGAGAAATAGAAACAAGATTTGGCTCGGTTTATGCAGG  
GGAAGACATCAAATCCTCTATTATAAAGATCAAACAACAGGTAAATCAGA  
TCATTGTTGGTTTAATAATTCTTAAACTACATTTGAAAAGTTTCATGTAA  
GTTTTTTATTATTGTCAAAAGCCGCAACCTATATTTTCAACTTTATATTT  
ATGTACTTTATGCAGGATTTCAAAAAAGCCAGGACTCTATTTAATGTGA  
10 AGTAAATACTAGAAGAGGTAAATTCTATTTACATGTCTCCTGATTGCCTA  
TTAATTAATGGCCTTTCAGTTCATGGTTTTTGGATGTATTCTTCATGATG  
ACGTGAATGTTTAAATACCCCACTAGTTAATTGTTAGGTTGAATGTTGAT  
GACCAAAGGACTATATGTCGGGAAGAATATTCAAGGAAAGAATTGTTTCAT  
CATATGAAGGGCATTAAATTAAGAAGAACATGGATGCTATGAAGATGTTG  
15 GGAAAATATATGAATCAAATAACAAGCTACTCACTTATCTAAGTTTGTG  
GTTGAGGATGTTGATTTTAATATTTCAAATTCATTGGTATCATTATATGG  
GTTTATCAGTAGTGTTAATGGGATAATGAGCAACTTAACCTTAAATTATG  
CTGTTGGTAAATGTTGGACTCAAGTATGGAAAATTAGGAATAACTTGTGA  
AAAATATATGCAAAAAGTAGGATTGAGATTTTCAATGAAAAAATTATGAA  
20 ACTATACTACTATAGTATATAAATAAATTCAACTTACTGTTGGGTATATT  
GGAAGCACATATCATGAAAGTAACTAGAAGCAGAATTTGTTCCCATCTTC  
ATCTACTTATAGTTTCCATTTCTTACTTGTAATAATCTGATTAACTTTA  
GAGTTATTTCTATTTTTTACCAACCAAAATTTTCATATAAAGGCCACAAG  
T (SEQ ID NO:107)

25

**RG2J deduced polypeptide sequence (SEQ ID NO:108)**

MSDPTGIVGAIINPIAQTALVPLTDHVGYMISCRKYVRDMQMKMTELNTSRISAEEH  
ISRNRNHLQIPSIKDWLDQVEGIRANVANFPIDVISCCSLRIRHKLGGQKAFKITEQI  
ESLTRQNSLIWTDEPVPLGRVGSMASTSAASSDHHDVFPSSREQIFRKALEALEPVQ  
30 KSHIALWGMGGVGKTTMMKKLKEVVEQKKTENIIVQVVEGKTNPIAIQQAVADY  
LSIELKENTKEARADKLKRFEADGGKNKFLVILDDVWQFFDLEDIGLSPLPNKGV  
NFKVLLTSRDSHVCTLMGAEANSILNIKVLKDVEGKSLFRQFAKNAGDDDLDPFI  
GIADSIASRCQGLPIAIKTIALSLKGRSKSAWDVALSRLENHKIGSEEVVREVFKISYD  
NLQDEVTKSIFLLCALFPEDFDIPIEELVRYGWGLKLFIEAKTIREARNRLNNCTERL  
35 RETNLLFGSHDFGCVKMHDVVRDFVLHMFSEVKHASIVNHGNMSEWPEKNDTSN  
SCKRISLTCKGMSKFPKDINYPNLLILKLMHGDKSLCFPENFYGKMEKVQVISYDKL  
MYPLLPSSLECSTNVRVLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIG  
NLKKLRLLDLTNCKGLRIDNGVLKNLVKLEELYMGVNRPYGQAVSLTDENCNEM  
VEGSKKLLALEYELFKYNAQVKNISFENLKRFKISVGC SLHGSFSKSRHSYENTLKL  
40 AIDKGELLESRMNGLFEKTEVLCLSVGDMYHLSDVKVKSSSFYNLRVLVVSECAEL  
KHLFTLGVAANTLSKLEHLKVYKCDNMEELIHTGGSEGDITTFPKLKL LYLHGLPNL  
LGLCLNVNAIELPKLVQMKLYSIPGFTSIYPRNKLEASSLLKEEVVIPEELIVEKCGSI  
EELFNIDLD CASVIGEEDNNSLRNINVENSMKLREVWRIKGADNSRPLFRGFQVVE

KIITRCKRFTNVFTPITTNFDLGALLEISVDCRGNDESDQSNQEQEQIEILSEKETLQE  
ATDSISNVVFPSCLMHSFHNQLKLILNRVKGEVVFIESESPTSRELVTTHHNQQQP  
VIFPNLQHLDLRGMDNMIRVWKCSNWNKFFTLPKQQSESPFHNLTINIDFCRSIKY  
LFSPLMAELLSNLKKVNIKWCYGIEEVVSNRDEDEEMTTFTSTHTTTILFPHLDSL  
5 TLSFLENLKCIGGGGAKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAR  
EISIEFCNALSSVIPCYAAGQMQLQVLTVSSCNGLKEVFETQLRRSSNKNNEKSGC  
DEGNGGIPRVNNNVIMLSGLKILEISFCGGLEHIFTFSALESRLQLEELTIMNCWSMK  
VIVKKEEDEYGEQQTTTTTTKGTSSSSSSSSSSSSSSPPSSSKKVVFPCLSIVLVNLP  
ELVGFFLGMNEFRLPSLDELIIEKCPKMMVFTAGGSTAPQLKYIHTRLGKHTIDQES  
10 GLNFHQDIYMPLAFSLDLQTSFQSLYGDTLGPATSEGTTWSFHNLIELDVKFNDK  
VKKIIPSELLQLQKLEKININSCVGVVEVFETALEAAGRNGNSGIGFDESSQTTTTTL  
VNLPNLREMNLWGLDCLRYTWKSNQWTAFEFPKLTRVEISNCNSLEHVFTSSMVGS  
LSQLQELHISQCKLMEEVIVKDAADVSV EEDKEKESDGKMNKEILALPSLKSLKLESL  
PSLEGFSLGKEDFSFPLDTRLIEECPAITTFTKGNSATPQLREIETRFGSVYAGEDIKS  
15 SIIKIKQQDFKKAQDSI.CEVNTR

**RG2K polynucleotide sequence (SEQ ID NO:109) and (SEQ ID NO:110)**

TGGGATTCCATATATAAAAAACATATATTTTTATAAAGTGGGATTCCATTG  
TTTATATAGATTTTTATTACCAATAGACAATAGATTAAAAAAGATATA  
20 AAAACATGTCGGCTTTTGACTAAAAATATAGATTTTTATGAATAGAATAT  
TCAATTTGCTTAACTCGTTTAAAAAAATGAAAAAGATGTCGATATAAAA  
TCTCATATGGGCCTTCTTTACCATTCAAATAGTAAAATAGTAAAAGATAC  
TTGTTTGGGGCATGAACTGACCATAGTCAAACCCATACAAAATCAAACGA  
ATCCACATGGATGATGACGATGGGGTCGCAGTAAATGTGTTTTGGTCCT  
25 TTTTTTTCGAGAGAACAGAAGCTTCTGCTCTTCATCTTCTTTAGATTTTG  
GGGATTTTCTGGTTTCAGGGGTTGTGAGTGGAACTAAATTGAAGCAAA  
AAAGTATGGTATAATTGGTTGCTAGTGAAATTGATGCTTTCTATTACTAT  
CATCTTTAAAATTGTCAAAACATTATGTATTAAATTATGAGATCGAAAGT  
GGTCTATGGGCCAAAGGTAATACAAGCTTACTCAATGAAATGAATCTAGG  
30 ATGCATCATGCATGTATTGGTTAGATTAAAGATTTTCATCAAATTTCTT  
TATCAAATTGTTGTATACCATGTTATGTAGGTGCTACCACAAGCCATAAC  
ATCGAGCAATGGAGTGTATTACTGGCATCTTTAGCAACCCGTTTGCTCAG  
TGTCTCATCGCTCCTGTGAAAGAACACCTTTGCCTTCTGATTTTCTATAC  
ACAATATGTAGGGGATATGCTTACTGCAATGACGGAGTTGAATGCTGCAA  
35 AAGACATTGTTGAAGAGCGGAAGAATCAAAACGTAGAAAAATGTTTTGAG  
GTTCCAAACCATGTCAACCGTTGGTTGGAAGATGTTCAAACAATCAACAG  
AAAAGTGGAACGTGTTCTTAACGATAATTGCAATTGGTTCAATCTATGTA  
ATAGGTACATGCTCGCAGTGAAAGCCTTGGAGATAACTCAGGAGATCGAT  
CATGCCATGAAACAACCTCTCTCGGATAGAATGGACTGATGATTCAGTTCC  
40 TTTGGGAAGAAATGATTCCACAAAGGCATCCACCTCTACACCATCAAGTG  
ATTACAATGACTTCGAGTCAAGAGAACACACTTTTAGGAAAGCACTTGAA  
GCACTTGATCCAACCACACATCCACATGGTAGCCTTATGGGGGATGGG

TGGAGTTGGGAAGACCACGATGATGAAGAGGCTGAAAAATATTATTAAAG  
AAAAGAGGACGTTTCATTATATTGTTTTGGTGGTTATAAAGGAAAATATG  
GATCTCATTTCCATCCAGGATGCTGTAGCAGATTATCTGGATATGAAGCT  
AACAGAAAAGCAATGAATCAGAAAAGAGCCGATAAACTTCGTGAAGGGTTTC  
5 AGGCCAAATCAGATGGAGGTAAGAATAGGTTCCATCATAATACTGGATGAT  
GTATGGCAATCTGTTAATATGGAAGATATTGGTTTAAGTCCTTTTCCGAA  
TCAAGGTGTCGACTTCAAGGTCTTGTTGACCTCGGAAAACAAAGATGTTT  
GTGCAAAAATGGGAGTTGAAGCTAATTTAATTTTCGACGTGAAATTCTTA  
ACAGAAGAAGAAGCACAAAGTTTGTTTTATCAATTTGTAAAAGTTTCTGA  
10 TACCCACCTTGATAAGATTGGAAAAGCTATTGTAAGAACTGTGGTGGTC  
TACCCATTGCCATCAAAACCATAGCCAATACTCTTAAAAATAGAAACAAG  
GATGTATGGAAGGATGCACTTTCTCGTATAGAGCATCATGACATTGAGAC  
AATTGCACATGTTGTTTTTCAAATGAGCTACGACAATCTCCAAAACGAAG  
AAGCTCAATCCATTTTTTTTGCTTTGTGGATTGTTTCCTGAAGACTTTGAT  
15 ATTCCTACTGAGGAATTGGTGAGGTATGGATGGGGATTGAGAGTATTTAA  
TGGAGTGTATACTATAGGAGAAGCAAGACACAGGTTGAACGCCTACATCG  
AGCTGCTCAAGGATTCTAATTTATTGATTGAAAGTGATGATGTTCACTGC  
ATC.AAGATGCATGATTTAGTTTCGTGCTTTTGTTTTGGATACGTTAATAG  
ATTCAAGCATTCTTTGATTGTTAACCATGGTAATGGTGGTATGTTAGGGT  
20 GGCCTGAAAATGATATGAGTGCCTCATCTTGCAAAAGAATTTCATTAATA  
TGC.AAGGGCATGTCCGATTTTCTAGAGACGTAAAGTTTCCAAATCTCTT  
GATTTTGAAACTTATGCATGCAGATAAGTCTTTGAAGTTTCTCAAGACT  
TTTATGGAGAAATGAAGAAGCTTCAGGTTATATCATACGATCACATGAAG  
TATCCCTTGCTTCCAACATCACCTCAATGCTCCACCAACCTTCGTGTGCT  
25 TCATCTTCATCAATGCTCATTGATGTTTGATTGCTCTTCTATTGGAAATC  
TGTTGAATCTGGAAGTGCTCAGCTTTGCTAATTCTGGTATTGAGTGGTTG  
CCTTCCACAATCGGAAATTTGAAGGAGCTAAGGGTACTAGATTTGACAAA  
TTGTGATGGTCTTCGTATAGATAATGGTGTCTTAAAGAAATTGGTGAAAC  
TTG.AAGAGCTTTATATGAGAGTTGGTGGTCGATATCAAAAGGCCATTAGC  
30 TTC.ACTGATGAAAAGTCAATGAAATGGCAGAGCGTTCAAAAAATCTTTC  
TGCATTAGAATTTGAGTTCTTCAAAAACAATGCTCAACCAAGAATATGT  
CATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGATGTTATTTTAAG  
GGAGATTTCCGGTAAGATCTTTCCTCTTTTGAAAACACGTTGCGGTTGGT  
CACCAACAGAACTGAAGTTCTTGAATCTAGGCTTAATGAGTTGTTTGAGA  
35 AAACAGATGTTCTTTATTTAAGTGTGGGAGATATGAATGATCTTGAAGAT  
GTTGAGGTAAAGTTGGCACATCTTCCTAAATCCTCTTCCTTCCACAATTT  
AAGAGTCCTTATCATTTCTGAGTGTATAGAGTTGAGATACCTTTTCACAC  
TTGATGTTGCAAACTTTGTCAAAGCTTGAGCATCTTCAAGTTTACGAA  
TGCGATAATATGGAAGAAATCATACATACAGAGGGTAGAGGAGAAGTGAC  
40 AATTACATTCCTCAAAGCTGAAGTTTTTATCATTGTGTGGGCTACCAAATC  
TGTTGGGTTTGTGTGGTAATGTGCACATAATTAATCTACCACAACCTCACA  
GAGTTGAAACTTAATGGCATTCCAGGTTTCACAAGCATATATCCTGAAAA  
AGATGTTGAAACATCTAGTTTGTGTAATAAAGAGGTAAATGTGTTTTATG

TTAATACAATACAATCTTTTCAATTAACCGTTTCAAAAATATATTGTATGA  
TTTATTTTTGTTTGGATGGGGTTATTAATGGGTGATTATTTCTCAGGTTG  
TAATTCCTAATTTGGAGAACTTGATATTAGTTATATGAAGGATTTGAAA  
GAGATATGGCCTTGTGAATTAGGGATGAGTCAGGAAGTTGATGTTTCTAC  
5 GTTGAGAGTGATTAAAGTAAGCAGTTGTGATAATCTTGTGAATCTATTCC  
CGTGCAATCCTATGCCATTGATACATCACCTTGAAGAGCTTCAAGTGATA  
TTTTGTGGTTCATTGAAGTGTTATTCAACATTGAGTTGGATTCTATTGG  
TCAAATTGGAGAAGGCATCAACAATAGCAGCTTGAGAATCATCCAATTGC  
AGAACTTAGGGAAGCTAAGTGAGGTGTGGAGGATAAAAGGTGCGGATAAC  
10 TCTAGTCTTCTCATCAGTGGCTTTCAAGGTGTTGAAAGCATTATCGTTAA  
CAAATGCAAGATGTTTAGAAATGTATTCACACCTACCACCACCAATTTTG  
ATCTGGGGGCACTTATGGAGATTCGGATACAAGATTGTGGAGAAAAGAGG  
AGAAACAACGAATTGGTAGAGAGTAGCCAAGAGCAAGAGCAGGTATGGCT  
TTCAATTTCACTTTCTTACTTAATGAAGGATTAAGCTCCTGCTTTTTTGAA  
15 TAAAAAGTGGATGAATGACTAAATTCGGGAATGCCACCCGGAAAGTTATC  
AACCATTTAGCTACACCATTTTTTTGAACTAATGTTGCAATAAATGCATAA  
TATAATTAAAAAATGGTCATTGATAAATGTAAACCAACCTTTTTTATTTA  
TAAAAATGTCTACAATAAATGATTTTCTTTATTATATATCATTTTATAAC  
AATAAGCTTAAAGATGTTTAAATAGCCAATGTCAGTTATAGATCGTAACT  
20 AATTTTTTATTAAGTATTTTAGTTAAGATATCACTCATTATTATTTTAA  
TAGAAAAAAGACAAGATTGGCTAATCCTCATAAGAATTTGGAAGATTTAA  
GCAAAATATAGAGCTTTTCCAAACATAGCCAATAGTTTCTTTTGCAGGTC  
CCATCTACGAAATTATCAATAGATTTGCGATTTTTTTTTTGGCACCCGGGA  
AATTTCCATTAATTAAGAAAAAAGTTCAAGCCATTTTGTAGTTGGCACCTG  
25 CAAAATGGTAGTTTGCACCTGCGGAAATCACCTTTCACCATTTTCGCATCT  
ATGACTTGTGAAAATGTTAATTTGTGAAATGGTCATGTGCACCTCATGAG  
AAATACGAAATGGTCAGTAATATGACTTTTTTATATAAATATGATGGTGG  
CATATATTTATAGGAAAATATAGCTGCACGATATTAATTAATAGTGAAAT  
TAGTTAACTGTATACGATAAGTATACAAAATTTATATGTATGAAGTATAC  
30 TCAATTTAGGACGACTCGGGCAATGAAATCATCATTTAATAGGAGCAATG  
AAATCATTTTCGAAAAATGTTTACAAATGAATAAAATATTAAATTAACT  
TAAACATTTTGTTAGTAGTTTGAATTTACAAACTGAAATTTGTTGTAT  
TTATTAACATTTATAAATGTTGTACTATGATTTTTTCCCTTGTTTGCAAAT  
ATTCCTTAAAAATCCACCTAAAATCAAAATAATTAATCTTTTCAAGTTG  
35 AAAAATGAAAATCGTATGATATAACCGTGTATGGATGTGGAATTATATAT  
CAGTTACTAATTACATTTTTTTGTTGGGATATATGTGCGCAGATTGATATT  
GCAATCCCATTCACTCTCACACACTCTTCCAAAACCTCCGTAAACTTGC  
TTTGGAAAAGTATGAAGGAGTGGAGGTGGTGTGAGATAGAGAGTCCAA  
CAAGTAGAGAATTGATAACAATTCACCATAATCAACAACCACTACTTCCC  
40 AACCTTGAGTTATTGGATATAAGTTTTATGGACAGCATGAGTCATGTATG  
GAAGTGCAACTGGAATAAATCTTCATTCTTCAAAAACAACAGTCAGAAT  
CCCCATTCTGTAATCTCACAACCATACATATTCAATATTGCCAAAGCATT  
AAGTACTTGTTTTCAACTCTCATGGCAAACTTCTTTCCAACCTAAAGAA

GGTCGAGGTAAGAGAGTGTCATGGTATTGAAGAAGTTGTTTCGAACAGAG  
ATGATGAAGATGAGGAAAAGACTACATTTACATCTACATCTTCTGAAAAA  
AGCATAATTTGTTCCCTCGTCTTGAATCTCTCGCTCTTATCAACTTCC  
AAATCTCAAGTGATTGGTGGTGGTGGTCTGCCAACAGTGGGAACAATG  
5 AAATATCTCTTGATAATTCACACTACTACTACTTCTTTTGTGATCAATCT  
AAGGTATGTTTTTTTTTTNGTTNCCCTT (SEQ ID NO:109)  
Sequence gap  
CCTCCCTAATAATACATGTTATGCACACTATACTAACATATTAGACACGT  
AAAGGATAAATGCTATGCCTCATATAATACGTTATATTTATAATCTTTAA  
10 ACAATCAAATTTATTAAACAAATAACTAAGTGTGAGCAAAGGCAGGTACC  
CGACTAAATTGCCAAAACCAGTCTGGTGGTTCGTGGAATGTTGGGCCAG  
GTCGTTAAAACGTCTACACACCGGTTCTTTAAATCACAGATCCGCTTCTC  
ATACTGTGAACCCGGTTTTAATTTTAAAAGAAAATTCATTATAAAGTAA  
ATGACTTAAACCATTACAAACAACAAAAATTTACCATTACAATGTTGGAC  
15 TATCATTATTTGCAACATAAACTGAAAATACACATATTTCTTCTGATA  
TCAGCATGAGTGGCTGGTTGGCTAACCCAAAAATCCATGCATTGTAGATG  
TGTGTTACAACACATAGTATCAATGAAAGGCATATTTTTAGGCTAGAATT  
TAACAATCTGTAATAATATCCCTAAAATAATATCATCATCAACCAACT  
AATATAAAACCATTGGGTTTCGTCAATTTTAGGTACAAAACATAGATTTTC  
20 TAAGCTTGTTGTATTTAAACATATGCTTTCTAAACTTAATTGATTTTGCA  
TTCCAAAATTTTAGGTTGTAAAGTGGTATGTCATTTGTTGTCTTTTCAAC  
ATTAAATTGTACAAAAACCAAACTACATAATTGATGTAGATATCATAACA  
ATTGTGTTATTTAGTATATAAAAACTAAATTTTGAATTGAATTTCTTATA  
CAAAGTTGTGTCTATGTATACATGTTTATGTAGGTAATAGACAATTAGT  
25 CTCTGTAAAGTATATGGAGTTTAATTTTAGACTAATTTTCATGTGTTG  
CAGTTTATCAGGCAGGTGGCGTTTTTTGGACGTTATGCCAATACTCCAG  
AGAGATAAATATAAGGGAGTGTTATGCATTGTCAAGTGTAATTCCATGTT  
ATGCAGCAGGACAGATGCAAAATGTTCAAGTGCTGAATATATACAGGTGC  
AACTCAATGAAGGAGTTATTTGAACTCAAGGGATGAACAACAACAATGG  
30 TGACAGTGGTTGTGATGAAGGAAATGGTTGTATACCAGCAATTCCAAGAC  
TAAATAACGTTATTATGCTACCCAATCTAAAGATATTGAAGATTGAAGAT  
TGTGGTCATCTGGAACATGTATTCACATTCTCTGCACTTGGAAGCCTGAG  
ACAGCTCGAAGAGTTAACGATAGAGAAATGCAAGGCAATGAAAGTGATAG  
TGAAGGAAGAAGATGAATATGGAGAGCAAACAACAAGGCATCTTCGAAG  
35 GAGGTTGTGGTCTTTCCTCGTCTCAAGTCCATTGAACTGGAAAATCTACA  
AGAGCTCATGGGTTTCTACTTAGGGAAGAATGAGATTCAGTGGCCTTCAT  
TGGATAAGGTTATGATCAAGAATTGCCAGAAATGATGGTGTGTTGCACCT  
GGTGAGTCCACAGTTCCCAAGCGCAAGTATATAAATACAAGCTTTGGCAT  
ATATGGGATGGAGGAGGTACTTGAACTCAAGGGATGAACAACAATAATG  
40 ATGACAATTGTTGTGATGATGGAAATGGTGGAAATCCAAGACTAAATAAC  
GTTATTATGTTTCCAAATATAAAGATATTGCAAATCAGCAATTGTGGCAG  
TTTGGAACATATATTCACATTCTCTGCACTTGAAAGCCTGATGCAGCTCA  
AAGAGTTAACAATAGCGGATTGCAAGGCAATGAAAGTGATTGTGAAGGAG



GAATATGATGTAGAGCAAACAAGGGTATTGAAGGCTGTGGTATTTTCTTG  
TCTAAAGTCCATTACACTATGCCATCTACCAGAGTTGGTGGGTTTCTTCT  
TGGGGAAGAATGAGTTCTGGTGGCCTTCATTGGATAAGGTTACCATCATT  
GATTGCCCACAAATGATGGGGTTCACACCTGGTGGGTCAACAACCTCCCA  
5 CCTCAAGTACATACTCAAGCTTAGGCAAACATACTCTTGAATGTGGCC  
TTAATTTCAAGTCACAACACTGCATATCATCAGGTATAATTATTATTCT  
TTNACACCATCTAATTATGGAATCATGACGCTAATTACAGTATTAAACAC  
(SEQ ID NO:110)

10 **RG2K deduced polypeptide sequence (SEQ ID NO:111)**

MECITGIFSNPFAQCLIAPVKEHLCLLIFYTQYVGDMLTAMTELNAKDIVEERK  
NQNVEKCFEVPNHVNRWLEDVQTINRKVERVLNDNCNWFNLCNRYMLAVKAL  
EITQEIDHAMKQLSRIEWTDDSVPLGRNDSTKASTSTPSSDYNDFESREHTFRKAL  
EALGSNHTSHMVALWGMGGVGKTTMMKRLKNIIEKRTFHYIVLVVIKENMDL  
15 ISIQDAVADYLDMLKTESNESERADKLREGFQAKSDGGKNRFLIILDDVWQSVN  
MEDIGLSPFPNQGVDFKVLTTSENKDVCAKMGVEANLIFDVKFLTEEEAQSIFY  
QFVKVSDTHLDKIGKAIVRNCGGLPIAKTIANLTKNRNKDVWKDALSRIEHHD  
IETLAHVVFQMSYDNLQNEEAQSIFLLCGLFPEDFDIPTEELVRYGWGLRVFNGV  
YTIGEARHRLNAYIELLKDSNLLIESDDVHCIMHDLVRAFVLDTFNRFKHSLIV  
20 NHGNGGMLGWPENDMSASSCKRISLICKGMSDFPRDVKFPNLLILKLMHADKS  
LKFPQDFYGEMKKLQVISYDHMKYPLLPTSPQCSTNLRVLHLHQCSLMFDCSSI  
GNLLNLEVLFSANGIEWLPSTIGNLKELRVLDLTNCDGLRIDNGVLKLVKLEELY  
MRVGGRYQKAISFTDENCNEMAERSKNLSALEFEFFKNNAQPKNMSFENLERFKIS  
VGCYFKGDFGKIFHSFENTLRLVTNRTEVLESRLNELFEKTDVLYLSVGDMDLED  
25 VEVKLAHLPKSSSFHNLRLVLIHSECIELRYLFTLDVANTLSKLEHLQVYECDNMEEH  
HTEGRGEVTITFPKLKFLSLCGLPNLLGLCGNVHIINLPQLTELKLNIGPGFTSIYPEK  
DVETSSLLNKEVVIPNLEKLDISYMKDLKEIWPCELGMSQEVVDVSTLRVIKVSSCDN  
LVNLFPCNPMPLIHHLEELQVIFCGSIEVLFNIELDSIGQIGEGINNSSLRRIQLQNLGK  
LSEVWRIKGADNSSLLISGFQGVESIIVNKCKMFRNVFTPTTTNFDLGALMEIRIQDC  
30 GEKRRNNELVESSQEQEQ

**RG2L polynucleotide sequence (SEQ ID NO:112)**

GGAAGACACAATGATGCAAAGACTGAAGAAGGTTGCCAAAGAAAATAGAA  
TGTTTCAGTTACATGGTCGAGGCAGTTATAGGGGAAAAGACAGACCCAATT  
35 GCTATTCAACAAGCTGTAGCCGATTACCTTCGTATACAGTTCAAAGAAAG  
CACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAGGCCCACT  
CTGNAGACGGTAAGAATAAGTTCCTCGTAATATTTGATGACGTCTGGCAG  
TCCGTTGATCTGGAAGATATTGGNTTAAGTCCTTTTCCAAATCAAGGTGT  
CGACTTCAAGGTCTTGTTGACTTCACGAGACGAACACGTTTGACAAATGA  
40 TGGGGGTTGAAGCTAATTCAGTTATTAATGTGGGACTTCTAACTGAAGTA  
GAAGCACAAAGTCTGTTCCAGCAATTTGTAGAAACTTTTGAGCCCGAGCT  
CTGTAAGATAGGAGAAGTTATCGTAAGAAAGTGTGCGGTCTACCTATTG

CCATCAAAACCATGGCGTGTACTCTAAGAAATAAAAGAAAGGATGCATGG  
AAGGATGCACTTTCACGTATAGAGCACTATGACATTCGTAGTGTTGCGCC  
TAAAGTCTTTGAAACAAGCTATCACAATCTCCAAGACAGGGAGACTAAAT  
CCGTGTTTTTGTATGTGTGGTTTGTTCCTGAAGACTTCAATATTCCTACC  
5 GAGGAGTTGATGAGGTATGGATGGGGCTTAAAGCTATTTGACAGAGTTTA  
TACAATTAGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTTG  
TGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATG  
CATGATCTGGTGCCTGCTTTTGTGTTTGGGTATGTATTCTGAAGTCGAGCA  
TGCTTCAATTGTCAACCATGGTAATATGCATGGGTGGACTAAAAATGATA  
10 TGAACGACTCTTGCAAAACAGTTTCTTTAACATGCGAGAGTGTGTCTGAG  
TTTCCAGGAGACCTCAAGTTTCCAAACCTAAAGCTTTTGAACCTTATGCA  
TGGAGATAAGATGCTAAGGTTTTCTCAAGACTTTTATGAAGGAATGGAAA  
AGCTCCAGGTAATATCATACCATAAAATGAAGTATCCATTGCTTCCCTCG  
TCACCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTTCATCGGTGTTT  
15 ATTACGGATGCTTGATTGCTCTTGATCGGAAATTTGACGAATCTGGAAG  
TGTTGAGCTTCGCTAATTCTGGCATTGAACGGATACCTTCAGCAATCGGA  
AATTTGAAGAAGCTTAGGCAACTTGATCTGAGAGGTCGTTATGGTCTTTG  
TATAGAACAGGGTGTCTTGAAAAATTTGGTCGAACTTGAAGAACTTTATA  
TTGGAAATGCATCTGCGTTTAGAGATTATAACTGCAATGAGATGGCAG  
20

**RG2L deduced polypeptide sequence (SEQ ID NO:113)**

EDTMMQRLKKVAKENRMFSYMVEAVIGEKTDP AIQQA VADYLRIQFKESTKPAR  
ADKLREWFKAHS?DGKNKFLVIFDDVWQSV DLEDIGLSPFPNQGVDFKVLLTSRDE  
HVCTMMGVEANSVINVGLL TEVEAQSLFQQFVETFEPELCKIGE VIVRKCCGLPIAI  
25 KTMAC TLRNKRKDAWKDALSR IEHYDIRSVAPKVFETSYHNLQDRETKSVFLMCG  
LFPEDFNIPTEELMRYGWGLKLFDRVYTIREARTR LNTCIERLVQTNLLIESDDVGC  
VKMHD LVRAFVLGMYSEVEHASIVNHG NMHGWTKNDMND SCKTVSLTCEVSSEF  
PGDLKFPNLKLLKLMHGD KMLRFSQDFYEGMEKLQVISYHKMKYPLLPSSPQCST  
NLRVLHLHRC SLRMLDCSCIGNLTNLEVLSFANS GIERIPSAIGNLKKLRQLDLRGR  
30 YGLCIEQGV LKNLVELEELYIGNASAFRDYNCNEMA

**RG2M polynucleotide sequence (SEQ ID NO:114)**

GGGGAAGACACAATAGATGCAAAGGCTGAAGAAGTTGCCAAAGAAAAGAG  
AATGTTTCAGTTATATCATTGAGGCGGTTATAGGGGAAAAGACAGACCCCA  
35 TTTCCATT CAGGAAGCTATATCATATTACCTTGGTGTAGAGCTCAATGCA  
AATACTAAGTCAGTAAGAGCTGATATGCTTCGTCAAGGGTTCAAGGCCAA  
ATCTGATGTAGGTAAGGATAAATTCTTAATAATACTCGACGATGTATGGC  
AGTCTGTTGATTGGAAGATAATTGGATTAAGTCCATTTCCAAATCAAGGT  
GTTAACTTCAAGGTCCTGTTAACATCACGAGACCGACATATTTGCACTGT  
40 GATGGGGGTTGAAGGTCATTCGATTTTTAATGTGGGACTTCTCACAGAAG  
CAGAAATCAAAAAGATTGTTCTGGCAGTTTGTAGAAGGTTCTGATCCTGAG  
CTCCATAAGATAGGAGAAGATATTGTAAGTAAGTGTGTGGTCTACCCAT

TGCCATTAAAACCATGGCATGTACACTTAGAGATAAAAGTACGGATGCAT  
GGAAGGATGCACTGTCTCGTTTAGAGCATCATGACATTGAAAATGTTGCC  
TCTAAAGTTTTTAGAGCGAGCTATGACCATCTCCAAGACGAGGAGACTAA  
ATCCACTTTTTTCTATGTGGATTGTTTCCAGAAGATTCCAATATTCCTA  
5 TGGAGGAGTTGGTGAGGTATGGGTGGGGATTGAAATTATTTAAAAAAGTG  
TATACCATAAGAGAAGCAAGAACTAGGCTCAACACTTGCATTGAGCGGCT  
CATCTATACCAATTTGTTGATAAAAGTTGATGATGTTTCAGTGCATCAAGA  
TGCATGATCTCATCCGTTCTTTTGTGTTTGGATATGTTTTCTAAAGTTGAG  
CATGCTTCGATTGTCAACCATGGTAATACGCTAGAGTGGCCTGCAGATNA  
10 TNTGCACGACTCTTGTAAGGGCTTTCATTAACATGCAAGGGTANATGTG  
AGTTTTGTGGAGACCTNAANTTTCCAACCCTAATGATTTTAAACTTATG  
CATGGAGATAAATCGCTAAGGTTT

**RG2M deduced polypeptide sequence (SEQ ID NO:115)**

15 GEDTIDAKAEVAKERMFYSYIIEAVIGEKTDPISIQEAYSYYLGVELNANTKSVRAD  
MLRQGFKA KSDV GKD KFLI LDDV WQSV DLED IGLSPFPNQGVNFKVLLTSRDRHI  
CTVMGVEGHSIFNVGLL TEAESKRLF WQFVEGSDPELHKIGEDIVSKCCGLPIA IKT  
MACTLRDKSTDAWKDALSRLEHHD IENVASKVFRASYDHLQDEETKSTFFLCGLFP  
EDSNIPMEELVRYGWGLKLFKKVYTIREARLNTC IERLIYTNLLIKVDDVQCIKM  
20 HDLIRSFVLD MF SKVEHASIVNHGNTLEW PAD??HDSCKGLSLTCKG?CEFCGDL?F  
PTLMILKLMHGDKSLRF

**RG2N polynucleotide sequence (SEQ ID NO:116)**

AGGTAAATCCATAACCCATAATGTTGGTACGCTCATATATCAAATTGCG  
25 TGTTTTGTTGAATGAAAAAGCATGCTCAAAAAACCAGTGTAAGGCACGG  
TATATGACATATTTATAGTTACTGATAACAAATTATGATAATTTTGGGTT  
TACRTAAGTTAGGATTCGTACTTCAACCAAATGTAATAGTTTTTGTGAGT  
CTATCTATGTATTTGGGGAATCACATTAGCAACGGGATTGTACTAGTAAT  
TCG.AAAAAGTCTTTTAAATAATTTTCTGTTTATAATTTATGAATAGTTT  
30 TAGCGACATCTAATATTAAATAGAATGTATCTGATATTGAATTAATGTCC  
TTAATGTGAACATAGACCTTTTCCATTTACTAATGCCTAATTATTAGTTT  
CTAATCAATAAATTTTAATTTCTGTTTTATGCTTCTAAGACAATAAAAAT  
CCATGATTTACCTTTAAATATTAACAAAAATGACCATAAATAAATAAAAA  
ATTAGGATACCAAACCCCCCGCCATGCCCAATGTCTAAATATTCTTGAT  
35 GCTTTTGCTTTTCCCTCTTTTCTTGTAGTCTATTATTCTGGAGAGTTT  
GAGAGAGTTTCATACAAGAAAATTTCAAGAAGAAAGCAAAGGTCCAGGTA  
TTCTCTTTTCTTAATTATGTATTAACCTTACAAGCATTTTTTACACGATCC  
ATGGTTTTTTGTGTATGTTTTTCAAATTGAACTAGATTGGGACTTTTGC  
CCTTGATGATTCATAAGATATTGCATGGAGTTGAGATTGTGTAAGAAAAG  
40 TGGTGAATAGAAAGAGCAAGTGAATCCAGATATAGTATTGGTAATATATG  
ATGATGAGATAGAGATATGTTAAACTGGCTAGAAAATTGTTTTAATTTG  
AAATTTAGGTKGTTGAATTTGAAAGATACCAAGCTAATAACTAATTAGTT

ATGCTAAWTAGTTATAAAGAACAACAAACTCTTAGTTTTTTTTTTCATGA  
TTTTCAACCTCTTTGTACCAAATAAATTATAGCAAAATTGAATATCATT  
CTCTGCAATCAATCTTAACCTTTGTTATTATCATCATGTCTAAAATTGCC  
ACAAGTTTATTTTCAAAGTCATATTGGATTATGAAAGGACTATTTTACC  
5 AATTACATCTTTACTTTATGGGCCAAAGCTAATACAATCCGACTAAACTA  
AAGGAATATGGGATGCATATAGTTTGCTTCCCGATTATAGATTTCTATCT  
AATTTGTCTATTGTACTAATTTAGGTGCCACCACAAGTAAATTTGTAAA  
TGGATATCGTTAATGCCATTCTTAAACCAGTTGTCGAGACTCTCATGGTA  
CCCGTTAAGAAACACATAGGGTACCTCATTTCTGCAGGCAATATATGAG  
10 GGAAATGGGTATCAAAATGAGGGGATTGAATGCTACTAGACTTGGTGTCTG  
AAGAGCATGTGAACCGGAACATAAGCAACCAGCTTGAGGTTCCAGCCCCAA  
GGCAGGGGTTGGTATGAAGAAGTAGGAAAGATCAATGCAAAAGTGGAAAA  
TTTTCTAGCGATGTTGGCAGTTGTTTCAATCTTAAGGTTAGACACGGGG  
TCGGAAAGAGAGCCTCCAAGATAATTGAGGACATCGACAGTGTCTATGAGA  
15 GAACACTCTATCATCATCTGGAATGATCATTCCATTCTTCTAGGAAGAAT  
TGATTCCACGAAAGCATCCACCTCAATACCATCAACCGATCATCATGATG  
AGTTCCAGTCAAGAGAGCAAACCTTTCACAGAAGCACTAAACGCACTCGAT  
CCTAACCACAAATCCCACATGATAGCCTTATGGGGAATGGGCGGAGTGGG  
GAAGACGACAATGATGCATCGGCTGAAAAAGGTTGTGAAAGAAAAGAAAA  
20 TGTTTAATTTTATTGTTGAGGCGGTTGTAGGGGAAAAAACAGACCCCATT  
GCTATTCAATCAGCTGTGGCAGATTACCTAGGTATAGAGCTCAATGAAAA  
AACTAAACCAGCAAGAAGTGAAGCTTCGTAAATGGTTTGTGGACAATT  
CTGCTGGTAAGAAGATCCTAGTCATACTCGACGATGTATGGCAGTTTGTA  
GATCTGAATGATATTGGTTTAAGTCCTTTACCAAATCAAGGTGTGCACTT  
25 CAAGGTGTTGTTGACATCACGAGACAAAGATGTTTGCACTGAGATGGGAG  
CTGAAGTTAATTCAACTTTTAATGTGAAAATGTTAATAGAAACAGAAGCA  
CAAAGTTTATTCCACCAATTTGTAGAAATTTTCGGATGATGTTGATCGTGA  
GCTCCATAATATAGGAGTGAATATTGTAAGGAAGTGTGGCGGTCTACCCA  
TTGTCATCAAAACCATGGCGTGTACTCTTAGAGGAAAAAGCAAGGATGCA  
30 TGAAGAATGCACTTCTTCGTTTAGTGAACTACAACATTGAAAATATAGT  
GAATGGAGTTTTTAAAATGAGTTACGACAATCTCCAAGATGAGGAGACTA  
AATCCACCTTTTTGCTTTGTGGAATGTTTCCCGAAGACTTTAATATTCTT  
ACCGAGGAGTTGGTGAGGTATGGATGGGGGTTGAAATTATTTAAAAAAGT  
GTATACTATAGGAGAAGCAAGAATCAGGCTCAACACATGCATTGAGCGGC  
35 TCATTACATACAAATTTGTTGATTGAAGTTGATGATGTTAGGTGCATCAAG  
ATGCATGATCTTGTCCGTGCTTTTGTGTTTGGATATGTATTCTAAAGTCGA  
GCATGCTTCCATTGTCAACCATGGTAATACACTAGAGTGGCATGTGGATA  
ATATGCACAACTCTTGTAAGAACTTTCATTAAACATGCAAGGGTATGTCT  
AAGTTTCTACAGACCTCAAGTTTCCAAACCTCTCGATTTTGAACTTAT  
40 GCATGAAGATATATCATTGAGGTTTCCCAAAAACCTTTTATGAAGAAATGG  
AGAAGCTTGAGGTTATATCCTATGATAAAATGAAATATCCATTGCTTCCC  
TCATCACCGCAATGCTCCGTCAACCTTTGCGTGTTTCATCTCCATAAATG  
CTCGTTAGTGATGTTTGACTGCTCTTGTATTGGAAATCTGTCTGAATCTAG

AAGTGCTTAGCTTTGCTGATTCTGCCATTGACCTGTTGCCTTCCACAATC  
GGAATTTTGAAGAAGCTAAGGCTACTGGATTGACAAATTGTTATGGTCT  
TTGTATAGCTAATGGTGTCTTTAAAAAATTGGTCAAACCTGAAGAGCTCT  
ATATGACAGTGGTTAATGGAGGAGTTCGAAAGGCGATCAGCCTCACTGAG  
5 GATAACTGCAATGAGATGGCAGAACGTTCAAAAGACCTTTCTGCATTAGA  
ACTTGAGTTCTTTGAAAACAATGCTCAGCCAAAGAATATGTCATTTGAGA  
AGCTACAACGATTCCAGATCTCAGTGGGGTGCTATTTATATGGAGCTTCC  
ATAAAGAGCAGGCACTCGTATGAAAACACATTGAAGTTGGTTATTGACAA  
AGGTGAATTATTTGAATCTTGAATGAACGGCCTGTTTAAGAAAACAGAGG  
10 TGTATGTTTAAGTGTGGGAGATATGAATGATCTTGAAGATRTTGAGGTT  
AAGTCATCCTCACAACYTCTTCAATCTTCTTCGTTCAACAATTTAAGAGT  
CCTTGTCGTTTCAAAGTGTGCAGAGTTGAAACACTTCTTCACACCTGGTG  
TTGCAAACACTTTAAAAAAGCTTGAGCATCTTGAAGTTTACAAATGTGAT  
AATATGGAAGAACTCATACGTAGCAGGGGTAGTGAAGAAGAGACGATTAC  
15 ATCCCCCAAGCTGAAGTTTTTATCTTTGTGTGGGCTACCAAAGCTATCGG  
GTTTGTGCGATAATGTCAAATAATTGAGCTACCACAACTCATGGAGTTG  
GAACCTGACGACATTCCAGGTTTCACAAGCATATATCCCATGAAAAAGTT  
TGAAACATTTAGTTTGTGAAGGAAGAGGTAAATATAAATTTTAAATGCT  
AATACATTACAAAGGATCTTTTCAGTTAAATCTTTCAAATATATTGTAA  
20 TTTGATTGTATGGGGTATTATTGTTGGATGGGACTATTAATAAATGATTA  
TCTTGCAAGTTCTGATTCTTAAGTTAGAGAACTGCATGTTAGTAGTATG  
TGGAATCTGAAGGAGATATGGCCTTGCGAATTTAATATGAGTGAGGAAGT  
TAAGTTCAGAGAGATTAAAGTGAGTAACTGTGATAAGCTTGTGAATTTGT  
TTCCGCACAAGCCCATATCTCTGCTGCGTCATCTTGAAGAGCTTAAAGTC  
25 AAGAATTGTGGTTCCATTGAATCGTTATTCAACATCCATTTGGATTGTGC  
TGGTGCAACTGGAGATGAATACAACAACAGTGGTGTAAGAATTATTAAG  
TGATCAGTTGTGATAAGCTTGTGAATCTCTTTCCACACAATCCCATGTCT  
ATACTGCATCATCTTGAAGAGCTTGAAGTCGAGAATTGTGGTTCCATTGA  
ATCGTTATTCAACATTGACTTGGATTGTGCTGGTGCAATTGGGCAAGAAG  
30 ACAACAGAAGCAGCTTAAGAAACATCAAAGTGAGAGATTTAGGGAAGCTA  
AGAGAGGTGTGGAGGATAAAAGGTGGAGATAACTCTCGTCCCCTTGTTCA  
TGGCTTTCAATCTGTTGAAAGCATAAGGGTTACAAAATGTAAGAGGTTTA  
GAAATGTATTACACCTACCACCACAAATTTTAATCTGGGGGCACTTTTG  
GAGATTTCAATAGATGACTGCGGAGAAAACAGGGAAAATGACGAATCGGA  
35 AGAGAGTAGCCATGAGCAAGAGCAGGTAAGGATTTCAATTTCACTTTCKT  
ACTTAATTAATGATTAAGCTCCTGCTTTTTRAATAAAAAAGGGACAAACC  
ATTTTCATGACTTAATGTAGCAATACAAGTCATGTATAAGAGTGACCAACT  
CTTTTTTATTTATAAAATGACTACAAAATATTTTTTTTCATTAGAGATCA  
TGTATAAATGTGACTAATTTTTCATCACCTAACTTTAGTTGATAAATCTT  
40 TATAAATGTCAGTAGTTACTTTTCAGTAAAATAACAAATTTAATAAATTA  
TCAACAAAAAGCATCAACTAAAAAATCCACAAACCCGTAATAATTTAAA  
ATAAAAGGATTTAACATCTAATACGAACAATTTTTTTTCTAAACATGATT  
TGGACCAAATATCACCAGCAACTCAAGTTTGGAATCGATTGAGCTTAAAA

CTTGACCARCATAATTAGATAGATGAGAGTTGAAGCTAAAGTGCCTATAT  
AAGTTCGTTTCATCTTTTTCTTGATCTTGATAGCAAGTTGAATSATTTT  
CTTCTTCAAAATTGATAAAAATCTACATTATAAAGAGACTAGCTTGAAAA  
AAAATGGTCTAGGTGGGTCTTGGGTCTGGTAGATGAAGATGGAAGGGAGA  
5 GTAGATTTCAAAGACACAAACACATCTTCATTTTATTTATTTATTTATTA  
TTATTATTTTTTGATATCTTGCTCATATTTGTTACAGATATGTGAGGTCT  
ATTAATCTTTTTAAATATATAAAAAATAAATACATAAATGAGAAAATTAA  
ATAAAGAATAAATTAATAAGGGCACAAATAGTCTTTTTTGGTAAGACAAGG  
ACCAAAAGCGCAACAAAAGTAAACAGTAGGGACCATCCGATTTAAAAAAT  
10 TAATTAGGGACCAAAAACATAAATTCCCCCAAACCATAGGGACCATTCTGT  
GTAATTTACTCTTGCTTTTCGTTTTGTTTCATATTTGGGTAACATTTTTTT  
TTGTACATATCTAGGTAACGAACTTGTTGAAAGTGTTACATCTACGATG  
TGACCTACTACAACCGATCATAATGGTCATATATGAACACTTCCAACAAG  
TTTGTTATCTAGGTGTGTACAAAAAAACGATAGTTACCATGATGTGAACA  
15 TACCAAAAAATTAATTACCTTAGCAAGTTATTTTCCCATTTAGGTTGTAT  
GGAAACAGTTCCTGAGACCGTGACTTGGATGGTAGATAAATTTAGTAAA  
CTTAACCCTTCAATTAACCTACCTTTTTCTTATTAACCTCAATTTCAAGCT  
AAATTCTGATTCTTGTTTGAAAGTAAGTTGCATCTTTATGTTTGTATTAT  
CTTGTTGCATAGGATCCTTAGCATCTTTTAATAATTTATTTGAAGGTGAA  
20 AGATCCAACATTTTTTAATCTGTTGGCATTTTCCATCATTTGCAACTGTT  
TCTTGAAAAAAA::TACCTAAAATCAAAATAACCATTTTCATATCCAAAA  
TTATAAGAGAGAATTGTTAACGGACATGGAATCATAAATCATTAACACAG  
TTCAGTACACAGGTTGCTAATTACATTTCTTGCTGTGCAGATTGAAATTC  
TATCAGAGAAAGAGACATTACAAGAAGCCACTGGCAGTATTTCAAATATT  
25 GTATTCCCATCCTGTCTCATGCACTCTTTTCATAACCTCCATAAACTTAA  
CTTGAACAGAGTTGAAGGAGTGGAGGTGGTGTGTTGAGATAGAGAGTGAGA  
GTCCAACAAGTAGAGAATTGGTAACAACCTACCATAACCAACAACAACCT  
ATTATACCTCCCAACCTCCAGGAATTGATTCTATGGAATATGGACAACAT  
GAGTCATGTGTGGAAGTGCGGCAACTGGAATAAATTCTTCACTCTTCCAA  
30 AAGAACAATCAGAATCCCCATTCCACAACCTCAGTAACATACATATTTAT  
GAATGCAAAAGCATTAAAGTACTTGTTTTACCTCTCATGGCAGAACTTCT  
TTCCAACCTAAAGCATATCGAGATAAGAGAGTGTGATGGTATTGAAGAAG  
TTGTTTCAAAAAGAGATGGTGAGGATGAAGACATGACTACATCTAC:::  
:::GCACACAACCACCACTTTTTCCCTCATCTTGATTCTCTCACTCTAAA  
35 GCAACTGAAGAATCTGAAGTGTATTGGTGGAGGTGGTGCCAAGGATGAGG  
GGAGCAATGAAATATCTTTCAATAATACCACTGCAACTACTGCTGTTCTT  
GATCAATTTGAGGTATGCTTTGTACATATTCAATTATTTATTTAATTTCC  
TTGTTAATTTCTTTTTCTTTGCAATATTCTATGAAAAAAATCACCAAA  
TCACAAATAAGAGATTTAAACTTTTATTTACACCCATGCGGACTCAAGA  
40 ATGGGATTTGGAGGCATATAAAGTTACATTCATTTGAACAAGTATTACCA  
TTTATTTGTTATTTATCATTTTCATATCATTTACTGATAACATTTCTTTT  
TTACTTTTCTAATTAGAAAAGGTCCACATGTCTAATTAGGTTTTCCATTC  
TATGTGAATCCTCTATTCTGTCTGTAATCAAGCATCTTAGATTATTTATC

CATTTTCATAATTGTGTTTATATTGACAGTTTTTTTCTTTTATAGTTGT  
AATTGCAACCTGTCATATWTTMWWKKCWWATKYWMWWARTAATACATTT  
TATACCCWCTATACTAAGATA

5 **RG2N deduced polypeptide sequence (SEQ ID NO:117)**

LGKTTMMHRLKKVVKEKKMFNFIVEAVVGEKTDPIAIQSAVADYLGIELNEKTKPA  
RTEKLRKWFVDNSAGKKILVILDDVWQFVDLNDIGLSPLPNQGVDFKVLLTSRDKD  
VCTEMGAENVSTFNVKMLIETEAQSLFHQFVEISDDVDRELHNIGVNIVRKCGGLPI  
VIKTMACTLRGKSKDAWKNAALLRLVNYNIENIVNGVFKMSYDNLQDEETKSTFLL  
10 CGMPEDFNIPTEELVRYGWGLKLFKKVYTIGEARIRLNTCIERLIHTNLLIEVDDVR  
CIKMHDLVRAFVLDMYSKVEHASIVNHGNTLEWHVDNMHNSCKRLSLTCKGMSK  
FPTDLKFPNLSILKLMHEDISLRFKPNFYEEMEKLEVISYDKMKYPLLPSSPQCSVNL  
CVFHLHKCSLVMFDCSCIGNLSNLEVLFSADSAIDLLPSTIGILKKLRLLDLTNCYGL  
CIANGVFKKLVKLEELYMTVVNGGVRKAISL

15

**RG2O polynucleotide sequence (SEQ ID NO:118)**

TTGTAAAACGACGGCCAGTCGAATCGTAACCGTTCGTACGAGAATCGCTG  
TCCTCTCCTTCATTTGAATCATGATATTTGAATATCGATACTTTTGACTG  
TAGCTTTTGGGTCGATTTTTTAGCAAGATACATAACTGGCCAAACCCATT  
20 GGCTATTTTAGCCCAAATATGAAATGGACTGGATTGTTTTTTCCTTTC  
TAACACGCACACATCTGGCGATCAGTATCACTCCATTATGAAGACCTAGT  
CAAATTCATTAACGTTTCAGTCGTTCCCTCAAAGTTTCAAAGTTCCAACCT  
CCAACCTCCCTCTTTTTTTTTTCTTTCCTCGATTCTGATTGAATCCGAT  
TCTGCGACGAAGGAGAGCTTGGTCAGAGGGCTGTGATTCTTGAGTCTTGA  
25 CCTCCGAATCTAGCTGGATTATTTTCGACACACCAGACCACGTATCAGGT  
TGCTCATCCCGAAATACTGCTTTGCAAACGTGTGTATCATCGCCTAGGAA  
ATTAAAGTTTCTTTTTTGGCTCTGTACTGAATCAGTAGCTTTGCAACTTG  
CTCATTATAAGCTGATCCATATTTTACATATCTTTTGAAGAATAATAGGT  
ACTGACTTTACCTTTCTGATGAGAGCGATTAAAGAGATACCTCTGTAAAA  
30 TCCATTTTTGTGAAGGGATCTGGGTTAGTTTTTAAAGGATTTGCTACAAC  
AGTATCCCAACAAACGATCTATTTCCCATTTNACTCATCCGCTCAAGATCT  
ATCCACCTTTATATATGTTAATTGGGAGTCTTCCATGGTGCAATGAATCT  
AGGATGCATTTAGAAGCCCAATCCATTACAAGTTTTCATCCAATTCATG  
TGACAAGTTGTTGGTTACTATGTAGGTACTTCCACAATTAAGAATTTCCA  
35 GCAATGGATGTTGTTAATGCCATTCTTAAACCAGTTGCCGAGACACTTAT  
GGAACCTGTTAAGAAACATCTAGGCTACATCATTTCCAGCACAAAACATG  
TGAGGGATATGAGTAACAAAATGAGGGAGTTGAACGCTGCAAGACATGCT  
GAAGAAGACCACTTGGACAGGAACATAAGAAGTCTGCTTGAGATTTCAAA  
TCAAGTTAGGAGTTGGTTAGAAGAAGTAGAAAAGATCGATGCAAAAAGTAA  
40 AAGCCCTTCCTAGTGATGTCACCGCTTGTTCAGTCTCAAGATCAAACAT  
GAAGTCGGAAGGGAAGCCTTGAAGCTAATTGTGGAGATTGAAAGTGCCAC  
AAGACAACACTCTTTGATCACCTGGACTGATCATCCCATTCCTCTGGGAA

AAGTTGATTCCATGAAGGCATCGATGTCCACAGCATCAACCGATTACAAT  
GACTTTCAGTCAAGAGAAAAAACTTTTACTCAAGCATTGAAAGCACTTGA  
ACCAAACAACGCTTCCCACATGATAGCGTTATGTGGGATGGGTGGAGTGG  
GGAAGACCACAATGATGCAAAGACTAAAAAAAGTTGCTAAACAAAATAGA  
5 ATGTTTCAGTTATATGGTTGAGGCAGTTATAGGGGAAAAGACGGACCCAAT  
TGCTATTCAACAAGCTGTAGCGGATTACCTTCGTATAGAGTTAAAAGAAA  
GCACTAAACCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAGGCCAAC  
TCTGGAGAAGGTAAGAATAAATTCCTTGTAATACTTGATGACGTCTGGCA  
GTCTGTTGATCTAGAAGATATTGGTTTAAAGTCCTTTTCCAAATCAAGGTG  
10 TCGACTTCAAGGTCTTATTGACTTCACGAGACGAACATGTTTGCACAGTA  
ATGGGAGTTGGATCTAATTCAATTCTTAATGTGGGACTTCTAATAGAAGC  
AGAAGCACAAAGTTTGTTCACAATTTGTAGAACTTCTGAGCCCGAGC  
TCCATAAGATAGGAGAAGATATTGTAAGGAAGTGTTCGGTCTACCTATT  
GCCATCAAAACCATGGCATGTACTCTTAGAAAATAAAAGAAAGGATGCTTG  
15 GAAGGATGCACTTTCGCGTATAGAGCACTATGACCTTCGCAATGTTGCGC  
CTAAAGTCTTTGAAACGAGCTACCACAATCTCCATGACAAAGAGACTAAA  
TCAGTGTTTTTGATGTGTGGTTTGTTCGGGAAGACTTCAATATTCCTAC  
TGAGGAGTTGATGAGGTATGGATGGGGATTAAAGATATTTGATAGAGTCT  
ATACATTTATAGAAGCAAGAAACAGGATCAACACCTGCATTGAGCGACTG  
20 GTGCAGACAAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGAT  
GCATGATCTGGTCCGTGCTTTTGTTTTAGGTATGTATTCTGAAGTAGAGC  
ATGCTTCAGTTGTCAACCATGGTAATATACCTGGATGGACTGAAAATGAT  
CCGACTGACTCTTGTAAGCAATTCATTAAACATGCGAGAGTATGTCTGG  
AAACATTCCAGGAGACTTCAAGTTTCCAAACCTAACGATTTTGAAACTTA  
25 TGCATGGAGATAAGTCGCTAAGATTTCCACAAGACTTTTATGAAGGAATG  
GAAAAGCTCCAGGTTATATCATACGATAAAATGAAGTATCCAATGCTTCC  
CTTGTCTCCTCAATGCTCCACCAACCTTCGAGTGCTTCATCTCCATGAAT  
GTTCAATTAAGATGTTTGATTGCTCTTGTATTGGAAATATGGCGAATGTG  
GAAGTGTTGAGCTTTGCTAATTCTGGCATTGAAATGTTACCTTCCACTAT  
30 CGGAAATTTAAAGAAGCTAAGGTTACTTGATTTAACAGATTGTCATGGTC  
TTCATATAACACACGGTGTCTTTAACAATTTGGTCAAACCTGAAGAGTTG  
TATATGGGATTTTCTGATCGACCTGATCAAACCTCGTGGTAATATTAGCAT  
GACAGATGTCAGCTACAATGAATTAGCAGAACGTTCAAAAGGCCTTTCTG  
CATTAGAGTTCCAGTTCTTTGAAAACAATGCCCAACCAATAATATGTCG  
35 TTTGGGAAACTTAAACGATTCAAGATCTCAATGGGATGCACTTTATATGG  
AGGATCAGATTACTTTAAGAAAACGTATGCTGTCCAAAACACATTGAAGT  
TGGTTACTAACAAAGGTGAACTATTGGACTCTAGAATGAACGAGTTGTTT  
GTTGAAACAGAAATGCTTTGTTTAAAGTGTTGATGATATGAATGATCTTGG  
TGATGTTTGTGTGAAGTCCTCACGTTCTCCTCAACCTTCTGTGTTCAAAA  
40 TTCTAAGAGTCTTTGTCGTTTCCAAGTGTTGAGTTGAGATACCTTTTC  
ACAATTGGTGTAGCCAAGGATTTGTCAAATCTTGAGCATCTTGAAGTTGA  
TTCATGTAATAATATGGAACAACCTCATATGTATTGAGAATGCTGGAAAAG  
AGACAATTACATTCCTAAAGCTGAAGATTTTATCTTTGAGTGGGCTACCA



AAGCTTTCGGGTTTGTGCCAAAATGTCAACAACTTGAGCTACCACAAC  
CATAGAGTTGAACTTAAGGGCATTCCAGGGTTCACATGCATTTATCCGC  
AAAACAAGTTGGAAACATCTAGTTTGTGAAGGAAGAGGTAGATATATGT  
TTTATGTTAATACAAGTTAAAAAATCTTTTAACTAAAAGTTTCAGTATA  
5 TATATCTATATGTCTATAATTTGATTATATGATGTATTAGTGTGGATG  
TGGCTATTAAGGGATGATTATTTTGCAGGTGTGATTCCTAAGTTGGAGA  
CACTTCAAATTGATGAGATGGAGAATTTAAAGGAAATATGGCATTATAAA  
GTTAGTAATGGTGAGAGAGTTAAGTTGAGAAAGATTGAAGTGAGTAAGTG  
TGATAAGCTTGTGAATCTATTTCCACACAACCCCATGTCTCTGCTGCATC  
10 ATCTTGAAGAGCTTGAAGTCAAGAAATGTGGTTCCATTGAATCGTTATTC  
AACATCGACTTGGATTGTGTTGATGCCATAGGAGAAGAAGACAACATGAG  
GAGCTTAAGAAACATTAAAGTGAAGAATTCATGGAAGTTAAGAGAAGTGT  
GGTGTATAAAAGGTGAAAATAACTCTTGCCCCCTTGTTTCTGGCTTTCAA  
GCTGTTGAAAGCATAAGCATTGAAAGTTGTAAGAGGTTTAGAAATGTATT  
15 CACACCTACCACCACCAATTTTAATATGGGGGCACTTTTGGAGATATCAA  
TAGATGACTGTGGAGAATACATGGAAAATGAAAAATCGGAAAAGAGTAGC  
CAAGAGCAAGAGCAGGTATGGATTTCATTTCACTTTCTTACTTACTTAA  
GGATTAAGCTTCTGTTTTTTGAATAAAAAAGGGACATCTTCTAATAATG  
CACATCTTAAATTAAAAAGTATTTAATTGTTGCATAGCAGCGTATAACAT  
20 CTTCTAATAATTTATCTGAAGGTGAAAGATCCAACCTACTTCTAATTTGTT  
AACAAATTTCAATCATTTGCAAATGTTCTTAAAAAATTAATTACCTGAAA  
TCAAAACAATCTTCTTCAAATCCAAAATTATGAGACAGAATTGAGAAGGG  
ATGTGAAATTATAAACCATTAAACACAATTCCATGCTCACGTTACTAATTA  
CATTTCTTGTGGGATATATATGTACAGACTGATATTTTGTGAGAGGAAG  
25 TGAATTACAAGAAGTCACTGATACTATTTCTAATGTTGTATTACATCG  
TGTCTCATACTCTTTTTATAACAACCTCCGTAAACTCAACTTGGAGAA  
GTATGGAGGAGTTGAGGTTGTGTTTGAGATAGAGAGTTCAACAAGTAGAG  
AATTGGTAACAACATACCATAAACAACAACAACAACAACCTATATTT  
CCC.AACCTTGAGGAATTATATCTATATTATATGGACAACATGAGTCATGT  
30 ATGGAAGTGCAACAACCTGGAATAAATTTTACAACAATCAGAATCCCCAT  
TCC.ACAACCTCACAACCATAACATGTCCGATTGCAAAAGCATTAAAGTAC  
TTGTTTTACCTCTCATGGCAGAACTTCTTTCCAACCTAAAGAGAATCAA  
TATTGACGAGTGTGATGGTATTGAAGAAATTGTTTCAAAAAGAGATGATG  
TGG.ATGAAGAA

35

**RG2O deduced polypeptide sequence (SEQ ID NO:119)**

MDV V N A I L K P V A E T L M E P V K K H L G Y I S S T K H V R D M S N K M R E L N A A R H A E E D H L D  
R N I R T R L E I S N Q V R S W L E E V E K I D A K V K A L P S D V T A C C S L K I K H E V G R E A L K L I V E I E  
S A T R Q H S L I T W T D H P I P L G K V D S M K A S M S T A S T D Y N D F Q S R E K T F T Q A L K A L E P N N  
40 A S H M I A L C G M G G V G K T T M M Q R L K K V A K Q N R M F S Y M V E A V I G E K T D P I A I Q Q A V A  
D Y L R I E L K E S T K P A R A D K L R E W F K A N S G E G K N K F L V I L D D V W Q S V D L E D I G L S P F P  
N Q G V D F K V L L T S R D E H V C T V M G V G S N S I L N V G L L I E A E A Q S L F Q Q F V E T S E P E L H K I

GEDIVRKCCGLPIAIKTMACTLRNKRKDAWKDALSRIEHYDLRNVAPKVFETSYHN  
LHDKETKSVFLMCGLFPEDFNIPTEELMRYGWGLKIFDRVYTFIEARNRINTCIERL  
VQTNLLIESDDVGCVKMHDLVRAFVLGMYSEVEHASVVNHGNIPGWTENDPTDSC  
KAISLTCEMSGNIPGDFKFPNLTILKLMHGDKSLRFPQDFYEGMEKLQVISYDKMK  
5 YPMLPLSPQCSTNLRVLHLHECSLKMFDSCSIGNMANVEVLSFANSIEMIPLSTIGN  
LKKLRLLDLTDCHGLHITHGVFNNLVKLEELYMGFSDRPDQTRGNISMTDVSUNE  
LAERSKGLSALEFQFFENNAQPNMNSFGKLKRFKISMGCTLYGGSDYFKKTYAVQ  
NTLKLVTNKGELLSRMNELFVETEMLCLSVDDMNDLGDVCVKSSRSPQPSVFKIL  
RVFVVSCKVELRYLFTIGVAKDLSNLEHLEVDSCNNMEQLICIENAGKETITFLKIKI  
10 LLSGLPKLSGLCQNVNKLLELPQLIELKLKGIPGFTCIYPQNKLETSSLLKEEVVIPKL  
ETLQIDEMENLKEIWHYKVSNGERVKLKIEVSNCDKLVNLFPHNPMSSLHHLEEL  
EVKKCGSIESLFNIDLDCVDAIGEEDNMRLRNKVKNSWKLREVWCICKGENNSCPL  
VSGFQAVESISIESCKRFRNVFTPTTTNFMGALLEISIDDCGEYMENEKSEKSSQEQ  
EQTDILSEEVKLQEVTDITISNVFTSCLHSFYNNLRKLNLEKYGGVEVVFIESSTS  
15 RELVTTYHKQQQQQPIFPNLEELYLYMDNMESHVWKCNNWNKFLQQSESPFHN  
LTTIHMSDCKSIKYLFSPLMAELLSNLKRINIDECDGI

**RG2P polynucleotide sequence (SEQ ID NO:120)**

CCCATTGCTATTCAGGAAGCAGTAGCAGATTACCTCNGTATAGAGCTCAA  
20 AGAAAAAACTAAATCNGCAAGAGCTGATATGCTTCGTAAAATGTTAGTTG  
CCAAGTCCGATGGTGGTAAAAATAAGTTCCTAGTAATACTTGACGATGTA  
TGGCAGTTTGTGATTTAGAAGATATCGGTTTAAGTCCTTTGCCAAATCA  
AGGTGTTAACTTCAAGGTCTTGCTAACATCACGGGATGTAGATGTTTGCA  
CTATGATGGGAGTCGAAGCCAATTCAATTCTCAACATGAAAATCTTACTA  
25 GATGAAGAAGCACAAAGTTTGTTCATGGAGTTTGTACAAATTTGAGTGTA  
TGTTGATCCCAAGCTTCATAAGATAGGAGAAGATATTGTAAGAAAGTGT  
GTGGTTTGCCTATTGCCATCAAAACCATGGCCCTTACTCTTAGAAATAAA  
AGCAAGGATGCATGGAGTGATGCACTTTCTCGTTTAGAGCATCATGACCT  
TCACAATTTTGTGAATGAAGTTTTTGAATTAGCTACGACTATCTTCAAG  
30 ACCAGGAGACTAAATATATCTTTTTGCTTTGTGGATTGTTTCCCGAAGAC  
TACAATATTCCTCCTGAGGAGTTAATGAGGTATGGATGGGGCTTAAATTT  
ATTTAAAAAAGTGTATACTATAAGAGAAGCAAGAGCCAGACTCAACACCT  
GCATTGAGCGGCTTATCCATACCAATTTGTTGATGGAAGGAGATGTTGTT  
GGGTGTGTAAAGATGCATGATCTAGCACTTGCTTTTGTATGGATATGTT  
35 TTCTAAAGTGCAGGATGCTTCAATTGTCAACCATGGTAGCATGTCAGGGT  
GGCCTGAAAATGATGTGAGTGGCTCTTGCCAAAGAATTTCAATTAACATGC  
AAGGGTATGTCTGGGTTTCTATAGACCTCAACTTTCCAAACCTCACAAT  
TTTAAACTTATGCATGGAGATAAGTTTCTCAAGTTTCTCCAGACTTTT  
ATGAACAAATGGAAAAGCTTCAAGTTGTATCGTTTCATGAAATGAAATAT  
40 CCGTTTCTTCCCTCGTCTCCTCAATATTGCTCCACCAACCTTCGAGTTCT  
TCATCTCCATCAATGCTCATTGATGTTTGATTGCTCTTGATTGGAAATC  
TGTTTAATCTGGAAGTGTGAGCTTTGCTAATTCTGGCATTGAATGGTTA

CCTTCCAGAATTGGAAATTTGAAGAAGCTAAGGCTACTAGATTTGACAGA  
TTGTTTTGGTCTTCGTATAGATAAGGGTGTCTTAAAAAATTTGGTCAAAC  
TTGAAGAGGTTTATATGAGAGTTGCTGTTTGAAGCAAAAAAGCCGAAAT  
AGAAAAGCCATTAGCTTCACAGATGATAACTGCAATGAGATGGCAGAGCG  
5 TTC

**RG2P deduced polypeptide sequence (SEQ ID NO:121)**

PIAIQEAVADYL?IELKEKTKSARADMLRKMLVAKSDGGKNKFLVILDDVWQFVDL  
EDIGLSPLPNQGVNFKVLLTSRDVDVCTMMGVEANSILNMKILLDEEAQSLFMEFV  
10 QISSDVPKLHKIGEDIVRKCCGLPIAKTMALTLRNKSKDAWSDALSRLHHDLHN  
FVNEVFGISYDYLQDQETKYIFLLCGLFPEDYNIPPEELMRYGWGLNLFKKVYTIRE  
ARARLNTCIERLIHTNLLMEGDVVGCVKMHDLLALAFVMDMFSKVQDASIVNHGS  
MSGWPENDVSGSCQRISLTCKGMSGFPIDLNFPNLTLKLMHGDKFLKFPDFYEQ  
MEKLQVVSFHEMKYPFLPSSPQYCSNLRVLHLHQCSLMFDCSCIGNLNFNLEVLFSF  
15 ANSGIEWLPSRIGNLKKLRLLDLTDCFLRIDKGVKLNLVKLEEVYMRVAVRSKKA  
GNRKAISFTDDNCNEMAERS

**RG2Q polynucleotide sequence (SEQ ID NO:122)**

TGGGGAAGACACAGTGATAGAAAAAAGAAATGTTGTGGAAAAGAGGA  
20 AAATGTTTGATTATGCTGTTGTGGCGGTTATAGGGGAAAAGACGGACCCT  
ATTGCTCTTCAGAAAAGTGTGCGGATTACTTGCATATTGAGCTAAATGA  
AAGCACTAACTAGCAAGAGCAGATAAACTTTGCAAATGGTTCAAGGACA  
ACTCGGATGGAGGTAAGAAAAAGTTCCTCGTAATACTCGACGATGTTTGG  
CAATCTGTTGATTTGGAAGATATTGGTTTAAGTACTCCTTTTCCAAATCA  
25 AGGTGTCAACTTCAAGGTTTTGTTGACATCACGAAAGAGAGAAATTTGCA  
CAATGATGGGAGTTGAAGCTGATTTAATTCTCAATGTCAAAGTCTTAGAA  
GAAGAAGAAGCACAAAAGTTGTTCCCTCCAGTTTGTAGAAATTGGTGACCA  
ATACCACGAGCTTCATCAGATAGGGGTACATATAGTAAAGAAGTGTTATG  
GTTTACCCATTGCCATTAAACCATTGGCTCTTACTTTAAGAAATAAAAGA  
30 AAGGATTCATGGAAGGACGCACTCTCTCGTTTAGAGGACCATGACACTGA  
AAATGTTGCAAATGCAGTTTTTCGAGATGAACTACCGCAATCTACAAGATG  
AGGAGACCAAAGCCATTTTTTTGCTTTGCGGTTTGTTCCTCGAAGACTTT  
GATATTCCTACTGAGGAGTTGGTGAGGTATGGATGGGGCTTAAATCTATT  
TAAAAAAGTGTATACCATAAGAAAGGCAAGAACGAGATCGCATACATGTA  
35 TTGAGCGACTCTTGGATTCAAATTTGTTGATTGAAAGTAACGATATTCGG  
TGCGTCAAGATACACGATCTGGTGCGGCTTTTGTGTTTGGATATGTATTG  
TAAAGTTGAGCATGCTTCAATTGTCAACCATGGTAATATGCGGACCGAAT  
ATAATATGGCTGACTCTTGCAAAACAATTCATTAAACATACAAGAGTATG  
TCTGGGTTTGAAGTTTCCAGGAGACCTCAAGTTTCCAAACCTAACAGTTTT  
40 GAACTTATGCANGGAGATAAGTCTCTAAGGTTTCCTCAAGACTTTTATC  
AATCAATGGAAAACTTCGGGTTATATCATATGATAAAATGAAGTATCCA  
TTGCTTCCCTCATCACCTCAATGCTCCACTAACATCCGAGTGCTTCGTCT

CCATGAATGTTTCATTAAGGATGTTTGATTGCTCTTGTATTGGAAAGCTAT  
TGAATTTGGAAGTCCTCAGCTTTTTTAATTCTAACATTGAATGGTTACCT  
TCCACAATCAGAAATTTAAAAAAGCTAAGGCTACTAGATTTGAGATATTG  
TGATCGTCTTCGTATAGAACAAGGTGTCTTGAAAAATTTGGTCAAACCTTG  
5 AAGAACTTTATACTGGATATACATCAGCGTTTACAGA

**RG2Q deduced polypeptide sequence (SEQ ID NO:123)**

GEDTVIEKKKNVVEKRKMFDYAVVAVIGEKTDPIALQKTVADYLHIELNESTKLAR  
ADKLCKWFKDNSDGGKKKFLVILDDVWQSVLEDIGLSTPFPNQGVNFKVLLTSR  
10 KREICTMMGVEADLILNVKVLLEEEEAQKLFLOFVEIGDQYHELHQIGVHIVKKCYG  
LPIAIKTMALTLRNKRKDSWKDALSRLEDHDTENVANAVFEMNYRNLQDEETKAI  
FLLCGLFPEDFDIPTEELVRYGWGLNLFKKVYTIRKARTRSHTCIERLLDSNLLIESN  
DIRCVKIHDLVRAFVLDMYCKVEHASIVNHGNMRTEYNMADSCKTISLTYKSMMSG  
FEFPGDLKFPNLTVLKLM?GDKSLRFPQDFYQSMEKLRVISYDKMKYPLLPSSPQCS  
15 TNIRVLRRLHECSLRMFDCSCIGKLLNLEVLSSFNSNIEWLPSTIRNLKKLRLLDLRYC  
DRLRIEQGVLKNLVKLEELYTGYSAFTE

**RG2S polynucleotide sequence (SEQ ID NO:124)**

ATTTGGGGTTTTACATTTAATTTTTTGTGCATGAATGTGAAAATAGACTG  
20 CTTATTGATTCTTTGTGTTTCATTGAGTTGATTTTCATTATTACTACCTT  
ACAAATTGCTCAGTGATAGATTTCCATTAATTTGCTAATTCGGTTGCTTC  
TAAATATGTAGGAGCTACTAAAAGCAAAAATATCGAGCAATGTCGGACCC  
AACGGGGATTGCTGGTGCCATTATTAACCCAATTGCTCAGAGGGCCTTGG  
TTCCCGTTACAGACCATGTAGGCTACATGATTTCCCTGCAGAAAATATGTG  
25 AGGGTCATGCAGACGAAAATGACAGAGTTGAATACCTCAAGAATCAGTGT  
AGAGGAACACATTAGCCGGAACACAAGAAATCATCTTCAGATTCCATCTC  
AAATTAAGGATTGGTTGGACCAAGTAGAAGGGATCAGAGCAAATGTGGAA  
AACTTTCCGATTGATGTCATCACTTGTTGTAGTCTCAGGATCAGGCACAA  
GCTTGGACAGAAAGCCTTCAAGATAACTGAGCAGATTGAAAGTCTAACAA  
30 GACAGCTCTCCCTGATCAGTTGGACTGATGATCCAGTTCCTCTAGGAAGA  
GTTGGTTCCATGAATGCATCCACCTCTGCATCATCAAGTGATGATTTCCC  
ATCAAGAGAGAAAACCTTTACACAAGCACTAAAAGCACTCGAACCCAACC  
AACAAATTCCACATGGTAGCCTTGTGTGGGATGGGTGGAGTAGGGAAGACT  
AGAATGATGCAAAGGCTGAAGAAGGCCGCTGAAGAAAAGAAATTGTTTAA  
35 TTATATTGTTAGGGCAGTTATAGGGGAAAAGACGGACCCCTTTGCCATTC  
AAGAAGCTATAGCAGATTACCTCGGTATACAACCTCAATGAAAAAACTAAG  
CCAGCAAGAGCTGATAAGCTTCGTGAATGGTTCAAAAAGAATTCAGATGG  
AGGTAAGACTAAGTTCCTCATAGTACTTGACGATGTTTGGCAATTAGTTG  
ATCTTGAAGATATTGGGTAAAGTCCTTTTCCAAATCAAGGTGTCGACTTC  
40 AAGGTCTTGTTGACATCACGAGACTCACAAGTTTGCATATGATGGGGGT  
TGAAGCTAATTCAATTATTAACGTGGGCCTTCTAACTGAAGCAGAAGCTC  
AAAGTCTGTTCCAGCAATTTGTAGAACTTCTGAGCCCGAGCTCCAGAAG

ATAGGAGAGGATATCGTAAGGAAGTGTTGCGGTCTACCTATTGCCATAAA  
AACCATGGCATGTACTCTTAGAAATAAAAGAAAGGATGCATGGAAGGATG  
CACTTTCGCGCATAGAGCACTATGACATTCACAATGTTGCGCCCCAAAGTC  
TTTGAAACGAGCTACCACAATCTCCAAGAAGAGGAGACTAAATCCACTTT  
5 TTTAATGTGTGGTTTGTTCCTCGAAGACTTCGATATTCCTACTGAGGAGT  
TGATGAGGTATGGATGGGGCTTGAAGCTATTTGATAGAGTTTATACGATT  
AGAGAAGCAAGAACCAGGCTCAACACCTGCATTGAGCGACTGGTGCAGAC  
AAATTTGTTAATTGAAAGTGATGATGTTGGGTGTGTCAAGATGCATGATC  
TGGTCCGTGCTTTTGTTCCTGGAAGTCGAGCATGCTTCT  
10 ATTGTCAACCATGGTAATATGCCCCGAGTGGACTGAAAATGATATAACTGA  
CTCTTGCAAAAGAATTCATTAACATGCAAGAGTATGTCTAAGTTTCCAG  
GAGATTTCAAGTTTCCAAACCTAATGATTTTGAAACTTATGCATGGAGAT  
AAGTCGCTAAGGTTTCTCAAGACTTTTATGAAGGAATGGAAAAGCTCCA  
TGTTATATCATACGATAAAATGAAGTACCCATTGCTTCCTTTGGCACCTC  
15 GATGCTCCACCAACATTCGGGTGCTTCATCTCACTAAATGTTCAATAAG  
ATGTTTGATTGCTCTTGTATTGGAAATCTATCGAATCTGGAAGTGCTGAG  
CTTTGCTAATTCTCGCATTGAATGGTTACCTTCCACAGTCAGAAATTTAA  
AGAAGCTAAGGTTACTTGATCTGAGATTTTGTGATGGTCTCCGTATAGAA  
CAGGGTGTCTTGAAAAGTTTAGTCAAACCTTGAAGAATTTTATATTGGAAA  
20 TGCATCTGGGTTTATAGATGATAACTGCAATGAGATGGCAGAGCGTTCTG  
ACAACCTTTCTGCATTAGAATTCGCGTTCCTTAATAACAAGGCTGAAGTG  
AAAAATATGTCATTTGAGAATCTTGAACGATTCAAGATCTCAGTGGGACG  
CTCTTTTGATGGAAATATCAATATGAGTAGCCACTCATACGAAAACATGT  
TGC.AATTGGTGACCAACAAAGGTGATGTATTAGACTCTAACTTAATGGG  
25 TTATTTTGAACAAAGGTGCTTTTAAAGTGTGCATGGCATGAATGA  
TCTTGAAGATGTTGAGGTGAAGTCGACACATCCTACTCAGTCCTCTTCAT  
TCTGCAATTTAAAAGTTCTTATTATTTCAAAGTGTGTAGAGTTGAGATAC  
CTTTTCAAACCTCAATCTTGCAAACACTTTGTCAAGACTTGAGCATCTAGA  
AGTTTGTGAATGCGAGAATATGGAAGAACTCATACATACTGGAATTTGTG  
30 GAGAAGAGACAATTACTTTCCTAAGCTGAAGTTTTATCTTTGAGTCAA  
CTACCGAAGTTATCAAGTTTGTGCCATAATGTCAACATAATTGGGCTACC  
ACATCTCGTAGACTTGATACTTAAGGGCATTCCAGGTTTCACAGTCATTT  
ATCCGCAGAACAAAGTTGCGAACATCTAGTTTGTGGAAGGAAGAGGTAGAT  
ATATGTTCTTTATGTTAATAACAATTTAAATAATATTTTCAACCAAATTT  
35 CATAATATATCTGTAATTTGATTGTATGATGTGTTATTGTTTATATGTGG  
CTATTAAGGGATGATTATTTTGCAGGTTGTGATTCCCTAAGTTGGAGACAC  
TTC.AAATTGATGACATGGAGAACTTAGAAGAAATATGGCCTTGTGAACTT  
AGTGGAGGTGAGAAAGTTAAGTTGAGAGAGATTAAAGTGAGTAGCTGTGA  
TAAGCTTGTGAATCTATTTCCGCGCAATCCCATGTCTCTGTTGCATCATC  
40 TTG.AAGAGCTTAAAGTCAAGAATTGCGGTTCCATTGAATCGTTATTCAAC  
ATTGACTTGGATTGTGTGCGGTGCAATTGGAGAAGAAGACAACAAGAGCCT  
CTT.AAGAAGCATCAACATGGAGAATTTAGGGAAGCTAAGAGAGGTGTGGA  
GGATAAAAGGTGCAGATAACTCTCATCTCATCAACGGTTTTCAAGCTGTT

GAAAGCATAAAGATTGAAAAATGTAAGAGGTTTAGCAATATATTCACACC  
TATCACCGCCAATTTTATCTGGTGGCACTTTTGGAGATTCAGATAGAAG  
GTTGCGGAGGAAATCACGAATCAGAAGAGCAGGTAACGCTTTC AATTTAA  
CTTTCTTAAGTAATTAAGGACTAACCTCCTGTTTTTTGAATAATAAAGAG  
5 GTGGGATGACTAAACTTGGGCATCACAATTGCAACAAAATGTTACAAACC  
ATGAAACGTTCAAACCATTCTTGAATTAAGGTTTCAATACAAGTCATT  
AAAAATATGGCTTAAATTTTTTATATTTATGTATCAACATGATTTTCA  
TTAGAGATCATTATTATAATAGTAAGTTTAAAGCAATTTAAATTAGAACT  
AATTCTAACTTTAGCTAATAAATCGTTATAAATGTAAATAATTACTTTTT  
10 AGTGAAATAAGCAACGGATTTAATAAGTTAACAACCTTAAATGTCATTTC  
TAACAAAAAACTATTTGGTTT CAGAAGAACCGTAATTCAAGATAACTAA  
AATAAAAAATATTTGACATTCACTAAGAGCATTTTTTTTTTCTAAATATGAT  
TGCAAATGAATAAACTTAAATTTATACAGAAAAGATTTTTATATATGTT  
ATACAAAATTTACAAATTGAACTGGATATGTTAATTAACGGTTTATAAT  
15 TCTGGTATCACAAGGGATATATAAATAAATATTATTTCTGTAGTCATT  
TATAATTGTACTAGTTTATAACCCGTGGGAACCATGAGTTCTAAAATTAG  
TTAAACTTTTATAATAAAAAATTTATAATTATTATTTATTTTAAATAAATT  
ATT.AATTAAGAGATGTATCAAAAATTTAAAGTTATTATAACTTCAAATTT  
AACATATAATTAGAAAATATATGATCATAACTTTCCGCAACTCTTCTTTT  
20 GTATTAAATGCCAGAGAAGCTCTTAGTAYATTTTCTAAATCAAAGTCA  
CAAACCTAATGAAGCATATAATTTTGTGAAAATCAATTAGCATTAGGTTT  
TAAGAGTCACCAAATTC AAAGAGTAATCCAATGCTTTCATTACCACTATG  
GAG.AAAATATTTTCTTAGTTTAAATGAAATGAAAACAAACATTCAAACCTA  
ATTGTTGCTTACTAAACCAAAGACCCATTACTTAGCCAAGAGTTTAAACCA  
25 AAA.AAAATTACATTCATGTATCATTATTCATGACTAGATATATATGAACA  
TGA.AGGGAGTTTTTATAGAAAATATAATCATAGATATTCAACATAACTTC  
ATGGAATTCCTCAAATAACCAAGTTATTCAAGAAATTACATCCAAGTCA  
ACC.AAAGAGAAGTTTAGCCTAGCATGGCTAACTCAAGAAAATAAAATAA  
GGATTAGAAGTACCAAACATGTAGTAAGAATCACAGTAAAAGATGATGTT  
30 GTTCTTGATGTTCTTCTAAGTTCTTCAAGTCTCCAGTTGCTCCTAATAAT  
GCA.AAGGAGAGCCATTAAATTCGTATGTATTGATCCCTTCAAAGCTGCA  
CCA.ACCTCCCTTAAATAACACTCAAAGCAAAAATGACAAAATTGCCCTG  
AAGGACCCTATGCGGGTGCCTTGCGCGGGTGGAGCTGAATACGAAAGGTC  
TTTGGTCTTTGTGAGGGTGATGCTGTGCGGGTTAGCTTGTGCGCATGCTTC  
35 CGCGCGGTTTCGCGCACATGTGCACAAGTGATGCATGGTGTGTACGTTCTT  
GAGTTTTGAGCCTCCGATGCTTAGTCCATTTGGCCCAATTCGAGTCCAAT  
CAGCTTATGACCCATTTTTCTTCAAGTTATCTTCAAGTTATCTTCAAGTT  
AAGCCCAAATTCCTTCTCAAATCATCCATAACTTCACAAAATCGCCCG  
TTC.ATCTTAATCCCGAATGCACAATTATTCTCCTGTCTTCTTTTAAAGCA  
40 AGATACCACCTTCTTCATGCTTCATCCATCAATAGTACACTTCATGTATC  
ATCTCTACTAGTTATTTAGTCCACAATCCTTATTGTCCTCCAAATTTAAT  
TATCTCATTTAGTTCCCGTTCCACTAGTTTCCTTAAATTTGCAATTAAG  
CTC.ACACAAATATTAAGTACCTGAAATGGTCATAAAATAACAAAAAGGAA



CTCATTACAATAACGAAAAGTTGAATATCCATATATTTATTTGGATGTGG  
AATTGAACAAATCTCGTCAAATTTTTGATTTTGTGATGGATTTGAGTAG  
AAGTTTGGGCAGAACGGGAATGATGGTCTGCAAGTGGTTATAAACTTGAT  
TCTGAGTTATTACTATATATGTAGCCTCTTTACAACGACCAAGGTTTCTT  
5 CCAGGTACCATTTGATCTTTTTAGAACCCAGTTGTCTGAAACACCCCTGAT  
TTGGATCAAATATCACCAACAACCTCTTAAAACTTGATTAATCAATTGTT  
TTCTTCATCTTGATAACAAGTGGAATGATTTTCTACTTAGATTAACCTGA  
AAAAAAAGGTCCATGTGCGTCTGGTGGATCTGGTAAATGAAGATGGAAGG  
GAGAGCTGACTTTAAAGACACAAACACGTCACCATATCTTTTATTTTATT  
10 TTAATTTGCTTTTTTTCCTATTTCTTTCTTTCTTGATCTCCAGATGGTAT  
GTGGTGTGGATAATTTACACATAGAGATTGGGAACGACTGTGTTTTAGAG  
AGGACGTGGCTTGGGGTTGAGGATGGTTTATGGCTGGCCGAGTTTCATTT  
ATATAAACAAACAAATATATAAAACAAGGGGTAAAATGGCCATCTTATAT  
GTATTTAACCGTCCTTTTTTATTTTTTTTTTATTTTTAAATTTAAGAAGG  
15 GGTATACCAAGTGTGAGCCTCTTATCCCAACCAGGCAACCAGTCAAATAG  
GGACTTAGGTTGTTTGGAAACAGTTCCGTGAGACCGTGACTTGATGGTA  
GATAAATTTAGTAACTTAACCCCTCAATTAACCTACCTTTTTCTTATTA  
ACTCAATTTCAACCTAAATTCTGATTCTTGTTGAAAATAAGTTGCATCT  
TTATGTTTGTATTATCCTGTTGCATAGGATCCTTAGCATCTTTTAATAAT  
20 TTATTTGAAGGTGAAAGATCCAACCTATTTTTTAGCTGTTGGCATTTTCCA  
TCATTTGCAACTGTTTCTTGAAAAAAAAATACCTAAAATCAAAATAACCA  
TTTTCAAATCCAAAATTATAAGAGAGAATTGTTAATGGACGTGGAATCGT  
AAATCATTAACACAGTTCAGTACACAAGTTGCTAATTACATTTCTTGCTG  
TGCAGATTGAAATTCTATCAGAGAAAGAGACATTACAAGAAGTCACTGAT  
25 ACTAATATTTCTAATGATGTTGTATTATTCCCATCCTGTCTCATGCACTC  
TTTTCATAACTCCATAAACTTAAATTGGAGAGAGTTAAAGGAGTGGAGG  
TGGTGTTTGAGATAGAGAGTGAGAGTCCAACAAGTAGAGAATTGGTAACA  
ACTCACCATAACCAACAACATCCTATTATACTTCCCAACCTCCAGGAATT  
GGATCTAAGTTTTATGGACAACATGAGTCATGTGTGGAAGTGCAGCAACT  
30 GGAATAAATTCTTCACTCTTCCAAAACAACAATCAGAATCCCCATTCAC  
AACCTCACAACCATAACACATGTTTCACTGTCAGAAGCATTAAGTACTTGTT  
TTCGCCTCTCATGGCAGAAGTTCTTTCCAACTAAAGGATATCTGGATAA  
GTGGGTGTAATGGTATTAAAGAAGTTGTTTCAAAGAGAGATGATGAGGAT  
GAAGAAATGACTACATTTACATCTACCCACACAACCACCATCTTGTTCCC  
35 TCATCTTGATTCTCTCACTCTAAGACTACTGGAGAATCTGAAGTGTATTG  
GTGGAGGTGGTGCCAAGGATGAGGGGAGCAATGAAATATCTTTCAATAAT  
ACCCTGCAACTACTGCTGTTCTTGATCAATTTGAGGTATGCTTTGTACA  
TATTCAATTATTTATTTAATTTCTTTTTCTTTGCAATATTCTATAAAT  
AATACATTTTATACCCACTATACTAAGATAATAATTACCTAGAGGGATGG  
40 ATGCTATGACACAGCTGCTACACTTCAGAACTCTAGTAAGGGCAGTTAT  
GGAAGTTCAATAAAATGATAATGGCATCTTTTGATGGGTAATATAGGCAA  
TTTAAGTTTTATTTCTGTAAAGCAGTATTTAGCAAGTACTGGCCAGTAG  
GAGAGGAGAATATCACCTTTTGTGAAAATCTGGTCATTGTACCCAAGAAT



TTAGTTAAATGTAACATTTTAGATATCAGGGGACATCAGGTGACAGATAT  
TGTAGAATAGAACAATATATAATATTACCCAAAACATTTTTTCTAAGGT  
TATTCTGTAAATATGTGCTTTCTTGATTTCATTGAATTTGCATTCCTAT  
ATTTTAGGTGGTAAAGTGATTGTCTCTTCAATAAATCCCGAAATTAATTA  
5 AAAAAAAAAAAAAACAAAAGTAAATTTTGTATATGGAGAGCACTGGTATCA  
TTTAGTATATAAAAAAACTAGATTTTGAATTAAGTTTCTTATATAAAAGC  
TGTGTATATAGTTTAATTAGTTTTACATCATTTTTCCATGTGGTGTGCA  
GTTGTCTGAAGCAGGTGGTGTCTTGGAGTTTATGCCAATACGCTAGAG  
AGATAGAGATATCTAAGTGTAATGTATTGTCAAGTGTGATTCCATGTTAT  
10 GCAGCAGGACAAATGCAAAAGCTTCAAGTGCTGAGAGTAACGGGTTGTGA  
TGGCATGAAGGAGGTATTTGAACTCAATTAGGGACGAGCAGCAACAAAA  
ACAGAAAGGGTGGTGGTGATGAAGGAAATGGTGGAAATCCAAGAGTAAAT  
AACAAATGTTATTATGCTTCCCAATCTAAAGACATTGAAAATCTACATGTG  
CGGGGGTTTGGAACATATATTCACATTCTCTGCACTTGAAAGCCTGACAC  
15 AGCTCCAAGAGTTAAAGATAGTGGGTGCTACGGAATGAAAGTGATTGTG  
AAGAAGGAAGAAGATGAATATGGAGAGCAGCAAAACAACAACAACAAC  
AACGAAGGGGGCATCTTCTTCTTCTTCTTCTTCTTCTTCTAAGAAGGTTG  
TGGTCTTTCCCGTCTAAAGTCCATTGAACTATTCAATCTACCAGAGCTG  
GTAGGATTCTTCTTGGGGATGAATGAGTTCGGGTTGCCTTCATTGGAAGA  
20 AGTTACCATCAAGTATTGCTCAAAAATGATGGTGTGTCAGCTGGTGGGT  
CCACAGCTCCCCAACTCAAGTATATACACACAAGATTAGGCAAACATACT  
CTTGATCAAGAATCTGGCCTTAACTTTCATCAGGTATATATATATTCCTT  
TAATTGGCATGATCTAATTAAGAAAGATATCATTCCCTGCCAAGTAAATTT  
ACTTCAAACACATTACACTGGTTTCAGTCTAAGTTTATGTTGTTCTAGG  
25 AAGGCCAAAATGGGAAAGCAAGATAGGGAAAAATAGTGTATTCAGTGGA  
AAGGGTATTTTAGGTATTTTCTGTCAAAAGTTGTTATTGCAGGCTTTTTA  
GTACCTGGAATCGTGTGTGGGAGGAGCGTTATTATTCTGATTTGCTTGT  
TCTTTATCATTTTTTCTTAGCCTCTCGAACAGCTAGAAACCCTTTTAATC  
TTTTGATTTTAAATGACAAAATTTTTCCCTGTTACTCTATTGATTGTTG  
30 TTCTTCATGGTTCTAAGTGAGTTATTGGCTCATCTGTTACTTCTTTTGAT  
TGTTATTTTCATATCATGTTGTCCTTTGAATCAAGCTTTTCCATTTTCAA  
CCAGGGCAAAAGGTCAAAAGTAACCTACTTTATGAGATCAAAAACAGCAA  
CCCATCGGATAACTTTTAGTTGGAGTTAATAGTTACAATTACCATTGTGA  
TTAATAATTATAATATCTTGTATTAATTCATTAATAATTGGTACAGCACAT  
35 ATATGACATTTTAAAGGTTTGTGTTTGTGTTWGACATATATATGCCTCTGGC  
GTTTTCTTTATTGGACATGCAGACCTCATTCCAAAGTTTATACGGTGACA  
CCTCGGGCCCTGCTACTTCAGAAGGGACAACCTGGTCTTTTCATAACTTG  
ATCGAATTAGATATGGAATTAAATTATGATGTTAAAAAGATTATCCATC  
CAGTGAGTTGCTGCAACTGCAAAAGCTGGAAAAGATTTCATGTGAGTAGTT  
40 GTTATTGGGTAGAGGAGGTATTTGAACTGCATTGGAAGCAGCAGGGAGA  
AATGGAAATAGTGGAAATTGGTTTTGATGAATCGTCACAACTACTACTAC  
TACTACTCTTTTCAATCTTCGAAACCTCAGAGAAATGAAGTTGCATTTTC  
TACGTGGTCTGAGGTATATATGGAAGAGCAATCAGTGGACAGCATTTGAG

TTTCCAAACCTAACAAGAGTTCATATAAGTAGGTGTAGAAGGTTAGAACA  
TGTATTTACTAGTTCCATGGTTGGTAGTCTATTGCAACTCCAAGAGCTAG  
ATATTAGTTGGTGCAACCATATGGAGGAGGTGATTGTTAAGGATGCAGAT  
GTTTCTGTTGAAGAAGACAAAGAGAGAGAATCTGATGGCAAGACGAATAA  
5 GGAGATACTTGTGTTACCTCGTCTAAAATCCTTGAAATTAAAATGCCTTC  
CATGTCTTAAGGGGTTTAGCTTGGGGAAGGAGGATTTTTTCATTCCCATT  
TTGGATACTTTAGAAATCTACAAATGCCCAGCAATAACGACCTTCACCAA  
GGGAAATTCTGCTACTCCACAGCTAAAAGAAATAGAAACAAGATTTGGCT  
CGTTTTATGCAGGGGAAGACATCAACTCCTCTATTATAAAAAGATCAAAC  
10 AACAGGTAAATCAGATCTTTGTTGCTTTAATAATTCTTAAACTACATTTG  
AAAAGCTTCATGCAAGTTTTTTTTTGTATATTGTCAAAAACCGCAACCTA  
CATTTTCAGCTTTATATTTATGTACTTTATGCAGGAGTTCAAACAAAAC  
CTGATTAATGTGAAGTGAATATTAAAGGTAAATTATATTTTCATGTTCTT  
AGTTGCCTATTAATTAATGGCCTTTTAGTTCRTGATTTTTTGGATGTAGTY  
15 WTCATGATGATGTGAATCTTCTAATACCCCATTCATTGTTTGGTTGAATG  
TTGACTCTATGTCAGGATGAATATTCAAGGGAAGAATTGTTTCATCATATG  
AAGGACATTAAAGAACATGGATGCTATGAAGATGTTGGAARAC

**RG2S deduced polypeptide sequence (SEQ ID NO:125)**

20 MSDPTGIAGAIINPIAQRALVPVTDHVGVMISCRKYVRVMQTKMTELNTSRISVEEH  
ISRNTRNHLQIPSIKDWLDQVEGIRANVENFPIDVITCCSLRIRHKLGGQKAFKITEQI  
ESLTRQLSLISWTDDPVPLGRVGS MNASTSASSSDDFPSREKTFTQALKALEPNQQF  
HMV'ALCGMGGVGKTRMMQRLKKAEEKKLFNYIVRAVIGEKTDPFAIQEAIADYL  
GIQLNEKTKPARADKLREWFKKNSDGGKTKFLIVLDDVWQLVDLEDIGLSPFPNQG  
25 VDFKVLLTSRDSQVCTMMGVEANSIINVGLL TEAEAQSLFQQFVETSEPELQKIGED  
IVRKCCGLPIAIKTMACTLRNKRKDAWKDALSRIEHYDIHNVAPKVFETSYHNLQE  
EETKSTFLMCGLFPEDFDIPTTEELMRYGWGLKLFDRVYTIREARTRLNTCIERLVQT  
NLLIESDDVGCVKMHDLVRAFVLGMFSEVEHASIVNHGNMPEWTENDITDSCKRIS  
LTCKSMSKFPDGFKFPNLMILKLMHGDKSLRFPQDFYEGMEKLHVISYDKMKYPLL  
30 PLAPRCSTNIRVLHLTKCSLKMFD CSCIGNLSNLEVLSFANSRIEWLPSTVRNLKKLR  
LLDLRFCDGLRIEQGV LKSLVKLEEFYIGNASGFIDDNCNEMAERSDNLSALEFAFF  
NNKAEVKNM SFENLERFKISVGRSFDGNINMSSHSYENMLQLVTNKG DVLD SKLN  
GLFLKTKVFLSVHGMNDLEDVEVKSTHPTQSSSFCNLKVLII SKCVELRYLFKLN  
ANTLSRLEHLEVCECENMEELIHTGICGEETITFPKLKFLSLSQLPKLSSLCHNVNIIG  
35 LPHLVDLILKGIPGFTVIYPQNKLR TSSLLKEEVVIPKLET LQIDDMENLEEIWPCELS  
GGEKVKLREIKVSSCDKLVNLFPRNPMSLLHHLEELKVKNCGSIESLFNIDLDCVGA  
IGEEDNKSLLRSINMENLGKLREVWRIKGADNSHLINGFQAVESIKIECKRFSNIFT  
PITANFYLVALLEIQIEGCGGNHESEEQIEILSEKETLQEVTD TNISNDV VLFPSCLMH  
SFHNLHKLKLERVKGVVFEIESESPTSRELVTTHHNQQHPHLPNLQELDLSFMD  
40 NM SHVWKCSNWNKFFTL PKQQSES PFHNLTTIHMFS CRSIKYLF SPLMAELLSNLK  
DIWISGCNGIKEVVSKRDEDEEMTFTSTHTTTILFPHLDSLTLRLLENLKCIGGGG  
AKDEGSNEISFNNTTATTAVLDQFELSEAGGVSWSLCQYAREIEISKCNVLSSVIPCY

AAGQMQLQVLRVTGCDGMKEVFETQLGTSSNKNRKGGGDEGNNGGIPRVNNNVI  
MLPNLTKLIYMC GGLEHIFTFSALES LTQLQELKIVG CYGMKVIVKKEE DEYGEQ  
QTTTTTTTKGASSSSSSSSKVVVFPRLKSIELFNLPELVGFFLGMNEFRLPSLEEVT  
IKYCSKMMVFAAGGSTAPQLKYIHTRLGKHTLDQESGLNFHQTSFQSLYGDTSGPA  
5 TSEGTTWSFHNLIELDMELNYDVKKIIPSELLQLQKLEKIHVSSCYWVEEVFETAL  
EAAGRNGNSGIGFDESSQTTTTTTLFNLRLNREMKLHFLRGLRYIWKSNQWTAFEF  
PNLTRVHISRCRRLEHVFTSSMVGSLLQLQELDISWCNHMEEVIVKDADVSVEEDK  
ERESDGKTNKEILVLPRLKSLKLCLPCLKGFSLGKEDFSFPLDLEIYKCPAITTFT  
KGN SATPQLKEIETRFSGSYAGEDINSSIIKRSNNRSSNKT LINVK .ILK

10

**RG2T polynucleotide sequence (SEQ ID NO:126)**

GGAAGACGACAATGGTGCAACGGTTGAAGAAGGTTGTGAAAGATAAGAAG  
ATGTTCCATTATATTGTCGAGGTGGTTGTAGGGGCAAACACTGACCCCAT  
TGCTATCCAGGATACTGTTGCAGATTACCTCAGCATAGAACTGAAAGGAA  
15 ATACGAGAGATGCAAGGGCTTATAAGCTTCGTGAATGCTTTAAGGCCCTC  
TCTGGTGGAGGTAAGATGAAGTTCCTAGTAATTCTTGACGATGTATGGAG  
CCCTGTTGATCTGGATGATATCGGTTTAAGTTCCTTGCCAAATCAAGGTG  
TTGACTTCAAGGTCTTGCTGACATCACGCAACAGTGATATCTGCATGATG  
ATGGGAGCTAGTTTAATTTTCAACCTCAATATGTTAACAGACGAGGAAGC  
20 ACATAATTTTTTCCGTCGATACGCAGAAATTTCTTATGATGCTGATCCCG  
AGCTTATTAAGATAGGAGAAGCTATTGTAGAGAAATGTGGTGGTTTACCC  
ATTGCCATCAAACTATGGCCGTTACTCTTAGAAATAAACGCAAAGATGC  
ATGGAAAGATGCACCTTCTCGTTTAGAGCACCGTGACACTCATAATGTTG  
TGGCTGATGTTCTTAAATTGAGCTACAGCAATATCCAAGACGAGGAGACT  
25 CGGTCGATTTTTTTGCTATGTGGTTTGTTCCTGAAGACTTTGATATTCC  
TACCGAAGACTTAGTGAGGTATGGATGGGGATTGAAAATATTTACCAGAG  
TGTATACTATGAGACATGCAAGAAAAAGGTTGGACACGTGCATTGAGCGG  
CTTATGCATGCCAACATGTTGATAAAAAGTGATAATGTTGGATTTGTCAA  
GATGCATGATCTGGTTCGTGCTTTTGTTTTGGGCATGTTATCTGAAGTCG  
30 AGCATGCATCAATTGTCAACCATGGGGATATGCCAGGGTGGTTTGAAACT  
GCAAATGATAAGAACAGCTTGTGCAAAAAGATTTTCAATTAACATGCAAAGG  
TATGTCTGCGATTCTGAAGACCTCACGTTTCCAAACCTCTCGATCCTGA  
AATTAATGGATGGAGACGAGTCACTGAGGTTTCCTGAAGGCTTTTATGGA  
GAAATGGAAAACCTTCAGGTTATATCATATGATAACATGAAGCAGCCATT  
35 TCTTCCACAATCACTTCAATGCTCCAATGTTTCGAGTGCTTCATCTCCATC  
ACTGCTCATTAAATGTTTGATTGCTCTTCTATTGGAAATCTTTTGAATCTC  
GAGGTGCTCAGCATTGCTAATTCTGCCATTAAATTGTTACCCTCCACTAT  
TGGAGATCTGAAGAAGCTAAGGCTCCTGGATTTGACAAATTGTGTTGGTC  
TCTGTATAGCTAATGGCGTCTTTAGAAATTTGGTCAAACCTTGAAGAGCTT  
40 TATATGAGAGTTGATGATCGAGATTCGTTTTTTGTGAAAGCTGATGACAG  
CAAGACCATTACCT

**RG2T deduced polypeptide sequence (SEQ ID NO:127)**

5 KTTMVQRLKKVVKDKKMFHYIVEVVVGANTDPIAIQDTVADYLSIELKGNTRDAR  
AYKLRECFKALSGGGKMKFLVILDDVWSPVDLDDIGLSSLPNQGVDFKVLLTSRNS  
DICMMM GASLIFNLNMLTDEEAHNFFRRYAEISYDADPELIKIGEAIVEKCGGLPIAI  
10 KTMAVTLRNRKDAWKDALSRLEHRDTHNVVADV LKLSYSNIQDEETRSIFLLCG  
LFPEDFDIPTEDLVRYGWGLKIFTRVYTMRHARKRLDTCIERLMHANMLIKSDNVG  
FVKMHDLVRAFLGMLSEVEHASIVNHGDMPGWFETANDKNSLCKRISLTCKGMS  
AIPEDLTFPNLSILKLMDGDESLRPEGFYGEMENLQVISYDNMKQPFLPQSLQCSN  
VRVLHLHHCSLMFDCSSIGNLLNLEVLSIANSIAIKLLPSTIGDLKKLRLLDLTNCVGL  
15 CIANGVFRNLVKLEEL YMRVDDRDSFFVKADDSKTIT

**RG2U polynucleotide sequence (SEQ ID NO:128)**

GCCTTGTGTGGGATGGGTGGAGTGGGAAAGACCACTGTGATGAAGAAGCT  
GAAGGAGGTTGTGGTAGGAAAGAACTGTTTAATCATTATGTTGAGGCGG  
15 TTATAGGGGAAAAGACAGACCCCATTTGCTATTCAACAAGCTGTTGCCGAG  
TACCTTGGTATAAGTCTAACCGAAACCACTAAACCAGCAAGAACTGATAA  
GCTCCGTACATGGTTTGCAAACAACCTCAAATGGAGGAAAGAAGAAGTTCC  
TGGTAATACTAGACGATGTATGGCAACCAGTTGATTTGGAAGATATTGGT  
TTAAGTCGTTTTCCAAATCAAGATGTTGACTTCAAGGTCTTGATTACATC  
20 ACGGGACCAATCAGTTTGCCTGAGATGGGAGTTAAAGCTGATTTAGTTC  
TCAAGGTGAGTGTCTGGAGGAAGCGGAAGCACACAGTTTGTTCCTCCAA  
TTTTTAGAACCTTCTGATGATGTCGATCCTGAGCTCAATAAAATCGGAGA  
AGAAATTGTAAAGAAGTGTTCGAGACTACCCATTGCTATCAAAACCATGG  
CCTGAACCTCTAGAAAGTAAAAGTAAGGATACATGGAAGAATGCCCTTTCT  
25 CGTTTACAACACCATGACATTAACACAATTGCGTCTACTGTTTTCCAAAC  
TAGCTATGACAATCTCGAAGACGAGGTGACTAAAGCTACTTTTTTGCTTT  
GTGGTTTATTTCCGGAGGACTTCAATATTCCTACCGAGGACCTATTGAGG  
TATGGATGGGGATTGAAGTTATTCAAGGAAGTAGATACTATACGAGAAGC  
AAGATCCAAGTTGAAAGCCTGCATTGAGCGGCTCATGCATACCAATTTGT  
30 TGATCGAAGGTGATGATGTTAGGTACGTAAAGATGCATGATCTGGTGCGT  
GCTTTTGTGTTTGGATATGTTTTCTAAAGCCGAGCATGCATCTATTGTCAA  
CCATGGTAGTAGTAAGCCAAGGTGGCCTGAAACTGAAAGTGATGTGAGCT  
CCTCTTGCAAAGAATTCATTAACATGCAAGGGTNTG

**35 RG2U deduced polypeptide sequence (SEQ ID NO:129)**

ALCGMGGVGKTTVMKKLKEVVVGKKLFNHYVEAVIGEKTDPPIAIQQAVA EYLGIS  
LTETTKPARTDKLRTW FANNNSGGKKKFLVILDDVWQPVDLEDIGLSRFPNQDVD  
FKVLITSRDQSVCTEMGVKADLV LKVSVEEA EAHSLFLQFLEPSDDVDPELNKIGE  
EIVKKCCRLPIAIKTMA.TLRSSKSDTWKNALSRLQHHDINTIASTVFQTSYDNLEDE  
40 VTKATFLLCGLFPEDFNIPTEDLLRYGWGLKLFKEVD TIREARSKLKACIERLMHTN

LLIEGDDVRYVKMHDLVRAFVLDMFSKAEHASIVNHGSSKPRWPETESDVSSSKR  
ISLTCKG?

**RG2V polynucleotide sequence (SEQ ID NO:130)**

5 CTGTGGAAGACACGAATGATSAAGAAGCTGAAGGAGGTCGTGGAACAAAA  
GAAAATGTTCAATATTATTGTTCAAGTGGTCATAGGAGAGAAGACAAACC  
CTATTGCTATTTCAGCAAGCTGTAGCAGATTACCTCTCTATTGAGCTGAAA  
GAAAACACTAAAGAAGCAAGAGCTGATAAGCTTCGTNAATGGTTCGAGGA  
CGATGGAGGAAAGAATAAGTTCCTTGTAATACTTGATGATGTATGGCAGT  
10 TTGTCGATCTTGAAGATATTGGTTTAAAGTCCTCTGCCAAATAAAGGTGTC  
AACTTCAAGGTCTTGTTGACGTTAAGAGATTCACATGTTTGCACCTCTGAT  
GGGAGCTGAAGCCAATTCAATTCTCAATATAAAAGTTTTAAAGATGTTN  
AAGGACAAAGTTTGTTCGCCAGTTTGCTAAAAATGCAGGTGATGATGAC  
CTGGATCCTGCTTTCAATGGGATAGCAGATAGTATTGCAAGTAGATGTCA  
15 AGGTTTGCCCATTTGCCATCAAACCATTGCCTTAAGTCTTAAAGGTAGAA  
GCAAGCCTGCGTGGGACCATGCGCTTTCTCGTTTGGAGAACCATAAGATT  
GGTAGTGAAGAAGTTGTGCGTGAAGTTTTTAAAATTAGCTATGACAATCT  
CCAAGATGAGGTTACTAAATCTATTTTTWTACTTTGTGCTTTATTTCTTG  
AAGATTTTGATATTCCTATTGAGGAGTTGGTGAGGTATGGGTGGGGCTTG  
20 AAATTATTTATAGAAGCAAAAACCTATAAGAGAAGCAAGAAACAGGCTCAA  
CACCTGCACTGAGCGGCTTAGGGAGACAAATTTGTTATTTGGAAGTGATG  
ACATTGGATGCGTCAAGATGCACGATGTGGTGCGTGATTTTGTTTGGTAT  
ATATTCTCAGAAGTCCAGCACGCTTCAATTGTCAACCATGGTAATGTGTC  
AGAGTGGCTAGAGGAAAATCATAGCATCTACTCTTGTAAGAATTTTCAT  
25 TAACATGCAAGGGTATGTCTGAGTTTCCCAAAGACCTCAAATTTCCAAAC  
CTTTCAATTTTGAACTTATGCATGGAGATAAGTCGNTGAGCTTTCCTGA  
AGACTTTTATGGAAAGATGGAAAAGGTTTCAGGTAATATCATATGATAAAT  
TGATGTATCCATTGCTTCCCTCATCACTTGAATGCTCCACTAACGTTCTGA  
GTGCTTCATCTCCATTATTGTTTCAATTAAGGATGTTTGATTGCTCTTCAAT  
30 TGGTAATCTTCTCAACATGGAAGTGCTCAGCTTTGCTAATTCTAACATTG  
AATGGTTACCATCTACAATTGGAAATTTGAAGAAGCTAAGGCTACTAGAT  
TTGACAAATTGTAAAGGTCTTCGTATAGATAATGGTGTCTTAAAAAATTT  
GGTCAAACCTGAAGAGCTTTATATGGGTGTTAATGTCCGTATGGACCAGG  
CCGT

35

**RG2V deduced polypeptide sequence (SEQ ID NO:131)**

LWKTRM?KKLKEVVEQKKMFNIIVQVVIGEKTNPPIAQQAVADYLSIELKENTKEAR  
ADKLR?WFEDDGGKNKFLVILDDVWQFVDLEDIGLSPLPNKGVNFKVLLTLRDSH  
VCTLMGAEANSILNIKVLKDV?GQSLFRQFAKNAGDDDLDPAFNGIADSIASRCQGL  
40 PIAIKTIALSLKGRSKPAWDHALSRLNHNKIGSEEVVREVFKISYDNLQDEVTKSIF?L  
CALFPEDFDPIEELVRYGWGLKLFIEAKTIREARNRLNTCTERLRETNLLFGSDDIG

CVKMH DVVRDFVWYIFSEVQHASIVNHG NVSEWLEENHSIY SCKRISLTCKGMSEF  
PKDLKFPNLSILKLMHGDKS?SFPEDFYGKMEKVQVISYDKLMYPLLPSSLECSTNV  
RVLHLHYCSLRMFDCSSIGNLLNMEVLSFANSNIEWLPSTIGNLKKLRLLDLTNCKG  
LRIDNGVLKNLVKLEELYMGVNVVRMDQAV

5

**RG2W polynucleotide sequence (SEQ ID NO:132)**

TTGGGAAAGAGACAATGATGAAGAATTGAAAGAGGTTGTGGTTGAAAAGA  
AAATGTTTAATCATTATGTGGAGGCGGTTATAGGGGAGAAGACGGACCCC  
ATTGCTATTCAGCAAGCCGTTGCAGAGTACCTTGGTATAATTCTAACAGA  
10 AACCATAAGGCAGCAAGAACCGATAAGCTACGTGCATGGCTTTCTGACA  
ATTCAGATGGAGGAAGAAAGAAGTTCCTAGTAATACTAGACGATGTATGG  
CATCCGTTTGATATGGAAGATATTGGTTTAAGTCGTTTCCCAAATCAAGG  
TGTCGACTTCAAGGTCTTGATTACATCACGGGACCAAGCTGTTTGCCTG  
AGATGGGAGTTAAAGCTGATTCAAGTTATCAAGGTGAGTGTCTAGAGGAA  
15 GCTGAAGCACAAAGCTTATTCTGCCAACTTTGGGAACCTTCTGATGATGT  
CGATCCTGAGCTCCATCAGATTGGAGAAGAAATTGTAAGGAAGTGTTGTG  
GTTTACCCATTGCAATAAAAACCATGGCCTGCACTCTTAGAAGTAAAAGC  
AAGGATACATGGAAGAATGCACTTTCTCGTTTACAACACCATGACATTAA  
CACAGTCGCGCCTACTGTTTTTCAAACCAGCTATGACAATCTCCAAGATG  
20 AGGTGACTGGAGATACTTTTTTGCTATGTGGTTTGTTCGGAGGACTTC  
GATATTCCTACTGAAGACTTATTGAAGTATGGATGGGGCTTAAATTATT  
CAAGGGAGTGGATTCTGTAAGAGAAGCAAGATACCAGTTGAACGCCTGCA  
TTGAGCGGCTCGTGCATACCAATTTGTTGATTGAAAGTGATGTTGTTGGG  
TGCGTCAAGTTGCACGATCTGGTGCCTGCTTTATTTTGGATATGTTTTG  
25 TAAAGCGGAGCATGCTTCGATTGTCAACCATGGTAGTAGTAAGCCTGGGT  
GGCCTGAAACTGAAAATGATGTGATCAGGACCTCCTGCAAAAGAATCTCA  
TTAACATGCAAGGGTATGATTGAGTTTTCTAGTGACCTCAAGTTTCCAAA  
TGTCTTGATTTTAAACTTATGCATGGAGATAAGTCGCTAAGGTTT

30 **RG2W deduced polypeptide sequence (SEQ ID NO:133)**

WERDNDEELKEVVVEKKMFNHYVEAVIGEKTDP IAIQQA VAEYLGILTETTKAAR  
TDKLRAWLSDNSDGGRRKKFLVILDDVWHPVDMEDIGLSRFPNQGVDFKVLITSRD  
QAVCTEMGVKADSVIKVSVLEEAEASLFCQLWEP SDDVDPELHQIGEEIVRKCCG  
LP IAIKTMACTLRSKSKDTWKNALSRLQHHDINTVAPT VFQTSYDNLQDEVTGDTF  
35 LLCGLFPEDFDIPTEDLLKYGWGLKLFKGVDSVREARYQLNACIERLVHTNLLIESD  
VVGCVKLHDLVRAFILDMFCKAEHASIVNHGSSKPGWPETENDVIRT SCKRISLTCK  
GMIEFSSDLKFPNVLILKLMHGDKSLRF

**RG5 polynucleotide sequence (SEQ ID NO:134)**

40 GGGGGGGTGGGGAAGNCGACTCTAGCCCAGAAGNTCTATAATGACCATAA  
AATAAAAGGAAGCTTTAGTAAACAAGCATGGATCTGTGTTTCTCAACAAT

ATTCTGATATTTTCAGTTTTGAAAGAAGTCCTTCGGAACATCGGTGTTGAT  
TATAAGCATGATGAAACTGTTGGAGAACTTAGCAGAAGGCTTGCAATAGC  
TGTCGAAAATGCAAGTTTCTTTCTTGTGTTGGATGATATTTGGCAACATG  
AGGTGTGGACTAATTTACTCAGAGCCCCATTAAACACTGCAGCTACAGGA  
5 ATAATTCTAGTAACAACCTCGTAATGATACAGTTGCACGAGCAATTGGGGT  
GGAAGATATTCATCGAGTAGAATTGATGTCAGATGAAGTAGGATGGAAAT  
TGCTTTTGAAGAGTATGAACATTAGCAAAGAAAGTGAAGTAGAAAACCTA  
CGAGTTTTAGGGGTGACATTGTTCTGTTTGTGTGGTGGCCTCCCCCTAGC  
CTT

10

**RG5 deduced polypeptide sequence (SEQ ID NO:135)**

GGVGKTTLAQK?YNDHKIKGSFSKQAWICVSQQYSDISVLKEVLRNIGVDYKHDET  
VGELSRRLAIAVENASFLLVLDIWWQHEVWTNLLRAPLNTAATGILVTRNDTVA  
RAIGVEDIHRVELMSDEVGWKLLKSMNISKESSEVENLRVLGVLDIVRLCGGLPLAL

15

**RG7 polynucleotide sequence (SEQ ID NO:136)**

GGTGGGGTTGGGAAGACAACGGGCACAAGGAGGCGACTGCCAATACTTCC  
GACTTTTATTCATAGAGATGACGAGTCTTATTTTCTACTACTATAGGGA  
GGATATTTGGTTGCGCGAGACGATTCATTGCGCGAAGGGATTCTATCCTT  
20 CTTTTTTTCCGCGAAGACTTCGTTCCGGAGGACGGGCTATATTCCCTTTA  
ATATTAGTCTAGCCCAGTCTAGGCCAACCATATGGCGATGCGGTAGACCT  
CCCAGAGATAGATACTTGATCTTAGAGGATTCACACGTTCAATGGTGGAA  
ACTTAAGGAACCGGCTAAGAGTGACTAAACGGAAAAACCCTATTCATTCC  
ATAGCCTCATCCGGTCGAGGCATTAAACAATCCATCCCAATCCTCTTTCC  
25 TTTGGTCTACTCTAATGATGTGCCCGTTTCGTTGGTGGGAATATCTCTTTAT  
ACCGACGATTTATATGGGGATTGCCACTAGCGTTG

30

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid construct comprising an RG polynucleotide which encodes an RG polypeptide having at least 60% sequence identity to an RG polypeptide from an RG family selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.
2. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising an leucine rich region (LRR).
3. The nucleic acid construct of claim 1, wherein the RG polynucleotide encodes an RG polypeptide comprising a nucleotide binding site (NBS).
4. The nucleic acid construct of claim 1, wherein the polynucleotide is a full length gene.
5. The nucleic acid construct of claim 1, wherein the further encodes a fusion protein.
6. The nucleic acid construct of claim 1, wherein the RG1 polypeptide is encoded by an RG1 polynucleotide sequence.
7. The nucleic acid construct of claim 6, wherein the RG1 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
8. The nucleic acid construct of claim 1, wherein the RG2 polypeptide is encoded by an RG2 polynucleotide sequence.
9. The nucleic acid construct of claim 8, wherein the RG2 polypeptide is encoded by a polynucleotide sequence selected from the group consisting of: SEQ ID NO:21 (RG2A);



SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).

10. The nucleic acid construct of claim 1, wherein the RG3 polypeptide is encoded by an RG3 polynucleotide sequence.

11. The nucleic acid construct of claim 10, wherein the RG3 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:68.

12. The nucleic acid construct of claim 1, wherein the RG4 polypeptide is encoded by an RG4 polynucleotide sequence.

13. The nucleic acid construct of claim 12, wherein the RG4 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:69.

14. The nucleic acid construct of claim 1, wherein the RG5 polypeptide is encoded by an RG5 polynucleotide sequence.

15. The nucleic acid construct of claim 14, wherein the RG5 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:134.

16. The nucleic acid construct of claim 1, wherein the RG7 polypeptide is encoded by an RG7 polynucleotide sequence.
17. The nucleic acid construct of claim 16, wherein the RG7 polypeptide is encoded by a polynucleotide sequence as set forth in SEQ ID NO:136.
18. The nucleic acid construct of claim 1, further comprising a promoter operably linked to the RG polynucleotide.
19. The nucleic acid construct of claim 18, wherein the promoter is a plant promoter.
20. The nucleic acid construct of claim 19, wherein the plant promoter is a disease resistance promoter.
21. The nucleic acid construct of claim 19, wherein the plant promoter is a lettuce promoter.
22. The nucleic acid construct of claim 18, wherein the promoter is a constitutive promoter.
23. The nucleic acid construct of claim 18, wherein the promoter is an inducible promoter.
24. The nucleic acid construct of claim 18, wherein the promoter is a tissue-specific promoter.
25. A nucleic acid construct comprising a promoter sequence from an RG gene linked to a heterologous polynucleotide.
26. A transgenic plant comprising a recombinant expression cassette comprising a promoter operably linked to an RG polynucleotide.

27. The transgenic plant of claim 26, wherein the plant promoter is a plant promoter.
28. The transgenic plant of claim 26, wherein the plant promoter is a viral promoter.
- 5 29. The transgenic plant of claim 26, wherein the plant promoter is a heterologous promoter.
30. The transgenic plant of claim 26, wherein the plant is lettuce.
- 10 31. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:1 (RG1A), SEQ ID NO:2 (RG1B), SEQ ID NO: 3 (RG1C), SEQ ID NO:4 (RG1D), SEQ ID NO:5 (RG1E), SEQ ID NO:6 (RG1F), SEQ ID NO:7 (RG1G), SEQ ID NO:8 (RG1H), SEQ ID NO:9 (RG1I), and SEQ ID NO:10 (RG1J).
- 15 32. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:21 (RG2A); SEQ ID NO:23 (RG2B); SEQ ID NO:25 (RG2C); SEQ ID NO:27 (RG2D); SEQ ID NO:29 (RG2E); SEQ ID NO:31 (RG2F); SEQ ID NO:33 (RG2G); SEQ ID NO:35 (RG2H); SEQ ID NO:37 (RG2I); SEQ ID NO:39 (RG2J); SEQ ID NO:41 (RG2K); SEQ ID NO:43 (RG2L); SEQ ID NO:45 (RG2M); SEQ ID NO:87 (RG2A); SEQ ID NO:89 (RG2B); SEQ ID NO:91 (RG2C); SEQ ID NO:93 (RG2D) and SEQ ID NO:94 (RG2D); SEQ ID NO:96 (RG2E); SEQ ID NO:98 (RG2F); SEQ ID NO:100 (RG2G); SEQ ID NO:102 (RG2H); SEQ ID NO:104 (RG2I); SEQ ID NO:106 (RG2J) and SEQ ID NO:107 (RG2J); SEQ ID NO:109 (RG2K) and (SEQ ID NO:110 (RG2K); SEQ ID NO:112 (RG2L); SEQ ID NO:114 (RG2M); SEQ ID NO:116 (RG2N); SEQ ID NO:118 (RG2O); SEQ ID NO:120 (RG2P); SEQ ID NO:122 (RG2Q); SEQ ID NO:124 (RG2S); SEQ ID NO:126 (RG2T); SEQ ID NO:128 (RG2U); SEQ ID NO:130 (RG2V); and, SEQ ID NO:132 (RG2W).
- 20 33. The transgenic plant of claim 26, wherein the RG polynucleotide is selected from the group consisting of SEQ ID NO:68 (RG3) and SEQ ID NO:69 (RG4).
- 25 30

34. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:134 (RG5).

5 35. The transgenic plant of claim 26, wherein the RG polynucleotide comprises a sequence as set forth in SEQ ID NO:136 (RG7).

36. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG1 polypeptide selected from the group consisting of SEQ ID NO:11 (RG1A), SEQ ID NO:12 (RG1B), SEQ ID NO: 13 (RG1C), SEQ ID NO:14 (RG1D), SEQ ID NO:15 (RG1E), SEQ  
10 ID NO:16 (RG1F), SEQ ID NO:17 (RG1G), SEQ ID NO:18 (RG1H), SEQ ID NO:19 (RG1I), and SEQ ID NO:20 (RG1J).

37. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG2 polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41  
15 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ  
20 ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O); SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID  
25 NO:133 (RG2W).

38. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG3 polypeptide with a sequence as set forth by SEQ ID NO:138.

30 39. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG4 polypeptide with a sequence as set forth by SEQ ID NO:139.

40. The transgenic plant of claim 26, wherein the RG polynucleotide encodes an RG5 polypeptide with a sequence as set forth by SEQ ID NO:135.

41. A method of enhancing disease resistance in a plant, the method comprising  
5 introducing into the plant a recombinant expression cassette comprising a promoter functional in the plant and operably linked to an RG polynucleotide sequence.

42. The method of claim 41, wherein the plant is a lettuce plant.

10 43. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide selected from the group consisting of SEQ ID NO:22 and SEQ ID NO:41 (RG2A); SEQ ID NO:24 and SEQ ID NO:42 (RG2B); SEQ ID NO:43 (RG2C); SEQ ID NO:44 (RG2D); SEQ ID NO:45 (RG2E); SEQ ID NO:46 (RG2F); SEQ ID NO:47 (RG2G); SEQ ID NO:48 (RG2H); SEQ ID NO:49 (RG2I); SEQ ID NO:50 (RG2J); SEQ ID NO:51  
15 (RG2K); SEQ ID NO:52 (RG2L); SEQ ID NO:53 (RG2M); SEQ ID NO:88 (RG2A); SEQ ID NO:90 (RG2B); SEQ ID NO:92 (RG2C); SEQ ID NO:95 (RG2D); SEQ ID NO:97 (RG2E); SEQ ID NO:99 (RG2F); SEQ ID NO:101 (RG2G); SEQ ID NO:103 (RG2H); SEQ ID NO:105 (RG2I); SEQ ID NO:108 (RG2J); SEQ ID NO:111 (RG2K); SEQ ID NO:113 (RG2L); SEQ ID NO:115 (RG2M); SEQ ID NO:117 (RG2N); SEQ ID NO:119 (RG2O);  
20 SEQ ID NO:121 (RG2P); SEQ ID NO:123 (RG2Q); SEQ ID NO:125 (RG2S); SEQ ID NO:127 (RG2T); SEQ ID NO:129 (RG2U); SEQ ID NO:131 (RG2V); and, SEQ ID NO:133 (RG2W).

44. The method of claim 41, wherein the RG polynucleotide encodes an RG polypeptide  
25 selected from the group consisting of SEQ ID NO:138 (RG3); SEQ ID NO:139 (RG4); and SEQ ID NO:135 (RG5).

45. The method of claim 41, wherein the promoter is a tissue-specific promoter or a plant disease resistance promoter.

46. The method of claim 41, wherein the promoter is a constitutive promoter or an inducible promoter.

5 47. A method of detecting RG resistance genes in a nucleic acid sample, the method comprising:

contacting the nucleic acid sample with an RG polynucleotide to form a hybridization complex; and,

wherein the formation of the hybridization complex is used to detect the RG resistance gene in the nucleic acid sample.

10

48. The method of claim 47, wherein the RG polynucleotide is an RG1 polynucleotide.

49. The method of claim 47, wherein the RG polynucleotide is an RG2 polynucleotide.

15 50. The method of claim 47, wherein the RG polynucleotide is an RG3 polynucleotide, an RG4 polynucleotide, an RG5 polynucleotide or an RG7 polynucleotide.

51. The method of claim 47, wherein the RG resistance gene is amplified prior to the step of contacting the nucleic acid sample with the RG polynucleotide.

20

52. The method of claim 51, where the RG resistance gene is amplified by the polymerase chain reaction.

53. The method of claim 47, wherein the RG polynucleotide is labeled.

25

54. An RG polypeptide having at least 60% sequence identity to a polypeptide selected from the group consisting of: an RG1 polypeptide, an RG2 polypeptide, an RG3 polypeptide, an RG4 polypeptide, an RG5 polypeptide, and an RG7 polypeptide.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/00615

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>IPC(6) : Please See Extra Sheet.<br>US CL : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205<br>According to International Patent Classification (IPC) or to both national classification and IPC  |  |  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
|---|--|--|--|-----|---|--|-----|--|--|-----|--|--|-----|---|--|--|--|--|--|--|
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>U.S. : 435/6, 91.2, 418, 419; 530/350; 536/23.1, 23.6, 24.1; 800/205<br>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched<br>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>APS, DIALOG  |  |  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |  |  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| Category <sup>a</sup>   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| Y   | PARAN et al. Development of Reliable PCR-Based Markers Linked to Downy Mildew Resistance Genes in Lettuce. Theor. Appl. Genet. 1993. Vol. 85, No. 8, pages 985-993, see entire article.                    | 1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| Y   | KESSELI et al. Analysis of a Detailed Genetic Linkage Map of Lactuca sativa (Lettuce) Constructed From RFLP and RAPD Markers. Genetics. April 1994. Vol. 136, No. 4, pages 1435-1446, see entire document. | 1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| Y   | MICHELMORE, RW. Isolation of Disease Resistance Genes from Crop Plants. Current Opinion in Biotechnology. 1995. Vol. 6, No. 2, pages 145-152, see entire document.   | 1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.  |  |  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| <table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T*</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Δ*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table> |  |  | * Special categories of cited documents: | *T* | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention | *A* document defining the general state of the art which is not considered to be of particular relevance | *X* | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | *B* earlier document published on or after the international filing date | *Y* | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *Δ* | document member of the same patent family | *O* document referring to an oral disclosure, use, exhibition or other means |  |  | *P* document published prior to the international filing date but later than the priority date claimed |  |  |
| * Special categories of cited documents:  | *T*  | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| *A* document defining the general state of the art which is not considered to be of particular relevance  | *X*  | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| *B* earlier document published on or after the international filing date  | *Y*  | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  | *Δ*  | document member of the same patent family  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| *O* document referring to an oral disclosure, use, exhibition or other means  |  |  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| *P* document published prior to the international filing date but later than the priority date claimed  |  |  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| Date of the actual completion of the international search<br>14 MARCH 1998  |  | Date of mailing of the international search report<br>13 APR 1998  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703) 305-3230   |  | Authorized/signed<br>PHUONG BUI<br>Telephone No. (703) 308-0196  |  |     |   |  |     |  |  |     |  |  |     |   |  |  |  |  |  |  |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/00615

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.                       |
|-----------|---|---|
| Y         | PARAN et al. Recent Amplification of Triose Phosphate Isomerase Related Sequences in Lettuce. Genome. 1992. Vol. 35, No. 4, pages 627-635, see entire document.   | 1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54 |
| Y         | PARAN et al. Identification of Restriction Fragment Length Polymorphism and Random Amplified Polymorphic DNA markers linked to Downy Mildew Resistance Genes in Lettuce, Using Near-Isogenic Lines. Genome. 1991. Vol. 34, No. 6, pages 1021-1027, see entire document. | 1-6, 8, 10, 12, 14, 16, 18-30, 41-42, 45-54 |



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/00615**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 7, 9, 11, 13, 15, 17, 31-40, 43-44  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
these claims are drawn to numerous sequences identified by SEQ ID NOs. However, since no computer readable form was submitted, no meaningful search could be carried out.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/00615

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A01H 1/00; C07H 21/04; C07K 14/00; C12N 5/04, 5/10; C12P 19/34; C12Q 1/68